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KEYNOTE LECTURES
1IN
LUNG CANCER SCREENING
H.J. de Koning Department of Public Health, Erasmus MC, Rotterdam, 
NETHERLANDS
Lung cancer is a public health problem of global magnitude and the leading 
cause of cancer death worldwide. Primary prevention, i.e. effective ways to 
have smokers quit and effective ways to prevent adolescents to start smok-
ing, are crucial to stop the epidemic, both in Europe and other parts of the 
world. At the same time, millions of men and women are presently at very 
high risk of developing lung cancer. With the new low-dose multi-detector 
computer technology available in the past decade, lung cancer screening 
may play an important role in reducing lung cancer mortality and morbid-
ity in high risk populations. In the Us, the National Lung screening trial 
(NLst) was the first large-scale lung screening project ever to show that 
offering lung (ct) screening to high risk persons lead to a significant 20% 
lung cancer mortality reduction (and 6.7% all-cause mortality reduction at 
a median 6.5-years of follow-up). In Europe, 5 population-based rcts of 
lung cancer screening have now completed their recruitment with almost 
30,000 enrollees. When considering whether lung cancer screening could 
or should be made available to the population, stringent standards must 
be applied. Early detection and prevention at public level does not guar-
antee effective prediction at an individual level, and to achieve positive 
outcomes we often need to implement programs for large groups of people, 
only some of whom will benefit. the newest criteria for early detection are 
therefore unambiguous. there must be substantial positive health outcomes 
in terms of additional years of life and a significant increase in treatment 
options. secondly, any adverse effects must be limited in nature: the level 
of overdiagnosis and the side-effects need to be estimated and expressed 
in terms of quality-adjusted life-years gained. there must be a reasonable 
balance between costs and benefits and measures must be taken to ensure 
that implementation will not lead to substantial unintended effects (such 
as widespread inequality, or increased smoking due to a health certificate 
effect or false reassurance by the test result). In this keynote lecture I will 
provide an overview of the current European trials, debate the position 
where we are now on these 3 aspects, and provide detailed data from the 
NELsON-trial, the largest EU-lung cancer screening trial.
Disclosure: All authors have declared no conflicts of interest.
2IN
THE EVOLUTION OF MOLECULAR TARGETED TREATMENT
D.r. Gandara, P.c. Mack, t. Li Cancer Center, University of California 
Davis, Sacramento, CA, UNITED STATES OF AMERICA
the term “targeted therapy”, in its most simple interpretation, implies that a 
drug target (generally molecular) is identified, is measurable with some reli-
ability in a reproducible fashion, and that patients whose tumors are action-
able for the target will derive more benefit than either unselected patients or 
patients with tumors not harbouring the molecular target in question. In fact, 
targeted therapy can be interpreted as including not only newer inhibitors of 
signal transduction or angiogenesis, but classic chemotherapeutic agents as 
well. And further, many patients with NscLc continue to be treated in an 
unselected fashion even with so-called targeted agents, bevacizumab being 
the prime example. thus at present, selection of chemotherapy regimens, 
or even so-called targeted therapies, for individual patients with NscLc 
remains largely an empiric process. Nevertheless, developing molecular-
based or pharmacogenomic (PG) approaches for selection of chemotherapy, 
or targeted therapies, through predictive biomarkers now appears feasible due 
to improved understanding of underlying molecular mechanisms. Although 
diverse terminology has been applied to molecular-directed selection of 
therapy on an individual patient basis (individualizing, customizing, or 
personalizing therapy), all rely on commonly shared principles for assess-
ing tumor or host-related factors. In this presentation, emerging data regard-
ing such approaches for treatment selection for non-small cell lung cancer 
(NscLc) are addressed, focusing primarily on the process by which pre-
dictive biomarkers for drugs directed against newly discovered targets are 
identified and developed in a cohesive manner with the drug itself. Lessons 
learned ranging from preclinical models to randomized clinical trials testing 
these concepts are described, including limitations in the clinical setting of 
advanced stage disease. Methodological and technical aspects are elucidated, 
recommendations for clinical application are provided, and new directions in 
this field are projected.
Disclosure: All authors have declared no conflicts of interest.
MEET THE EXPERT SESSIONS
3IN
HIGH-RISK PATIENTS WITH ADVANCED NSCLC
E. Quoix Pneumology Service, Nouvel Hopital Civil, Strasbourg, FRANCE
Lung cancer is more and more frequently diagnosed in elderly pts for 2 rea-
sons: increase of life expectancy and increased risk of developing a cancer 
with age. thus, median age of pts at diagnosis is now around 65–70 years. 
there has been for a long time some nihilism regarding elderly pts with 
advanced NscLc as well from the pts themselves, their relatives and even 
doctors. Until recently there were no studies devoted to elderly pts and the 
body of knowledge came from trials including pts with no upper limit of age. 
In most of these studies, the results obtained in pts aged did not differ from 
those obtained in their younger counterparts. However, only hyperselected 
elderly pts were included and even though there was no upper limit of age, 
there were no very old pts. the 1st study devoted to pts aged >= 70 years was 
a randomization between vinorelbine (VNr) alone and best supportive care 
(bsc). there was a highly significant survival gain in the chemotherapy arm 
and single agent became the standard of care. the following studies compared 
single agent to non-platinum based doublet and the conclusion was that there 
was no advantage to doublet. As a consequence, the European recommenda-
tions in 2010 were to treat pts aged >=70 years with single agent therapy 
such as gemcitabine or VNr. In a recent IFct trial comparing VNr or gem-
citabine vs carboplatine + weekly taxol in 451 elderly Ps 0–2 pts, there was 
a highly significant benefit of survival (Mst 10.3 vs 6.2 mos) in the doublet 
arm. this result was seen in every prognostic subgroup and the new paradigm 
of treatment for pts aged 70–89 with Ps 0–2 should probably be this doublet. 
regarding Ps 3 pts there is nowadays no recommendation for chemotherapy 
and bsc is probably indicated in most cases. Ps 2 pts represent 25% of all 
lung cancer cases and even more in stage IV disease with a consistent poorer 
prognosis compared to Ps 0–1 pts. cisplatin is clearly contra-indicated. In 
a subgroup analysis of Ps 2 pts, Lilenbaum demonstrated that there was a 
survival gain in favor of carboplatine-taxol vs taxol alone. Further studies 
resulted in similar conclusions. In molecularly unselected Ps 2 pts, there is no 
advantage to targeted therapies as 1stline therapy. In conclusion, carboplatin-
based doublet is probably the best for elderly and Ps 2 pts but more dedicated 
studies are needed.
Disclosure: E. Quoix: No stock ownership, no corporate-sponsored research; 
Advisory boards with Lilly, boehringer Ingelheim, Astra Zeneca, roche; 
travel grants for meetings: Amgen, Lilly, roche, astra Zeneca.
4IN
RARE TUMORS OF THE LUNG
H. Asamura Division of Thoracic Surgery, National Cancer Center Hospital, 
Tokyo, JAPAN
chest physicians, thoracic surgeons, and radiation oncologists are prin-
cipally dealing with patients with primary lung carcinoma of usual 
histologies in their daily practice. they are mostly adenocarcinoma, 
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squamous cell carcinoma, small cell carcinoma, and large cell carci-
noma of lung origin. However, according to the “WHO histological 
classification of tumours of the lung”, lots of other primary and meta-
static histologies are being recognized with their own pathobiological 
natures. Fundamental knowledge about these “rare tumours” might be 
reflected in a proper management of patients with such tumours despite 
their “rarity”. WHO classification roughly divides tumours into the fol-
lowing categories: malignant epithelial tumours (including mesenchy-
mal tumours), benign epithelial tumours, Lymphoproliferative tumours, 
miscellaneous tumours, and metastatic tumours. Among these, all the 
tumours except for malignant epithelial tumours and metastatic tumours 
are rarely encountered. One cautious note is that even a common subtype 
like adenocarcinoma includes rare variants such as “fetal adenocarci-
noma”, “colloid carcinoma”, “mucinous cystadenocarcinoma”, “signet 
ring adenocarcinoma”, and “clear cell adenocarcinoma”. As one of the 
subtypes of large cell carcinoma, “large cell neuroendocrine carcinoma” 
has been mentioned, and its clinicopathological profiles have recently 
been well characterized. However, this subtype comprises only 3% of 
whole resected cases (“rare”) despite well-known recognition. Other 
rare but important histologies of epithelial tumours includes salivary 
gland tumours (mucoepidermoid carcinoma, adenoid cystic carcinoma, 
and epithelial-myoepithelial carcinoma) and sarcomatioid carcinoams. 
rare mesenchymal tumours of the lung are angiosarcoma, inflammatory 
myofibroblastic tumour, and synovial sarcoma. Various types of lym-
phomas arise in the lung with different grade of malignancy. they are 
MALt lymphoma, diffuse large-cell lymphoma, and Hodgkin’s disease. 
the modern molecular approach and biopsy technique obtaining enough 
amount of tumour tissue play the crucial role to establish the precise 
diagnosis for these rare tumours.
Disclosure: All authors have declared no conflicts of interest.
5IN
MEDIASTINAL STAGING: EBUS, EUS, 
MEDIASTINOSCOPY OR WHAT?
P. De Leyn Department of Thoracic Surgery, University Hospital Leuven, 
Leuven, BELGIUM
Mediastinal lymph node (LN) involvement is present in 30 to 45% of 
newly diagnosed lung cancers. A subgroup of patients with positive medi-
astinal LN’s benefit from surgical multimodality treatment. therefore, 
mediastinal staging procedures can select patients for resection, based 
on both baseline and post-induction assessment. PEt scan has largely 
improved mediastinal LN staging. However PEt positive mediastinal 
findings should always be cyto-histologically confirmed. Due to the high 
NPV of PEt scan, invasive staging can be omitted in patients with stage I 
NscLc. In central tumours, PEt N1 nodes or ct-enlarged LN’s invasive 
staging is recommended (De Leyn, 2007). Different techniques of invasive 
mediastinal staging are available. they vary in accuracy and procedure-
related morbidity. Ultrasound-guided bronchoscopy with fine-needle aspi-
ration (EbUs-FNA) and endoscopic esophageal ultrasound-guided FNA 
(EUs-FNA) are techniques that provide cyto-histological diagnosis and 
are minimally invasive. Although some studies have shown equal accuracy 
of EbUs and mediastinoscopy (Yasufuku, 2011), it is accepted in case 
of negative results of EbUs/EUs-FNA, an invasive surgical technique 
is indicated. A recent prospective study showed that combining endo-
sonography and surgical staging compared with surgical staging alone 
resulted in greater sensitivity for mediastinal nodal metastasis end fewer 
unnecessary thoracotomies (Annema, 2010). For restaging in a surgical 
multimodality regimen, invasive techniques providing cyto-histological 
information are advisable despite the encouraging results with the use of 
re-PEt/ct imaging. the accuracy of remediastinoscopy and EbUs/EUs-
FNA is much lower than in baseline staging. baseline staging of mediasti-
nal LN’s with endoscopic techniques and restaging after induction therapy 
with mediastinoscopy seems to be a valuable tool to select patients with 
N2 disease for surgical multimodality treatment. We conclude that opti-
mal staging is a truly multidisciplinary process, with a variety of possible 
techniques, to be performed by experienced hands. the proficiency of the 
physician performing the procedure plays a role in varying sensitivity and 
specificity observed and each center has to adopt its own guidelines pend-
ing on their performance.
Disclosure: All authors have declared no conflicts of interest.
6IN
BRAIN AND BONE METASTASES MANAGEMENT
F. de Marinis1, s. ricciardi2 11st Oncological Pulmonary Unit, Azienda 
Ospedaliera San Camillo Forlanini, Roma, ITALY, 2Department of Lung 
Disease, AO San Camillo-Forlanini, Rome, ITALY
brain metastases (bM) are the most frequent neurologic complication 
related to cancer. the risk of developing bM varies according to primary 
tumor type, with lung cancer accounting for approximately one half of 
all brain metastases. the median survival time of untreated patients 
is approximately 1 month. With treatment, the overall median survival 
time after diagnosis is approximately four months. Head/brain scans 
with ct or MrI are the way that the vast majority of brain metastases 
are detected. surgery plays important role for patients with a single 
bM and an operable lung cancer: relieving mass effect from a large 
symptomatic lesion, confirming the diagnosis when needed, improving 
local control. the most widely used treatment for patients with multiple 
brain metastases is whole brain radiotherapy (Wbrt) with 30 Gy in ten 
3 Gy fractions. stereotactic radiosurgery treats only single bM with 
a precise delivery of a single, high dose of rt in a one-day session. 
chemotherapy has traditionally played a limited role in thetreatment of 
bM because the most agents are either too large or hydrophilicto cross 
the blood–brain barrier. temozolomide is a new orally administered 
alkylating agent that crosses the blood–brain barrier and attains thera-
peutic concentrations. several phase II trials suggest that single agent 
temozolomide has modest activity in patients with recurrent or pro-
gressive brain metastases. Approximately 30-40% of NscLc patients 
develop bone metastases. bone metastases are associated with a sig-
nif icant increase in skeletal-related events (srEs). traditionally, radia-
tion therapy and surgery were the mainstays of treatment for patients 
with bone metastases. In recent years, however bisphosphonate have 
emerged as an additional treatment option. the principal mechanism of 
action is the suppression of bone resorption through the inhibition of 
osteoclast recruitment and adhesion. Actualy, the only bisphosphonate 
to have received worlwide approval for use in patients with lung cancer 
is zoledronic acid. the treatment with 4 mg of zoledronic acid reduces 
the proportion of patients with an srE (38 vs 47%; p=0.039), and the 
rate of skeletal morbidity to 2,2 events/year vs 2,7 events/year for pla-
cebo (p=0.017).
Disclosure: All authors have declared no conflicts of interest.
7IN
THYMOMA
E. ruffini1, F.c. Detterbeck2, G. rocco3, P.A. thomas4, D. Van raemdonck5, 
F. Venuta6, W. Weder7 1Department of Thoracic Surgery, University of 
Torino, Torino, ITALY, 2Thoracic Surgery, Yale University School of 
Medicine, New Haven, CT, UNITED STATES OF AMERICA, 3Department of 
Thoracic Surgery and Oncology, National Cancer Institute, Naples, ITALY, 
4Department of Thoracic Surgery & Diseases of The Esophagus, University 
of the Mediterranean & University Hospitals System of Marseille (AP-HM), 
Marseille, FRANCE, 5Thoracic Surgery, University Hospitals Leuven, Leuven, 
BELGIUM, 6Toracica Dipartimento Paride Stefanini, Policlinico Umberto I 
Cattedra di Chirurgia, Rome, ITALY, 7Thoracic Surgery, Universitätsspital 
Zürich, Zürich, SWITZERLAND
thymic malignancies comprise thymomas and thymic carcinomas (tc), 
the latter also including neuroendocrine thymic tumors (NEtt). the 
most used staging system (Masaoka) is based upon the surgical-patho-
logic local extent of invasion. the system presents some limitations for 
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tc and NEtt, in which the rate of lymphatic spread is not negligible. 
For this reason, tNM-based systems have been proposed where the t 
descriptor is derived from the Masaoka classification, and the N descrip-
tor is based upon the spread to the regional lymphnodes. A global effort 
is under way (ItMIG, IAsLc, regional thymic interest groups of Ests, 
EActs, JArt) to propose a consistent staging classification for the 8th 
edition of the tNM staging manual. the WHO histologic classification 
(A, Ab, b1, b2, b3, tc, NEtt) is widely recognized among the pathol-
ogists, but there are some gray areas which need clarification , includ-
ing the inter-observer variability among b-types, the identification of 
type A thymomas with atypical features, the lack of a clear definition 
between b3 and tc. treatment of thymic malignancies is stage-depen-
dent. stage I thymomas (encapsulated) are surgically treated with no 
further therapy. stage II tumors are treated by upfront surgery followed 
by adjuvant therapy on a selective basis (high-risk tumors, including 
b2-b3 and tc). stage III tumors which are deemed to be resectable 
should be approached with upfront surgery followed by adjuvant therapy 
in case of incomplete resection or high-risk tumors. stage III tumors 
which are not resectable should undergo induction chemotherapy and 
surgery in case of response, followed by adjuvant radiotherapy. stage 
IV tumors should be approached in a multidisciplinary setting with che-
motherapy, surgery and postoperative radiotherapy. sternotomy repre-
sents the standard surgical access, but small tumors can also be resected 
with a minimally-invasive approach (VAts, robotic), while in case of 
extended tumors resection of the neighboring structures is justif ied to 
achieve a complete resection. Very recently, promising reports have 
been published evaluating the efficacy of biologic (targeted) therapies 
in thymic tumors including EGFr inhibitors (cetuximab) in thymomas, 
KIt inhibitors (imatinib) in tc, somatostatin analogues (Octreotide) in 
octreotide-scan positive tumors.
Disclosure: All authors have declared no conflicts of interest.
THE EPIDEMIOLOGY OF LUNG CANCER
8IN
SMOKING AND LUNG CANCER
No abstract received at time of going to press.
9IN
THE BURDEN OF LUNG CANCER IN NON-SMOKERS
P. boffetta Oncology, International Prevention Research Institute, Lyon, 
FRANCE
the incidence of lung cancer in never-smokers in the United states 
and Europe is estimated in the range 10-15/100,000 person-years. the 
incidence of lung cancer among non-smoking women is higher in East 
Asia than in other regions (data in men are complicated by variabil-
ity in the effect of tobacco smoking across regions). recognized causes 
of lung cancer in never smokers include second-hand smoke, indoor 
radon, indoor coal burning for cooking and heating (mainly relevant 
to non-smoking Asian women), and exposure to occupational carcino-
gens. suspected causes of lung cancer in never-smokers include chronic 
inflammatory conditions, outdoor air pollution, hormonal factors, and 
low intake of fresh fruits and vegetables. the distribution of histologic 
types of lung cancer in never-smokers is different from that of smok-
ers, with a higher proportion of adenocarcinoma (62% vs. 19%), and 
lower proportion of squamous cell carcinoma (18% vs. 53%). Population 
attributable fractions for individual risk factors ranged from 0.40% to 
19.93%, these estimates vary by geographic region and reflect the vari-
able prevalence of exposure to known risk factors. In general, they are 
higher in East Asia than in Europe and North America. Genetic variants 
consistently associated with lung cancer susceptibility in never smok-
ers are on chromosomes 5p15.33 (tErt and cLPtM1L genes) 6q and 
13q31. the role of a locus identified in GWAs at 15q25 has not been 
confirmed in never-smokers.
Disclosure: No disclosure received at time of going to press.
10IN
THE MOLECULAR PATHOGENESIS OF LUNG CANCER 
IN NEVER SMOKERS
A.F. Gazdar The Hamon Center for Therapeutic Oncology Research, 
University of Texas Southwestern Medical Center, Dallas, TX, UNITED 
STATES OF AMERICA
While lung cancer in smokers is the leading cause of cancer deaths in the 
world with about 900,000 deaths/year, lung cancer in lifetime never smok-
ers (LcNs), with about 300,000 deaths per year, is the 7th leading cause 
of cancer deaths. LcNs shows major pathological, ethnic and gender 
differences, favoring adenocarcinoma histology, female gender and East 
Asian ethnicity. the major pathogenic cause(s) are largely unknown, with 
exposure to environmental exposure to tobacco smoke playing a minor 
role. Major molecular differences between lung cancers in smokers and 
Ns have been demonstrated. the best studied changes include the rela-
tive frequency of EGFr mutations and ALK translocations in LcNs, the 
relative paucity of KrAs mutations, and differences in the spectrum of 
tP53 mutations. In addition, the methylation patterns of the two forms 
of cancers are different. recent evidence suggests that global changes in 
copy number and the frequencies of mitochondrial mutations may also 
vary between these groups. Lung cancers in smokers and never smokers 
appear to be two distinct diseases arising in the same organ. these differ-
ences impact on diagnosis and clinical management.
Disclosure: All authors have declared no conflicts of interest.
11IN
ISSUES SURROUNDING GENDER
s. Novello1, M. Longo2 1Thoracic Oncology Unit, Ospedale San Luigi, Turin, 
ITALY, 2Thoracic Oncology Unit, University of Turin, Orbassano, ITALY
For a long period of time lung cancer has been considered as a malig-
nancy affecting only males, but epidemiological data have shown a dra-
matic increase of its incidence among women, mainly as a consequence 
of the huge spread of tobacco consumption. considering that this increase 
in women continues worldwide, the incidence of lung cancer is projected 
to be identical in both sexes over the next decade. Gender differences in 
terms of susceptibility to carcinogens and natural history of the disease 
have been reported and several case-control studies suggested that women 
are more vulnerable to tobacco carcinogens than men. Histological sub-
types also differ significantly according to gender being adenocarcinoma 
the commonest histologic subtype in women. Although tobacco smoking 
remains a significant risk factor for adenocarcinoma, approximately 20% 
of women with lung cancer are never smokers. the rate of lung cancer 
in never smokers is higher in women than in men, being the hormonal 
status one potential explanation for such difference. Estrogens may be 
involved in lung tumorigenesis through several mechanisms such as cell 
proliferation induced by ligand-estrogen receptor (Er) interaction, the 
cross-talk between estrogen receptors and other growth factor receptors 
(i.e. epidermal and insulin growth factor receptors). When compared with 
men, women are more likely to be younger (50 years old) at the time of 
diagnosis and to have a better survival at any stage and independently 
from the therapeutic approach. An improvement in understating genetic, 
metabolic, and hormonal factors that could affect the way women react to 
carcinogens and lung cancer represents a research priority.
Disclosure: All authors have declared no conflicts of interest.
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PATHOLOGY: CHANGES IN MORPOHOLOGICAL 
AND MOLECULAR APPROACHES
12IN
MORPHOLOGICAL CLASSIFICATION OF 
ADENOCARCINOMA
K. Kerr Pathology, Aberdeen Royal Infirmary, Aberdeen, UNITED 
KINGDOM
Morphology is the core approach to the classification of all lung cancers. the 
new IAsLc/Ats/Ers recommendations for this classification reflects the fact 
that adenocarcinoma (AD) morphology is complex, it has important clinical 
and molecular associations, there was considerable confusion and misuse of 
the term bronchioloalveolar carcinoma (bAc) and the current WHO classifica-
tion was not fully applicable to most AD diagnosis; that made on small biopsy/
cytology samples. Most resected AD show a mixture of patterns; combinations 
of acinar (Ac), solid (sOL), papillary (PAP) and bAc pattern that by WHO 
would be ‘mixed type’ AD. the dominance of particular patterns has impli-
cations for the tumour biology, behaviour and molecular pathology. A fifth 
micropapillary (MP) pattern has emerged, and is especially aggressive. the 
preponderance of sOL and MP patterns confers stage for stage, a poor prog-
nosis, Ac or PAP predominance an intermediate outcome while bAc predomi-
nant tumours are less aggressive. studies have shown that this classification 
is reproducible. these differences should be exploited to select for adjuvant 
therapy trials, especially in stage 1 disease. the WHO classification calls bAc 
a small lesion of pure bAc pattern with no metastatic potential, essentially 
AD in situ (AIs). Yet the term bAc is still used to describe invasive AD with 
a bAc component, most of which have metastatic potential and multifocal 
AD of diverse biology, differing histology (usually non-mucinous or mucinous 
cytology) and a distinctive, slowly progressive clinical course. Pathologists, 
surgeons and oncologists using the same term in different ways predicts mis-
communication and clinical mishap. thus, the following recommendations 
were made: · Drop the term bAc. · the bAc pattern is referred to as ‘lepidic’. · 
Lepidic predominant AD has a favour prognosis, especially lesions <3cm 
with a non-lepidic component <5mm dia when 5Ys is ~100% and the term 
minimally invasive AD (MIA) is recommended. · Multifocal lepidic AD are 
special types, especially when mucinous. Difficulty in AD diagnosis in small 
samples led to the term NscLc-NOs in cases of doubt. therapeutic choices 
now require its minimal use and predictive immunohistochemistry (IHc) is 
used to reduce NscLc-NOs to under 10% of cases.
Disclosure: K. Kerr: consultant/speaker fees from roche, Lilly, AZ, bI, 
GsK, Pfizer, Merck serono.
13IN
MOLECULAR PATHOLOGY OF ADENOCARCINOMA
Y. Yatabe Department of Pathology and Molecular Diagnostics, Aichi Cancer 
Center, Nagoya, JAPAN
the current therapeutic strategy for the lung cancer patients was shifted 
by EGFr-tKI treatment in combination with patient selection with EGFr 
mutation. In addition to such clinical impact, understanding EGFr mutations 
sheds new light on a landscape of the molecular pathogenesis of lung adeno-
carcinoma. EGFr mutation occurs in very early stage of cancer development, 
as it seen in a precursor lesion, atypical adenomatous hyperplasia. Invasive 
growth is driven by many genetic alterations, and EGFr gene amplification is 
revealed to be involved in this process. Invasive parts within individual tumors 
exclusively showed EGFr gene amplification in contrast to no amplification 
in the in-situ carcinoma component. Whereas the mechanism has not been 
elucidated, the gene amplification is closely associated with EGFr muta-
tion, e.g., the amplification occurs mostly in EGFr-mutated tumors, and the 
mutated alleles are specifically amplified. the combination of mutated allele 
specific amplification and prevalence of gene amplification in invasive area 
could explain pseudo-heterogeneity of EGFr mutation that has been reported 
in the literature. As already known, not all adenocarcinomas harbor EGFr 
mutation, and EGFr is exclusively mutated in a subset of adenocarcinoma 
with ttF-1 expression. recently, ttF-1 gene amplification is reported to 
be associated with metastasis, and the mutations of other addiction genes, 
including ALK, HEr2 and brAF, were also involved in this subset of adeno-
carcinoma. Interestingly, the subset of adenocarcinoma frequently develops 
in females and non-smokers. these findings could be integrated into a simple 
concept, a cellar lineage of lung adenocarcinoma. this concept is supported 
by molecular classification of lung cancer based on expression profiling.
Disclosure: All authors have declared no conflicts of interest.
14IN
IDENTIFYING GENOMICS-BASED THERAPEUTIC 
TARGETS IN LUNG CANCER
r. thomas Max-Planck-Institut für Neurologische Forschung, Cologne, 
GERMANY
cancer is a disease of the genome; genetic lesions (gene mutations, gene 
copy-number changes, structural genetic changes, etc.) lead to irreversible 
changes in the intracellular signal transduction pathways that the tumor cells 
become dependent upon. A new class of cancer therapeutics targeting spe-
cific signaling pathways activated by genetic lesions has shown clinical suc-
cess. Understanding the dependency associated with each genetic alteration 
is crucial in order to device specific inhibitory strategies to interfere with 
the activity of the respective oncogene or the pathways activated downstream 
of the oncogene. such preclinical work can help expediting the preclinical-
to-clinical transition of novel cancer therapeutics and to make them more 
effective. similarly, linking drug response and clinical features of patients 
to genetic alterations is essential for a continuous re-assessment of the valid-
ity of such preclinical predictions. Our laboratory has created a conceptual 
framework as well as methodological strategies for approaching these needs. 
We have developed an international network for cancer genome analyses and 
we have developed a platform for functional cell biology analysis of the novel 
mutations that we discover. We have successfully applied this two-pronged 
approach to the discovery of cancer genotypes that are connected with drug 
response.
Disclosure: No disclosure received at time of going to press.
15IN
DEVELOPMENTS IN GENE EXPRESSION SIGNATURES
D. carbone Henry-Joyce Cancer Clinic, Vanderbilt-Ingram Cancer Center, 
Nashville, TN, UNITED STATES OF AMERICA
Normal cells are extremely complex, and their derangements during malignant 
transformation are even more so. It can also be observed that tumors exhibit 
a tremendous variability in their behavior in patients, from total chemoresis-
tance and rapid progression and metastasis to indolence and lack of progres-
sion for years. While single genetic alterations are extremely important in 
guiding therapy today, it is impossible that understanding these single driver 
lesions, or even small numbers of them can allow for a complete understand-
ing of cancer behavior and potential therapeutic interventions. In this context, 
“high content” analyses of the entire genetic sequence, methylation patterns, 
expression levels of tens of thousands of rNAs, both coding and non-coding, 
and proteomic patterns of expression and modification are being evaluated for 
an improved understanding of cancer beyond single driver mutations. these 
measurements are now technically feasible, however, these efforts are ham-
pered by the huge number of data points and much smaller numbers of tumors 
available for analysis, and no signatures have found proven utility in the prac-
tical management of lung cancer patients to date. Many of the positive studies 
to date have also been hampered by severe methodological flaws ranging from 
systematic biases in sample collection, poor clinical annotation, inappropriate 
choice of cases to answer the hypothesis, and poor signature evaluation strate-
gies. some of these pitfalls, proposed solutions, and some of the promising 
candidate signatures under evaluation will be discussed.
Disclosure: D. carbone: consulting work for EMD/serono, Genentech, OsI, 
boehringer, biodesix, Pfizer, and Novartis.
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MESOTHELIOMA REVISITED
16IN
FUTURE MESOTHELIOMA RATES IN RELATION TO 
PAST AND CURRENT ASBESTOS EXPOSURE LEVELS
J. Peto1, c. rake1, c. Gilham1, A. Darnton2, J. Hodgson2, G. burdett3 1Dept 
of Non-Communicable Disease Epidemiology, London School of Hygiene 
and Tropical Medicine, London, UNITED KINGDOM, 2CSEAD, Health and 
Safety Executive, Bootle, UNITED KINGDOM, 3Analytical Sciences, Health 
and Safety Laboratory, Buxton, UNITED KINGDOM
We have calculated future worldwide mesothelioma rates from trends in 
national death rates published by the WHO. However, current mesothelioma 
rates, and hence predicted future rates based on them, reflect asbestos expo-
sure levels 30 or more years ago when asbestos was still widely used. the 
public health benefit of regulations and continuing expenditure on asbestos 
monitoring and abatement within the European community and elsewhere 
cannot be assessed, because it is not known how much asbestos released 
from older buildings is being breathed in by workers and the general popu-
lation today, or what mesothelioma risks this will cause in the future. We 
are conducting two studies in the UK to answer these questions. MALcs 
(Mesothelioma and Lung cancer study): We are collecting lifetime occu-
pational histories from mesothelioma and lung cancer patients born before 
1965, together with lung samples for asbestos fibre counting by transmission 
electron microscopy (tEM). the results show a linear relationship between 
mesothelioma risk and asbestos lung burden. tIPs (the Inhaled Particles 
study): the aim of tIPs is to determine the range of asbestos levels in the 
lungs of the general population, and of construction and other workers born 
since 1965, all of whom started work after 1980 when use of asbestos had 
virtually ceased in the UK. We are collecting lifetime occupational histories 
from pneumothorax patients, together with lung samples obtained at opera-
tion for tEM asbestos fibre counting. these data will determine the extent 
of continuing asbestos exposure due to current working conditions and in 
the general environment. In combination with the MALcs results, this will 
provide an estimate of future mesothelioma rates due to current occupational 
and environmental asbestos exposure levels in the UK. similar studies are 
needed in other countries.
Disclosure: All authors have declared no conflicts of interest.
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A MULTIDISCIPLINARY APPROACH
H. Pass Division of Thoracic Surgery, New York University Medical Center, 
New York, NY, UNITED STATES OF AMERICA
Malignant pleural mesothelioma (MPM) is a uniformly fatal disease that has 
been recalcitrant to curative therapies. the median survivals of 8-18 months 
have, for the most part, led to a sense of frustration and nihilism in the medi-
cal and surgical community with regard to management of the disease, and 
the relatively small numbers of patients with mesothelioma have made it an 
orphan among other cancers with regard to research efforts and funding. this 
review will comment on the clinical presentation of the disease, and therapeu-
tic options which are available at this time. the role, timing, degree, and avail-
ability of cytoreductive surgery in the context of a multimodality approach for 
MPM will be highlighted, and various strategies which incorporate adjuctive 
therapies either before, during or after the operation will be discussed. Newer 
cytotoxic chemotherapies, either alone or in combination, are reviewed with an 
emphasis on the increasing number of options with increased response rates that 
are becoming available for MPM patients. the results of protocols at selected 
centers which offer gene therapy, photodynamic therapy, hyperthermic chemo-
therapeutic perfusion, as well as intrapleural chemokines will be discussed, as 
well as newer preclinical approaches which base targeted therapies on novel 
molecular findings. In considering these newest novel approaches for the dis-
ease, the reader is encouraged to seek specialty consultation at centers that are 
concentrating programmatic efforts on mesothelioma in order to design trans-
lational-based approaches on preclinical findings. by using such an approach, 
the patient and his physician will find that there are considerably more options 
in the new century for mesothelioma than simply supportive care.
Disclosure: H. Pass: rosetta Genomics, research collaboration; no stock; 
patents-microrNA for mesothelioma somaLogic, research collaboration; 
no stock; research funding Fujirebio, research collaboration; no stock; pat-
ent -osteopontin in asbestos related diseases.
18IN
BIOLOGY AND TARGETED APPROACHES
D.A. Fennell Thoracic Oncology, University of Leicester, University Hospitals 
of Leicester NHS Trust, Leicester, UNITED KINGDOM
Despite the continuing worldwide increase in the incidence of Mesothelioma 
and its very poor prognosis, the available therapeutic options remain extremely 
limited, reflecting an unmet need. Over the last few years, our understanding 
of the underlying biology of mesothelioma has increased substantially. this 
raises the possibility that more effective, targeted approaches for treating this 
cancer can be identified and implemented for patient benefit. such approaches 
include 1) the re-targeting of conventional drug treatment based on emerging 
knowledge of somatic gene alterations which confer sensitivity or resistance 
2) identifying novel vulnerabilities associated with oncogene addiction, and 
3) synthetic lethal strategies. Examples of these strategies will be presented.
Disclosure: No disclosure received at time of going to press.
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PET-CT IMAGING
b.M. Fischer Deparment of Nuclear Medicine and Pet, Rigshospitalet, 
Copenhagen, DENMARK
Positron Emission tomography with computer tomography (PEt-ct) and the 
clinical use of this imaging technology has developed rapidly during the last 
decade, especially in the field of lung cancer. the first PEt-ct scanner was 
introduced in 2000 in the United states, combining the functional information 
from the PEt scanner with anatomical structures obtained by ct. During the last 
decade app. 2000 PEt/ct scanners have been installed in the United states (6.5 
scanner per million people), 70 in Germany (1.2 scanner per million people) and 
350 PEt/ct scanners in Europe as a whole (0.4 scanner per million people). 
the role and potential impact of PEt/ct in diagnosing and staging patients with 
non-small lung cancer is well established and incorporated in several clinical 
guidelines and recommendations. the European society of thoracic surgery 
(Ests) as well as the American college of chest Physicians (AccP) has pub-
lished guidelines for proper preoperative mediastinal staging, both including a 
PEt/ct examination. PEt/ct is potentially hampered by a relatively high fre-
quency of false positive findings; however, both specificity and sensitivity can 
be increased by detailed knowledge of patient history and side-by-side reading 
by an experienced radiologist and nuclear medicine physician. this presentation 
includes a brief introduction to the technology; including limitations and pit-
falls. through a presentation of recent meta-analyses as well as clinical studies, 
the role of PEt/ct in staging patients with non-small cell lung cancer will be 
described and discussed. current issues of controversies, e.g. the value of sUV 
and the use of low dose versus diagnostic ct will be addressed, as well as con-
siderations on cost-effectiveness and future perspectives.
Disclosure: All authors have declared no conflicts of interest.
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THE ROLE OF ENDOSCOPIC PROCEDURES
J.t. Annema Division of Pulmonary Medicine, Leiden University Medical 
Center, Leiden, NETHERLANDS
transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUs-
FNA) and endobronchial ultrasound guided transbronchial needle aspiration 
(EbUs-tbNA) are novel techniques for the diagnosis and staging of lung 
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cancer. Worldwide, over one million patients with lung cancer are diagnosed 
annually of whom one third present with mediastinal metastases. Accurate 
diagnosis and staging is important for both prognostic and therapeutic rea-
sons. Patients with non-small cell lung cancer (NscLc) and mediastinal 
lymph node metastases or mediastinal tumour invasion (stage III) are prefer-
ably treated with chemo- radiation therapy, whereas patients without locally 
advanced disease are treated primarily by surgical resection of the lung tumour. 
current mediastinal tissue staging of patients with NscLc critically depends 
on surgical interventions, predominantly mediastinoscopy. EUs-FNA and 
EbUs-tbNA are incorporated in current guidelines as minimally invasive 
alternatives for surgical staging to demonstrate nodal metastases. recently 
it has been shown that starting mediastinal staging with endosonography 
improves mediastinal nodal staging and reduces unnecessary thoracotomies 
in comparison to surgical staging by mediastinoscopy. In this talk the role of 
EUs-FNA and EbUs-tbNA for the diagnosis and staging of lung cancer will 
be evaluated. Indications of both methods will be addressed as well as the 
concept of complete echo-endoscopic staging of the mediastinum. the impact 
of EUs and EbUs on patient management will be discussed, in particular 
their role in preventing surgical staging procedures as well as the position of 
endosonography in non-small cell lung cancer staging algorithms.
Disclosure: All authors have declared no conflicts of interest.
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SURGICAL TECHNIQUES
G. Leschber Thoracic Surgery, ELK Berlin Chest Hospital, Berlin, 
GERMANY
the importance of correct staging is without debate, especially in 
patients with resectable lung cancer. False positive ct or PEt findings 
may exclude curable patients from the best treatment option. If medi-
astinal lymph nodes are enlarged on ct scan or positive on PEt scan 
indicating N2/ N3 disease this should be proven histologically. Despite 
newer techniques which are less invasive than surgical methods there is 
a role for mediastinoscopy - in guidelines still considered the goldstan-
dard - or video-assisted thoracic surgery (VAts). Mediastinoscopy pro-
vides a larger amount of lymphatic tissue than non-surgical techniques 
(EbUs/EUs) which is important to exclude minimal metastatic disease. 
compared to conventional mediastinoscopy video-assisted mediastinos-
copy (VAM) has a number of advantages: due to bimanual dissection of 
the mediastinum more lymph nodes stations and complete lymph nodes 
can be removed with a lower complication rate. standardisation and 
teaching of the method has been improved since implementation of the 
video technique which should therefore be the method of choice when 
performing mediastinoscopy. to prove mediastinal lymph node involve-
ment and for selecting optimal stage-oriented therapy namely neoadju-
vant therapy followed by surgery, the pathway could include EbUs/EUs 
for primary staging. For restaging after chemotherapy VAM should be 
performed followed by the definitive surgical procedure. the technique 
of VAMLA (video-assisted mediastinal lymphadenectomy) with en bloc 
resection of lymph node compartments further improves radicality and is 
seen a first step in patients eligible for VAts-lobectomy as dissection of 
the subcarinal region is facilitated and more complete. VAts as part of 
the staging procedure can be used in case of lymph nodes non accessible 
by mediastinoscopy and for exclusion of M1a disease or infiltration of 
viable structures. If pleural dissemination is confirmed immediate talc 
poudrage can be performed. Also, removal of a contralateral lesion to 
rule out metastatic disease may be indicated as lesions are not always 
malignancies.
Disclosure: All authors have declared no conflicts of interest.
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WHICH TEST IS NEEDED FOR WHICH PATIENT?
J. Vansteenkiste Leuven Lung Cancer Group, Respiratory Oncology Unit 
(Pulmonology), Leuven, BELGIUM
Pre-treatment staging for non-small cell lung cancer (NscLc) nowadays is a 
multidisciplinary process involving imaging techniques, endoscopic and sur-
gical procedures, and discussion of the findings at a multidisciplinary tumor 
board. the endpoint is maximal accuracy in order to avoid false positive inter-
pretations leading to a false stage III or IV approach in early stage patients, 
or false negative findings leading to a false early stage approach in patients 
with locally advanced or advanced disease. ct-scan remains the non-invasive 
test with the best anatomical detail of tumour spread, but lacks information 
on the biological nature of the lesions. FDG-PEt is able to add this informa-
tion based on metabolic properties of tissues, but lacks fine spatial resolution. 
therefore, contemporary imaging relies on combination of both, preferably 
in a fusion PEt-ct scan, which is indicated for most patients with a potential 
for radical therapy. When distant metastasis is excluded, assessment of lymph 
node spread will usually direct the further therapy. the combined information 
of both ct and PEt will guide the approach. Absence of suspect lymph nodes 
on both imaging tests has a high negative predictive value, and no further pre-
operative tests are needed, at least if the tumour is not centrally located. the 
same is true for patients with major lymph node involvement on their scan, 
histological confirmation is often not needed there. In all other cases, tissue 
verification by the most appropriate technique is warranted. the historical 
standard of mediastinoscopy is nowadays complemented and in quite some 
patients replaced by endoscopic techniques such as endobronchial ultrasound 
guided transbronchial needle aspiration (EbUs-tbNA) or esophageal ultra-
sound fine needle aspiration (EUs-FNA). Each of these techniques remains 
important in modern staging algorithms [1]. A practical scheme for rational 
staging will be discussed.
[1] Vansteenkiste J, Dooms c, De Leyn P: Early stage NscLc: challenges in 
staging and adjuvant treatment: evidence-based staging. Ann Oncol 21 suppl 
7:189-195, 2010.
Disclosure: All authors have declared no conflicts of interest.
BIOMARKERS AND THE IMPACT ON FUTURE 
CLINICAL TRIALS
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MOLECULAR PORTRAITS/LANDSCAPE OF LUNG 
CANCER IN FRANCE
J. soria1, F. Nowak2, F. calvo2 1Medecine, Institut Gustave Roussy, Villejuif, 
FRANCE, 2Recherche, Institut National du Cancer, Boulogne, FRANCE
Molecular profiling of tumor tissues, now a standard in the management of 
certain treatments, requires that molecular diagnostics be introduced into rou-
tine clinical practice. In the setting of NscLc, EGFr mutation is a prerequi-
site for implementing gefitinib therapy, while ALK translocation is mandatory 
before the use of crizotinib. In anticipation of an increasing number of new 
available molecular tests, the French National cancer Institute (INca) and the 
French Ministry of Health decided as soon as 2006 to allocate specific funds 
for the development of a national network of 28 regional molecular genetics 
platforms. these facilities perform selected molecular tests free of charge for 
all patients in their region, regardless of the health institution where they are 
treated. In order to further increase the reactivity of this organization and to 
allow platforms to be immediately operational as soon as new targeted thera-
pies are available for patients, a program of prospective detection of emerging 
biomarkers was set up. the program targets biomarkers for which clinical 
trials are currently ongoing for stratified subgroups of patients and was first 
launched for melanoma, lung and colorectal cancer. since the beginning of 
2011, lung tumor samples that are sent to a platform for EGFr mutation 
screening are also screened for brAF, KrAs, PI3KcA and HEr2 mutations, 
as well as for the EML4-ALK gene translocation. the table herebelow pro-
vides a summary of the activity in the French platforms in 2011.
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Marker 
Number 
of patients 
screened 
Number of 
patients with 
a mutation 
Mutation 
rate 
EGFr activating mutation 20 761 2 009 9,6 
rAs mutation 17 153 4 358 25,4 
brAF mutation 10 017 184 1,8 
EML4/ALK translocation 4 543 208 4,6 
PI3KcA mutation 5 329 111 2,1 
HEr2 Exon 20 mutation 7 731 69 0,9 
Disclosure: All authors have declared no conflicts of interest.
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THE LUNGSCAPE PROJECT
r.A. stahel1, F. blackhall2, s. Peters3, L. bubendorf4, O. Dafni5, K. Kerr6, M. 
taron7, E. thunissen8, W. Weder9, r. rosell7 1Labor für Molekulare Onkologie, 
Universitätsspital, Zurich, SWITZERLAND, 2The Christie NHS Foundation 
Trust, Manchester, UNITED KINGDOM, 3Multidisciplinary Oncology 
Center, Lausanne, SWITZERLAND, 4University Hospital Basel, Institute for 
Pathology, Basel, SWITZERLAND, 5Frontiers of Science, Athens, GREECE, 
6Anchor Unit, Aberdeen Royal Infirmary, Aberdeen, UNITED KINGDOM, 
7ICO-Hospital Germans Trias i Pujol, Barcelona, SPAIN, 8Department of 
Pathology, VUMC Amsterdam, Amsterdam, NETHERLANDS, 9Thoracic 
Surgery, University Hospital Zurich, Zürich, SWITZERLAND
Lungscape is a translational research project designed by EtOP. It aims to 
address the challenges of studying the molecular epidemiology of lung can-
cer by coordinating and harmonizing the procedures of a group of lung can-
cer specialists working in translational research across Europe and allowing 
analysis of larger series of cases. this initiative has the potential to expedite 
knowledge of the prevalence and context of current and emerging molecu-
lar biomarkers with clinical significance and facilitate more rapid translation 
of biomarker knowledge to the clinic. Lungscape is evolving in step-wise 
fashion, starting with a retrospective analysis of 2400 completely resected 
NscLc in 12-15 institutions. the fundamental approach of Lungscape was to 
build a decentralized biobank (termed ibiobank) of samples from lung cancer 
patients with annotated clinical and pathological data and at least three years 
of documented follow-up. the virtual nature of ibiobank and the introduction 
of standardized biomolecular assessments - in which samples are tested using 
identical protocols across local laboratories- removes the need of transferring 
samples to a central location for evaluation. Lungscape consists of a master 
protocol, with defined modules to be added over time. the first module is a 
retrospective cohort study of ALK gene rearrangement aiming to describe 
prevalence, natural history, and genomic characteristics of patients in Europe 
harboring this rare genetic alteration, and to correlate this genetic alteration 
with long term outcome. A standardized IHc technique is used for screening 
with confirmation by FIsH. subsequent modules have been defined, including 
PI3K amplification, PtEN IHc, MEt IHc and amplification, EGFr IHc and 
mutation and multiplex mutation testing. Lungscape will raise standards of 
translational research in EtOP and eventually lead to the building of compre-
hensive and practical diagnostic algorithms for personalized medicine.
Disclosure: All authors have declared no conflicts of interest.
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BIOMARKERS AND IMPACT ON FUTURE CLINICAL 
TRIALS: A JAPANESE PERSPECTIVE
t. Mitsudomi Department of Thoracic Surgery, Aichi Cancer Center Hospital, 
Nagoya, JAPAN
currently, lung cancer is regarded as a mixture of heterogeneous diseases 
rather than single entity of the disease in terms of prognosis and therapeutic 
response. Incorporating biomarkers that help distinguish different classes 
of lung cancer into clinical trials became very important in clinical trials. 
the discovery of EGFr mutations in 2004 as a predictive factor for EGFr 
tyrosine kinase inhibitors (tKI) made us appreciate importance of individual-
ized approach to lung cancer. East-Asian people with lung cancer are blessed 
with higher incidence of EGFr mutation. A lot of data on EGFr mutation 
as a biomarker were generated from Japan. Among them, it is noteworthy 
that two randomized phase 3 studies that compared gefitinib with platinum 
doublet therapy for patients with EGFr mutation (WJtOG 3405 and NEJ 
002) were performed in Japan. they both showed significantly longer PFs in 
the gefitinib arm. However, acquired resistance inevitably emerges after ~10 
months even in such patients. Development of countermeasures for acquired 
resistance based on biomarkers is urgent clinical need. Japanese group headed 
by Prof. Mano found EML4-ALK fusion in 2007. It soon became evident that 
crizotinib, an ALK-tKI, was very active for this type of lung cancer in a phase 
I/II study conducted in Us and Korea. Prof. bang in seoul kindly accepted 
many Japanese patients who were diagnosed as ALK+ through ALcAs (ALK 
Lung cancer study group) which Prof. Mano organized. crizotinib will be 
approved soon in Japan. In the mean time, the Japanese Lung cancer society 
recently published “Guidance for ALK gene testing in lung cancer patients” 
to distribute right knowledge on diagnosis of ALK+ lung cancer. In addition, 
newly identified targets such as DDr2 mutation, FGFr1 amplification, or 
rOs1 fusions also appear to belong to the same oncologic paradigm as EGFr 
or ALK. In planning future clinical trials, “ordinary” lung cancers and those 
with distinct targets should be handled separately. We have recently launched 
a randomized clinical trial comparing gefitinib with cisplatin plus vinorelbine 
as adjuvant treatment for resected stage II-III patients with EGFr mutation 
(IMPAct trial). However, it would be more difficult to deal with lung cancers 
with distinct molecular changes but with very low incidence.
Disclosure: t. Mitsudomi: honoraria from AstraZeneca, roche, chugai, 
boehringer-Ingelheim, Pfizer, Eli-Lilly.
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IMPACT OF BIOMARKERS ON CLINICAL TRIALS: A US 
PERSPECTIVE
M. Kris Thoracic Oncology Service, Memorial Sloan-Kettering Cancer 
Center, New York, NY, UNITED STATES OF AMERICA
the discovery that the presence of a driver mutation in a tumor specimen from 
a person with lung cancer can be used to direct care has changed practice in 
the Us. the latest version of the NccN Guidelines advises routine testing 
for EGFr mutations and ALK rearrangements at diagnosis for all NscLcs 
except those where the diagnosis of squamous cell lung cancer is certain. 
Initial treatment with erlotinib or crizotinib is recommend for mutation 
positive patients and chemotherapy selected based on histology for all oth-
ers. this change in medical oncology practice has mobilized interventional 
radiologists, pulmonologists and thoracic surgeons to obtain tissue specimens 
adequate to permit mutation testing whenever lung cancer is suspected. A 
growing number are ordering these tests when the diagnosis of NscLc is 
confirmed. Pathology departments have organized to triage specimens after 
the histologic diagnosis is made and to prepare and submit tissues for molecu-
lar tesing either within their own institutions or to the growing number of 
commercial laboratories. Once adequate material is received by the molecular 
lab the testing can be accomplished in days. Although there is no consensus, 
many laboratories perform EGFr and ALK testing in parallel to speed the 
process so the information can be used to guide care. Many methodologies 
are used to detect EGFr mutations but all use the FDA-approved FIsH test to 
detect ALK positive cases. A growing number of laboratories utilize multiplex 
testing that includes all driver mutations (KrAs, PI3K, HEr2, brAF, AKt1, 
MEK1, NrAs, and MEt amplification). As technology improves, an even 
larger number of genes will be assayed simultaneously to give a more com-
phrensive picture and provide the data even quicker. the availability if this 
information will change the conduct of clinical trials as the presence molecu-
lar abnormalities will be known when the patient first sees the oncologist and 
based on the swiftness of the crizotinib approval based on only 255 molecu-
larly selected patients, eligibility for targeted therapy trials will increasingly 
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be restricted to individuals with the target, even in Phase 1. since tumors from 
the majority of patients have a driver mutation, each can be directed to a clini-
cal trial specific to their molecular lesion.
Disclosure: M. Kris: My institution receives research support and I have 
received consulting fees from Pfizer, Inc. and boehringer Ingelheim. I have 
received an honorarium fron roche china. I have also served as a consultant 
to chugai Pharmaceuticals.
OLIGOMETASTATIC NSCLC
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THE CONCEPT OF OLIGOMETASTATIC NSCLC
J. Pfannschmidt Abt. Thoraxchirurgie, Artz Thoraxklinik Heidelberg, Heidelberg, 
GERMANY
Of patients with NscLc, approximately 20-50% will present with stage IV 
disease, often diagnosed with multiple dissemination sites in the brain, bone, 
liver, and adrenal glands. Abundant clinical and molecular research suggests 
that the process of metastasis proceeds in sequential steps, which eventually 
produces polymetastatic disease. With this view, there is an oligometastatic 
state of less biologically aggressive tumor behavior that lies between the com-
pletely absent and diffuse metastatic states. this intermediate state remains 
stable over time with limited metastatic spread. because of the different 
lymphatic and vascular drainage patterns of NscLc and the organ-specific 
enhancement or suppression of different tumor sites, there is a hierarchy 
for the oligometastatic state related to the time to metastasis, the number of 
metastases, and the location of the secondary sites. the paradigm of an oligo-
metastatic state can be subdivided into a de novo intermediate stage of limited 
metastatic capacity and the limited remaining tumor deposits following the 
successful eradication of all other cancer metastatic tumors by systemic ther-
apy. However, even with modern diagnostic imaging, it is not possible to deter-
mine or predict whether limited metastases represent a true oligometastatic 
state or a transitional stage to disseminated metastases. With the development 
of more effective and individualized systemic therapies, a novel approach for 
the diagnosis and treatment of patients with oligometastatic disease is needed. 
Part of the application of this expanded concept is reflected in the localized 
aggressive treatment for oligometastatic disease. clinical trials are needed 
to further define recommendations to adjust different treatment modalities. 
However, it is clear that the rarity of oligometastatic disease in patients with 
NscLc makes it unlikely that larger randomized prospective trials will be 
used to compare different treatment regimens with systemic therapy versus 
the combination of systemic therapy and local aggressive therapy. In conclu-
sion, current retrospective data indicate a window of opportunity where local 
therapy using surgical or radiation treatments at secondary sites may improve 
long-term survival for a highly selected subset of patients.
Disclosure: All authors have declared no conflicts of interest.
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BRAIN METASTASES
c. Faivre-Finn Department of Clinical Oncology, The Christie NHS 
Foundation Trust, Manchester, UNITED KINGDOM
Oligometastatic NSCLC - Brain metastases: brain metastases (bM) are 
the most common intracranial tumours in adults, occurring in 20-40% of 
patients with cancer. Up to half of bM originate from lung primaries. In the 
last decade we have been faced with a new paradigm;
the incidence of bM is increasing due to the use of improved systemic •	
therapies.
Improved imaging increases the likelihood of discovering and diagnosing •	
occult bM. However most patients are diagnosed with multiple bM and 
less than 20% of patients have solitary bM at presentation based on Mr 
imaging.
bM present more often in the context of well controlled systemic disease •	
and are more likely to be treatable than in the historic context of multi-organ 
metastatic disease.
In the context of stable thoracic and systemic disease treatment options for 
oligometastatic (OM) brain disease include surgery, stereotactic radiotherapy 
± whole brain radiotherapy (Wbrt) and systemic treatments.
Surgey: surgery can play an important role in patients with bM and particu-
larly patients with mass effect from a large symptomatic lesion. randomised 
controlled trials with single bM have demonstrated that the addition of sur-
gery to Wbrt improves survival.
Stereotactic radiosurgery (SRS): srs can be used as the sole treatment 
or as a ‘booster therapy’ in addition to Wbrt to improve local control (1). 
typically, srs is reserved for patients with controlled extracranial disease 
and life expectancy >6 months, 1 to 4 bM, metastases less than 3cm in maxi-
mum diameter and metastases inaccessible for surgical resection. Although 
use of srs has increased considerably in recent years there remains uncer-
tainty with regard to the effectiveness of srs alone and when to combine 
treatment options as well as how to appropriately select patients. the current 
questions are:
Is srs better than Wbrt?•	
Is srs + Wbrt better than srs alone?•	
Is srs + Wbrt better than Wbrt alone?•	
How does srs compare to neurosurgery?•	
Systemic therapy: the role of systemic treatment is unclear in patients with 
OM and bM due to the lack of prospective studies in this group of patients. 
the efficacy of EGFr tKIs in bM patients has been suggested but the evi-
dence is limited.
Disclosure: All authors have declared no conflicts of interest.
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ADRENAL METASTASES
L. Molins Thoracic Surgery, University of Barcelona, Barcelona, SPAIN
Oligometastatic disease is considered a solitary extrapulmonary disease, 
potentially resectable. Adrenal metastases (M1) are a frequent site of solitary 
metastases from NscLc but, should be treated? Is there any difference in 
survival with synchronous versus metachronous solitary adrenal metastasis?
the incidence in autopsies of adrenal metastasis caused by lung cancer (Lc) 
is 18-42%. Even so, there are few patients who present solitary metastasis 
(M1) and operable Lc.
Porte HL listed possible inclusion criteria to indicate surgery in patients with 
adrenal M1 of Lc: the primary tumour has to be potentially controlled, not 
to include patients in stage III, to use explorations that confirm a solitary 
M1 before the surgery and to handle synchronous and metachronous M1 in 
similar way. In 2008 tanvetyanon reviewed the studies published on adrena-
lectomy for synchronous metastases vs. metachronous ones. It includes 
10 publications with a total of 114 patients. the median overall survival 
was lower in patients with synchronous metastases that in metachronous, 
12 months vs. 31 months, (p=0.02). However, the estimated survival at 5 years 
was equivalent, 26% and 25% respectively. He observed lower survival in 
synchronous metastases may suggest a greater biological aggressiveness of 
the tumour and its metastases.
Our experience during the last 10 years: seven patients has been considered, 
4 men and 3 women between 38 and 71 years old (median 64 years) who 
underwent surgery in both the primary tumour and the adrenal metastasis. In 3 
patients the resection of the metastases was performed synchronous to the pri-
mary tumour and in four patients resection was metachronous with an interval 
10 to 39 months (median 25 months). the stage of the primary tumour was: 
Ib in 1 patient, IIb in 1, IIIA in 2 and IV in 3 patients (N0 in two patients and 
N1 in one). Five patients underwent a lobectomy and two a pneumonectomy. 
the mean patient survival was 41 months (Ic 95%:7–74) and the median 
survival of 20 months (Ic 95%:7–32).
In conclusion, the resection of the adrenal solitary metastasis of pulmonary 
origin offers a life expectancy to consider. Multicentre studies with larger 
number of patients are required to establish the real utility of this resection 
compared to other systemic treatments.
Disclosure: All authors have declared no conflicts of interest.
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SATELLITE NODULES, IPSI OR CONTROLATERAL LUNG 
METASTASES AND PLEURAL INVOLVEMENT
P. Mordant, F. Le Pimpec-barthes, M. riquet Thoracic Surgery Unit, Hôpital 
Européen Georges Pompidou, Paris, FRANCE
According to the 2009 tNM classification of non–small cell lung cancers 
(NscLc), second parenchymatous localizations are classified as t3 if located 
in the same lobe, t4 if located in a different lobe of the same lung, and M1a 
if located in the opposite lung, and aggregated in the group of multiple lung 
cancers (MLc). MLc represent up to 5% of all NscLc and 10% of resected 
NscLc. It is generally considered that determining if the second tumour is 
a second primary NscLc or a lung metastasis would change staging, prog-
nosis, and management. However, neither pathologic nor genetic analyses 
allow a clear distinction between a second primary and a lung metastasis. 
Furthermore, recent work emphasise the prognostic value of pathologic stage, 
but failed to demonstrate any correlation between histology discrepancy and 
prognosis. resected MLc demonstrate a median survival of 30 months and 
a 5-year survival rate of 32%, whereas metastatic NscLc treated exclu-
sively with chemo and/or targeted therapies have a median survival of 6 to 
12 months and anecdotic 5-year survival. changing the staging by establish-
ing the diagnosis of pulmonary metastasis of NscLc is probably an impor-
tant issue warranting further biologic research, but in the meantime, current 
management should include surgical resection of both tumours and radical 
mediastinal lymph node dissection whenever feasible. Metastatic pleural 
extension (M1a) of NscLc includes malignant cells in the pleural fluid defin-
ing malignant pleural effusion, limited and localized pleural nodules defining 
limited metastatic pleural extension, and numerous and disseminated nodules 
defining pleural carcinomatosis. the finding of M1a extension is reported in 
1-7% of patients with NscLc, and usually precludes surgery. However, some 
limited and localized pleural nodules may be resectable. When an undiag-
nosed limited pleural malignant disease is discovered during thoracotomy, 
selected patients may undergo a complete surgical resection, with median 
and 5-year survivals of 15 months and 16%, as compared to 8 months and 
4% after exclusive medical management. the long term results of complete 
surgical resection of both primary NscLc and limited pleural nodules consti-
tute a plea for the inclusion of surgery in multimodality treatment of NscLc 
patients with M1a extension.
Disclosure: All authors have declared no conflicts of interest.
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LOCAL TREATMENT FOR SYSTEMIC DISEASE: THE 
SURGICAL APPROACH
b. Passlick Department of Thoracic Surgery, University Medical Center 
Freiburg, Freiburg, GERMANY
Lung metastases occur in about 30 -50 % of all patients with solid tumors. 
About 30 % of this population has isolated lung metastases and these are 
potential candidates for a surgical resection. Other prerequisites for a cura-
tively intended removal of lung metastases are that the primary tumor is con-
trolled, that a complete resection of all lung metastases is technically and 
functionally possible, and that there are no other extra-pulmonary metastases 
with the exception of patients with colorectal carcinomas. In this selected 
group of patients the detection of liver metastases is no contraindication for 
the pulmonary resection as long as the liver lesion can be treated as well. 
Prognostic factors in patients with lung metastases are the type of the pri-
mary tumor, the disease-free interval between the primary tumor resection, 
and the detection of lung metastases as well as in a certain respect the number 
of metastases. the most significant prognostic factor, however, is the com-
pleteness of the pulmonary metastasectomy. recently, new resection tech-
nologies have been developed. by the use of a “lung laser” the dissection of 
also multiple metastases as well as the resection of central lesions without 
anatomical resections (e.g. lobectomy) are possible. It has been shown that 
also multiple pulmonary metastases can be resected without major morbidity 
and zero mortality. In patients with isolated well-controlled metastases also 
minimal-invasive (VAts) resections are possible without formal thoracotomy. 
Overall 5-year survival rates after pulmonary metastasectomy vary between 
20 and 45%.
Disclosure: All authors have declared no conflicts of interest.
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THE ROLE OF STEREOTACTIC RADIOTHERAPY
s. senan Department of Radiation Oncology, VU University Medical Centre 
(VUMC), Amsterdam, NETHERLANDS
the hypothesis underlying the treatment of oligometastatic disease is that it 
represents a distinct clinical disease state, between loco-regionally confined 
and widely spread metastatic disease [Hellmann s, 1995]. For such patients, 
it has been postulated that complete metastasectomy is a curative treatment 
option. It is also been hypothesized that local therapy to the primary tumor 
site can retard distant disease progression and prolong survival in patients 
with metastatic disease [Morgan s, 2011]. Despite long-term survivals 
reported with ablative treatment for oligometastatic disease, the level of 
evidence to support such treatments is weak in many cases, often based on 
single-arm studies without appropriate controls. stereotactic ablative radio-
therapy (sAbr) was first introduced more than a decade ago to treat stage 
I NscLc. It entails the precise delivery of very high radiation doses in a 
short period of time, commonly in 3-8 fractions using co-called‘risk-adapted’ 
schemes, where smaller dose fractions are used when tumors in close proxim-
ity to critical normal organs. Local control rates in excess of 90% have been 
reported for lung tumors in prospective multicenter studies in Europe and 
North America. the growing interest and rapid spread of sAbr has largely 
been driven by advances in radiotherapy planning and imaging techniques, 
both of which allow for increased treatment precision. the ability to perform 
outpatient sAbr procedures without anesthesia is an additional advantage. 
As patterns of lung fibrosis after sAbr can evolve up to more than 3 years 
post-treatment, such changes must be distinguished from tumor progression. 
the widespread use of sAbr has set the scene for prospective random-
ized clinical trials to evaluate its role in metastatic disease to the lung. One 
approach would be to design trials that compare the use of a single ablative 
modality (e.g. sAbr) plus standard care (which may be chemotherapy), ver-
sus only standard care. Another approach is to evaluate the combination of 
one or more ablative therapies (surgery, rFA, sArt or combinations thereof) 
in combination with chemotherapy, versus chemotherapy alone. such trials 
are necessary in order to ensure that what are apparently promising results 
with sAbr in the treatment of pulmonary oligometastases are not solely due 
to patient selection.
Disclosure: s. senan: the department of radiation oncology at VU 
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RADIOFREQUENCY ABLATION
t. de baere Department of Interventional Radiology, Institut Gustave Roussy, 
Villejuif, FRANCE
today rFA is used primary lung neoplasms are close to those for surgical 
resection, in a curative intent in non-surgical or boarderline surgical candi-
dates with t1A or t1b tumors. Inoperability is due to poor either respira-
tory function in relation do cObP in primary tumors, and iterative surgery or 
general comorbidities. Pre-ablation imaging work-up must be equivalent to a 
pre-surgical one, namely with PEt_ct. because size is strong redictive factor 
of success, the largest diameter of the tumor should be ideally smaller than 
3 cm, and in any manner larger than 5cm. A review of 17 of the most recent 
publication demonstrated a median reported rate of complete ablation of 90%, 
even if high variability exists between publications with a range from 38% to 
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97%. Most studies report a statistically significant lower success rate of abla-
tion with tumors larger than 2 to 3 cm in diameter. Oversizing ablation relative 
to the tumor improve complete ablation rate up to 96% at 18 months ablation 
when the ratio between the area of post-rFA ground glass opacity and the 
tumor area before treatment was at least 4. Ground glass opacity margins have 
been reported absent in 85% of post rFA ct of incompletely ablated tumors. 
contact with a large vessel (>3 mm) has been reported by Hiraki et al and 
Gillams et al as a negative predictive factor of complete tumor ablation in lung. 
In our 8 years experience with 548 patients with 886 metastases from various 
origin treated in 622 rFA sessions, we were able to control 89.6% of the tar-
geted metastases. the overall survival rate was 69.7% at 3 years. In multivari-
ate analysis, number of metastases, size of metastases and disease free interval 
between primary tumor and occurrence of lung metastases significantly impact 
survival. survival is close to surgical series. tolerance was excellent with 10% 
chest tube placement and a median hospital stay of 3 days.
Disclosure: All authors have declared no conflicts of interest.
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ISOLATED LUNG PERFUSION
P. Van schil, W. den Hengst, J.M. Hendriks Department of Thoracic and 
Vascular Surgery, Antwerp University Hospital, Edegem, BELGIUM
surgical resection of lung metastases is a widely accepted procedure but due 
to local and distant recurrences reported 5-year survival rates are only 30 to 
40% [1]. Main prognostic factors are histological type and complete resection. 
A better survival is reported in patients with a single metastasis and a disease-
free survival of more than 3 years. reoperations are feasible but often patients 
become inoperable due to insufficient pulmonary reserve and new treatment 
modalities are looked for. In some cases combined modality treatment is indi-
cated. the maximal dose of intravenous chemotherapy is limited due to sys-
temic side-effects, mainly haematological. As isolated limb and liver perfusion, 
isolated lung perfusion has the advantage of selectively delivering an agent 
into the lung while diverting the venous effluent [2]. Other related methods 
of delivering high-dose locoregional chemotherapy include embolic trapping 
(chemo-embolization) and pulmonary artery infusion without control of the 
venous effluent [2]. Isolated lung perfusion has proven to be highly effective 
in experimental models of pulmonary metastases with a clear survival advan-
tage. Lung levels of cytostatic drugs are significantly higher after isolated lung 
perfusion compared to intravenous therapy without systemic exposure. Phase 
I human studies have shown that isolated lung perfusion is technically feasible 
with low morbidity and without compromising the patient’s pulmonary func-
tion. recently, promising long-term results have become available [3]. Further 
experimental and clinical studies are necessary to determine its definitive effect 
on local recurrence, long-term toxicity, pulmonary function and survival. 
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STATE OF THE ART: STAGE I AND II NSCLC
W. Weder Division of Thoracic Surgery, Universitätsspital Zürich, Zürich, 
SWITZERLAND
Early stage non small cell lung cancer (NscLc) includes patients with stage I 
(t1,t2a N0 M0) or stage II (t1,2 N1 M0 or t2b,t3 N0 M0). Approximately 
30% of all patients present with stage I or stage II disease at diagnosis. 
clinical experience based on large retrospective data indicates that the best 
chance of cure for patients with stage I and stage II lung cancer is surgical 
resection. the 5 year survival rates are 60 – 80% for stage I and 40 – 50% for 
stage II. Lobectomy including systematic lymph node dissection is adequate 
for most patients who tolerate this procedure. Lesser resection than lobec-
tomy (sublobar resection) including lymph-adenectomy is indicated for small 
peripheral lesions (< 2cm) even in fit patients. However, local recurrence rate 
(when tumors <3cm are included) is increased two to three fold but long term 
survival differs only minimally. Additionally, patients who do not tolerate 
larger resection due to poor lung function may be treated by a segmentec-
tomy as long as a radical resection can be achieved. Definitive radiotherapy 
by conventionally fractionated radiotherapy (>60Gy) or cHArt for surgi-
cally inoperable patients is considered a good treatment modality. stereotactic 
radiotherapy should be performed in centres with adequate equipment and 
experience. surgery is best performed by thoracic surgeons with prominent 
focus on lung cancer treatment since perioperative mortality and long term 
survival are better compared to general surgeons who do the operation occa-
sionally. the use of minimal invasive procedure by VAts is a highly valuable 
alternative to conventionnal procedures done by open thoracotomy. recovery 
after surgery is faster and potential adjuvant chemotherapy is better tolerated. 
Intraoperative systematic mediastinal lymph node dissection is an integral part 
of the surgical treatment and allows accurate pathological staging. Platinum 
based adjuvant chemotherapy should be offered to patients with completely 
resected stage II lung cancer and good performance status. Adjuvant radio-
therapy is not indicated in stage I and II r0 resected patients.
Disclosure: All authors have declared no conflicts of interest.
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STATE OF THE ART: STAGE III NSCLC
G. stamatis Thoracic Surgery and Endoscopy, Ruhrlandklinik, University of 
Essen, Essen, GERMANY
Lung cancer remains one of the most common malignancies and is the lead-
ing cause of cancer-related deaths in Europe and North America. In non-small 
cell lung cancer (NscLc) the main curative therapeutic approach is surgery 
for early stages IA to IIb. However early stages constitute only 20-25% of 
all NscLc patients, whereas the majority of patients initially present with 
locally advanced stages IIIA /IIIb or even with metastasized disease. Only 
small subsets of patients with the so called “minimal N2 disease” and some 
subgroups of t4 disease are widely accepted as potential candidates for sur-
gical approaches. the majority of IIIA/IIIb patients were not considered 
for surgery and palliative systemic approaches consist of combinations of 
platinum-based chemotherapy and radiotherapy as standard of treatment. 
For locally advanced stages IIIA and IIIb NscLc chemotherapy alone or 
associated with radiotherapy are used to downstage tumors and render them 
complete resectable. cisplatin-based combination treatment found to achieve 
response rates of 50% to 75% in localized unresectable disease and eradica-
tion of micrometastasis were suggested. Preoperative radiotherapy resulted to 
sterilisation of mediastinal nodes so that patients with initial unresectable dis-
ease underwent surgery. Whereas a possible survival improvement related to 
induction treatment before surgery was suggested, several studies highlighted 
postoperative risks with increase of morbidity and mortality. concurrent 
application of chemotherapy and radiation was considerably more toxic and 
recent results of EOrtc 08941 and the Intergroup study 0139 have shown 
however, that the extent of surgery determines the postoperative mortality and 
that only in a subgroup of patients with lobectomy there was a survival ben-
efit. In our experience pulmonary resection for locally advanced NscLc after 
induction chemotherapy or chemoradiotherapy can generally be performed 
with acceptable morbidity and mortality. Patients should be carefully selected 
for operation especially with respect to their age, performance status and to 
their pulmonary and cardiovascular function tests. Future decision-making 
will have to take into account treatment morbidity and mortality and param-
eters of organ-sparing surgery following induction.
Disclosure: All authors have declared no conflicts of interest.
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TREATMENT ALGORYTHMS FOR STAGE IV NSCLC
c. Gridelli Division of Medical Oncology, S.G. Moscati Hospital, Azienda 
Ospedaliera “SG Moscati”, Avellino, ITALY
A first-line treatment algorithm for stage IV NscLc should consider as first 
step the presence of an activating EGFr mutation, to be screened in all adeno-
carcinoma histology, and in this case an anti-EGFr tyrosine kinase inhibi-
tors (gefitinb or erlotinib) should be used. For EGFr wild-type or unknown 
NscLc a subsequent step should consider patients age (over 70 years) and 
performance status (Ps): platinum-based chemotherapy should be the pre-
ferred option in fit elderly Ps 0-1 patients and adequate organ functions and 
single agent should be preferred in unfit elderly patients. In Ps 2 patients 
either single agent or platin-based combinations are valid options. In patients 
under 70 years and Ps 0-1 first-line platin-based chemotherapy for 4-6 cycles 
should be offered at diagnosis even to asymptomatic patients, deserving 
cisplatin combinations in fit Ps 0-1 patients with adequate organ functions. 
Another crucial step for treatment algorithm is histology even if there is not 
a standard platin-based doublet. two pre-planned subgroup analyses showed 
cisplatin and pemetrexed to be superior in non-squamous histology and infe-
rior in squamous histology as compared to cisplatin and gemcitabine but with-
out comparison with other doublets. Furthermore bevacizumab combined to 
platin-based chemotherapy is a treatment option for non-squamous histology 
only, due to safety concerns, in particular when carboplatin plus paclitaxel is 
the chemotherapy backbone. cetuximab, if available, added to platin-based 
chemotherapy can be considered a treatment option for patients with high 
score (<200) EGFr IHc positive tumor. switch maintenance with erlotinib 
or pemetrexed following completation of first-line chemotherapy is an option. 
Factors to consider in deciding for switch maintenance include histology, type 
and response to first line chemotherapy, residual toxicity, patient’s symptoms 
and preference. Patients with tumour harbouring an activating EGFr mutation 
should receive EGFr tKI’s as maintenance, if not yet received. continuing 
maintenance with pemetrexed for patients receiving induction chemotherapy 
with cisplatin plus pemetrexed is a treatment option.
Disclosure: c. Gridelli: Honoraria as speaker bureau and advisory board 
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STATE OF THE ART: SUGGESTED TREATMENT 
ALGORYTHMS FOR SMALL CELL LUNG CANCER 
TREATMENT
c. Le Pechoux1, D. Planchard2 1Department of Radiotherapy, Institute 
Gustave Roussy, Villejuif, FRANCE, 2Departement de Medecine, Institut 
Gustave Roussy, Villejuif, FRANCE
small-cell lung carcinomas (scLc) represent less than 20% of all lung cancers. 
As it has a high propensity for early metastatic dissemination, less than a third of 
patients have limited disease (t0-4 N0-3 M0). As recommended by the EsMO 
lung cancer guidelines, the new tNM classification should be used for scLc. 
Platin and etoposide-based chemotherapy is the cornerstone treatment for all 
patients. response rates to both chemotherapy and radiotherapy are impressive 
but relapses are frequent as disease is often bulky at time of diagnosis. the current 
state-of-the-art treatment for M0 patients involves 4 to 6 cycles platin-etoposide 
based chemotherapy, combined with early thoracic radiotherapy administered 
concomitantly. surgery can only be discussed in very selected patients with early 
disease. because of the high risk of brain metastases, prophylactic cranial irradi-
ation is indicated in responders and should be part of the standard management. 
the 5-year survival rate may reach 25% in M0 patients, but does not exceed 
10% at 2 years in metastatic patients. Most patients relapse within the first two 
years, and there are few treatment options in second line as opposed to NscLc. 
Drugs such as irinotecan, topotecan, amrubicin have shown efficacy in first or 
second line. research for better identification of pathways that could be targeted 
with new drugs should continue. Pursuing clinical trials at all stages constitutes 
a challenge for thoracic researchers and oncologists.
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PATHOLOGICAL CLASSIFICATION
M.G. Papotti Department of Clinical & Biological Sciences, University of 
Turin, Orbassano Turin, ITALY
A spectrum of neuroendocrine (NE) tumors (NEt) of the lung exists, classi-
fied in the 2004 WHO scheme by combining architectural patterns (organoid 
versus diffuse growth) with the mitotic index and presence of necrosis. typical 
carcinoids (tc) represent <1% of lung tumors and have a classical organoid 
(trabecular, acinar) pattern with polygonal, minimally atypical cells. Necrosis 
is always absent and mitoses are <2/10 high power fields (HPF). small tumors 
with similar features, but < 5 mm in size are labelled tumorlets. Atypical car-
cinoids (Acs) are extremely rare, cigarette smoking-related low grade tumors, 
though often associated with regional and distant metastases. their morphol-
ogy overlaps that of tc, except that necrosis is present and/or the mitotic 
count is 2-10/10 HPF. Large cell NE carcinoma (LcNEc) partly resembles 
Ac, but has large cells, extensive necrosis and a high mitotic index (>10/10 
HPF). In the 2004 WHO scheme, LcNEc is classified with non-NE large cell 
carcinomas, from which it should be distinguished based on chromogranin or 
synaptophysin expression, in the absence of high molecular weight cytokera-
tins. small cell lung carcinoma (scLc) is the most common lung NEt and is 
made of small cells with scant cytoplasm and condensed small nuclei: these 
features require a careful differential diagnosis with poorly differentiated 
squamous or basaloid carcinomas and other small cell tumors. “combined 
NE carcinomas” rarely occur as an association of scLc or LcNEc with a 
squamous or adenocarcinoma component. Focal NE differentiation in con-
ventional squamous or adeno- carcinomas is not considered in this context, 
since no impact on prognosis has so far been demonstrated. the molecular 
profile of lung NEts has been extensively investigated to identify helpful 
diagnostic, prognostic and therapeutic predictive markers. specific chromo-
somal alterations, oncogene mutations and cell cycle molecule disregulation 
have been documented, as well as the expression of receptors or factors tar-
geted by bio- or chemo-therapeutic agents (eg somatostatin receptors, mtor 
pathway molecules, thymidylate synthase, topoisomerase, etc). All such data 
may ultimately provide a “molecular classification” of NEts to be integrated 
with morphology, for a future more appropriate therapeutic strategy.
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SURGICAL TREATMENT OF NEUROENDOCRINE LUNG 
TUMORS
E. Lim Royal Brompton Campus, National Heart & Lung Institute, London, 
UNITED KINGDOM
bronchopulmonary neuroendocrine tumours consist of a spectrum of tumours 
(typical carcinoid, atypical carcinoid, large cell neuroendocrine and small cell 
lung cancer) that range from benign to malignant. As the tumours are rare, 
there are limited evidence on which clinicians able to use to guide manage-
ment. typical carcinoid tumours may present in the central airways and is 
usually managed by lung parenchymal sparing surgery. Peripheral carcinoid 
tumours, atypical carcinoid tumours and large cell neuroendocrine tumours 
are usually managed by surgical resection in patients with localised disease. 
In patients with advanced disease, treatment options include chemotherapy, 
radiotherapy, radionuclide therapy and biologic agents. the management of 
small cell lung cancer is usually non-surgical, however increasing number of 
centres are publishing good results with surgery, raising the question if sur-
gery should be re-evaluated as a primary treatment modality. the prognosis 
of the tumours are largely dependant on cell type, and then by stage. Further 
study with international collaboration is required to allow us to advance our 
understanding and the management of our patients with this disease.
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DEVELOPMENTS IN SMALL CELL LUNG CANCER
G. Giaccone Medical Oncology Branch, National Cancer Institute, Bethesda, 
MD, UNITED STATES OF AMERICA
Very few developments have occurred in small cell lung cancer (scLc) treat-
ment and understanding of the biology of the tumor, in over 20 years. Although 
this is a tumor that is thought to be metastatic at the outset, the major improve-
ments in survival have been obtained by the use of radiotherapy rather than 
the introduction of novel systemic treatments. chest radiation given concomi-
tantly to chemotherapy and prophylactic cranial irradiation (PcI) have both 
significantly improved survival of patients with limited disease. PcI was also 
able to significantly increase survival in extensive disease in a randomized 
trial. Among the systemic treatments available, no novel agent has received 
approval after topotecan for relapsed scLc. A limited number of targeted 
agents have been tested in scLc and so far the results have not been encour-
aging. A better understanding of the biology of this tumor will help devise 
novel strategies and identify potential targets for treatment. From cGH analy-
sis of scLc, it appears that this tumor has a very high number of genomic 
abnormalities which will potentially signify a high level of complexity and 
difficulty in finding driving oncogenic events. Exome sequencing programs 
are presently underway, which might shed some light onto the more common 
genetic abnormalities. Functional validation of these potential targets will 
need to be performed in adequate in vitro and in vivo models. Development 
of in vivo models that mimic more closely human scLc has been attempted 
with some recent success.
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LARGE CELL NEUROENDOCRINE CARCINOMA: HOW 
SHOULD IT BE TREATED?
s. Popat Medicine, Royal Marsden Hospital, London, UNITED KINGDOM
LcNEc is an uncommon non-small cell lung cancer (NscLc) sub-type 
accounting for up to 5% of all lung tumours, predominantly affecting males 
and smokers. because LcNEc is uncommon the optimal management of the 
condition is unknown as trials have not been performed. Many series have 
reported outcomes of surgically resected patients and most report 5-year 
survival rates of <30%. centres reporting stage-matched outcomes have 
demonstrated significantly inferior survival for LcNEc compared to other 
NscLcs, approaching that of scLc. the largest dataset comes from the 
sEEr database, where survival from scLc was worst, and other large cell 
carcinomas the best, with outcomes from LcNEc similar to other large cell 
carcinomas. relapse rates are high, with brain a common relapse site. several 
series have reported a potentially clinically meaningful benefit for platinum-
doublet adjuvant chemotherapy, which has been also observed for stage 1 
patients. Outcomes may vary by systemic therapeutic, with some reporting 
better outcomes with scLc-like chemotherapy compared to NscLc-like 
therapy. Further series support the notion that relapsed LcNEc is relatively 
chemo-refractory; a single-centre series, reported responses for chemonaive 
patients of 64% compared to 17% in previously treated patients. Data from 
JMDb suggest a benefit of pemetrexed in large cell carcinomas. However, 
this is likely a heterogenous group with large cell morphology including 
LcNEcs. Preclinical data demonstrate that pemetrexed cytotoxicity is con-
tingent on expression of thymidylate synthase, and the scLc, squamous-
subtype NscLc, and LcNEcs have highest ts expression compared to 
adenocarcinomas and other large cell NscLc-types, suggesting that pem-
etrexed may therefore have limited activity in LcNEcs. However, this needs 
prospective validation. somatic molecular analyses have not identified com-
mon potentially druggable molecular aberrations, although one case reports 
a somatic EGFr exon 19 deletion that responded to gefitinib. In summary 
LcNEc is a rare high-grade NscLc for which the international community 
has little robust data to make recommendations, and international collabora-
tive working is urgently required.
Disclosure: All authors have declared no conflicts of interest.
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FUNCTIONAL OPERABILITY: LESSONS LEARNED
A. brunelli Division of Thoracic Surgery and Head of Section of Minimally 
Inavsive Thoracic Surgery, Ospedali Ruiniti Ancona, Ancona, ITALY
Assessment for pulmonary resection must include a preliminary cardiac eval-
uation. Patients deemed at prohibitive cardiac risk should be evaluated and 
treated as per American Heart Association/American society of cardiology 
guidelines. PpoDLcO is a reliable predictor of pulmonary complications 
and mortality. the correlation between FEV1 and DLcO is poor and more 
than 40% of patients with normal FEV1 may have reduced DLcO. A low 
ppoDLcO is a reliable predictor of cardiopulmonary morbidity and mortal-
ity but also in patients with normal respiratory function. thus DLcO should 
be measured in all lung resection candidates. PpoFEV1 is not accurate in 
predicting surgical risk and residual pulmonary function in patients with 
pulmonary obstructive disease. One third of cOPD patients improve their 
FEV1 3 months after pulmonary lobectomy. thus poFEV1 should not be 
used alone for patients selection. Exercise testing allows global assessment 
of the physical fitness. Low-technology tests such as stair climbing test and 
shuttle walk test can provide only a rough estimation of the aerobic capacity 
of the patients. they are typically ideal as screening tests. shuttle walk test 
tends to underestimate the exercise capacity at the lower range of VO2max, 
but there is a linear relationship between oxygen consumption and distance 
walked. Patients climbing less than 12m at stair climb test had a 2-fold and 
13-fold higher rates of complications and mortality compared to those climb-
ing higher than 22m. cardiopulmonary exercise test provides several direct 
and derived measures that permit, in case of a limited aerobic reserve, to pre-
cisely identify possible deficits in the oxygen transport system. the recently 
published Ers-Ests functional guidelines recommended its use in patients 
with cardiac co-morbidity or impaired pulmonary function or both, and in 
those patients with a reduced exercise tolerance at low-technology exercise 
tests. VO2peak greater than 20 ml/kg/min or 75% of predicted represents a 
safe threshold to undergo any kind of pulmonary resection. On the other hand, 
a value lower than 10 ml/kg/min or 35% of predicted usually contraindicates 
a major pulmonary resection.
Disclosure: All authors have declared no conflicts of interest.
44IN
SURGICAL APPROACHES BEYOND LOBECTOMY AND 
PNEUMONECTOMY
A. D’Andrilli1, I. cavaliere1, F. cassiano1, A.M. ciccone1, M. Ibrahim1, F. 
Venuta2, E. rendina1 1Thoracic Surgery, Azienda Ospedaliera Sant’Andrea, 
Rome, ITALY, 2Thoracic Surgery, Policlinico Umberto I - University 
LaSapienza, Rome, ITALY
Lobectomy with bronchovascular reconstruction may allow radical resection 
in a number of lung cancer patients for whom simple lobar resection is not 
feasible and a pneumonectomy would be otherwise required. From a func-
tional point of view, sleeve lobectomy (sL) is strictly indicated in patients 
who cannot withstand pneumonectomy (PN), but recent experiences have 
shown that the advantages of sparing lung parenchyma are evident also in 
patients without cardio-pulmonary impairment. Most studies show similar or 
better survival results for parenchymal sparing resections (including pulmo-
nary artery reconstructions) if compared with PN. Moreover, in the analysis 
of 5-year survival according to stage and nodal status, sL results in higher 
survival rates for stages I, II and III, although the survival advantage in stage 
III appears to be limited and the benefit is not always confirmed for stage III-
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N2 patients [table 1]. therefore the role of parenchymal sparing operations 
in patients with N2 disease still remains not completely defined. Postoperative 
morbidity and mortality data reveal overall better results for patients undergo-
ing sL with respect to PN [table1]. Looking at literature data, when morbid-
ity is evaluated according to the type of complication, PN patients appear to 
experience a higher rate of cardiac complications, while sL patients show 
increased pulmonary and airway complications incidence. the preservation 
of lung parenchyma has been indicated by some authors as the possible cause 
of a theoretical increased risk for locoregional recurrence after sL. However, 
although in some experiences (Fadel’02) an higher local recurrence rate is 
reported for sleeve resection with advanced nodal status (N2), the few studies 
(Fadel’02, terzi’02, Kim’05) analysing risk factors for recurrence, show that 
the tumor stage and the nodal status are the only negative predictive factors, 
rather than the type of operation performed. table 1:
Author (year) 
Stage I 
5-yr (%) 
survival 
Stage II 
5-yr(%) 
survival 
StageIII 
5-yr (%) 
survival 
Complications 
(%) 
Postoperative 
mortality 
(%) 
Local 
recurrence 
(%) 
SLEEVE LOBECTOMY 
Gaissert (‘96) 42 53 43 11 4 14 
tronc (‘00) 63 48 8 16 1.6 22 
Fadel (‘02) 55 62 21 16 2.9 15 
terzi (‘02) 60 32 22 14.5 12 5 
Deslauriers 
(‘04) 
66 50 19 - 13 22 
Kim (‘05) 88 52 8 74.9 6.1 22 
Ludwig (‘05) 57 40 22 38 4.3 - 
takeda (‘06) 45  
(stage I-II) 
45  
(stage I-II) 
21 45.2 1.6 9.7 
PNEUMONECTOMY 
Gaissert (‘96) - 43 - 16 9 - 
Deslauriers 
(‘04) 
50 34 22 - 5.3 35 
Kim (‘05) 75 36 38 44 4.1 6 
Ludwig (‘05) 45 42 13 26 4.6 - 
takeda (‘06) 38  
(stage I-II) 
38  
(stage I-II) 
52 40.9 1.8 10.9 
Disclosure: All authors have declared no conflicts of interest.
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WHAT CAN RADIOTHERAPY PROVIDE BEYOND  
THE STANDARD?
D. De ruysscher Radiotherapy, Maastricht University Medical Center 
(MUMC), Maastricht, NETHERLANDS
the technical evolution that radiotherapy has witnessed of the last 5-10 years 
is impressive. techniques that were considered as science fiction are now 
already outdated. Much of this evolution is due to the revolution in imag-
ing and computer sciences, which we witness also in many other aspects in 
daily life. Due to these technical advances, more insight has been gained in 
fundamental biological processes and the rational combination of medica-
tions and radiotherapy. As a consequence, radiotherapy can now target very 
precisely stage I-II NscLc to extremely high ablative doses. stereotactic 
body radiotherapy is therefore now called stereotactic Ablative radiotherapy 
(sAbr). In large prospective series, sAbr results in even more than 95% 
freedom from local progression after 5 years. the fact that residual masses 
do not progress after such a long period, supports the idea that long-term 
local tumour control can indeed be obtained. Importantly, these results can be 
achieved in old and frail patients with very few side effects. Experience in the 
Netherlands shows that sAbr can be introduced safely on a large scale in a 
standardised way. sAbr is increasing used for new primary lung cancers and 
local recurrences after surgery. radiotherapy plays an integral role in stage III 
NscLc therapy, mostly in a multimodality setting. technological advances 
and individualised dose prescriptions together with integration with molecu-
lar imaging allow the delivery of radical radiation doses in almost all patients. 
severe late side effects are only rarely observed. Local tumour progression is 
seen in less than 30% of patients. recent improvements such as volumetric 
arc therapy and intensive image-guided radiotherapy will allow the delivery 
of either higher doses to the tumour or less exposure of the normal tissues. 
the integration of molecular biology with radiotherapy offers great promises. 
tumours with different radiosensitivities will be identified thus further indi-
vidualising the treatment. targeted agents combined with radiotherapy based 
on molecular rationale have the potential for improving cure. Finally, with 
proton therapy coming to maturity, sparing of normal tissues will become 
even more prominent.
Disclosure: All authors have declared no conflicts of interest.
INDIVIDUALISED TREATMENT OF ADVANCED 
NSCLC WITH AVAILABLE AGENTS
46IN
CHEMOTHERAPY
K. O’byrne Department of Medical Oncology, St. James’s Hospital, Dublin, 
IRELAND
chemotherapy remains the standard of care for the majority of patients with 
advanced non-small cell lung cancer (NscLc). recently there has been a 
shift to treat non-squamous NscLc with platinum/pemetrexed and squamous 
cell cancer with platinum/gemcitabine however the choice is largely empiri-
cal. An increased understanding of the molecular biology of lung cancer is 
identifying factors that may predict benefit from, or resistance to individual 
chemotherapeutic agents. there is increasing evidence that patients with high 
thymidylate synthase may be resistant to pemetrexed, although randomised 
controlled trial data evaluating this factor in a treated vs control untreated 
population remain to be presented. High brcA1 mrNA levels are associated 
with docetaxel sensitivity whilst high rrM1 levels may predict resistance to 
gemcitabine. A particular effort is being made globally to identify patients 
that are sensitive to and factors that predict for resistance to cisplatin, the most 
effective single agent in NscLc. these include Ercc1 that in the adjuvant 
setting appears to identify patients resistant to cisplatin. these observations 
have proven difficult to confirm in advanced disease, nonetheless a number 
of avenues appear promising. Experimental models have shown that acquired 
resistance to cisplatin is associated with upregulation of cD133+, cD44+ and 
aldehyde dehydrogenase, factors associated with tumour stemness. there is 
an associated increase in sOX2, Nanog and OctA. Furthermore upregulation 
of c-MEt and ß-catenin indicate that platinum resistant cells may also have 
features associated with epithelial-mesenchymal transformation. the search 
for resistance markers has identified novel factors associated with DNA repair 
that may become targets for therapy. An example is the PArP protein family 
and the more recently identified factors MyrIP and hssb1. Finally a num-
ber of mirNAs have been found to be associated with cisplatin resistance 
although their precise role in this process remains to be established. In sum-
mary in the future chemotherapeutic agents will be administered in a person-
alised manner to patients most likely to benefit from therapy, mechanisms will 
be targeted to overcome drug resistance and novel agents will emerge that in 
themselves will have activity through enhancing DNA damage and inducing 
apoptosis.
Disclosure: No disclosure received at time of going to press.
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EGFR (TKIS AND ANTIBODIES)
t.s.K. Mok Prince of Wales Hospital, The Chinese University of Hong Kong, 
Hong Kong, CHINA
Epidermal growth factor receptor (EGFr) is overexpressed in >70% of 
NscLc and was proposed as a target by inhibition of cellular growth and 
proliferation. EGFr tyrosine kinase inhibitors (tKI) compete with AtP to 
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bind the EGFr tK domain and prevent downstream signalling, while mono-
clonal antibody (Mab) prevents dimerization of receptor. total of 6 random-
ized studies comparing first line EGFr tKI with standard chemotherapy have 
demonstrated superiority in tumor response rate and progression free survival 
(PFs). seventh study (LUX lung 3) comparing Afatinib, a second generation 
pan-HEr tKI, with pemetrexexd/cisplatin will be presented in AscO 2012. 
Possibility is that this will add a third EGFr tKI for first line treatment of 
patients with EGFr mutation. Another second generation tKI, Dacotinib, is 
being compared with erlotinib as second/third line therapy and KrAs nega-
tivity is a co-primary endpoint. EGFr tKI resistance is the major barrier 
to optimization of benefit from EGFr tKI. rEcIst cristeria is used as the 
standard definition of tKI resistance, however, this may not be entirely appli-
cable. AsPIrAtION is an ongoing Asian study on the use of erlotinib beyond 
rEcIst progression and results may provide insight on new set of criteria. 
IMPrEss is an Asian/Europe comparative study on continuation of tKI in 
combination with pemetrexed/carboplatin in patients who progressed on gefi-
tinib. these studies help to establish future management of tKI resistance. 
A recent phase II study on combination of afatinib and cetuximab reported 
tumor response rate of 36% in patients with resistance to gefitinib or erlotinib. 
A phase III study is at planning stage. FLEX is a phase III study compar-
ing combination of chemotherapy and cetuximab with chemotherapy that 
reported marginal Os benefit. However, positive result didn’t gain authority 
approval for the Mab. Only in recent subgroup analysis, patients with high 
EGFr H-score (>200) were found to have longer survival with the combi-
nation (12 vs 9.6 months), while there was no benefit in patients with low 
H-score. Data is being assessed by EMEA in this biomarker selected popula-
tion. EGFr tKI is a standard first line therapy for patients with EGFr muta-
tions and strategies against resistance are being investigated. Use of Mab may 
be limited to biomarker-selected population.
Disclosure: t.s.K. Mok: consultancy: Astrazeneca, roche, Pfizer, Eli Lilly, 
bMs, AVEO, Merck serono, bI, Eisai, taiho speaker: Astrazeneca, roche, 
Pfizer, Eli Lilly, Merck serono, bI, Eisai, taiho.
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VEGF INHIBITORS
M. reck Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, 
GERMANY
Dysregulation of angiogenesis in solid tumors enables tumor growth and 
metastasis. receptors that mediate angiogenesis, and their ligands, have been 
identified; among these, vascular endothelial growth factor (VEGF) and its 
receptor tyrosine kinase play a central role. besides bevacizumab which 
blocks VEGF binding to its receptors, various small-molecule tyrosine kinase 
inhibitors are currently in clinical development.
VEGF and VEGF receptor antibodies: A Metaanalysis which summarized the 
efficacy of the VEGF antibody bevacizumab in combination with platinum 
based chemotherapy in the available four randomized trials confirmed a sig-
nificant improvement of Progression Free survival (PFs) (Hr 0.72; p<0.001) 
and Overall survival (Os) (Hr 0.89; p=0.03) by treatment with bevacizumab. 
However also a significant increase in the frequency of characteristic side 
effects was noted (1). A randomized phase II trial which was performed in 
order to identify predictive markers for efficacy of bevacizumab and which 
look on a broad panel of serum and tissue based markers as well as dedicated 
imaging approaches couldn´t demonstrate any significant correlation between 
the baseline set of candidate markers (bFGF, E-selectin, IcAM, PLGF, VEGF 
A, VEGFr 1, VEGFr 1) and response rate. However in an exploratory analy-
sis a significant correlation between the VEGFA level and PFs was found. 
Further results especially regarding the dynamic marker sampling will be 
presented on upcoming meetings (2). In the field of Maintenance therapy 
the combination of bevacizumab and Pemetrexed as Maintenance treatment 
demonstrated a significant improvement of PFs compared to the conven-
tional Maintenance treatment with bevacizumab (Hr 0.5; p<0.001) in the 
AVAPErL trial (3). currently ramucirumab, a VEGF receptor 2 antibody, 
is under clinical investigation in combination with chemotherapy in different 
stages of disease.
VEGF-tKI: In randomized phase III trials Motesanib as well as sorafenib 
failed to induce a significant improvement of Os in combination with plati-
num based chemotherapy compared to chemotherapy alone in first-line 
treatment (4, 5, 6). A signal in PFs was seen in the “NEXUs” trial with 
sorafenib and in the “MONEt” trial with Motesanib. treatment induced 
toxicity and mortality was higher in the squamous cell lung cancer popula-
tions. In second line treatment Vandetanib was investigated either in com-
bination with chemotherapy (ZODIAc, ZEAL), as monotherapy compared 
to Erlotinib or as monotherapy compared to placebo after failure of a prior 
EGFr-tKI (ZEPHYr). the ZODIAc trial was the only trial which met the 
primary endpoint of PFs. All the other trials couldn´t confirm the results. 
However clinical activity of Vandetanib with improvement of response and 
PFs was seen in most of them. sunitinib in combination with Erlotinib didn´t 
led to a significant improvement of Os compared to Erlotinib in the “sun” 
trial but comparable to other approaches response rate (rr) and PFs were 
improved (7). similar results were seen in the recently presented “VItAL” 
trial which investigated the VEGF-Fusionprotein Aflibercept in combination 
with Docetaxel and showed a significant improvement of rr (23.3% v 8.9%, 
p<0.0001) and PFs (Hr 0.82, p: 0.003) but no impact on Os (Hr 1.01) com-
pared to Docetaxel (8). Nintedanib (bIbF1120) another strong VEGF-tKI 
but also high inhibiting activities on the FGF-receptor and PDGF-receptor 
is currently in clinical investigation in two randomized phase III trials in 
combination with Docetaxel and Pemetrexed. First results are awaited for 
2012.
Conclusion: besides the confirmed efficacy of the anti VEGF antibody 
bevacizumab in eligible patients the role of antiangiogenic tKI in treatment 
of NscLc hasn´t been defined yet and is currently investigated in a large 
number of randomized phase III trials. One of the most important challenges 
for the future is the identification of predictive markers which might help to 
select patients who benefit from treatment with these new drugs.
Literature: 1. soria J et al, Ann Oncol (2010) 21 (suppl 8): Abstract 437P 2. 
Mok t et al, EJc (2011) (suppl): Abstract 9003 3. barlesi F et al, EJc (2011) 
(suppl): Abstract 34LbA 4. scagliotti GV et al, J clin Oncol (2010) 28: 1835-
42 5. Gatzemeier U et al, Ann Oncol (2010) 21 (suppl 8): Abstract LbA16 
6. scagliotti GV et al, J clin Oncol (2011) 29 (suppl): Abstract LbA7512 
7. scagliotti GV et al, J clin Oncol (2012)20: In press 8. Novello s et al, J 
thorac Oncol (2011) 6 (suppl): Abstract O43.06)
Disclosure: M. reck: Honoraria for speaking: Hoffmann-La roche, Lilly, 
Daiichi, AstraZeneca, Member of Advisory board: Hoffmann-La roche, 
Lilly, bMs, Daiichi, AstraZeneca, Pfizer, Merck, Genentech.
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ALK INHIBITORS
F. blackhall Medical Oncology, The Christie NHS Foundation Trust, 
Manchester, UNITED KINGDOM
the EML4-ALK fusion gene is a validated oncogenic driver and therapeutic 
target in patients with non-small cell lung cancer (NscLc). It is estimated to 
occur in around 4% of cases. crizotinib (Pfizer), a small molecule tyrosine 
kinase inhibitor (tKI), is the first in class ALK inhibitor to be approved by 
the Food and Drug Administration in the United states for any line of treat-
ment in patients with NscLc bearing EML4-ALK. single arm phase I/II 
trials of crizotinib in pretreated patients have demonstrated response rates 
of 50-60% with median durations of response ranging from 42-48 weeks. 
toxicity is reported to be generally mild with predominantly visual and gas-
trointestinal effects. randomised trials to compare crizotinib with first or sec-
ond line standard chemotherapy are currently recruiting, as is an expanded 
phase II study (PrOFILE-1005,-1007,-1014). several other ALK inhibitors 
are in earlier stages of clinical development. these include the small mol-
ecule tKIs LDK378 (Novartis), AsP3026 (Astellas) and AP26113 (Ariad); 
and heat shock protein 90 inhibitors, IPI-504 (Infinity) and stA9090 (synta). 
It is notable that crizotinib inhibits MEt and AP26113 inhibits EGFr t790M 
in addition to ALK. the potential for these multitargeted agents to be of ben-
efit to a broader spectrum of patients with NscLc (lacking EML4-ALK) 
is of interest. this hypothesis is also being tested in a study of crizotinib 
combined with the pan-HEr inhibitor, dacomatinib (Pfizer). EML4-ALK 
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appears to be associated with younger age, non-squamous histology, never 
or light former smoker and EGFr wildtype status but contradictory reports 
caution the restriction of testing to clinical subgroups. An emerging ques-
tion is how best to diagnosis EML4-ALK, given its rarity, cost-effectively? 
Immunohistochemistry shows promise to identify cases for further definitive 
testing using fluorescent in situ hybridisation (FIsH). Other areas of impor-
tance to now address in the clinical development of ALK inhibitors are how 
best to schedule with standard chemotherapy and/or radiotherapy, taking into 
account the prognostic and predictive role of EML4-ALK on standard treat-
ments that are not targeting ALK, and resistance mechanisms.
Disclosure: F. blackhall: I have received speaker fees, honoraria and research 
support and am an advisory board member for Pfizer, Astra-Zeneca, Lily.
SCREENING AND CONSEQUENCES
50IN
GROUND GLASS LESIONS: HOW TODEAL WITH THEM
M. tsuboi1,2 1Department of Thoracic Surgery, Kanagawa Cancer Center, 
Yokohama, Kanagawa, JAPAN, 2Department of Thoracic Surgery and 
Oncology, Tokyo Medical University, Tokyo, JAPAN
Pulmonary nodules detected by low-dose ct lung cancer screening are classi-
fied into three types: a homogeneous ground-glass opacity type (pure GGO), 
a mixed GGO and a solid nodule type on thin-section ct images. A GGO is 
defined as a focal area of increased pulmonary attenuation through which nor-
mal parenchymal structures, such as airways, vessels, and interlobular septa, 
can be seen.1. the definition of radiological peripheral non-invasive lung ade-
nocarcinoma; what is the candidate for the sublobar resection?Pathologically, 
lepidic growth pattern replacing bronchioalveolar epithelium without vas-
cular invasion and lymphatic permeation is considered to non-invasiveness.
such lesion is visualized as GGO predominant nodule with little consolida-
tion on preoperative thin-section ct scans. therefore, the findings of thin-
section ct scans can be used to predict non-invasive lung adenocarcinoma 
indicated for wide wedge resection. Multicenter JcOG 0201 study has dem-
onstrated that both of the radiological criteria of c/t ratio ≤ 0.25 in t1a and 
0.50 in t1ab on thin section ct tumor were able to define the homogeneous 
group of patients with superb prognosis before surgery. these patients were 
considered as the good candidates for limited resection.2. Management of 
ct-screening-detected Pulmonary Nodulesthe tentative guidelines produced 
by the Japanese society of ct screening are as follows1) Mixed GGO type; A 
mixed GGO is sometimes seen on ct scans showing evidence of pneumonia, 
and in such cases a 3-month follow-up examination is recommended to deter-
mine whether the mixed GGO is persistent or not. If the size of a mixed GGO 
is < 10 mm, follow-up ct is an option instead of resection.2) Pure GGO type; 
If the size of a GGO is ≥ 15 mm, a diagnostic work-up is recommended. If the 
size of a GGO is ≥ 5 mm but < 10 mm, follow-up cts at 3, 12, and 24 months 
are recommended. If the GGO increases in size or in density during follow-
up, a diagnostic work-up is recommended. If the size of the GGO is ≥ 10 mm 
but < 15 mm, follow-up ct or resection depend on the hospital’s criteria. If 
the GGO increases in size or density during follow-up, a diagnostic work-up 
is recommended. If the GGO is still stable at the time of the 24-month follow-
up examination, further follow-up ct examinations are recommended.
Disclosure: All authors have declared no conflicts of interest.
51IN
BIOMARKERS AND RISK MODELS FOR LUNG CANCER 
SCREENING
J.K. Field, O.Y. raji, M.P. Davies, t. Liloglou Molecular Oncology, University 
of Liverpool, Liverpool, UNITED KINGDOM
the results of the NLst screening trial for lung cancer showed evidence of a 
20% mortality reduction in the screened arm of the study. However, the long 
term success of future National screening Programmes as early diagnosis 
tools will be dependent upon identifying populations at sufficient risk of 
developing the disease. the current lung cancer risk models include those 
of; bach, spitz, NELsON, LLP and the PLcO. the Liverpool Lung Project 
(LLP) risk Model estimates an individual’s 5-year absolute risk of lung 
cancer. the model was based on five epidemiological risk factors: smoking 
duration, prior diagnosis of pneumonia, family history of lung cancer, occu-
pational exposure to asbestos and prior diagnosis of other cancer. Validation 
of the LLP risk Model has been undertaken in the Harvard and European 
Early Lung cancer (EUELc) case-control and LLP prospective cohort stud-
ies. there was evidence of good discrimination in Harvard (AUc= 0.76) 
and LLP cohorts (c-index= 0.77, 0.82), with no significant difference in dis-
crimination by age, gender and smoking status. the LLP risk model is used 
to select individuals from the UK Lung cancer ct screening trial (UKLs). 
the long term objective is to incorporate biomarkers based on susceptibility 
genes or acquired genetic and epigenetic changes into the risk models, to 
improve their level of discrimination. Early work on susceptibility genes has 
provided some evidence that the models may be improved, however currently 
the most promising are methylation and microrNA biomarkers in high risk 
individuals. Preliminary evidence points to the value of utilising a set of 6 
methylation biomarkers as shown in the LLP case-control study of bronchial 
lavage specimens. stratification of the results by cytology indicated that the 
best discriminatory algorithm is particularly useful for cytology negative 
subjects as there was a tremendous increase in sensitivity among this group 
of subjects (3% to 74%) with a moderate decrease in specificity (100% to 
82%). the sozzi team in Italy have demonstrated that mirNA expression 
profiling in plasma collected 1–2 y before the onset of disease, provided 
strong predictive, diagnostic, and prognostic signatures (AUc≥ 0.85) at the 
time of ct detection and in disease-free smokers enrolled in the screening 
trial.
Disclosure: J.K. Field: scientific Advisory board member for Epigenomics 
(berlin) - ended December 2011 All other authors have declared no conflicts 
of interest.
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AN OVERVIEW OF EUROPEAN SCREENING STUDIES
G. Veronesi Division of Thoracic Surgery, European Insitute of Oncology, 
Milan, ITALY
the Us National Lung screening trial showed that low-dose computed 
tomography (LDct) can significant reduce lung cancer mortality com-
pared to chest X-ray. to confirm that LDct screening is beneficial, several 
randomized controlled trials are ongoing in Europe. the largest of these, 
the Dutch-belgian NELsON study, recruited 15,422 high risk persons to 
LDct vs. no screening. NELsON mortality data are not yet available, but 
the study found volume-based determinations of growth were more reli-
able than visual two-dimensional assessments. A semi-automated volume-
based growth determination method was often used, but often needed to 
be complemented by visual assessment. Preliminary results the Italian 
DANtE trial were published in 2009. this trial randomized 2472 partici-
pants to LDct vs. annual clinical examination: the numbers of advanced 
and lethal lung cancers were identical in the two arms, so screening had no 
apparent benefit. the Italian Mild study (2208 screened subjects) compared 
one- with two-year screening intervals: preliminary data (personal commu-
nication) support a two-year interval. the Danish DLcst study assessed 
the impact of screening on participants’ quality of life and smoking: screen-
ing per se did not favour stopping smoking and effective anti-smoking inter-
ventions were considered necessary; however screening did not facilitate 
smoking continuation either, as claimed by detractors of ct screening. the 
Italian cosmos study, the largest non-randomized single centre study (5203 
screened subjects), introduced a completely non-invasive diagnostic algo-
rithm and assessed the utility of ct-PEt in nodule management with satis-
factory results. cosmos data were used to develop a personalised predictor 
of lung cancer risk. this appears to reliably stratify participants after base-
line so that the screening interval can be reduced in low risk individuals. 
Data from cosmos and Mild also contributed to the development of sensi-
tive and specific microrNA marker of early lung cancer, of potential use for 
first-line screening. these European initiatives have significantly increased 
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knowledge of issues related to lung cancer screening, and definitive data on 
mortality are awaited.
Disclosure: All authors have declared no conflicts of interest.
53IN
OPPORTUNITIES FOR PROGRESS FOLLOWING THE 
NATIONAL LUNG SCREENING TRIAL
J.L. Mulshine Internal Medicine, Rush Medical College, Rush University, 
Chicago, IL, UNITED STATES OF AMERICA
the recent NcI-sponsored, randomized trial of helical ct compared to chest 
X-ray screening in a high risk cohort was stopped as planned when a 20% 
reduction in lung cancer mortality was observed. this trial established that 
ct-based lung cancer screening fulfills a critical criterion as an effective can-
cer screening tool. the Dutch/belgian screening study is ongoing and this 
study provides a significant opportunity to further enhance our understand-
ing of the value of a defined diagnostic work-up approach, the use of nodule 
growth criteria for case selection and other related issues. Against this back 
drop, where does the field of screening go? the innovative approach for case 
detection employed by the NELsON study highlights how the efficiency of 
case detection can be improved. the recent IAsLc screening statement points 
out the opportunity to refine the risk modeling in indentifying more appropri-
ate potential lung cancer screening candidates. What are the core expectations 
for performance quality that should be expected of a lung cancer screening 
site? In this regard, as reported by van Klaveren and co-workers, volumetric 
determination of suspected lung cancers could enable efficient and accurate 
lung cancer case detection. How can an individual be assured that they are 
obtaining screening services from a site that also achieves such work-up accu-
racy? the surgical management of early stage lung cancers is increasingly 
employing video-assisted thoroscopic surgery. recent studies demonstrate 
lower complications and more favorable operative mortality rates compared to 
standard, open thorocotomy approaches. should a recommendation be made 
to standardize the use of minimally invasive approaches to reduce the possi-
bility of over-treatment in the screening setting? should the surgical manage-
ment of screen detected tumors include molecular analysis of the tumor tissue 
to identifying patients at high risk of recurrence? As the evolution of effec-
tive and efficient early lung cancer management unfolds how such measures 
are added to standard of care for this new approach? Population-based care 
of early lung cancer is a new field. Given the controversies surround cancer 
screening in general, it is timely to proactively consider measures to allow 
more consistent success with improving lung cancer outcomes.
Disclosure: All authors have declared no conflicts of interest.
DEVELOPMENTS IN TARGETED THERAPY
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OVERCOMING TKI RESISTANCE
s. Peters Oncology, Multidisciplinary Oncology Center, Lausanne, 
SWITZERLAND
Aberrant signaling of physiological receptor tyrosine kinase (rtK) path-
ways plays a key role in distinct types of human cancers biology. In some 
specific tumours, a single genetic alteration was shown to be able to induce 
and sustain tumorigenesis, and can be thus referred to as “driver muta-
tion”. this « oncogene addiction » was most often shown to be related to a 
rtK gene specific alterations, through mutations (EGFr, KrAs, brAF, 
c-kit, PIK3cA), amplifications (MEt, PIK3cA; FGFr) or translocations 
(EML4-ALK, bcr-AbL) increasing kinase activity and amplifying or 
initiating downstream signaling cascades. best strategy to block rtK acti-
vation - using AtP competitive or allosteric tKIs, combined strategy of 
blockade of rtK or multi-tKI inhibitors - remains unsettled. Noteworthy, 
it has become obvious that almost all oncogene-addicted tumors become 
resistant to targeted treatments, sometimes rapidly, illuminating an 
intriguing and clinically relevant aspect of plasticity of cancer pathways. 
collectively, tKIs can not be considered as a curative modality, even in the 
context of well-described and supposed circumscribed tumorigenic phe-
nomenon. two concepts are relevant for tKI resistance to date. First, the 
appearance of secondary mutations - acting as gatekeepers - in the same 
gene or in a downstream player of the pathway can impede or indirectly 
counterbalance the inhibition of the activated rtK, as reported for EGFr. 
secondary, a « kinase switch », using a side-road to activate downstream 
interconnected canonical pathways, as demonstrated for MEt amplifica-
tion ability to confer resistance to EGFr tKIs by triggering the alternative 
oncogenic signaling through Erb3. Interestingly, tKI resistance remains 
poorly described, and the current evidences reveal a prominent lack of 
knowledge in most of the clinical situations encountered. In order to 
reach a personalized medicine, efforts should be maintained to compre-
hensively describe genomic events as well as their interactions in various 
types of tumours. However, there will be a strong need to focus on how 
these dynamic networks might respond and adapt to drug interference. 
tKI resistance deserves research priority, teaching us that facing complex 
interplays is likely to become the norm in establishing new approaches 
prone to circumvent resistance.
Disclosure: All authors have declared no conflicts of interest.
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C-MET INHIBITORS
A.A. Adjei Department of Medicine, Roswell Park Cancer Institute, Buffalo, 
NY, UNITED STATES OF AMERICA
the c-MEt pathway is dysregulated in many human cancers and promotes 
tumor growth, invasion and metastasis. the MEt receptor is activated by a 
number of mechanisms including protein overexpression, gene amplifica-
tion gene mutation, protein overexpression and/or a ligand-dependent auto-
crine/paracrine loop. In addition, abnormalities in MEt signaling is a poor 
prognostic factor. thus, c-MEt has been seen as an attractive target for 
cancer therapy. A wide variety of agents targeting different elements in the 
c-MEt signaling pathway have been introduced into the clinic and are being 
explored in phase I, II and III clinical trials across multiple tumor types 
(table 1). clinical activity with minimal toxicity has been documented, 
albeit not as robust as anticipated. the most active compounds appear to 
be those with other targets in addition to c-MEt.Predictive biomarkers are 
being explored. the current state of development of this class of compounds 
will be discussed.
TABLE 1: c-MET Inhibitors in the Clinic
TARGET DRUG STAGE OF 
DEVELOPMENT 
SELECTIVE 
Oral tKI tivantinib, tAK-
701, EMD1214063, 
EMD1204831,INcb28060, 
sGX-523, JNJ-38877605 
Phase I – Phase III 
Antibody rilotumumab, ficlatuzumab, 
onartuzumab, AMG-337 
Phase I – Phase III 
NON-SELECTIVE OTHE TARGETS
Oral tKI bMs-796302 ron, Axl, VEGFr2, Flt3 
E7050 VEGFr2 
cabozantinib VEGFr2, ret, Kit, Flt3, tie2 
crizotinib Alk, ron, Axl, tie-2 
Foretinib VEGFr2, ret, Kit, Flt3, tie2 
Antibody 
AMG-208 ron 
Disclosure: All authors have declared no conflicts of interest.
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MTOR AND S6 KINASES AS BIOMARKERS/TARGETS IN 
LUNG CANCER
M.J. seckl Cancer Medicine, Charing Cross Hospital, London, UNITED 
KINGDOM
Most patients die from lung cancer as a consequence of therapy resistant meta-
static disease. consequently, understanding the biological mechanisms that 
control multi-agent resistance and metastasis should provide novel therapeu-
tic strategies and/or bio-markers to enable improved survival. several growth 
factors have been implicated in lung cancer cell biology. Unless a particular 
growth factor/receptor is dominant it may be preferable to identify intracel-
lular signalling target(s) that serve as a point of convergence in growth fac-
tor action. Western blot comparison of multiple signaling proteins in normal 
versus malignant lung cells revealed that mtOr, s6K1 and s6K2 are over-ex-
pressed in all tumours examined. We have shown that mtOr/s6K1 signalling 
is critical for mediating proliferation while s6K2 is a key inducer of multi-
drug resistance. Interestingly, in immunohistochemical tissue biopsy studies 
the expression levels of mtOr correlate with worse survival and elevated 
s6K2 appears to be predictive of poor response to therapy. consequently, 
inhibitors of mtOr/s6K1 or s6K2 signalling may work best in those patients 
over-expressing these molecules. In a separate rNAi library based-screen we 
identified more than 50 novel kinases that control metastases. Amongst these 
silencing of p90 ribosomal s6 kinase 1 (rsK1) enhanced migration and inva-
sion in vitro. Moreover silencing rsK1 promoted metastasis in vivo and its 
increased expression in primary tumours correlated with the presence of more 
metastasis in lung cancer patients. these findings suggest that rsK1 expres-
sion might serve as a biomarker predictive of disease progression.
Disclosure: All authors have declared no conflicts of interest.
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TARGETING MEK AND BRAF IN NON-SMALL-CELL 
LUNG CANCER (NSCLC)
D. Planchard Departement de Medecine, Institut Gustave Roussy, Villejuif, 
FRANCE
Non-small-cell lung cancer (NscLc) has recently been associated with molec-
ular characteristics that have important implications in carcinogenesis and 
response to targeted therapies. targeted therapies, if given to a patient subpopu-
lation enriched by the presence of relevant molecular targets, can often abrogate 
cell signaling that perpetuates cancer progression. For instance, several molecu-
lar alterations have been defined as “driver mutations,” such as mutations in 
EGFr, KrAs, and EML4-ALK fusion gene. Other key signaling pathways 
such as rAs/rAF/MEK, have also been identified as novel targets for lung can-
cer treatment. constitutive ErK signaling is common in human cancer and is 
often the result of activating mutations in brAF, rAs and upstream receptors. 
Missense brAF kinase domain mutations are frequently observed in melanoma, 
colon and thyroid cancers and less frequently in lung (~5% in Adenocarcinomas 
and 1% in sqamous carcinoma) and other cancer types. the vast majority 
involve a glutamic acid for valine substitution at codon 600 (V600E), which 
results in elevated brAF kinase activity. Vemurafenib produced improved rates 
of overall and progression-free survival in melanoma patients with the brAF 
V600E mutation. brAF appears to be a druggable mutation that also defines 
subgroups of lung cancer patients. KrAs is frequently mutated in NscLc (up 
to 30%), resulting in the activation of the MEK/ErK pathway. targeting down-
stream effectors and MEK inhibition has been the subject of intense scientific 
and clinical research for some time now. Inhibitors of the pathway with selectiv-
ity for brAF and MEK are now in Phase 1 and 2 clinical trials with promising 
early results. to maximize the likelihood of success with these agents, clinical 
trials enriched with patients whose tumors possess brAF and rAs mutations 
have been proposed. this presentation reviews the current status of brAF and 
MEK inhibitors with regard to their clinical development.
Disclosure: All authors have declared no conflicts of interest.
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DEVELOPMENTS IN TARGETED THERAPY: FGFR1 
INHIBITION IN LUNG CANCER
J. Wolf1, L. Nogova1, L.c. Heukamp2, M. bos1, M. schuler3, L. sequist4, 
G.G. tian5, F. ringeisen6, r. buettner2, r. thomas7 1Department I of Internal 
Medicine, Center for Integrated Oncology, University Hospital Köln, 
Cologne, GERMANY, 2Department of Pathology, University Hospital Köln, 
Koeln, GERMANY, 3Department of Internal Medicine, University Hospital 
Essen, Essen, GERMANY, 4Department of Medicine, Massachusetts General 
Hospital, Boston, MA, UNITED STATES OF AMERICA, 5, West Clinic, 
Memphis, TN, UNITED STATES OF AMERICA, 6Oncology Translational 
Medecine, Novartis, Basel, SWITZERLAND, 7Funktionelle Krebsgenomik, 
Max-Planck-Institut für neurologische Forschung, Köln, GERMANY
specific targeting of oncogenic protein kinases increasingly leads to treat-
ment approaches in lung cancer superior to conventional chemotherapy. such 
“druggable” targets have been almost exclusively identified in lung adenocar-
cinoma. recently, within the cologne Lung cancer Genome Project, focal 
amplification of fibroblast growth factor receptor 1 (FGFr1) was identified in 
a large set of squamous cell carcinomas (scc) of the lung using high resolu-
tion copy number analysis and confirmed by fluorescene in situ hybridiza-
tion (FIsH) in an independent cohort of scc samples with high frequency 
(22%). since the fibroblast growth factor receptor family plays a critical role 
in cell proliferation and survival in different tumor types, amplified FGFr1 
represents an attractive target for the development of a personalized treatment 
approach in scc of the lung. this was confirmed by the demonstration of 
growth inhibition and apoptosis induction by a FGFr inhibitor specifically in 
lung cancer cells harbouring amplified FGFr1 in vitro and by the induction 
of tumor shrinkage by this compound in a murine model of FGFr1 amplified 
lung cancer. subsequently, a standardized reading and evaluation strategy for 
diagnosis of FGFr amplification in lung cancer tissue was developed using a 
two colour FIsH assay. so far, several small molecules for FGFr inhibition 
have been developed and, partly, are clinically evaluated in different tumor 
types. the oral pan FGF-r kinase inhibitor bGJ398 is currently evaluated in 
a phase I first in man trial in adult patients with advanced solid malignancies 
(clinical trial protocol cbGJ398X2101). After discovery of FGFr1 amplifi-
cation as frequent genetic alteration in scc of the lung, this trial was opened 
for recruitment of FGFr1 amplified scc of the lung and treatment of several 
patients has already been initiated. the evaluation of exclusively patients with 
FGFr1 amplification already in this early clinical development phase will 
rapidly answer the question whether FGFr1 amplification represents the first 
effective personalized treatment approach in scc of the lung.
Disclosure: J. Wolf: consulting and lecture fees: roche, Novartis. boehringer-
Ingelheim, AstraZeneca, bayer, Lilly, Merck, Amgen; research support: 
roche, bayer, Novartis, boehringer-Ingelheim. L. Nogova: Honoraria: 
scientific talk for Novartis 2006 travel Grand: Novartis 2010. F. ringeisen: 
Employment: clinical program leader at Novartis. stocks: stocks of Novartis. 
All other authors have declared no conflicts of interest.
UNRESOLVED ISSUES
59IN
HOW TO FOLLOW UP AFTER CURATIVE TREATMENT 
OF NSCLC
V. Westeel Service de Pneumologie, CHU Hôpital Jean Minjoz, Besançon, 
FRANCE
Although surgery-based treatment strategies are those which offer the best 
chance for cure of a non-small cell lung cancer (NscLc), five-year survival 
after a complete resection of a stage I-IIIA NscLc varies between 20% and 
70% depending on the stage of the disease. the purpose of follow-up is to 
early detect disease recurrence. there are no robust data published on the fol-
low-up after surgery for NscLc. It has never been demonstrated that follow-
up after surgery for NscLc detects earlier recurrences and/or improves life 
expectancy. Whether it is of interest and the optimal follow-up program are 
questions which remain unanswered. there are different international clinical 
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guidelines, reflecting rather expert opinions than evidence-based data. Most 
of them recommend regular clinic visits and thoracic imaging procedures, 
either chest X-ray or chest ct-scan. After a radiotherapy-based strategy, tho-
racic ct-scan has a poor discriminating capacity between recurrent tumour 
and post-treatment changes. PEt-ct has been shown to be more accurate 
than ct after thoracic radiotherapy, especially if performed not earlier than 
3 months after radiotherapy to avoid false-positive results due to post-radio-
therapy inflammatory changes. PEt-ct has been hypothesized to increase 
the proportion of recurrent diseases amenable for curative salvage treatment. 
A prospective evaluation suggested that PEt-ct at 3 months after radiother-
apy might be cost-effective, especially if only performed in asymptomatic 
patients. the best follow-up intervention needs to be evaluated through a 
robustly designed randomized control study, taking into account cost-effec-
tiveness, patient-orientated outcomes such as quality of life and the penibility 
of follow-up procedures. A large randomised study, the IFct 0302 study, is 
ongoing in France. It compares 2 follow-up programs in completely resected 
stage I-IIIa NscLc, with overall survival as the primary end point. Patients 
are randomised between history + physical examination + chest X-ray and 
history + physical examination + chest X-ray + chest ct-scan + fiberoptic 
bronchoscopy (optional for adenocarcinomas).
Disclosure: All authors have declared no conflicts of interest.
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N2 DISEASE
F. Venuta Toracica Dipartimento Paride Stefanini, Policlinico Umberto I 
Cattedra di Chirurgia, Rome, ITALY
N2 disease, according to the tNM staging system, is defined by the pres-
ence of metastatic disease in the ipsilateral mediastinal lymph nodes. Only 
selected patients with N2 disease may benefit from primary surgery; a care-
ful preoperative work including ct scan PEt and invasive procedures like 
EbUs and mediastinoscopy should be carried out to assess this parameter. 
In fact, the best treatment option for these patients include induction therapy 
followed by surgery. Preoperatively proven N2 disease requires a multidis-
ciplinary approach with chemotherapy or chemoradiotherapy. However, in 
these patients, complete resection of the primary lesion still remains among 
the strongest prognostic factors for long term survival. radical mediastinal 
lymphadenectomy should always be performed, since it is certainly an added 
value at least for correct staging. the impact of induction chemo-radiotherapy 
on postoperative morbidity is still being evaluated. However, after induction 
therapy, less extended resections and bronchoplastic reconstructions should 
be always considered to avoid pneumonectomy. When completely resected, 
occult N2 found at thoracotomy, skip metastases and single level N2 in 
selected locations are reported to portend a relatively encouraging outcome. 
In particular single level metastases within station 5 (AP window) has long 
been considered less unfavorable from the prognostic point of view, when 
compared to other sites.
Disclosure: All authors have declared no conflicts of interest.
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PROPHYLACTICAL CRANIAL PCI IN NSCLC
No abstract received at time of going to press.
62IN
HOW TO IMPROVE THE OUTCOME WITH 
CHEMORADIOTHERAPY
E.E. Vokes Medicine, The University of Chicago Medical Center, Chicago, 
IL, UNITED STATES OF AMERICA
For patients with unresectable locoregionally advanced non small cell lung 
cancer (NscLc) current standard treatment consists of concurrent chemo-
radiotherapy usually with cisplatin-etoposide or weekly low dose carbopla-
tin-paclitaxel. randomized studies have indicated no added benefit from the 
addition of induction or consolidation chemotherapy. Median survival times 
in recent multi-institutional trials have exceeded 20 months. clinical and 
molecular factors contributing to the heterogeneity of clinical presentations 
are increasingly being recognized. recent investigations have attempted to 
optimize radiation. A randomized trial testing the hypothesis that increasing 
total radiation doses from 60 Gy to 74 Gy would result in better locoregional 
control and increased survival times was closed early based on a futility anal-
ysis. An alternative hypothesis is that larger daily fraction sizes could lead 
to higher tumor cell kill. the cALGb is currently planning a Phase I trial 
of carboplatin-paclitaxel with concurrent radiation with daily fraction sizes 
beginning at 2.25 Gy and aiming in a sequential cohort design to escalate 
up to 3 Gy. there has also been interest in introducing novel chemotherapy 
agents. In particular for patients with non-squamous cell histology the use 
of pemetrexed as a radiation sensitizer is of interest. A large international 
randomized trial (PrOcLAIM) is comparing concurrent chemoradiotherapy 
with cisplatin-etoposide vs. cisplatin-pemetrexed. Of note, both regimens can 
be administered at full chemotherapy doses thus optimizing systemic che-
motherapy exposure. An alternative approach has been the use of targeted 
therapies. Anti-EGFr directed therapy with cetuximab is currently undergo-
ing investigation. Pilot data utilizing tyrosine kinase inhibitors of EGFr have 
been disappointing. It is possible however that erlotinib or gefitinib in patients 
with EGFr mutations and similarly of crizotinib in patients with EML4-
ALK fusion could lead to improved outcomes. Pilot trials investigating this 
approach are under discussion. the use of anti-angiogenic agents has been 
disappointing. Finally, the use of stereotactic body radiation therapy (sbrt) 
is being explored for patients with early stage disease as well as those with 
oligometastatic disease.
Disclosure: E.E. Vokes: Dr. Vokes is a consultant for Amgen, Avoa, 
boehringer-Ingelheim, Genentech, and Novartis.
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63O_PR
EFFECTIVENESS OF CHEST DIGITAL TOMOSYNTHESIS 
FOR EARLY DETECTION OF LUNG CANCER: FIRST–
YEAR RESULTS FROM OBSERVATIONAL STUDY
A. terzi1, L. bertolaccini1, A. Viti1, L. comello2, r. Priotto2, M. Grosso2 
1Thoracic Surgery, S. Croce e Carle Hospital, Cuneo, ITALY, 2Radiology, S. 
Croce e Carle Hospital, Cuneo, ITALY
Objective: screening with low-dose ct reduces mortality from Lung cancer 
(Lc); but, before public policy recommendations, cost-effectiveness and radi-
ation adsorbed dose must be rigorously analyzed. Other strategies to select 
peoples who are best suited for ct must be searched. We present the 1st-year 
results of sOs trial, an observational study using Digital chest tomosynthesis 
(Dt) for early detection of Lc. Dt is limited angle tomography that allows 
reconstruction of multiple image planes and provides high-resolution images 
in coronal planes at radiation doses and costs much lower than ct.
Methods: Accrual started in December 2010 and ended in December 2011. 
smokers or former smokers of at least 20 pack-years, aged 45–75 years, 
were considered potentially eligible and preassessed for eligibility during a 
telephone interview. Participants were requested to fill out a questionnaire 
on occupational history, smoking habits, past and present health conditions. 
subjects were considered ineligible if they had history of previous malig-
nancy within 5 years before accrual. All subjects enrolled had Dt. One–yearly 
Dt round was planned: one at baseline, and one yearly repeats. When suspi-
cious pulmonary lesion is found on Dt, first-line ct is warranted. sample 
size of 2000 subjects was calculated on basis of incidence and mortality data 
reported in Piedmont cancer registry.
Results: At December 2011, a total of 1843 subjects were preassessed. 1703 
(92%) subjects were finally enrolled; mean age 61 ys (95% cI, 48 – 73), 
active smokers 766 (77%). On first 1000 patients analyzed, at least one pul-
monary abnormality was detected in 154 subjects, extrapulmonary abnormal-
ities in 7 patients: effusions (2), pleural lesions (3), mediastinal lymph node 
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enlargement (2). 96 patients (9.6%) underwent first-line ct; false positive Dt 
nodules were 32 (3.2%). Lc detection rate was 1.1%.
Conclusion: Dt detected non-calcified nodules in a percentage comparable 
to ct. Up until now Lc was detected in 1.1% of cases. Dt seems to be a 
promising first line tool for Lc screening.
Table:
comorbidities 658 
Any abnormality in Dt 154 
First-line ct 96 
Follo-up ct 53 
ct/PEt 16 
Negative nodules for Lc 7 
Positive nodules for Lc 11 
Lobectomy 5 
Pneumonectomy 1 
STAGE 
IA 3 
Ib 2 
IIb 1 
IIIb 1 
IV 4 
HISTOLOGY 
Adenocarcinoma 7 
squamous cell 3 
carcinoid 1 
Disclosure: All authors have declared no conflicts of interest.
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LUNG CANCER RISK DETERMINATION WITH 
LOW COHERENCE ENHANCED BACKSCATTERING 
SPECTROSCOPY (LEBS) ANALYSIS OF BUCCAL 
MUCOSA
H.K. roy1, N. Mutyal2, t. Hensing3, H. Du4, D. ray3, b. Jancan5, V. backman2 
1Internal Medicine, NorthShore University HealthSystems/University of 
Chicago Medical Center, Evanston, IL, UNITED STATES OF AMERICA, 
2Biomedical Engineering, Northwestern University, Evanston, IL, UNITED 
STATES OF AMERICA, 3Oncology, NorthShore University HealthSystems/
University of Chicago Medical Center, Evanston, IL, UNITED STATES OF 
AMERICA, 4Research, NorthShore University HealthSystems/University of 
Chicago Medical Center, Evanston, IL, UNITED STATES OF AMERICA, 
5Internal Medicine/research, NorthShore University HealthSystems/University 
of Chicago Medical Center, Evanston, IL, UNITED STATES OF AMERICA
Low dose ct may allow population screening for lung cancer (NEJM 2011). 
However, the low disease prevalence even in this enriched population results 
in a prohibitive false positive rate supporting need for better risk evaluation 
(Ann Int Med 2010). Field carcinogenesis represents a promising approach 
for cancer risk stratification. the buccal mucosa is in the smoking “field of 
injury” and represents a well established “molecular mirror of lung carcin-
ogensis (cancer Prev res 2008). Our group has focused on using a novel 
optical technique, LEbs, to detect the micro-architectural consequences of 
the genetic/epigenetic alterations in field carcinogenesis (reviewed in Gastro 
2011). We now assess the diagnostic ability of buccal LEbs analysis for lung 
cancer.
Methods: We performed a case-control study (n=63) using a training/blinded 
testing set design. cases were pathologically confirmed primary lung cancer 
(mainly NscLc) prior to any treatment. controls were age/gender-matched 
smokers (current or past history). LEbs analysis was performed with a novel 
LEbs fiberoptic probe gently pressed to buccal mucosa. Five readings (each 
requiring 250 msecs) were obtained and analyzed by an investigator blinded 
to clinical data.
Results: Univariate analysis of our training set identified 5 markers that dis-
criminated cases from controls (enhancement, spectral slope (ss), M, OHb 
and bVD with p values of 0.011, 0.015, 0.277, 0.0035 and 0.0024 respec-
tively). these markers were not confounded by age, gender, smoking inten-
sity, histological subtype or stage of disease. A prediction rule with only ss 
and bVP had excellent performance (AUrOc=0.906). the training set deter-
mined threshold value yielded very encouraging results when prospectively 
applied to an independent testing set (sensitivity =100%, specificity=70%, 
PPV=81%, NPV=100%).
Conclusions: buccal mucosal interrogation with our novel fiberoptic LEbs 
probe appears accurate in identifying lung cancer patients. While the mod-
est sample size necessitates caution, the diagnostic performance along with 
the clinical practicality suggests that this minimally intrusive buccal LEbs 
approach represents a promising pre-screen for lung cancer.
Disclosure: H.K. roy: co-founder/share holder in American bioOptics LLc 
and Nanocytomics LLc study funded by Us National Institutes of Health. 
V. backman: co-founder/share holder in American bioOptics LLc and 
Nanocytomics LLc study funded by Us National Institutes of Health. All 
other authors have declared no conflicts of interest.
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MIR-34C IS A POTENTIAL BIOMARKER FOR 
HISTOLOGICAL RESPONSE IN LUNG CANCER 
CHEMOPREVENTION STUDIES
c. Mascaux1, r.L. Keith2, W.J. Feser3, M.t. Lewis4, A.E. barón3, D.t. 
Merrick4, W.A. Franklin4, P. bunn1, Y.E. Miller2, F.r. Hirsch1, 4 1Department 
of Medicine, Division of Medical Oncology, University of Colorado, 
Anschutz Medical Campus, Aurora, CO, UNITED STATES OF AMERICA, 
2Department of Pulmonary Science and Critical Care Medicine, University 
of Colorado, Anschutz Medical Campus, Aurora, CO, UNITED STATES 
OF AMERICA, 3Department of Biostatistics and Informatics, University of 
Colorado, Anschutz Medical Campus, Aurora, CO, UNITED STATES OF 
AMERICA, 4Department of Pathology, University of Colorado, Anschutz 
Medical Campus, Aurora, CO, UNITED STATES OF AMERICA
Endobronchial histology is currently considered the best intermediate 
endpoint for chemoprevention studies. While histologic grading is repro-
ducible between specialized pathologists, more quantitative biomarkers 
of response would be desirable. We analyzed the expression of selected 
mirNA as potential surrogate biomarkers in the Iloprost lung cancer 
chemoprevention trial, which is the first to meet a pre-determined pri-
mary endpoint of histology improvement (Keith, cancer Prev res 2011). 
Matched biopsies (baseline-bL and the same site at follow-up-FU after 6 
months of Iloprost or placebo) were obtained in 125 high-risk individuals 
who completed the trial: 40/35 and 25/25 current/former smokers in the 
Iloprost and placebo arm, respectively. We analyzed 496 biopsies includ-
ing 4 matched biopsy pairs per patient: the best and the worst histology at 
bL and the 2 biopsies from same site at FU. total rNA was extracted from 
formalin fixed paraffin embedded sections adjacent to the diagnostic sec-
tion and 14 selected mirNA previously identified in high-grade bronchial 
preneoplasia were analyzed by qrt-Pcr (Mascaux, Eur resp J 2009). 
In the earlier and current studies, mir-34c expression was inversely cor-
related with bL histology grade (r=0.36, p<0.001, false discovery rate 
(FDr) <0.1). the current study demonstrated that the change in mir-34c 
expression between bL and FU biopsies was also inversely correlated with 
histology changes (r=0.23 p=0.0003, FDr<0.1) and this was independent 
of treatment arm or smoking status. In addition, a lower mir-34c expres-
sion at bL, and consequently its increase at FU, was significantly associ-
ated with histological response in the Iloprost (p=0.0022, FDr<0.1) and 
placebo arms (p=0.0025, FDr<0.1). the changes in mir-34c (a transcrip-
tional target of p53) expression were inversely correlated with histological 
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changes at FU. In responders, mir-34c expression is significantly lower 
at bL and increased at FU, related with a worse histology at bL and its 
down-grading at FU. We conclude that the change in mir-34c expression 
in FU biopsies is correlated with histological response and may be a quan-
titative biomarker of response in lung chemoprevention studies.
Disclosure: r.L. Keith: collaborator on a patent application for prostacy-
clin analogs to prevent cancer. P. bunn: Dr. bunn has consulted for bayer, 
the manufacturer of iloprost, on matters not related to iloprost. Y.E. Miller: 
collaborator on a patent application for prostacyclin analogs to prevent can-
cer. F. r. Hirsch: consultant: bMs, boehringer-Ingelheim, clovis, roche/
Genenetech, Lilly, celgene, Imclone, Merck serono. Patent: co-inventor 
of university of colorado owned patent: Egfr biomarkers (FIsH and IHc) 
for prediction of sensitivity to EGFr inhibitors. Patent licenced to Abbot. 
research Funding (through University of colorado): OsI/Aestellas, Imclone, 
Morphotek, celgene, AstraZeneca. All other authors have declared no con-
flicts of interest.
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AIRWAY OBSTRUCTION AND RESPIRATORY ILL-
HEALTH IN A POPULATION AT INCREASED LUNG 
CANCER RISK
F. Nordin1, r. booton2, P. barber2, t. Frank2, K. Mccalman2, A. Povey1 
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Manchester, UNITED KINGDOM, 2North West Lung Centre, University 
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Background: Lung cancer is clinically silent and more than two-thirds of 
lung cancers present at a late stage and less than 10% of people survive for 5 
years. Detection of lung cancer at an early stage may then potentially increase 
survival rates. As lung cancer risk is associated with airflow obstruction and 
increases with decreasing FEV
1
, in this study we are investigating the feasi-
bility of detecting high risk individuals by identifying airflow obstruction and 
monitoring respiratory symptoms.
Method: this is a population-based cohort study, with subjects aged 40–75 
and registered with GP practices in the Wythenshawe District of Manchester 
recruited between November 2010 and December 2011. Data on risk factors 
for lung cancer were obtained from a face-to-face interview together with 
spirometry. respiratory symptoms were assessed using a questionnaire based 
on the Medical research council Questionnaire (MrcQ). the association 
between the risk factors for lung cancer and recorded airflow obstruction was 
examined at baseline.
Results: 2700 subjects were invited to participate. 273 (10.1%) subjects 
completed the baseline assessment and 260 (95.2%) completed spirom-
etry. 175 participants (67.3%) reported no underlying respiratory disease. 
Ever smoking (p<0.05) but not exposure to passive smoke or occupa-
tional carcinogens and a family history of lung cancer was associated 
with airflow obstruction. Airflow obstruction was most severe (the lowest 
percentage of FEV
1
 predicted) in smokers compared with non-smokers. 
85 + 21, n=189 vs. 98 + 18, n=71, p<0.05). Airflow obstruction was sig-
nificantly associated with chronic cough, cough with phlegm, wheezing 
and shortness of breath in smokers (p<0.05). compared to asymptomatic 
participants, subjects with respiratory symptoms were strongly associated 
with airflow obstruction; for chronic cough Or 3.69 (95% cI 1.94 –6.99); 
 for cough with phlegm Or 4.09 (95% cI 2.10–8.00); for wheezing Or 
3.68 (95% cI 1.95–6.98) and for shortness of breath Or 4.40 (95% cI 
2.30–8.42).
Conclusion: the community based study reaffirms that smokers with respi-
ratory symptoms are at higher risk of having airflow obstruction, a powerful 
marker of lung cancer risk. respiratory symptoms in smokers, with or with-
out spirometry, may assist in targeting a high risk population for lung cancer 
screening.
Disclosure: All authors have declared no conflicts of interest.
67P
DO GENETIC POLYMORPHISMS OF GSTS ELEVATE THE 
RISK OF DEVELOPMENT OF LUNG ADENOCARCINOMA 
AND SQUAMOUS CELL CARCINOMA IN SLOVAK 
POPULATION?
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1Department of Medical Biology, Jessenius Faculty of Medicine, Martin, 
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Martin, SLOVAK REPUBLIC, 3Department of Medical Chemistry, Jesseniu 
Faculty of Medicine, Martin, SLOVAK REPUBLIC, 4Clinic of Pulmonary 
Disorders, Jesseniu Faculty of Medicine, Martin, SLOVAK REPUBLIC
the slovak republic belongs to the countries with high incidence of lung 
cancer. Gene polymorphisms of the glutathione s-transferases (Gsts) may 
play a role in individual lung cancer susceptibility. In presented case-control 
study we investigate the incidence of polymorphism of Gstt1, GstM1, 
GstP1 genes and their combinations as possible predictive factors for iden-
tification of individuals with increased risk of formation and development of 
adenocarcinoma (Ac) and squamous cell carcinoma (scc) of lung in slovak 
population. the study was conducted on 520 individuals consisting of 118 
patients with adenocarcinoma, 112 patients with squamous cell carcinoma 
and 290 control individuals. Gstt1, GstM1, GstP1 gene polymorphisms 
were assayed by standard Pcr and Pcr-rFLP technique. the results of this 
study indicate that the Gstt1 null-genotype and combinations Gstt1 null 
and GstM1positive, Gstt1 null and Ile/Val or Val/Val are associated with 
increased risk of lung adenocarcinoma in slovak population. A significant 
association with 2.13 - fold increased risk was observed between lung adeno-
carcinoma and Gstt1 null genotype (95% cI = 1.29–3.51; p= 0.004). Also it 
was proved 2.17 times statistically higher risk for development of this histo-
logical type of lung cancer (95% cI =1.07–4.39; P = 0.046) in combination of 
Gstt1 null and GstM1 positive genotypes and statistically significant risk 
with Or = 2.83 was observed in combination of Gstt1 null and Ile/Val or 
Val/Val genotypes (95% cI =1.34–6.01; P = 0.009). Gstt1, GstM1, GstP1 
polymorphism did not show any significant association with scc. Our study 
suggests that genetic make-up in metabolizing genes may increase suscepti-
bility towards lung cancer development.
Acknowledgements: this work was supported by the Ministry of Health of 
the slovak republic, Grant No. MZ 2007/47-UK 13 and by the “Authorised 
center for development and research in diagnosis and therapyof oncologi-
cal disorders” co-financed from Ec sources and the European regional 
Development Fund.
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One of the causes of tumor development is known to be disbalance of activa-
tion, inactivation and removal of toxic compounds. change in the activity 
of xenobiotic biotransformation enzymes related to the existence of genetic 
polymorphism results in increased susceptibility of organism to deleterious 
effects and, in consequence, to a rise in a risk of developing various onco-
pathologies. On this connection it is necessary to take into account the total 
contribution of polymorphic variants of genes encoding enzymes of I and 
II xenobiotic biotransformation phases as well as P-glycoprotein in detect-
ing predisposition to Lc. the study comprised 118 Lc patients undergoing 
treatment at Minsk Oncologic Dispensary over the period from 2003 to 2009. 
the control group includes 329 persons without oncopathology permanently 
living in the area of belarus. Pcr-rFLP and multiplex Pcr methods were 
used for studying polymorphism of genes: cYP1A2 (c734A) – the activation 
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phase; Gstt1 (deletion), GstM1 (deletion), NAt2 (c481t, G590A and 
G857A) – the detoxication phase and MDr1 (c3435t) – the removal phase. 
the examined individuals were divided into “fast” and “slow” acetylators 
according to the results of genotyping for three NAt2 sites (c481t, G590A 
and G857A). the combination of genotypes “734cAcYP1A2/ Gstt1(+)/
GstM1(+)/3435ctMDr1” was revealed to exert a protective effect when 
the genes cYP1A2 and MDr1 are represented with heterozygote and the 
genes Gstt1 and GstM1 do not contain homozygous deletion. the risk of 
Lc development is increased in the individuals with the genotype combina-
tions “734AAcYP1A2/Gstt1(-)” or “Gstt1(-)/3435ccMDr1”. the com-
bination “734AAcYP1A2/Gstt1(-)/3435ccMDr1” and “734AAcYP1A2/
Gstt1(-)/3435cc MDr1” is of the highest risk importance, especially when 
the carrier of such a combination is a “slow” acetylator. thus, the study of 
genetic polymorphism of enzymes at all phases of xenobiotic biotransforma-
tion in an individual increases the degree of prognosis accuracy of his pre-
disposition to Lc. Association of homozygous Gstt1 gene deletion with 
predisposition to Lc was detected in residents of belarus. combinations of 
polymorphic gene loci of biotransformation enzymes exert a modifying effect 
on risk importance of Gstt1 genotype in lung cancer development.
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USEFULNESS OF BONE RESORPTION MARKERS CTX, 
TRAP5B, AND PINP IN PATIENTS WITH NON-SMALL 
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PRELIMINARY STUDY
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Background: Non-small cell lung carcinoma (NscLc) is the most common 
lung cancer, which represents the major cause of cancer death worldwide. the 
early diagnosis of NscLc is difficult, and the sensitivity of common serum 
tumor markers, such as carcinoembryonic antigen (cEA) and fragments of 
cytokeratin 19 (cYFrA 21-1), is low. Unfortunately, bone metastases (bMs) 
are common in patients with NscLc, and their early detection and treatment 
may improve both disease-free interval and survival. several serum biomark-
ers have been proposed for the detection of bMs, such as carboxy-terminal 
telopeptide of type I collagen (ctX), tartrate-resistant acid phosphatase 
isoform type 5b (trAP5b), and amino-terminal propeptide of type I colla-
gen (PINP), which are markers of bone resorption. the aim of this prelimi-
nary study was to evaluate the usefulness of a panel of serum biomarkers in 
patients with NscLc and bMs.
Patients and methods: sixteen patients (11 males, 5 females, median age 64 
years, range 54-68) with NscLc and bMs (cases), and 18 age- and gender-
matched patients without bMs (controls) underwent serum ctX, trAP5b, 
PINP, cEA, and cYFrA 21-1 measurements. ctX was measured by auto-
mated immunometric assay, trAP5b and cEA by two-site enzyme-linked 
immunosorbent assay (ELIsA), PINP by radioimmuno assay (rIA), and 
cYFrA 21-1 by immunochemiluminescent assay. the cut-off values were 
400 pg/mL (ctX), 5 U/L (trAP5b), 3.5 ng/mL (cEA), 65 μg/L (PINP), and 
45 pg/mL (cYFrA 21-1), respectively.
Results: ctX (443.7±945.1 vs. 402.7±28.4 pg/mL, p=0.003), and PINP 
(75.9±11.4 vs. 64.1±7.5 μg/L, p=0.001), were significantly higher in patients 
with bMs, while the other markers did not differ (p=Ns) between cases and 
controls. the sensitivity, specificity and accuracy were 73.7%, 86.7%, and 
79.4% (Or=18.2, 95% cI 2.99-110.7, p<0.0001) for ctX; 30.4%, 76.2%, 
and 67.6% (Or=6.22, 95% cI 1.06-36.5, p=0.038) for trAP5b; 72.2%, 
81.2%, and 76.5% (Or=11.26, 95% cI 2.21-57.20, p=0.002) for PINP; 
55.5%, 62.5%, and 58.8% (Or=2.08, 95% cI 0.53-8.23, p=0.29) for cEA; 
65.0%, 78.61%, and 70.6% (Or=6.81, 95% cI 1.41-32.8, p=0.012) for 
cYFrA 21-1, respectively.
Conclusions: In patients with NscLc, both ctX and PINP measurements 
can be useful in the detection of bMs.
Disclosure: All authors have declared no conflicts of interest.
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FURTHER VALIDATION OF DR-70 BLOOD BIOMARKER 
IN THE EARLY DETECTION OF NON-SMALL CELL 
LUNG CANCER
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Non-small cell lung cancer (NscLc) accounts for 85-90% of all lung can-
cers with a death rate of 85%. there is no routinely used blood biomarker test 
that can be used for lung cancer diagnosis with high sensitivity. Onko-sure® 
is a regulatory approved blood test for detection and monitoring of lung can-
cer treatment/recurrence. It measures the accumulation of fibrin/fibrinogen 
degradation products in the serum using anti-Dr-70 antibody. the purpose of 
this study was to further validate Dr-70 utility in lung cancer early detection. 
A total of 232 serum samples were retrospectively obtained and were tested 
with Dr-70. the samples were divided into two arms: confirmed healthy con-
trol (n= 120) and biopsy-confirmed NscLc (n= 112). the data were analyzed 
to find the optimal cut point to differentiate the normal vs the cancer group 
along with sensitivity and specificity of the test. the data were further broken 
down into different stages followed by the analysis of sensitivity and specific-
ity. the sensitivity and specificity achieved with Dr-70 test at the cut point 
of 1.2 were 65.2% and 87.5%, respectively. A consistent high sensitivity was 
observed throughout all stages with the highest sensitivity reached for stage 
II (70.4%). Furthermore, Dr-70 showed a sensitivity of 81.8% in acinar cell 
carcinoma, a subcategory of non-small cell lung cancer subcategories. chest 
X-ray is the routine first diagnostic step in lung cancer detection with the 
sensitivity of 78.3%; however, it misses lesions smaller than 1 cm. ct scan, 
with the sensitivity of 88.9%, may be ordered to further explore the situation 
which exposes the patient to further amount of radiation. In this study, Dr-70 
biomarker showed a high sensitivity for the detection of lung cancer which 
was in line with many previous studies. these findings highlight this test as 
an additional first line diagnostic tool that can be combined with X-ray to 
increase the diagnostic sensitivity. Dr-70 showed 60% sensitivity in stage I 
of NscLc, which will promise a higher sensitivity if used along with X-ray. 
An enhanced ability to diagnose NscLc in an early stage should significantly 
improve prognosis, treatment options and survival rate for patients with lung 
cancer.
Disclosure: All authors have declared no conflicts of interest.
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EARLY DETECTION OF ENDOBRONCHIAL CARCINOMA 
USING AUTOFLUORESCENCE BRONCHOSCOPY
s. saenghirunvattana1, K. saenghirunvattana2, P. Masakul1 1Medicine, 
Samitivej Hospital, Bangkok, THAILAND, 2Medicine, Prince Songklanakarin 
Hospital, Songkla, THAILAND
Introduction: the earlier the stage we can detect lung cancer, the better for 
the patient’s prognosis.
Objective: the objective of this study was to evaluate the benefit of using 
autofluorescence bronchoscopy for the detection and localization of endo-
bronchial carcinoma.
Method: Autofluorescence bronchoscopy was used to examine 350 patients, 
aged 35 to 90 years ,who were either current or ex-smokers of more than 20 
pack-years, and suspected of having lung cancer based on abnormal chest 
roentgenogram or computer tomogram of the chest.
Results: there were 262 men and 88 women with mean age of 64 years. 
One man and one woman developed carcinoma in situ, which was destroyed 
by electrocautery. Annual follow up by autofluorescence bronchoscopy was 
normal for the following 4 years for both patients.
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Another man developed severe dysplasia which was ablated by using elec-
trocautery. Open lung biopsy of left lower lobe lesion revealed bronchiolitis 
obliterans.
Conclusion: Autofluorescence bronchoscopy is able to enhance early detec-
tion of endobronchial cancer.
Disclosure: All authors have declared no conflicts of interest.
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LUNG CANCER (LC) RISKS IN WOMEN WITH 
PREVIOUS BREAST CANCER (BC): ANALYSIS OF 
CLINICOPATHOLOGICAL CHARACTERISTICS AND 
BIOMARKERS EXPRESSION
c. sini1, G. barletta1, c. Genova1, E. rijavec1, M.G. Dal bello1, N. Diaz 
Gaitan1, c. Donato1, P. Pronzato2, F. Grossi1 1Lung Cancer Unit, National 
Institute for Cancer Research, Genova, ITALY, 2Medical Oncology A, National 
Institute for Cancer Research, Genova, ITALY
Background: several studies in bc patients (pts) suggest that older radio-
therapy techniques and smoking are associated with an increased risk of 
developing Lc in the ipsilateral lung especially with squamous cell histotype. 
Aim of this study is to evaluate if there are, in pts with previous bc, clinico-
pathological characteristics and a biomarkers profile, evaluated in bc and Lc 
tissues, able to predict an increased risk of developing a subsequent Lc. the 
bc and Lc biomarkers profile will be compared with the biomarkers profile 
in pts with only bc or only Lc. 
Patients and methods: From 2006 to 2011, thirty-five pts with a previous 
bc were resected for Lc. bc and Lc tissues are currently used to evaluate 
the following biomarkers: Estrogen receptors (Er), Progesterone receptor 
(Pgr), Aromatase, Human Epidermal Growth Factor receptor 2 (HEr 2), 
Ki-67, breast cancer 1(brcA1), breast cancer 2(brcA2), p53, Epidermal 
Growth Factor receptor (EGFr), Kirsten rat sarcoma Viral Oncogene 
(KrAs) mutations, Excision repair cross-complementing 1(Ercc1), 
ribonucleotide reductasi (rrM1), thymidylate synthase (ts) and class 
III -tubulin (-tub-III). Immunohistochemistry, real-time Pcr and gene 
sequencing for mutations of EGFr and KrAs are used. 
Results: the median age at diagnosis of bc was 55.5 years. the mean time 
between diagnosis of bc and Lc was 6.25 years. Fourteen pts (40%) were 
never smokers, 8 pts (22%) were former smokers and 13 pts (37%) were 
smokers at the time of bc diagnosis. twenty-four patients (69%) received 
adjuvant radiotherapy after bc resection and 14 of these pts (58%) had ipsi-
lateral Lc. Adenocarcinoma is the most common Lc (26 pts, 74%) followed 
by squamous cell carcinoma (4 pts, 11%) and scLc (3 pts, 9%). biomarkers 
study are ongoing and the final results will be presented at the conference.
Conclusion: In this study adjuvant breast radiotherapy and smoking do not 
seem to be strictly associated with the development of Lc in pts with a pre-
vious bc and adenocarcinoma is the most frequent Lc histotype. the bio-
markers study could increase our knowledge about the relationship between 
aetiological factors, individual susceptibility and gene-enviroment in devel-
oping a subsequent Lc. 
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Introduction: With the cancer risk 14.6% before the age of 65 yrs. belongs 
the czech republic to the most vulnerable amongst 185 countries. Proper 
clinical decision-making can add further support to the effort for prolonging 
survival of cancer patients with subsequent neoplasm in regard to an expected 
prevalence of 12,700 survivors of Lc in 2015.
Material and methods: the primary and subsequent lung cancers (Lc) 
based in the czech cancer registry in 1976-2005 were analysed in relation 
to the occurence of cancers at other sites (IcD-10: c00-D48).the differ-
ence between cases and persons indicate the multiple malignant neoplasms 
(MMNs).
Results: Among total of 147,185 new Lc in males collected during 1976-
2005 years there were 3,278 (2.2%) primary and 8,849 (6%) subsequent 
cases. Among total of 29,208 new Lc in females were 667 (2.3%) primary 
and 2,708 (9.3%) subsequent cases. the average interval between primary Lc 
and subsequent neoplasms was 6.1 years. After primary Lc the most frequent 
were 26,4% cancers of gastrointestinal and 16.1% urinary tract, 14.2% skin, 
13% female genital and 13.2% other respiratory tract, 11.3% male genital 
and 11.2% breast. the most frequent preceding neoplasms before subsequent 
Lc were 29.8% cancer of skin, 26% female genital, 16% breast, 13% of gas-
trointestinal, 12% urinary, 10.3% other respiratory tract. the 23,462 subse-
quent Lc reported as a second cancer included early stages in 29.6% males 
and 27.9% females, advanced stages in 31.2% males and 31.3% females, 
unknown stages in 39.3% males and 40.8% females.
Conclusion: Individual treatment algorithms should pay more respect to the 
stage and prognostic markers of primary cancers. Most of subsequent can-
cers, particularly those of advanced stage could be prevented by the use of 
standards for follow-up care. the czech screening programme and medical 
surveillance seems at present insufficient.
Disclosure: All authors have declared no conflicts of interest.
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Introduction: cadmium (cd) is heavy metal known to induce carcinogenesis 
by induction of reactive oxygen species resulting in alteration of DNA meth-
ylation or by over expression of the cellular proto-oncogene eEF1A2. the 
exact mechanism is currently not well established. cigarette smoke inhalation 
is one of the routes for cd exposure. the objective of this clinical study was 
to evaluate the effect of smoking on serum cd levels and establish its relation 
to the development of lung cancer in the syrian population.
Methods: three groups were included in the study, comprising of lung can-
cer patients (n=40) with prior history of smoking, healthy smokers (n=23) 
and healthy non-smokers (n=23). the effect of smoking on serum cd levels 
was compared between the groups by blood samples collection and analysis. 
Alpha-fetoprotein (AFP) levels were also measured for biomarker level esti-
mation between them. Graphite furnace atomic absorption spectrometry and 
enzyme-linked immunosorbent assay were used to detect the cd and AFP 
levels in serum, respectively. ANOVA test was used for comparison of serum 
cd and AFP levels between them.
Results: the mean smoking history was 36.6 and 34.8 years in patients and 
healthy smokers respectively. cd levels were highest in lung cancer patients 
(4.80±5.0 μg/L) followed by healthy smokers (2.06±1.04 μg/L) and least in the 
healthy non-smokers (0.87±0.43 μg/L). the difference in cd levels between 
all the groups was statistically significant (p<0.05). serum AFP levels in 
lung cancer patients (4.82±4.26 IU/mL) were marginally higher compared to 
healthy smokers (4.70±1.52 IU/mL) and healthy non-smokers (3.63±1.63 IU/
mL) with no statistical significance.
Conclusions: High serum levels of cd in smokers compared to non-smokers 
in this study further supports evidence that smoking is major source of cd 
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exposure. And the significantly higher level of cd in lung cancer patients with 
substantial smoking history is suggestive of its role in carcinogenesis.
Disclosure: All authors have declared no conflicts of interest.
75P
DEVELOPMENT OF A NATIONAL CLINICAL LUNG 
CANCER REGISTRY: NEED FOR COLLABORATIVE 
EFFORTS WITH ESMO/WHO
V. shankpal Medicine, DS Mandali Clinic, Dhule, INDIA
Background: Data from lung cancer registry provides for health profession-
als/researchers and politics, detailed information on incidence, trend and sur-
vival statistics. traditional cancer registries are population-based and seek to 
describe incidence, rates and trends of lung cancer within set populations. 
they supplement effectiveness of population-based registries in improving 
lung cancer patient care. Development of such databases is long awaited in 
India.
Objective: Our cancer NGO developed a primary plan in consultation with 
four divisional hospitals & the Health Ministry. We aim to establish a plat-
form for the multi-clinician, multi-centric collation of clinical oncology data-
sets with lung cancer as a pilot disease entity. We plan to integrate this concept 
at major cancer institutes in Asia with expertise from EsMO/WHO. Proposal 
of intent has been approved at national level.
Methods: Here we relate our experience of an initiative aimed at establishing 
methodology, statistical analysis & control center for privacy, security and 
ownership concerns. We have developed national database but need participa-
tion of private cancer care institutes & naturopathy clinics. total participants 
projected by 2013 are 46.
Conclusion: Our experience with this initiative over the past three years 
has shown that data can be collated centrally in a secure and private man-
ner. Multicentre, multi-clinician collaboration is possible with collaborative 
efforts with EsMO/WHO. but a major subject of concern is haphazard data/
protocol maintenance by private entities. Most difficult data outsourcing was 
about survival statistics. A national lung cancer registry is a distant dream in 
resource-poor nations. but we have taken steps in a forward direction on this 
burning issue.
Disclosure: All authors have declared no conflicts of interest.
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Background: the EML4-ALK fusion gene is an oncogenic driver mutation, 
which defines a small subgroup of lung adenocarcinomas (ADc) and predicts 
response to the dual ALK/MEt inhibitor crizotinib. the gold standard for 
detection of ALK gene rearrangements is fluorescence in situ hybridization 
(FIsH). the goals of this study were 1) to test the performance of the recently 
FDA approved Vysis ALK break Apart FIsH Probe (Abbott Molecular, Inc.) 
on diagnostic non-small-cell lung carcinoma (NscLc) specimens and 2) 
to test the prevalence of ALK-gene rearrangements in a western European 
population.
Materials and methods: 190 formalin fixed and paraffin embedded histo-
logical NscLc specimens (101 small biopsies and 89 resection specimens), 
were retrospectively analysed by the new Vysis ALK break Apart FIsH Probe 
(Abbott Molecular, Inc.) according the guidelines of the manufacturer.
Results: FIsH evaluation was successful in 165/190 NscLc (87%), which 
included 117 ADc, 22 NscLc favour ADc, 12 NscLc not otherwise 
specified (NOs), 8 large cell carcinomas, 3 large cell neuroendocrine car-
cinomas, 2 adenosquamous carcinomas and one NscLc favour squamous 
cell carcinoma. 22/190 NscLc (11.6%) were not evaluable by FIsH due 
to lack of adequate numbers of tumor cells and only 3/25 (1.6%) due to 
hybridization failure. this compares to a high 24% non-interpretable 
hybridizations in a previous series of 34 specimens that were analysed with 
a FIsH assay not yet optimized for pulmonary biopsies. 5/165 NscLc 
(3%), 3 ADc and 2 NscLc NOs, were ALK FIsH positive. these were 
lung cancers from 4 female and 1 male patients with a median age of 56 
years (range 27-77).
Conclusion: the Vysis ALK break Apart FIsH Probe is well applicable to 
diagnostic NscLc specimens with a highly improved hybridization success 
rate. the prevalence of ALK gene rearrangements of 3% in our unselected 
population of NscLc is comparable to published data.
Disclosure: s. savic: this study has been funded by Abbott Molecular, Inc, 
UsA. L. bubendorf: L.b. received speaker’s honoraria from Abbott and Pfizer 
and research funds from Abbott, and attended advisory board meetings from 
Pfizer. All other authors have declared no conflicts of interest.
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Background: the benefit from platinum-based adjuvant chemotherapy 
(Act) in non small cell lung cancer (NscLc) was demonstrated in 4 ran-
domized trials (IALt, Jbr10, cALGb 9633 and ANItA). Following central 
review of 1587 NscLc cases by one (Eb: IALt) or two (Eb, Mt) special-
ized pathologists (WHO 2004 classification); there were 624 adenocarcinoma 
(ADc), 727 squamous cell carcinoma (scc) and other 236 NscLc (Other). 
Lymphocytic infiltration (intense infiltration: yes vs. no) was studied concur-
rently. Lymphocytic infiltration was a borderline favourable prognostic factor 
on overall survival (Os) in IALt (n=783 patients): hazard ratio (Hr) 0.67, 
95% confidence interval [0.46–0.98], p=0.04. (brambilla; Lung cancer 2005; 
49 (suppl. 2): s44). therefore the LAcE-bio group performed a validation of 
these results on ANItA, Jbr10 and cALGb trials.
Methods: since there was no evidence of a different prognostic role in the 
chemotherapy and control arms in IALt (test of interaction between lympho-
cytic infiltration and treatment arm p = 0.85 on Os), the prognostic values 
were studied for validation in all patients with adjustment for treatment arm. 
Prognostic analyses were performed with cox models stratified by trials and 
adjusted for treatment, sex, age, performance status, type of surgery, stage 
and histology.
Results: Out of 804 patients, 763 were evaluable. Intense lymphocytic infil-
tration was observed in 6% of the validation patients, ranging between 4 and 
7% according to the trial, as compared to 11% in IALt. It was associated with 
histology: 10% in scc and ~4% in ADc and other NscLc (p=0.001). No 
association was found with the other covariates. Intense lymphocytic infiltra-
tion was correlated with longer overall and disease-free survival (Hr=0.45 
[0.24–0.85], p=0.01 and Hr=0.44 [0.24-0.78], p=0005) without heterogene-
ity among trials.
Conclusion: Intense lymphocytic infiltration, found in only a minority of 
tumours, was validated as a favourable prognostic factor for survival in resec-
table NscLc.
Unrestricted grants from Ligue Nationale contre le cancer and sanofi.
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Background: We aimed to define subgroups of patients with candidate driver 
genes in patients with non-small cell lung cancer. 
Methods: Patients with primary lung cancer who underwent clinical genetic 
tests at Guangdong General Hospital were enrolled. Driver genes were 
detected by sequencing, high-resolution melt analysis, qPcr, or multiple 
Pcr and rAcE methods. 
Results: 524 patients were enrolled in this study, and the differences in driver 
gene alterations among subgroups were analyzed based on histology and 
smoking status. In a subgroup of non-smokers with adenocarcinoma, EGFr 
was the most frequently altered gene, with a mutation rate of 49.8%, followed 
by EML4-ALK (9.3%), PtEN (9.1%), PIK3cA (5.2%), c-Met (4.8%), KrAs 
(4.5%), and brAF (1.9%). the three most frequently altered genes in a sub-
group of smokers with adenocarcinoma were EGFr (22.0%), KrAs (12.0%), 
and EML4-ALK (4.5%). We only found EGFr (8.0 %), c-Met (2.8%), and 
PIK3cA (2.6%) alterations in the non-smoker with squamous cell carcinoma 
(scc) subgroup. PtEN (16.1%), PIK3cA (7.2%), and EML4-ALK (6.5%) 
were the three most frequently enriched genes in smokers with scc. DDr2 
and FGFr2 only presented in smokers with scc (4.4% and 2.2%, respec-
tively). Among these four subgroups, the differences in EGFr, KrAs, and 
PtEN mutations were statistically significant. 
Conclusions: the distinct features of driver gene alterations in different 
subgroups based on histology and smoking status were helpful in defining 
patients for future clinical trials that target these genes.
Disclosure: All authors have declared no conflicts of interest.
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RIBONUCLEOTIDE REDUCTASE SUBUNIT 2 (RRM2) 
PREDICTS SHORTER SURVIVAL IN RESECTED STAGE 
I-III NON-SMALL CELL LUNG CANCER (NSCLC) 
PATIENTS
M.G. Dal bello1, G. savarino2, E. rijavec1, c. sini1, G. barletta1, c. Genova1, 
M. truini3, D. Merlo4, U. Pfeffer2, F. Grossi1 1Lung Cancer Unit, National 
Institute for Cancer Research, Genova, ITALY, 2Integrated Molecular 
Pathology, National Institute for Cancer Research, Genova, ITALY, 
3Department of Pathology, National Institute for Cancer Research, Genova, 
ITALY, 4Epidemiology, Biostatistics and Clinical Trials Unit, National Institute 
fo Cancer Research, Genova, ITALY
Background: biomarkers can help in identifying patients (pts) with early-
stage NscLc with high risk of relapse and bad prognosis. the aim of this 
study was to investigate the relationship between the levels of expression 
of 7 biomarkers, clinicopathological characteristics and their prognostic 
significance. 
Methods: tumor tissue from 82 radically resected stage I-III NscLc pts were 
consecutively collected to investigate the mrNA expression and protein lev-
els of the following biomarkers: excision repair cross-complementation group 
1 (Ercc1), breast cancer 1 (brcA1), ribonucleotide reductase subunit 1 
(rrM1), rrM2, p53r2, thymidylate synthase (ts) and class III beta-tubulin 
(-tub-III) using quantitative reverse transcriptase real-time Pcr (qrt-Pcr) 
and immunohistochemistry (IHc) with tissue microarray technique. 
Results: In univariate analysis, p53r2 expression was significantly higher 
in adenocarcinoma (ADK) compared to squamous cell carcinoma (ssc) 
samples (p=0.002) and in stage I compared to stage II-III (p≤0.001). Ercc1 
expression was significantly higher in female compared to male (p=0.03) and 
-tub-III expression was significantly higher in ADK than in ssc (p=0.03). 
Pts with lower rrM2 expression survived longer than pts with higher rrM2 
expression (p=0.069). the multivariate analysis confirmed rrM2 as an inde-
pendent prognostic marker of shorter survival (p= 0.031). the comparison of 
survival curves with qrt-Pcr and IHc showed that there was similar results 
with a trend towards longer survival among Ercc1 negative pts, brcA1 
negative, p53r2 positive and among pts with low levels of rrM1 and rrM2 
although the difference was not statistically significant in both methods. qrt-
Pcr and IHc have shown that -tub-III and ts had no significant impact 
on survival. 
Conclusions: this is the first study that identifies rrM2 expression as a 
negative prognostic factor in resected stage I-III NscLc. Moreover, we have 
demonstrated the different expression of p53r2 and -tub-III in ADK com-
pared to ssc and higher expression of p53r2 in stage I compared to stage 
II-III pts.
Disclosure: All authors have declared no conflicts of interest.
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SERUM PROTEOMIC CLASSIFIER FOR PATIENTS WITH 
ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) 
TREATED WITH ERLOTINIB AND BEVACIZUMAB IN 
FIRST LINE: POOLED ANALYSIS OF PHASE II TRIALS 
SAKK19/05 AND NTR528
O. Gautschi1,2, A.c. Dingemans3, s. crowe1, H. roder4, F. Zappa5, M. Pless6, 
M. brutsche7, s. Peters8, D. carbone9, E.F. smit10 1SAKK Coordinating Center, 
Bern, SWITZERLAND, 2Medical Oncology, Cantonal Hospital, Luzern, 
SWITZERLAND, 3Department of Pulmonary Diseases, Maastricht University 
Medical Center, Maastricht, NETHERLANDS, 4Biodesix, Broomfield, CO, 
UNITED STATES OF AMERICA, 5Clinica Luganese, Lugano, SWITZERLAND, 
6Medical Oncology, Cantonal Hospital, Winterthur, SWITZERLAND, 
7Pulmonology, Cantonal Hospital, St. Gallen, SWITZERLAND, 8Cancer 
Center, University Hospital CHUV, Lausanne, SWITZERLAND, 9Vanderbilt-
Ingram Cancer Center, Nashville, TN, UNITED STATES OF AMERICA, 10VU 
University Medical Center, Amsterdam, NETHERLANDS
Background: Veristrat® proteomic classifier is a serum test utilizing mass 
spectrometry which reports two labels: Veristrat Good (VsG) or Veristrat 
Poor (VsP). Published data show VsG pts to perform better than VsP pts 
upon treatment with EGFr tKIs. We retrospectively explored Veristrat’s abil-
ity to separate pts with advanced non-squamous NscLc treated in first-line 
with bevacizumab and erlotinib (bE) into better and worse progression-free 
survival (PFs) and overall survival (Os) groups.
Methods: Individual data and archived serum samples from 117 pts previ-
ously enrolled in 2 European phase II trials of first-line bE (Nct00354549 
and Ntr528) were analyzed. Veristrat was performed centrally by biodesix 
(UsA). PFs and Os were evaluated using the Kaplan-Meier method; groups 
were compared using the log-rank test. the hazard ratio (Hr) was assessed 
using cox proportional hazards (cPH) models. For the multivariate analyses, 
both endpoints were analyzed using cPH and stepwise selection to check the 
importance of selected factors.
Results: Veristrat analysis performed in 117 pts sera from both trials classi-
fied 87 (74%) as VsG, 27 (23%) as VsP and 3 (3%) as “indeterminate”. VsG 
and VsP demonstrated a statistically significant difference in Os (p = 0.0027, 
Hr=0.480, 95% confidence interval (cI): 0.294–0.784) but significance 
for PFs was not reached (p = 0.2632, Hr = 0.768, 95% cI: 0.482–1.223). 
PFs and Os were also assessed using multivariate analyses on the combined 
VsG and VsP pts. stepwise selection indicated the following associations: 
smoking status (p < 0.0001) and histology (adenocarcinoma versus large cell 
carcinoma and not otherwise specified) (p < 0.0001) with PFs, Veristrat clas-
sification (p = 0.0042) and smoking status (p < 0.0001) with Os.
Conclusions: these results support the notion that Veristrat may be useful for 
clinical decision-making, representing a prognostic and potentially a predictive 
biomarker for treatment with EGFr tKIs. this predictive value of Veristrat 
will be tested in a prospective clinical trial in advanced squamous cell lung 
carcinoma, sponsored by the European thoracic Oncology Platform (EtOP).
S31Copyright © 2012 by the European Lung Cancer Conference and the International Association for the Study of Lung Cancer
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Disclosure: O. Gautschi, A. Dingemans and s. Peters: honoraria from roche 
for advisory boards. H. roder: employment by biodesix. All other authors 
have declared no conflicts of interest.
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UPFRONT GENOMIC TESTING FOR PATIENTS 
WITH NON-SMALL CELL LUNG CANCER (NSCLC) 
RECEIVING FIRST-LINE PLATINUM-BASED REGIMEN: 
PRELIMINARY RESULT OF THE MSN STUDY
D. Planchard1, A. rahal1, L. Lacroix2, M. Ngocamus1, N. Auger3, P. saulnier2, 
P. Dorfmuller4, t. Le chevalier1, J. soria1, b. besse1 1Departement de Medecine, 
Institut Gustave Roussy, Villejuif, FRANCE, 2Departement de Recherche 
Translationnelle, Institut Gustave Roussy, Villejuif, FRANCE, 3Departement 
de Cytogénétique, Institut Gustave Roussy, Villejuif, FRANCE, 4Département 
D’anatomopathologie, Centre Chirurgical Marie-Lannelongue, Le Plessis 
Ronbison, FRANCE
Background: recent advances in lung cancer have identified potential driver 
mutations that may be targeted. to identify new predictors of response as well 
as novel targets for therapy, we have initiated a comprehensive large-scale re-
sequencing analysis of genes potentially mutated in NscLc.
Methods: Genomic DNA was extracted prospectively from untreated 
advanced NscLcs. All tumors were obtained on Irb-approved protocols and 
after patients’ consent (MsN trial “Melanoma –small-cell lung cancer – Non-
small cell lung cancer”). Pathology specimens were macrodissected in order 
to obtain more than 30% of tumor cells and, after DNA extraction, 96 selected 
exons from 30 genes were analyzed by sanger sequencing. ALK rearrange-
ments were detected by fluorescence in-situ hybridization. All results were 
discussed monthly in a molecular thoracic multidisciplinary staff. second or 
third lines of treatment were adapted to mutation profiling.
Results: thus far (between 09/01/2010 and 06/01/2011), 82 tumors have 
been analyzed for AKt, ALK, brAF, EGFr, Erbb2, FGFr, GNAQ, HrAs, 
KIt, KrAs, MAP2K, MEt, NOtcH1, PDGFrA, PI3KcA, PtEN, rEt, 
stK11, tP53, and VHL mutations. the median age was 60 years (range 
26-76), 29 (35%) were female, 58 (70%) had adenocarcinoma, 72 (67%) 
were former/current smokers. Nine patients had incomplete genomic analysis 
due mostly to insufficient tumor cells in the specimen or poor quality DNA. 
Median tumor cells ratio was 50%. Mutations were identified in 43/82 (52%) 
patients (EGFr: 9; KrAs: 10; stK 11: 8; brAF: 4; MEt: 2; PtEN: 2; 
ALK:2, NrAs: 1; Erbb2: 1; PIK3cA: 1…) of whom 11 had concurrent 
mutations. EGFr and KrAs mutations were mutually exclusive. No muta-
tions were identified among 5 never smokers analyzed. the median time 
to complete testing for this initial phase was 30 days. Half of patients with 
genomic alterations were treated with molecularly targeted therapy based on 
their genetic alteration. 
Conclusions: Mutational profiling of NscLc is feasible, can distinguish rel-
evant molecular subsets of lung cancer, and may present an impact on treat-
ment at our cancer institute. Furthers sequencing are in progress and updated 
results will be presented in April 2012.
Disclosure: All authors have declared no conflicts of interest.
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CANCER-ASSOCIATED ONCOGENIC BARD1 ISOFORMS: 
FROM BIOMARKER EXPRESSION STUDIES TO 
DEVELOPMENT OF A BLOOD TEST FOR EARLY 
DETECTION OF LUNG CANCER
I. Irminger-Finger Gynecology and Obstetrics and Medical Genetics and 
Laboratory, University Hospitals Geneva, Geneva, SWITZERLAND
the bArD1 protein binds to, stabilizes, and enhances the tumor suppressor 
functions of brcA1. Highly upregulated expression of aberrant isoforms of 
bArD1, derived from differential splicing, was correlated with poor prognos-
tic factors in breast and ovarian cancer (1, 2) and decreased patient survival 
in lung cancer (3). Previous and ongoing studies have shown that bArD1 
isoforms are tumor drivers and act antagonistically to the E3 ubiquitin ligase 
functions of the bArD1-brcA1 heterodimer. In particular, isoform bArD1 
is promoting cell proliferation by stabilizing the Aurora kinases (4, 5). since 
bArD1 and bArD1π are specifically upregulated and correlated with poor 
prognosis in lung cancer (3) they might act as suitable biomarkers of lung 
cancer progression. to develop a blood test based on bArD1 isoforms, we 
performed ELIsA tests with antibodies against different regions of bArD1 
for the detection of bArD1 isoforms in the blood of lung cancer patients. We 
also generated a peptide library representing 40 epitopes mimicking bArD1 
isoforms, for the detection of autoimmune antibodies recognizing epitopes 
expressed by bArD1 isoforms. bArD1 protein isoforms could be detected 
by ELIsA in various serum samples, however, using peptides for capturing 
autoimmune antibodies directed against bArD1 isoforms seemed more prom-
ising. serum samples from 60 non-small cell lung cancer (NscLc) patients, 
obtained at time of diagnosis, and 40 control sera from phenotypically healthy 
volunteers, should significant differences between NscLc cancer patients and 
controls. Applying a combination of seven peptides, lung cancer was detected 
with 87% sensitivity and 68% specificity. thus, antibodies against bArD1 
isoforms are telltales of lung cancer and their detection can be further devel-
oped towards a blood test. Experiments including larger patients and control 
group numbers, sera from patients with different types of lung cancer, as well 
as the comparison of this bArD1 isoform test with the standard test for lung 
cancer detection (ct scan), are currently ongoing, and should lead to opti-
mized test conditions and a definition of the target patient set.
1) Wu et al. Int J cancer 118, 1215-1226.
2) Li et al. cancer res 67, 11876-11885. 
3) Zhang et al. Int J cancer. 2011 Aug 3. doi: 10.1002/ijc.26346. [Epub ahead 
of print].
4) ryser et al. Int J cancer. 2011 Aug 3. doi: 0.1002/ijc.26346. [Epub ahead 
of print].
5) bosse et al. can res, 2012 in press.
Disclosure: I. Irminger-Finger: Author of patent submitted, scientific advi-
sory of biotech company.
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DNA METHYLATION PROFILING DEFINES CLINICALLY 
RELEVANT BIOLOGICAL SUBSETS OF NON-SMALL 
CELL LUNG CANCER
D.s. shames1, K. Walter1, t. Holcomb1, L.c. Amler1, G. Hampton1, r. Yauch1, 
r. bourgon2, P. Du2 1Oncology Biomarker Development, Genentech Inc., 
South San Francisco, CA, UNITED STATES OF AMERICA, 2Bioinformatics, 
Genentech Inc., South San Francisco, CA, UNITED STATES OF AMERICA
Purpose: NscLcs comprise multiple distinct biological groups with differ-
ent prognoses. Patients with epithelial-like (EL) tumors have a better prog-
nosis and exhibit greater sensitivity to inhibitors of the EGFr pathway than 
patients with mesenchymal-like (ML) tumors. Here we test the hypothesis 
that EL NscLcs can be distinguished from ML NscLcs on the basis of 
global DNA methylation patterns.
Methods: to determine whether phenotypic subsets of NscLc can be defined 
based on their DNA methylation patterns, we combined microfluidics-based 
gene expression analysis and genome-wide methylation profiling. We derived 
robust classifiers for both gene expression and methylation in cell lines and 
tested these classifiers in surgically resected NscLc tumors. We validate our 
approach using quantitative rt-Pcr and methylation specific Pcr in FFPE 
biopsies.
Results: We show that patterns of methylation divide NscLcs into EL 
and ML subsets as defined by gene expression and that these signatures are 
similarly correlated in NscLc cell lines and tumors. We identify multiple 
DMrs, including one in Erbb2 and one in ZEb2, whose methylation status 
is strongly associated with an epithelial phenotype in NscLc cell lines, surgi-
cally resected tumors, and FFPE biopsies from NscLc patients who went on 
to fail front-line chemotherapy.
Conclusions: Our data demonstrate that patterns of DNA methylation can 
divide non-small lung cancers into two phenotypically distinct subtypes of 
S32 Copyright © 2012 by the European Lung Cancer Conference and the International Association for the Study of Lung Cancer
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tumors and provide proof of principle that differences in DNA methylation can 
be used as a platform for predictive biomarker discovery and development.
Disclosure: D.s. shames, K. Walter, t. Holcomb, L.c. Amler, G. Hampton, 
r. Yauch, r. bourgon, P. Du are all employees of Genentech.
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MAINTENANCE OF DNA REPAIR IN PREINVASIVE 
SQUAMOUS BRONCHIAL LESIONS
s. Lantuejoul1, J. soria2, L. Mescam1, s. Gazzeri3, A. toffart4, c. Dumontet5, 
L. Jordheim5, D. Moro-sibilot4, c. brambilla6, E. brambilla7 1Department 
of Pathology, Grenoble University Hospital, Inserm U823, Grenoble Cedex, 
FRANCE, 2Department of Medicine, Institut Gustave Roussy, Villejuif, 
FRANCE, 3Inserm U823, Institut Albert Bonniot, La Tronche, FRANCE, 
4Thoracic Oncology, Grenoble University Hospital, Grenoble Cedex, 
FRANCE, 5Faculté Rockefeller, Inserm 1052 / CNRS 5286 - CRCL - Lyon, 
Hospices Civils de Lyon, Lyon Cedex, FRANCE, 6Department of Pneumology, 
Grenoble University Hospital, Inserm U823, Grenoble Cedex, FRANCE, 
7Department of Pathology, Grenoble University Hospital, Grenoble Cedex, 
FRANCE
Background: Preinvasive lesions occur frequently in squamous cell carci-
noma (scc) as the result of a stepwise accumulation of genetic and molecular 
alterations driving their progression at multicentric sites in the cancerization 
field. We have already shown that P53, cyclin D1 and E, bcl2 and VEGF over-
expression as well as telomere shortening are characteristics of these preinva-
sive states and progress from low grade to high grade lesions. We have also 
demonstrated a progressive escape from G2 cell cycle checkpoints (AtM, 
cHK2 phosphorylation) increasing the genetic instability.
Objective: We assessed the level of expression of DNA repair genes of the 
NEr pathway (Ercc1, brcA1, rrM1) in order to evaluate the capacity of 
DNA repair following DNA injury, toxics and drugs.
Methods: Immunohistochemical (IH) scores of Ercc1, brcA1 and rrM1 
were assessed in 28 patients with several preinvasive lesions in the bronchial 
tree in the vicinity of an invasive scc. We examined 22 metaplasia, mild 
dysplasia and moderate dysplasia, 21 severe dysplasia and carcinoma in situ 
(cIs) and corresponding invasive scc.
Results: IH scores were calculated by multiplying intensity (1-3) by percent-
age of positive cells (0-300). the cut-off of high level versus low level was 
determined by the median score of these expressions on the normal bronchial 
epithelium: 140, 100, 105, for Ercc1, brcA1 and rrM1, respectively. the 
mean scores of metaplasia (190, 130, 133), mild dysplasia (220, 150, 150), 
moderate dysplasia (250, 180, 180), severe dysplasia (250, 200, 180) and their 
corresponding cIs (250, 200, 200) were observed for Ercc1, brcA1 and 
rrM1, respectively, although the invasive scc mean scores were 160, 170, 
170, respectively. At the two ends of the spectrum, metaplasia/mild dysplasia 
and invasive carcinoma, a few lesions were of low score: 30%, 13%, 20% 
of metaplasia; 5%, 7%, 14% of mild dysplasia, 31%, 0%, 5% of scc for 
Ercc1, brcA1 and rrM1, respectively, whereas moderate, severe dyspla-
sia and cIs displayed high level compared with normal bronchi.
Conclusion: there was a “cloche” phenomenon in the expression of DNA 
repair genes and overall a maintenance of DNA repair along the spectrum 
of preinvasive lesions. We conclude that genetic instability is not impaired 
through DNA repair gene loss in preinvasive squamous lesions.
Disclosure: All authors have declared no conflicts of interest.
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A NEW MEDICAL DEVICE FOR IN-VIVO ISOLATION OF 
CIRCULATING TUMOR CELLS IN NON SMALL CELL 
LUNG CANCER (NSCLC) PATIENTS
L. Gasiorowski1, s. Herold2, N. Morgenthaler2, G. Dworacki3, K. Luecke2, 
W. Dyszkiewicz1 1Thoracic Surgery, Poznan University of Medical Sciences, 
Poznan, POLAND, 2Lung Cancer Research, GILUPI GmbH, Potsdam, 
GERMANY, 3Clinical Immunology, Poznan University of Medical Sciences, 
Poznan, POLAND
Background: In NscLc, the number of circulating tumor cells (ctcs) is dis-
cussed as a prognostic and stratification biomarker, and could also judge the 
treatment efficacy. currently, ctcs are isolated in vitro from small limited vol-
umes of blood samples. Furthermore, results for NscLc are scarce. the aim of 
the study was to assess a functionalized and structured medical wire (FsMW) 
for in vivo isolation of ctcs directly from the blood of NscLc patients.
Material and methods: the device was inserted in a cubital vein through 
a standard iv cannula for 30 minutes. the interaction of target ctcs with 
the FsMW was mediated by an antibody directed against the epithelial cell 
adhesion molecule (EpcAM). to confirm the ctcs binding to the wire, the 
immunohistochemical staining against EpcAM as well as cD45 for nega-
tive cell selection was performed. there were 72 applications of the wire 
in 48 NscLc patients staged from IA to IIIb and 12 non-cancer patients. 
Enumeration data from 34 NscLc patients with 46 applications and 8 non-
cancer patients were assessed. 
Results: the device was well tolerated in all 72 applications without side 
effects. We obtained in vivo isolation of ctcs in 94 % NscLc patients. the 
sensitivity was similar for early and late stage NscLc patients. the median 
(range) of isolated EpcAM-positive ctcs was 13 (0-300). In the non-cancer 
patients, no ctcs were detected. 
Conclusions: this proof of concept study may have important clinical impli-
cations, as the implementation of the device into clinical practice may improve 
early detection, prognosis and therapy monitoring of NscLc patients.
Disclosure: Ms. Herold is a study coordinator for GILUPI GmbH. Dr. 
Morgenthaler is a cMO for GILUPI GmbH. Dr. Luecke is a cEO for GILUPI 
GmbH. All other authors have declared no conflicts of interest.
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NEW SYNERGISM BETWEEN AZACITIDINE AND 
DASATINIB IN LUNG CANCER CELL TREATMENT
s.I. rothschild1,2, M.P. tschan1,3, M. Gugger4, O. Gautschi1,5 1Department of 
Clinical Research, University of Bern, Bern, SWITZERLAND, 2Department 
of Internal Medicine, Medical Oncology, University Hospital Basel, Basel, 
SWITZERLAND, 3Department of Medical Oncology, Inselspital, Bern 
University Hospital and University of Bern, Bern, SWITZERLAND, 4Institute 
of Pathology, University of Bern, Bern, SWITZERLAND, 5Medical Oncology, 
Luzerner Kantonsspital, Luzern, SWITZERLAND
src is frequently overexpressed in human lung cancers and regulates the 
growth and survival of lung cancer cells in vitro. Nevertheless, clinical trials 
failed to demonstrate significant antitumor activity by src inhibition alone in 
patients with advanced, pretreated lung cancer so far (reviewed in: rothschild, 
clin Lung cancer 2010). We recently found that exogenous mir-29b expres-
sion sensitized lung cancer cells to to src kinase inhibitors by targeting ID1 
(rothschild, Oncogene 2012). because mir-29b is known to target DNA 
methyltransferase (DNMt), we speculated that pharmacological inhibition of 
DNMt may mimic the effects seen by mir-29b expression in response to src 
tryrosine kinase inhibitors. to test our hypothesis, we studied the differential 
effect of src kinase inhibiton (saracatinib and dasatinib) and DNMt inhibition 
(decitabine and azacitidine) on ID1 mrNA expression by rtqPcr in human 
lung cancer cell lines, and found that the reduction of ID1 mrNA was greater 
with combined src and DNMt inhibition compared with inhibition of src or 
DNMt alone. then, we examined the effect of the novel combination on cell 
migration using scratch assays, and found that azacitidine at clinically relevant 
concentrations (100-1’000 nM) significantly increased the effect of dasatinib, 
compared with dasatinib alone. Moreover, the combination of azacitidine and 
dasatinib induced cell death as measured by alamar blue assay and clonogenic 
assay, whereas dasatinib was merely cytostatic as a single agent. these prelimi-
nary results support our hypothesis and justify further preclinical work on a 
new, rationally designed drug combination for the treatement of lung cancer.
Disclosure: All authors have declared no conflicts of interest.
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THE ALK/MET INHIBITOR CRIZOTINIB INHIBITS 
EXPRESSION OF THE STEM CELL GENE ID1 AND 
MIGRATION OF MET-POSITIVE LUNG CANCER CELLS 
INDEPENDENTLY OF ALK-FUSION
E. stutz*1,2, s.I. rothschild*1,3, M.F. Fey1,2, M. Gugger4, M.P. tschan1,2, 
O. Gautschi1,5 1Department of Clinical Research, University of Bern, Bern, 
SWITZERLAND, 2Department of Medical Oncology, Inselspital, Bern 
University Hospital, Bern, SWITZERLAND, 3Medical Oncology, University 
Hospital Basel, Basel, SWITZERLAND, 4Institute of Pathology, University 
of Bern, Bern, SWITZERLAND, 5Medical Oncology, Cantonal Hospital, 
Lucerne, SWITZERLAND. *Both authors contributed equally
Background: Anaplastic lymphoma kinase (ALK) fusion-type oncopro-
teins are found in a subgroup of non-small cell lung cancer (NscLc) (soda 
2007).the ALK inhibitor crizotinib (Xalkori®) is highly active in patients 
with ALK fusion-positive tumors (shaw 2010). crizotinib also targets MEt 
and its downstream target src (Zillhardt 2010). We previously identified 
the inhibitor of differentiation 1 (ID1) as an important downstream effector 
of src (Gautschi 2008). ID1 and src are frequently expressed in NscLc 
(rothschild 2011). In the current study, we explored the effects of crizotinib 
on ID1 expression and cell migration in NscLc cell lines. 
Methods: two ALK fusion-negative (A549, H460) and two ALK fusion-posi-
tive lung cancer cell lines (H2228, H3122) were incubated with crizotinib, the 
MEt inhibitor PHA, or the src inhibitor saracatinib. ID1 mrNA levels were 
measured by quantitative real-time rt-Pcr. Western blotting was performed 
for p-ALK, ALK, p-MEt, MEt, p-src, src and ID1. Migration assays were 
performed using A549 cells. Lentiviral vectors expressing shMEt were used 
to stably knock-down MEt expression. 
Results: In the ALK-positive cell lines H2228 and H3122, crizotinib decreased 
ID1 mrNA, p-MEt, and ID1 protein levels in a dose-dependent manner. In 
H2228 p-src levels were reduced upon crizotinib. PHA and saracatinib led 
to similar effects on ID1 expression as crizotinib. Expression of p-MEt was 
detected in A549 cells, but not in H460 cells. A decrease of p-MEt, p-src 
and ID1 upon crizotinib was detected only in A549 cells. crizotinib as well 
as stable MEt knock-down decreased ID1 and induced the level of p-src 
in H3122 cells. stable MEt knock-down decreased ID1 expression and the 
migratory potential of A549 cells in a similar way than crizotinib. 
Conclusions: these preliminary results indicate that the effects of crizotinib 
on ID1 expression and cancer cell migration are associated with the presence 
of activated MEt, rather than ALK fusion. Ongoing studies will determine 
whether crizotinib has clinical activity in ALK fusion-negative tumors that 
contain MEt activation, and if compensatory reactivation of src mediates 
resistance to MEt inhibitors.
Disclosure: s.I. rothschild, M. Gugger and O. Gautschi: Honorary for 
advisory boards from Pfizer. All other authors have declared no conflicts of 
interest.
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PROGNOSTIC IMPACT OF HYPOXIA-INDUCIBLE 
MICRORNA-210 IN PATIENTS WITH LUNG 
ADENOCARCINOMA
J. Osugi, Y. Kimura, N. Okabe, t. Hasegawa, A. Yonechi, M. Hoshino, M. 
Higuchi, Y. shio, H. suzuki, M. Gotoh Regenerative Surgery, Fukushima 
Medical University, Fukushima City, JAPAN
Purpose: Hypoxia-inducible factor 1 (HIF-1) is overexpressed in many 
tumors, including in non-small cell lung cancer (NscLc). the importance of 
HIF-1 is based on its association with patient mortality. A study published 
in 2007 revealed that mir-210 is the most upregulated microrNA in hypoxic 
tissues, with roles in various functions such as apoptosis and tumor growth. 
Furthermore, mir-210 is regulated by HIF-1. since HIF-1 is associated 
with poor prognosis in NscLc, we investigated mir-210 expression in vitro 
and in vivo to make correlations with NscLc clinical characteristics, and 
thus investigate its potential as a prognostic factor. 
Patients and methods: We used qrt-Pcr to examine two NscLc cell lines 
and 80 NscLc tissue samples (62 adenocarcinomas, 18 squamous cell carcino-
mas) paired with 30 matched normal adjacent tissue samples. HIF-1 mrNA 
and mir-210 mirNA expression in NscLc samples was analyzed to clarify 
the prognostic impacts in NscLc. Furthermore, the effect of hypoxic induction 
of HIF-1 and mir-210 expression was compared between an adenocarcinoma 
cell line (A549) and a squamous cell carcinoma cell line (rErF-Lc-AI). 
Results: both HIF-1 and mir-210 expression showed an inverse cor-
relation with disease-free survival of NscLc patients (p=0.007, p=0.001, 
respectively). Multivariate cox analysis indicated mir-210 expression was 
an independent prognostic factor for disease-free survival (p=0.012). We 
further analyzed the prognostic significance of mir-210 expression by his-
tological subtype and found it correlated with lymph node metastasis, late 
disease stages, and poor prognosis in patients with adenocarcinoma (p=0.034, 
p=0.019, p=0.021 respectively), whereas no relationship was found in patients 
with squamous cell carcinoma. In vitro, hypoxia induced much higher HIF-1 
and mir-210 expression in adenocarcinoma cells than squamous cell carci-
noma cells (p<0.001). 
Conclusions: We determined that mir-210 is overexpressed in node-positive 
adenocarcinoma, and it is associated with poor clinical characteristics in ade-
nocarcinoma, but not in squamous cell carcinoma. Our study provides the first 
evidence for the clinical impact of mir-210 in lung cancer and its importance 
as a prognostic biomarker.
Disclosure: All authors have declared no conflicts of interest.
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ERCC1 AND BETA-TUBULIN III IN ADVANCED NSCLC 
PATIENTS TREATED WITH CISPLATIN-VINORELBINE
G. de castro Jr.1, c.r. Victor2, F.J. bigaton2, t.K. takahashi1, O. Feher1, A.M. 
Ab´saber3, t.Y. takagaki4, s.A.c. siqueira5, r. chammas6, P.M.G. Hoff1 
1Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Sao Paulo, 
BRAZIL, 2FMUSP, Faculdade de Medicina da Universidade de Sao Paulo, 
Sao Paulo, BRAZIL, 3Pathology, Instituto do Câncer do Estado de São Paulo, 
Sao Paulo, BRAZIL, 4Pneumology, Hospital das Clinicas da Faculdade de 
Medicina da Universidade de Sao Paulo, Sao Paulo, BRAZIL, 5Pathology, 
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao 
Paulo, Sao Paulo, BRAZIL, 6Lim-24 - Experimental Oncology, Faculdade de 
Medicina da Universidade de Sao Paulo, Sao Paulo, BRAZIL
Background: Platinum-containing chemotherapy remains as the standard 
treatment in advanced/metastatic non-small-cell lung cancer (NscLc) 
patients (pts). Increased Ercc1 expression has been associated with resis-
tance to platinum-based therapies, and beta-tubulin III (tUbb3) was shown 
to be involved in resistance to antimicrotubule agents. Here we studied these 
tumor markers in NscLc pts treated with cisplatin-vinorelbine and corre-
lated their expression with survival. 
Methods: It is a retrospective study on pts diagnosed with advanced/meta-
static NscLc (tNM 6th ed), consecutively identified. All pts were treated 
with cisplatin 80 mg/m2 d1 and vinorelbine 30 mg/m2 d1, d8, d15, every 21 
days, 4–6 cycles, in our Institution, between sep/2002 and Oct/2008. Ercc1 
(clone 8F1) and tUbb3 (clone tUJ1) expression were evaluated by immuno-
histochemistry, and biomarker expression was considered as high when more 
than 10% of tumor cells presented moderate to strong staining, nuclear or 
cytoplasmic, respectively. Overall survival (Os) was estimated by the Kaplan-
Meier method and curves were compared with log-rank. 
Results: 142 pts were studied; median age 63 y (34-87), 67% male and 86% 
current smokers. Adenocarcinoma (ADc, 58 pts, 43%), followed by squamous 
cell carcinoma (scc, 50 pts, 37%) were the most frequent histologic types. 
100 pts (71%) were staged as IV and 34 pts (24%) as IIIb. the median num-
ber of cycles was 4 (1-7). Median Os was 7.9 mo. Overall, high Ercc1 
expression was observed in 61/104 pts (59%) and high tUbb3 expression in 
55/109 pts (51%). According to histologic types, low Ercc1 expression was 
observed in 7/42 scc pts (16%) and in 35/63 ADc pts (56%) (p=0.0004). 
Among ADc pts, 1-y Os rate was 28% and 47% in pts which tumors pre-
sented with high and low Ercc1 expression, respectively (Hr 1.57, 95% cI 
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0.9-2.7, p=0.08). tUbb3 expression neither presented any difference between 
scc and ADc types, nor any prognostic impact in terms of Os. 
Conclusions: Low Ercc1 expression was observed more frequently in pts 
with advanced lung ADc and it was a favorable prognostic factor in ADc pts 
treated with cisplatin-vinorelbine.
supported in part by FAPEsP 2010/15761-9 and 16134-8 grants.
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KI67 AS A PROGNOSTIC MARKER IN MALIGNANT 
PLEURAL MESOTHELIOMA
b. Ghanim1, G. Ostoros2, M.A. Hoda1, t. Klikovits1, M. Filipits3, b. Dome1, 
U. setinek4, W. Klepetko1, W. berger1, b. Hegedus1 1Thoracic Surgery, Medical 
University of Vienna, Vienna, AUSTRIA, 2Department of Tumor Biology, 
National Koranyi Institute of Pulmonology, Budapest, HUNGARY, 3Institute of 
Cancer Research, Medical University of Vienna, Vienna, AUSTRIA, 4Division 
of Pathology, Otto Wagner Hospital, Vienna, AUSTRIA
Purpose: Malignant pleural mesothelioma (MPM) is an aggressive malig-
nancy with increasing incidence. Despite the various immunohistochemis-
try markers used in mesothelioma pathology, there is only one pathological 
prognosticator accepted, namely the histological subtype. therefore, we have 
investigated the prognostic value of the Ki76 mitotic index in MPM.
Patients and methods: the clinical relevance of the proliferation marker 
Ki67 was first studied in an Austrian cohort (AUt) of paraffin-embedded tis-
sue samples from 55 MPM patients. Next, we confirmed these findings in an 
independent Hungarian cohort (HUN) of 42 patients. the results were docu-
mented as the percentage of tumor cells with nuclear Ki67 per high power 
field and correlated with the clinical outcome of the patients.
Results: Median percentage of Ki67 positive tumor cells was 10% for all 
patients, 10% for the AUt and 11% for the HUN cohort. Patients with low 
Ki67 index (≤ 10%) had a significantly longer overall survival than those 
with high Ki76 indices (AUt: hazard ratio [Hr] 2.49, 95% confidence inter-
val [cI] 1.30–4.79, p<0.01; HUN: Hr 2.54, cI 1.26–5.13, p<0.01). In the 
multivariate analyses of the Austrian cohort (n=54) Ki67 index retained the 
prognostic power independent of gender, age, treatment, stage and histology. 
treatment (Hr 4.02, cI 1.82–8.90, p<0.01) and Ki67 index (Hr 2.19, cI 
1.07-4.47, p=0.03) were the remaining independent significant prognostica-
tors in the multivariate cox regression model. In this analysis biphasic histol-
ogy showed a tendency for worse prognosis when compared to the epitheloid 
subtype (Hr 1.96, cI 0.94-4.07, p=0.07).
Conclusion: this study reveals Ki67 index as an independent, reproducible 
prognostic factor in malignant pleural mesothelioma and warrants further 
prospective investigation in MPM patients.
Disclosure: All authors have declared no conflicts of interest.
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ANALYTICAL PERFORMANCE AND WORKFLOW 
COMPARISON STUDY OF THREE METHODS FOR 
DETECTING EGFR MUTATIONS IN FORMALIN-FIXED 
PARAFFIN-EMBEDDED TISSUE (FFPET) SPECIMENS OF 
NON-SMALL CELL LUNG CANCER (NSCLC)
F. Lopez-rios1, b. Angulo1, b. Gomez2, D. Mair2, r. Martinez1, E. conde1, 
F. shieh3, J. tsai3, H.J. Lawrence3, D. Gonzales de castro2 1Hospital 
Universitario Madrid Sanchinarro, Laboratorio de Dianas Terapeuticas, 
Madrid, SPAIN, 2Institute of Cancer Research, Royal Marsden NHS Hospital, 
Surrey, UNITED KINGDOM, 3Genomics and Oncology, Roche Molecular 
Systems, Pleasanton, CA, UNITED STATES OF AMERICA
Anti-EGFr tyrosine kinase inhibitors are indicated as first line therapy of 
metastatic EGFr–mutant NscLc, so it is critical to have a robust, accurate 
and reproducible EGFr test method with rapid time to results. We conducted 
a 2-site method comparison study of 2 cE-IVD marked assays - 1) Allele - 
specific Pcr-based cobas® EGFr Mutation test, which detects 41 mutations 
in exons 18, 19, 20, and 21, and 2) ArMs-scorpion Pcr-based therascreen® 
EGFr29 Mutation Kit, which detects 29 mutations in the same 4 exons - 
and 2x bi-directional sanger sequencing. We tested 125 FFPEt specimens 
of NscLc with all 3 methods in a blinded manner; the cobas® test was 
performed at both sites. Positive (PPA) and negative (NPA) percent agree-
ments were determined for the cobas® test vs. each of the other 2 methods. 
specimens with discrepant results were tested using quantitative massively 
parallel pyrosequencing (454 Gs-titanium). Invalid rates, turnaround times 
and repeatability were assessed. PPA between cobas® and sanger was 93.3%; 
NPA was 76.7%. Overall there were 13 discrepant results. Of 7 specimens 
that were mutation-positive by cobas® and negative by sanger, 454 con-
firmed an exon 19 deletion in 3 cases and an exon 21 L858r mutation in 4 
cases. Amongst the 6 discrepant specimens that were mutation-negative by 
cobas®and positive by sanger, 5 cases were rare L861Q mutations, which the 
cobas test is not designed to detect. In one case sanger detected an insertion 
in exon 20 and was called wild-type by 454. PPA between cobas® and ther-
ascreen® was 95.8% and NPA was 100%. there were 4 discrepant results, 3 
of which represented L861Q mutations. Invalid rates were 0.4% for cobas®, 
0% for therascreen® and 3.2% for sanger. Approximate turnaround times 
were 1 day for cobas® and 7 days for sanger for 24 samples, and 1 day for 
therascreen® for 10 samples. repeatability of the cobas® test between the 2 
sites was 99.2%. the invalid rates for the cobas® test and therascreen® were 
lower than sanger sequencing. the cobas® and therascreen® assays showed a 
high degree of concordance, and both were more sensitive for the detection 
of exon 19 deletions and L858r mutations than sanger. the cobas® test was 
highly reproducible between the two testing sites, had the greatest throughput 
and the shortest estimated turnaround time, and was the only assay with auto-
mated results reporting.
Disclosure: F. Lopez-rios, b. Angulo, b. Gomez, D. Mair, r. Martinez, E. 
conde, D. Gonzales de castro: this study was funded by roche Molecular 
systems. Felice shieh is an independent consultant for roche Molecular 
systems. Julie tsai and Jeffrey Lawrence are full time employees at roche 
Molecular systems.
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FEASIBILITY OF EPIDERMAL GROWTH FACTOR 
RECEPTOR MUTATION TESTING IN CYTOLOGY 
SAMPLES
t.L.A. Malfait1, L. Ferdinande2, J.P. van Meerbeeck1, D. Galdermans3, 
V. surmont1, r. Forsyth2, K. Vermaelen1, M. Praet2, K.G. tournoy1 1Respiratory 
Medicine, Univerity Hospital Ghent, Ghent, BELGIUM, 2Department of 
Pathology, University Hospital Ghent, Gent, BELGIUM, 3Respiratory 
Medicine, ZNA Middelheim, Antwerp, BELGIUM
Background: cytology samples obtained by endobronchial ultrasound 
(EbUs) fine needle aspiration (FNA), transoesophageal ultrasound (EUs) 
FNA, transthoracic (tt) ct guided FNA and bronchial washings are increas-
ingly used to diagnose non-small cell lung cancer (NscLc). testing for the 
activating Epidermal Growth Factor receptor (EGFr) mutations in these 
cytology samples can be challenging and is increasingly needed due to the 
lack of other adequate diagnostic material.
Aim: to compare the yield of testing for activating EGFr mutations in cytol-
ogy samples versus histology samples in a consecutive series of patients (pts) 
with NscLc diagnosed at Ghent University Hospital.
Methods: Medical files of pts with NscLc in between December 2009 and 
December 2011 and tested for an activating EGFr mutation were reviewed. 
EGFr mutation testing was done with therascreen®: EGFr29 Mutation Kit 
– Pcr based. Differences were evaluated using the Fisher’s exact test.
Results: there were 99 patients tested for EGFr mutation: 69 (70%) had his-
tology samples and 30 (30%) had cytology samples. Histology samples were 
surgical resection specimens (n=50) and biopsy samples (n=19). cytology 
samples were EUs (n=2), EbUs (n=25), tt (n=1) and bronchial washing 
(n=2). In histology samples mutation test was not feasible in 3/69 (4%). In 
cytology samples mutation testing was not feasible in 8/30 (27%; p=0,003). In 
the surgical resection specimens only 1/50 (2%) samples could not be evalu-
ated while this was 2/19 (11%; p=0,18) in the biopsy samples. the prevalence 
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of EGFr mutation was 13/66 (20%) in the histology specimens and 4/22 
(18%; N.s.) in the cytology samples.
Conclusion: EGFr mutation testing in cytology specimens is feasible espe-
cially in EUs/EbUs FNA samples, but is associated with a higher rate of 
non-evaluable samples compared to histology specimens.
Histology (n=69) Cytology (***) 
(n= 30) 
Resection 
Specimen (*) 
(n=50) 
Biopsy (**) 
(n=19) 
n % n % n % 
Wt 37 74 16 84 18 60 
Mutations 12 24 1 5 4 13 
Non Evaluable 1 2 2 11 8 27 
*Every specimen obtained by a surgical procedure ** Endobronchial biopsy or core 
biopsy *** EUs / EbUs / transthoracic FNA (tt) / endobronchial washing 
Disclosure: All authors have declared no conflicts of interest.
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CTL ANTIGEN 4 (CTLA-4) AND KI67 AS PROGNOSTIC 
FACTORS IN RESECTED STAGE I-III NON-SMALL CELL 
LUNG CANCER (NSCLC) PATIENTS
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M. truini3, M.P. Pistillo2, D. Merlo4 1Lung Cancer Unit, National Institute 
for Cancer Research, Genova, ITALY, 2Genetics and Epigenetics, National 
Institute for Cancer Research, Genova, ITALY, 3Department of Pathology, 
National Institute for Cancer Research, Genova, ITALY, 4Epidemiology, 
Biostatistics and Clinical Trials Unit, National Institute for Cancer Research, 
Genova, ITALY
Background: ctLA-4 is a negative regulator of t-cell activation, the admin-
istration of anti-ctLA-4 monoclonal antibody therapy can reduce efficiently 
the migration and proliferation of hematologic and solid tumours. We pre-
viously reported that ctLA-4 is expressed by NscLc cell lines providing 
evidence of its involvement in apoptosis induction upon engagement with 
soluble ctLA-4 ligands (contardi E, Int J cancer 2005). the aim of this 
study was to investigate the relationship between expression of ctLA-4 and 
other two markers functionally related to ctLA-4, -catenin and Ki67, with 
clinicopathologic characteristics and overall survival (Os) to explore their 
prognostic significance.
Methods: We evaluated ctLA-4, -catenin, Ki67 protein expression using 
specimens from 81 patients (pts) resected between 7/2005-3/2007 with stage 
I-III NscLc. the median H-score, calculated using the formula (1 + I) x 
Pc where I is the staining intensity and Pc the percentage of tumor cells 
that stained at each intensity, of 20 and 160 was used as a threshold to define 
ctLA-4 and -catenin overexpressing tumours respectively while a cut-off 
value of 15% was assumed to define Ki67 overexpression.
Results: ctLA-4 expression was positive in 47% of tumours, similar in males 
and females (47% vs 47%) and former-never or current smokers (46% vs 
47%) while was significantly higher in non-squamous than in squamous car-
cinoma (53% vs 36%). similar results were found for Ki67. We also assessed 
the association between ctLA-4 expression and Ki67: 51.1% of patients with 
Ki67≤15 showed ctLA-4 overexpression compared to 38.7% of patients with 
Ki67>15. Patients with lower Ki67 expression and higher ctLA-4 expres-
sion survived longer than those with a higher Ki67 expression (p= 0.069) 
and lower ctLA-4 expression (p=0.078). No significant association was seen 
between -catenin and ctLA-4 and between -catenin and survival.
Conclusion: In conclusion, we found that patients with higher expression 
of ctLA-4 and lower expression of Ki67 had better Os than patient with 
opposite result. this retrospective study represents the first investigation of 
ctLA-4 expression and Ki67 expression as possible prognostic factors for 
Os.
Disclosure: All authors have declared no conflicts of interest.
94P
SYSTEMATIC DETERMINATION OF EPIDERMAL 
GROWTH FACTOR RECEPTOR (EGFR) MUTATION 
STATUS IN PATIENTS WITH NEWLY NON SMALL CELL 
LUNG CANCER (NSCLS): ONE YEAR EXPERIENCE OF A 
SINGLE CENTER
s. Ponce Aix1, A.b. Enguita Valls2, L.c. Iglesias Docampo1, J.A. Nuñez 
sobrino1, E. Vega Alonso3, M. Dorta suarez3, s. Hoyos3, H. cortes-Funes3, 
J.L. rodriguez Peralto2 1Medical Oncology - Lung Cancer Unit, Hospital 12 
de Octubre, Madrid, SPAIN, 2Molecular Pathology, Hospital 12 de Octubre, 
Madrid, SPAIN, 3Medical Oncology, Hosptial 12 De Octubre, Madrid, 
SPAIN
Background: Activating mutations in the epidermal growth factor receptor 
gene (EGFr) are associated with response to the tyrosine kinase inhibitors. 
Detection of EGFr mutations has become an important issue for therapeutic 
decision-making in non–small cell lung cancer. We implemented in our center 
a systematic determination of EGFr.
Methods: We have selected all patients with newly diagnosed non small 
cell lung cancer non squamous between January 2011 to December 2011. 
the objective was to evaluate the EGFr mutation status in a population of 
Hospital 12 de Octubre, Madrid, spain. the therascreen EGFr 29 Mutation 
test Kit (kit for detection of specific mutations, insertions, and deletions in 
the EGFr gene using real-time Pcr) was used.
Results: two hundred and fourteen patients were included, 74 (34.58%) 
women and 140 (65.42%) men; 206 (97.07%) non squamous (including ade-
nocarcinoma, large cell carcinoma and other subtypes), 8 (2.93%) squamous 
cell carcinoma. current smoker 64 (29.91%), former smoker 58 (27.1%), 
never smoker 43 (20.09%) and unknown 49 (22.9%). the tumor samples 
were paraffin embebed 92.36% and cytology 7.63%. Mutation(s) in the kinase 
domain (exon 18 to exon 21) of the EGFr gene were identified in 23 patients 
(10.75%). the mutation rate in women was 82.61% (19) and 17.39% (4) in 
men. Mutations were more frequent in adenocarcinoma 15 (65.22%), large 
cell carcinoma 7 (30.4%), former bronchiole-alveolar carcinoma 1 (4.35%) 
and no mutation was detected in squamous cell carcinoma. the proportion 
of positive mutations was 65.22% (15) in non smokers/former smokers and 
only 4.7% (2) in current smokers. Of the 23 patients with positive mutation 
69.57% had exon 19 deletions, 26.09% had a mutation at exon 21, 4.35% had 
an insertion at exon 20, with no multiple mutation found. the median time 
to diagnosis was 4.05 days and we only had 1.4% patients with unevaluable 
tumour sample. 
Conclusions: systematic determination of EGFr in a public large center is 
feasible offering an acceptable time to result and with good performance. 
the prevalence of EGFr mutation was minor than reported previously due to 
the selection just by histology type. Nowdays EGFr mutation is been doing 
inside a larger molecular diagnosis platform in our center.
Disclosure: All authors have declared no conflicts of interest.
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FREQUENCY OF EGFR MUTATIONS IN NON-SMALL-
CELL LUNG CANCER (NSCLC) FROM GREEK PATIENTS
E. Papadopoulou, s. Murray, c. Efstathiadou, G. Nasioulas Molecular 
Biology, GeneKor SA., Gerakas, Athens, GREECE
Background: NscLc patients harboring activating somatic mutations within 
the tyrosine kinase (tK) domain of the epidermal growth factor receptor 
(EGFr) significantly benefit from EGFr targeted therapy. treatment with 
the recently approved EGFr inhibitor IrEssA (gefitinib) leads to improved 
response and survival outcomes, therefore screening for EGFr mutations has 
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entered routine clinical practice. several clinico-pathological factors corre-
late with these mutations including gender, smoking history, and histology. 
the frequency of EGFr mutations is also ethnicity-dependent, wherein the 
incidence in Asian populations is ~30%, while in caucasians (Whites) it is 
lower, ~15%. However, limited data is available on intra-ethnic differences 
throughout Europe.
Aim: the aim of this study was to determine the frequency and spectrum of 
EGFr mutations in an unselected group of Greek NscLc patients and inves-
tigate technical aspects of analysis.
Methods: We set up High resolution Melting Analysis (HrMA) assays 
to identify mutations in exons 18-21 of the EGFr gene and validated their 
analytical sensitivity by making serial dilutions of samples with known 
mutations and tumor cell content (tcc). A total of 698 NscLc patients 
were screened with HrMA for somatic EGFr mutations in exons 18-21 
and mutation status was verified by bi-directional sequencing. ME-Pcr 
(mutant enriched-Pcr) was used in conjunction with standard bi-directional 
sequencing in a further 300 patients. Pathological review was obtained for 
all samples and macro-dissection was used to ensure a %tcc of >75% in 
all possible cases.
Results: the sensitivity of our HrM assays was found to be ≤1.5% Using 
HrMA and bi-directional sequencing a frequency of 19.05% was obtained; 
105 x exon 19, 21 x exon 21, 6 x exon 20 and 1 x exon 18. Using ME-Pcr 
the mutational frequency was 16.3%; 21 x exon 19, 22 x exon 21, 4 x exon 
20 and 2 x exon 18.
Conclusions: Applying a very sensitive mutation detection technique in a large 
cohort of unselected Greek NscLc patients in routine diagnostic practice, we 
obtained an overall mutation frequency of 19.05%. this mutation frequency is 
similar to that found by the sLADb and EUrtAc studies in European popula-
tions. Differences in sensitivity between techniques suggest that more than one 
technique should be advised in routine diagnostic practice.
Disclosure: All authors have declared no conflicts of interest.
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ACTIVATING EGFR MUTATIONS IN PATIENTS WITH 
NON SMALL CELL LUNG CANCER: PREVALENCE AND 
PREDICTORS IN A CAUCASIAN SERIES
t.L.A. Malfait1, L. Ferdinande2, K.G. tournoy1, D. Galdermans3, M. Praet2, 
V. surmont1, r. Forsyth2, K. Vermaelen1, J.P. van Meerbeeck1 1Respiratory 
Medicine, University Hospital Ghent, Ghent, BELGIUM, 2Department 
of Pathology, University Hospital Ghent, Gent, BELGIUM, 3Respiratory 
Medicine, ZNA Middelheim, Antwerp, BELGIUM
Background: somatic mutations in epidermal growth factor receptor (EGFr) 
gene predict for sensitivity to tyrosine kinase inhibitors (tKI’s) in patients 
(pts) with advanced non small cell lung cancer (NscLc). Most data were 
obtained in Asian pts.
Aim: to measure the prevalence and clinical distribution of EGFr muta-
tions in a single institutional series of caucasian pts from Ghent University 
Hospital.
Methods: Medical files between December 2009 and December 2011 were 
reviewed for activating EGFr mutation testing. (therascreen®: EGFr29 
Mutation Kit – Pcr based). Differences between mutation postives and nega-
tives were evaluated using the Fisher’s exact test.
Results: 99 patients were identified. Median age was 65 years. the test was 
not feasible in 11 (11%) due to inadequate sampling. so EGFr mutation prev-
alence was assessed in 88 (89%) of the samples. In 19% (17/88), an activating 
mutation was found (Mut+ group, n=17)): 8/17 (47%) L858r mutations, 8/17 
(47%) exon 19 deletions and 1/17 (6%) exon 20 insertion. In wild type (Wt) 
(Mut – group, n=71) 45% (32/71) were female while in the mutation positive 
group this was 88% (15/17; p<0.05). In wild type (Wt) 8% (6/71) were never 
smokers while in the mutation positive group this was 53% (9/17; p<0.05). 
Median turnaround time was about 11 days (range 6-29).
Conclusion: In our series EGFr-mutation in caucasians has a prevalence of 
19% and is related to the female gender and a history of never smoking.
Total  
(n= 88) 
Mut – 
(n=71) 
Mut + 
(n=17) 
Gender P < 0.05 
Female 47/88 (53%) 32/71 (45%) 15/17 (88%) 
smoking 
History 
P < 0.05 
Never 15/88 (17%) 6/71 (8%) 9/17 (53%) 
type tumor 
Non squamous 87/88 70/71 17/17 
squamous 1/88 1/71 0/17 
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EXTERNAL QUALITY ASSESSMENT OF EGFR TESTING 
IN WESTERN FRANCE: A 2-YEAR EXPERIENCE
M.G. Denis1, L. Karayan-tapon2, G. Legac3, A. Lespagnol4, A. Morel5, 
J. Pages6 1Institut De Biologie, Laboratorie de Biochimie, Nantes, FRANCE, 
2CHU de Poitiers, UM Oncologie Moléculaire, Poitiers, FRANCE, 
3Laboratorie de Génétique, CHU de Brest, Brest, FRANCE, 4CHU de Rennes, 
Plateforme de Génétique Moléculaire des Cancers, Rennes, FRANCE, 
5Institut de Cancérologie de L’ouest, Département de Biopathologie des 
Cancers, Angers, FRANCE, 6CHRU Trousseau, Service de Biochimie et 
Biologie Moléculaire, Tours, FRANCE
Background: EGFr testing for NscLc patients is routinely performed in 
France, within 28 regional platforms receiving a financial support from the 
French National cancer Institute (INca). In order to evaluate the quality of 
the tests performed in these plateforms, we developed an external quality 
assessment (EQA) protocol.
Method: 6 centers from the western France were involved. Altogether, these 
platforms perform 3.500 EGFr tests per year. the EQA scheme was based 
on the analysis of FFPE lung tumors. One stained section and one unstained 
10 μm section prepared from 2 cases of NscLc were sent by one of the 6 
platforms to all the centers, every second month during the first year (2010), 
and every third month during year 2 (2011). Upon analysis, the following 
informations were collected: percentage of neoplastic cells in the samples, 
mutations tested, techniques used, and EGFr testing results.
Results: During this time period, 20 samples were analyzed by the 6 plat-
forms. slight differences in the estimation of the percentage of cancer cells 
in the samples were observed. technically, different methods were used: 
pyrosequencing, HrM, allele-specific Pcr, sNAPshot, standard sequenc-
ing. Despite these differences, concordant results were obtained for all the 
tested samples. Eight tumors were found to contain an EGFr mutation (4 
exon 19 deletions and 4 p.L858r point mutations). the remaining 12 samples 
presented a wild type EGFr genotype.
Conclusion: since the EQA did not rely on a single center, it was very cost-
effective and not time consuming. It allowed to obtain a continuous evalua-
tion of the platforms and provided useful informations on how the tests were 
performed. the main limitation was that we only used resection specimens 
and not lung biopsies (limited in size). We could complete this EQA by test-
ing, in addition to clinical samples, DNAs prepared from cell lines harbouring 
known EGFr mutations, fixed and embedded as clinical samples.
Acknowledgements: We wish to thank the French National cancer Institute 
for tests funding, and the colleagues involved in this EQA scheme : V. Verriele, 
M. boisdron-celle (Angers) ; L. Doucet, I. Quintin-roue, c. Le Maréchal 
(brest) ; c. sagan, A. Vallée (Nantes) ; P. Levillain, c. Villava (Poitiers) ; s. 
caulet-Maugendre, J. Mosser, N. rioux-Leclercq (rennes) ; s. Guyetant, c. 
collin (tours).
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CLINICAL AND IMMUNOLOGICAL EFFECTIVENESS OF 
DENDRITIC CELL IMMUNOTHERAPY IN LUNG CANCER 
PATIENTS: 5-YEARS FOLLOW-UP PERIOD
N. Khranovska1, V. Ganul2, Y. Grinevich3, V. Orel4, V. sovenko2, A. Ganul2, 
O. skachkova1, V. sitko1, O. Gorbach1, N. svergun1 1Research Laboratory 
of Experimental Oncology, National Cancer Institute, Kiev, UKRAINE, 
2Thoracic Oncology, National Cancer Institute, Kiev, UKRAINE, 3Research 
Laboratory of Clinical Immunology, National Cancer Institute, Kiev, 
UKRAINE, 4Research Laboratory of Medical Physics and Bioengineering, 
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Vaccination using dendritic cells (Dc) represents a novel and promising 
method of lung cancer immunotherapy. Valuable proofs-of-principle have 
been obtained, which favor the use of Dc in subsequent, more standard-
ized clinical trials. Here, we represent a data of 5-years follow-up study of 
Dc-vaccine immunotherapy effectiveness in non-small cell lung cancer 
(NscLc) patients.
Material and methods: Ninety-four eligible patients with IIb-IIIA stage 
NscLc were enrolled into the study. Patients were randomly allocated into 
two groups: 1st - patients who received Dc-vaccine as immunotherapy after 
surgery (lobectomy, pneumonectomy), 2nd - control group of patients who 
received surgery only. comparable groups were similar by age of the patients, 
histotypes of tumors, stages, volumes of surgical intervention. Dc in amount 
4,62 ± 0,37x106 per injection were injected intravenously in 1–3 courses (6 
months interval). One course consisted of 5 injections with one-month inter-
val. clinical and immunological monitoring of Dc-vaccine immunotherapy 
was performed.
Results: Dc-immunotherapy was well tolerated without significant toxicity. 
the comparatively superior survival of patients who received Dc-vaccine 
immunotherapy in comparison with control group was found. During 1- year 
follow-up period 21,5% of patient died in 1st group, 33,8% of patients died in 
control (2nd) group (p=0.029). For patients in Dc-vaccine group the 3-years 
survival rate was 49,1% in contrast to 33,1% in patients of control group 
(p=0.0085). At 5-years follow-up, we could observe that the difference in 
survival rates between two groups decreases, but remains statistically signifi-
cant: 19,2% vs 13,6 % (p=0.0096). Interestingly, all patients (7 patients) who 
received 3 courses of Dc-immunotherapy are alive without sign of disease 
during 29,5 ± 1.34 months. Patient-specific immune response evaluated by 
flow cytometric measurement of interferon-γ-producing t-cells before and 
after vaccination revealed in 44,5% of patients.
Conclusions: Our study demonstrated that Dc-vaccine immunotherapy 
could be conducted without major toxicity and induced tumor cell-specific 
immunological and clinical responses in NscLc patients.
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Background and object: receptor tyrosine kinase (rtK) pathways play 
important roles in tumorigenesis and characteristics of lung adenocarcino-
mas, which has three downstream routes: ras/raf/ErK pathway, PI3K/Akt 
pathway and Jak/stAt pathway. Previously, we demonstrated that the acti-
vated PI3K-Akt pathway was relevant to advanced stages and phosporylated 
(p-) Akt was a poor prognosis marker. Here, to investigate stAt3 activation 
status and its correlation with clinicopathological features of lung adenocar-
cinoma, classified by oncogene changes (EGFr and KrAs mutations and 
EML4-ALK rearrangements).
Methods: Expression of p-stAt3 was detected by immunohistochemistry 
(IHc) in surgically-resected tumors from 212 invasive adenocarcinomas. 
Likewise, we analyzed expression of p-Akt, p-Erk1/2, p-mtOr, p-s6K, 
p-GsK3 as well as ttF-1, a cell lineage marker, and compared with clini-
copathological features, EGFr/KrAs mutation status and EML4-ALK rear-
rangements, using univariate and multivariate analyses. correlations of signal 
transduction molecules including p-stAt3 were analyzed using the Pearson’s 
correlation coefficient.
Results: Positive p-stAt3 expression was detected in 149 of the 212 patients 
(70%). by the univariate analysis, p-stAt3 expression was significantly cor-
related with never smoking, lower stages, well histological differentiation, 
papillary rather than acinar histology, less lymphatic invasion, less vascular 
invasion, less pleural invasion, mutated EGFr and wild-type KrAs status. 
Among 111 patients with mutated EGFr, 88 (79%) patients had positive 
p-stAt3 expression. six of 13 (46%) ALK rearranged tumors showed stAt3 
activation. by the multivariate analysis using the logistic regression model, 
stAt3 activation was independently associated with never or light smokers 
(p=0.026) and the papillary rather than acinar structure (p=0.049). by the 
Pearson’s correlation coefficient, positive correlation was identified between 
p-stAt3 and p-Erk1/2, p-s6K, p-GsK3 and ttF-1 expression.
Conclusion: the stAt3 activation was observed significantly in non-smok-
ers, EGFr-mutated and KrAs wild-type cases, tumors of a ttF-1 positive 
lineage and about half of ALK rearranged tumors.
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Purpose: Many kinds of mechanism involving immunosuppression in cancer 
patients have been reported to date. regulatory t cells (tregs), which express 
the master control transcription factor Foxp3, are thought to have a major role 
in hampering antitumor immune response. However, the clinical impact of 
tregs in patients with lung cancer is still unclear. the aim of this study was 
to investigate the clinical significance of tregs both in peripheral blood and 
in resected cancer tissue. 
Experimental design: We analyzed peripheral blood mononuclear cells 
(PbMc) and resected specimens obtained from 65 patients with non-small 
cell lung cancer (NscLc). Peripheral tregs (ptregs) were detected as cD4+ 
and Foxp3+ cells by flow cytometry. Immunohistochemical staining for cD4, 
cD8 and Foxp3 expression was also performed quantitatively by analyzing 
three randomly selected fields from central regions (ccD4, ccD8 and cFoxp3), 
and interstitial regions of the tumors (icD4, icD8 and iFoxp3). relationships 
between the expression frequencies in selected cells and clinicopathological 
parameters were statistically analyzed. 
Results: the frequency of ptregs was significantly higher in patients who 
had pleural invasion (P=0.0049), vessel invasion (P=0.0009), lymphatic ves-
sel invasion (P=0.0053), and recurrent disease (P=0.0112). Patients who had 
t1 factor had significantly higher frequency of ccD4 (P=0.0199) and ccD8 
(P=0.0058), although cFoxp3 expression was not significant (P=0.0935). 
Patients who had high frequency of ptregs exhibited significantly poorer 
recurrence-free survival (P=0.0071). Multivariate analysis showed ptreg fre-
quency was an independent prognostic factor (P=0.0458). 
Conclusion: Although pathological analyses remains controversial, the 
frequency of ptregs in patients with NscLc could be a useful prognostic 
biomarker.
Disclosure: All authors have declared no conflicts of interest.
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ERYTHROPOIETIN-RECEPTOR (EPOR) EXPRESSION 
AND THE TUMOR SPECIFIC EFFECT OF EPO 
TREATMENT IN LUNG CANCER
b. Hegedus Thoracic Surgery, Medical University of Vienna, Vienna, 
AUSTRIA
Erythropoietin (EPO) is part of the standard care for lung cancer patients with 
anaemia but the clinical findings on the tumor related effects of this treatment 
are inconsistent. Hypoxic tumors are less sensitive to a number of anticancer 
therapies and hypoxia itself promotes progression. Nevertheless, the receptor 
of EPO (EPOr) can also be expressed on lung cancer cells that may sup-
port their survival and growth. Accordingly, we determined the expression 
of EPOr in lung cancer tissue samples and cells and investigated the effect 
of EPO treatment in vitro and in vivo using xenografts of human lung cancer 
cells. First, we analyzed bronchoscopy samples of 99 and 27 patients with 
NscLc and scLc, respectively. the expression of EPOr was measured in 
the tumor and adjacent non-tumorous samples of each patient by real-time 
Pcr. Next, we measured the expression of EPOr in lung cancer cell cultures. 
Finally, we characterized the proliferation of EPO treated lung cancer cell 
cultures and the tumor growth and vascularization in mice carrying xenograft 
subcutaneous human lung cancer cell tumors and treated with recombinant 
human EPO. the expression of EPOr was significantly higher in the NscLc 
bronchoscopy samples when compared to scLc. Nevertheless, we found 
no significant association between EPOr expression levels and survival. 
Although a number of lung cancer cell lines expressed EPOr, EPO treatment 
had no effect on in vitro cell proliferation. Importantly, EPO treatment of 
mice with xenograft tumors resulted in increased proliferation of endothelial 
cells in the tumor and decreased tumor size. Our study suggests that EPO can 
support the proliferation of intratumoral endothelial cells. this, in turn, can 
result in better perfusion of tumor tissue, decrease tumor hypoxia and improve 
the therapeutic efficacy of anti-cancer treatment. However, further studies are 
needed to establish the effect of EPO treatment on the clinical outcome of 
lung cancer.
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SIRT1 REGULATES ENDOTHELIAL DLL4/NOTCH 
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Introduction: sirtuin 1 (sIrt1), nicotinamide adenine dinucleotide 1 
(NAD1)-dependent class III histone deacetylase (HDAc), acts as a key regu-
lator of vascular endothelial homeostasis, angiogenesis, and endothelial dys-
function. However, underlying mechanism of sIrt1-mediated lung cancer 
angiogenesis remains unknown.
Methods: We established lewis lung cancer (LLc) xenograft model in 
endothelial cell-restricted sIrt1, sIrt1 (H363Y) (sIrt1 mutant that lacks 
deacetylase activity) transgenic mice and wild type c57bL/6J mice. Lung 
cancer derived-vascular endothelial cells (Ecs) were isolated from xenograft 
tumor of sIrt1 transgenic mice. Quantitative chromatin immunoprecipita-
tion (qchIP) analysis was used to confirm the binding of sIrt1 and Notch1.
Results: sIrt1 deacetylase activity reduced the abundance of acetylated 
Notch1 intracellular domain (N1Ic). qchIP analysis demonstrated sIrt1 
directly controled Notch1 expression by recruiting to the proximal promoter 
region of Notch1. Knockdown of sIrt1 by sirNA exhibited markedly 
enhanced activity of N1Ic and up-regulated expressions of Notch1 target 
genes HEY1 and HEY2 in lung cancer derived-Ecs. sprouting angiogenesis 
was reduced after knock-down of sIrt1. However, exposure to Notch inhibi-
tor, DAPt (N-[N-(3, 5-difluorophenacetyl)-L-alanyl]-s- phenylglycine t-butyl 
ester), abrogated the inhibition of angiogenic response in sIrt1 sirNA-trans-
fected lung cancer derived-Ecs. consistent with in vitro findings, expres-
sion of sIrt1 was inversely associated with N1Ic expression through its 
deacetylation activity and that deacetylase-defective mutant of sIrt1 (sIrt1 
H363Y) had no effect on N1Ic in vivo. compared to sIrt1 transgenic mice, 
tumor growth in sIrt1 H363Y transgenic mice was much slower and simi-
lar to that in wild type mice. blocking deacetylase activity of sIrt1 using 
HDAc inhibitor, nicotinamid (NAM), resulted in decreased tumor growth in 
the sIrt1 transgenic mice. the stunted tumor growth in sIrt1 H363Y trans-
genic mice was associated with decreased tumor vascularization.
Conclusions: sIrt1 facilitates endothelial branching and proliferation by 
down-regulation of Notch signaling, thereby promoting vascular growth and 
tumor vessel density.
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FACTOR IN NON-SMALL CELL LUNG CANCER
r. berardi1, A. santinelli2, A. Onofri1, A. brunelli3, c. Pierantoni4, P. 
Mazzanti4, A. sabbatini5, I. bearzi2, s. cascinu1 1Clinica di Oncologia Medica, 
Università Politecnica Marche, Ancona, ITALY, 2Anatomia Patologica, 
Università Politecnica Marche, Ancona, ITALY, 3Division of Thoracic Surgery 
and Head of Section of Minimally Inavsive Thoracic Surgery, Ospedali Ruiniti 
Ancona, Ancona, ITALY, 4Clinica di Oncologia Medica, Ospedali Riuniti di 
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Background: Maspin is a unique member of the serine protease inhibitor 
superfamily that suppresses tumour growth, angiogenesis and metastasis. the 
aim of our study was to evaluate the prognostic impact of maspin expression 
in resected non-small cell lung cancer (NscLc) patients.
Patients and methods: From 1996 to 2001, 439 patients underwent radi-
cal surgery for NscLc at Polytechnic University of Marche region. Maspin 
expression was detected as cytoplasmic and nuclear staining of neoplastic 
cells. For the cytoplasmic staining the cases were classified as follows: nega-
tive (<5%), low positive (5-50%) and high positive (>50%). Moreover, in the 
positive cases, the intensity of the staining was also considered and scored as 
1+ (low), 2+ (medium) and 3+ (high). A similar classification was used for 
nuclear staining; in this case, the intensity was not considered.
Results: the analysis showed that smoking history, pathological stage of dis-
ease, N status, histological grading, sex and EcOG performance status had 
a prognostic impact on overall survival (Os). Expression of maspin was also 
found to be an independent prognostic factor. A statistically significant lon-
ger Os was seen in patients with higher as compared with lower expression 
of nuclear maspin (p=0.0098) and a poorer Os was present in patients with 
a higher intensity of cytoplasmic staining (p=0.024). Nuclear expression of 
maspin was also found to be an independent prognostic factor at multivariate 
analysis.
Conclusion: the results of this study suggest that over-expression of maspin 
is correlated with a favourable prognosis in NscLc and may be a useful clini-
cal marker in this disease.
Disclosure: All authors have declared no conflicts of interest.
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Background: current data suggest that cancer stem cells (cscs) are respon-
sible for tumor development, growth and progression. the inefficacy of con-
ventional therapies might be ascribed to the stem cell population explaining 
cancer chemoresistance and the high frequency of relapse in the majority of 
S39Copyright © 2012 by the European Lung Cancer Conference and the International Association for the Study of Lung Cancer
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tumors. In the present study we investigated whether cscs could be isolated 
in patients with metastatic NscLc and whether in vitro cscs sensitivity 
assay could identify an effective treatment.
Materials and methods: cscs were isolated from effusions or fresh cancer 
tissue from primary tumor or metastasis of NscLc patients progressing after 
standard therapies. cscs were propagated in vitro and tested for different che-
motherapeutic drugs or targeted agents. the more effective treatment induc-
ing highest cscs mortality rate, was further administered to the patients.
Results: the study included 17 patients with a median age of 58 years (range 
27-81). the procedure for cscs isolation was repeated in two patients (two 
and three times, respectively). cscs were obtained from liver metastases in 
16 cases (80%), pleural biopsy in 1 case (5%), lung nodule excision in 1 case 
(5%) and by pleural or peritoneal effusion in 2 cases (10%). cscs were suc-
cessfully isolated in 13 patients (76%). Failure in cscs isolation might be 
attributed to inadequate material (6 cases) or contamination (1 case). cscs 
sensitivity assay was performed in 6 cases (30%), with a median of 6 drugs 
or combinations tested (range 4–10). the median time required for sensitivity 
assay results was 40 days (range 30–46).
Conclusion: Our preliminary data indicate that cscs isolation and in vitro 
sensitivity assay are feasible in patients with metastatic NscLc. Efficacy 
analysis is ongoing and definitive data will be available for the meeting.
Disclosure: All authors have declared no conflicts of interest.
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Background: Malignant pleural mesothelioma (MPM) is a highly aggressive 
and therapy-resistant tumor with rising incidence related to asbestos expo-
sure. Growth factors of the activin family are deregulated in a number of 
malignancies including Hcc, NscLc and esophageal cancer. Here we show 
that activin signals may contribute to aggressiveness of MPM cells. 
Methods: Expression of activin subunits and activin receptors was deter-
mined in 10 MPM cell lines by QPcr. Moreover, activin A (INHbA) 
expression was analyzed by immunohistochemistry (IHc) in MPM tissue 
samples (n=53). to determine whether INHbA gene expression can be epi-
genetically regulated via promotor demethylation and/or histone acetylation, 
cells were treated with 5-azacytidine and/or trichostatin A. For functional 
analyses, MPM cells were exposed to exogenous activin A, sirNA-mediated 
INHbA silencing or activin receptor inhibitors. Mtt and clonogenic growth 
assays were used to assess cell proliferation and survival. cell migration was 
analyzed by scratch and transwell assays, and smad2 phosphorylation by 
Western blots. 
Results: Expression analysis revealed high expression of activin A and 
activin receptors in most MPM cell lines. IHc in paraffin-embedded tis-
sue sections of MPM patients showed a significant association of activin A 
expression with epitheloid histology (P < 0.05), but not with patient survival, 
stage or nuclear Ki67 expression. Within tumors with biphasic histology, 
activin A was predominantly present in the epithelial compartment.With 
regard to the consequences of promotor demethylation or histone acetyla-
tion on INHbA gene expression, no clear evidence for repression of INHbA 
in MPM was found. treatment with activin A lead to a strong induction of 
smad2 phosphorylation in MPM cell models and stimulated growth and clo-
nogenicity in a subset of cell lines. silencing of INHbA in contrast lead to 
reduced growth, clonogenic survival and migration, demonstrating the impor-
tant role of INHbA expression for MPM cells. targeting activin receptors 
with two different kinase inhibitors (sb431542, A8301) confirmed these 
results. Conclusions: these data suggest that deregulated INHbA expression 
contributes to the malignant phenotype of MPM cells and that activin signals 
should be further evaluated as therapeutic targets.
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Gene profiling became a key role for accurately classifying tumors in individual 
patients, for predicting the response to the available treatments and for personal-
izing cancer treatment. common techniques require tissue specimen and thus 
are invasive, time consuming and may delay therapy. Here, we report on a new 
concept for profiling of genetic mutations of (lung) cancer cells. Headspace 
samples of several cell lines with specific well-defined genetic mutations 
(EGFr and KrAs mutations and ALK fusion) were studied and compared. 
the headspace VOcs from the cell lines was collected using passive sampling 
badges containing tenax tA as a sorbent material in duplicates throughout the 
whole incubation time. the headspace was then exposed to a vacuum chamber 
containing an array of four cross-reactive gold nanoparticles (GNPs) coated 
with organic capping for blind samples of various genetic mutations. the sig-
nals collected from the GNP sensors were analyzed using a discriminant factor 
analysis (DFA). the nature and chemical composition of the VOcs associated 
with each of the investigated genetic mutations was explored and determined 
through complementary chemical analysis and discussed in terms of metabolic 
pathways. based on the new profiling approach, we present a volatile fingerprint 
assay based on nine binary tests that improved the number of correctly identi-
fied samples in a blind test. While the reported concept was obtained through 
in vitro studies, as a way to eliminate confounding factors that are associated 
with clinical samples or patients/animals, it is reasonable to assume that similar 
findings could be detected directly from blood or the exhaled breath samples. 
those will allow immediate testing to predict a clinical benefit from targeted 
therapy. the reported approach could help guiding treatments by tracking 
genetic alterations, so that patients could benefit from safer, more timely and 
effective interventions that improve survival and quality of life while reducing 
hospitalizations caused by unnecessary invasive procedures.
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Background: sarcomatoid carcinoma (sc) of the lung include, according 
to the 2004 WHO classification, pleiomorphic carcinoma, spindle cell carci-
noma, and giant cell carcinoma. they predominate in smokers, and are char-
acterized by Epithelial to Mesenchymal transition (EMt) properties and a 
dismal prognosis; however no specific therapy has been proposed to date for 
locally advanced and metastatic cases.
Objectives: the purpose was to determine if sc could be sub-divided in ade-
nocarcinomas and squamous cell carcinoma subtypes to better guide mutation 
analyses, and to characterize their mutational and EMt profiles, in order to 
define new potential therapeutic targets.
Methods: ttF1, P63 and cK 5-6 staining were performed in 22 sc of the 
lung. K-ras, EGFr and LKb1 mutations were analysed by sequencing, 
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FGFr1 amplification and EML-ALK rearrangement by FIsH, and EMt 
phenotype by immunohistochemistry regarding pan-cytokeratins, vimentin, 
E cadherin, snail, FAK and mtOr expressions.
Results: All tumors but one concerned smokers. seven out of 22 harbored an 
adenocarcinomas immunophenotype with ttF1 expression, 8 an scc pheno-
type with P63 positivity, one had an adenosquamous profile, and 6 were ttF1-/
P63-. None were EGFr mutated, but 4 with ADc immunophenotype were 
K-ras mutated, one case being also LKb1 mutated. None was FGFr1 amplified 
or ALK rearranged. Pancytokeratin and E-cadherin expressions predominated 
in sc with ADc and scc immunophenotype, and in epithelial component of 
pleiomorphic carcinoma and in giant cell carcinoma; they were lost in mesen-
chymal component, in contrast with vimentin and snail, which negatively regu-
lates E cadherin, which were also expressed mainly in ttF1-/P63- sc. FAK, 
involved in cellular migration, and mtOr, in cellular proliferation downstream 
of LKb1 inactivation, were widely expressed in all sarcomatoid carcinoma.
Conclusions: As expected, only K-ras and LKb1 mutations were observed 
in our series of sc arising in smokers, and only in cases with ADc immuno-
phenotype, justifying an immunosubtyping of sc to guide mutation analyses; 
EMt phenotype characterizes sc, as well as FAK and mtOr overexpression, 
the latter representing a potential therapeutic target, which needs to be further 
evaluated in larger series.
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Plasma chemokines are significant in developing theories concerning the biol-
ogy of NscLc. PF4 appears to be important in the regulation of angiogenesis 
associated with tumourigenesis, bet the role of PF4 in angiogenesis in NscLc 
is unknown. We report the results of clinical study aimed to reveal association 
between PF4 plasma levels and development of NscLc. the study involved 
30 patients with early stage NscLc who underwent pulmonary resection. 
Paired blood samples were collected intraoperatively – peripheral venous blood 
sample, representing systemic circulation and pulmonary venous blood sample 
from lobar pulmonary vein that received drainage directly from the tumor, rep-
resenting tumor circulation. Additional peripheral blood samples from patients 
with metastatic NcsLc (n=10) and healthy controls (n=10) were collected. 
Plasma PF4 levels were determined by ELIsA. PF4 levels were significantly 
higher in the peripheral blood samples compared to pulmonary blood samples 
(median 13001 pg/mL vs. 11489 pg/mL) (p=0.001). the median PF4 level 
was 10509 pg/mL in patients with metastatic NscLc and 10691 pg/mL in 
healthy individuals with no difference between groups (p=0.86). At the same 
time PF4 levels were higher in peripheral blood of early stage NscLc patients 
compared to patients with metastatic NscLc (p=0.041) and healthy controls 
(p=0.021). In the local tumor microenviroment, net angiogenesis is determined 
by an imbalance in the over-abundance of angiogenic, compared with relative 
under-expression of angiostatic factors. PF4 binds to heparin-like molecules 
and other sulphated glycosaminoglycans that are required for the binding of 
proangiogenic factors modulating the effect of proangiogenic growth fac-
tors. the up-regulation of PF4 in peripheral blood could be a way of systemic 
response in order to counterbalance angiogenic growth factors. reduced PF4 
levels observed in tumor draining blood could indicate that angiostatic effect 
of PF4 was not able to counterbalance the angiogenic growth factors present 
in the tumor. the changes in PF4 may have the potential to convey valuable 
clinical information about the angiogenic potential of the tumor, and be an 
additional tool for a non-invasive diagnosis.
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Background: EML4-ALK is a fusion-type protein tyrosine kinase iden-
tified recently in a subset of human lung carcinomas and seems to be a 
promising candidate for a therapeutic target as well as for a diagnostic 
molecular marker in NscLc. Indeed, ALK kinase inhibitors (crizotinib 
PF0234-1066, Pfizer) have already been developed and have been reported 
to be efficient only in patients positive for the EML4-ALK fusion. to date, 
several EML4-ALK variants have been identified in lung cancer samples. 
A variety of methods have been used for the detection of these fusions, 
including IHc, FIsH, and rt-Pcr, which is the only method that can 
distinguish between different variants. Existing rt-Pcr methods though, 
are designed to amplify large cDNA fragments and are inadequate for 
the analysis of formalin-fixed paraffin-embedded (FFPE) tissues which 
produce cDNA fragments of limited size. thus, we designed an rt-Pcr 
assay that can detect all published EML4-ALK variants and is suitable for 
use with this commonly available material.
Methods: the study included FFPE specimens from NscLc patients without 
EGFr and K-rAs mutations. Pathological review was obtained for all sam-
ples and macro-dissection was used to ensure a tumor cell content of >75%. 
Detection of all EML4-ALK fusions was achieved using a multiplex rt-Pcr. 
specific primers that enhance specifically EML4-ALK transcripts 1, 2, 3a, 3b, 
4, 5a, 5b, 6, 7, “4”, and “5” were designed. DNA sequencing analysis was 
performed to confirm the specificity of the obtained Pcr products. the sensi-
tivity of the method was calculated by adding to 1&mug rNA serial dilutions 
of the synthetic DNA fragments. It was found that up to 22 copies of the 
translocation can be detected per & mug of rNA. We are currently increasing 
our sample size of Greek patients and are in collaboration with other centres 
to further understand the clinical impact of the variant spectrum.
Results: None of the 96 FFPE specimens tested so far, was positive for the 
EML4-ALK fusion. control EML4-ALK FIsH positive samples were posi-
tively subtyped using rt-Pcr and sequencing.
Conclusions: We designed a robust multiplex rt-Pcr assay that permits the 
sensitive detection of all published EML4-ALK variants. It’s suitable for use 
with commonly available materials such as FFPE speciments, cytological 
speciments and other aspirates.
Disclosure: All authors have declared no conflicts of interest.
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THE CLINICAL UTILITY OF PLASMA DNA 
QUANTIFICATION IN NSCLC DIAGNOSTICS AND 
RADICAL THERAPY EFFECTIVENESS MONITORING
A. szpechcinski1, J. chorostowska-Wynimko1, W. Kupis2, K. Maszkowska-
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K. roszkowski-sliz4 1Laboratory of Molecular Diagnostics and Immunology, 
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2Department of Thoracic Surgery, National Institute of Tuberculosis and 
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Background: Increased concentrations of free DNA are detectable in 
peripheral blood of most cancer patients including non-small cell lung 
cancer (NscLc). Our aim was to evaluate the clinical value of plasma 
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DNA quantification for early NscLc diagnostics and assessment of radi-
cal therapy effectiveness. 
Methods: Plasma DNA concentration was measured in 60 resectable 
NscLc patients (stage I-IIIA) prior and following the radical treatment 
using real-time Pcr. Patients with distinctive scenarios of chronic respi-
ratory inflammation (34 cOPD, 35 sarcoidosis and 32 persistent asthma) 
were included into the study to assess the diagnostic accuracy of plasma 
DNA quantification in NscLc detection. 10 orthopedic patient undergoing 
hip joint surgery and 40 healthy volunteers comprised control groups.
Results: NscLc patients (8.0 ng/ml) demonstrated significantly higher 
mean plasma DNA concentration with respect to patients with chronic 
respiratory inflammation (3.4 ng/ml), orthopedic patients (3.0 ng/ml) and 
healthy controls (2.3 ng/ml; p<0.0000). the cut-off point of >2.8 ng/ml 
provided 90% sensitivity and 80,5% specificity in discriminating NscLc 
from healthy individuals (AUc=0.89, p<0.0001). However, 56% specific-
ity and 90% sensitivity were calculated, when patients with chronic respi-
ratory inflammation were also considered (AUc=0.80, p<0.0001). similar 
raise in plasma DNA levels was detected a week after the surgery in either 
resected NscLc (68.7 ng/ml, p<0.0000) or orthopedic patients (28.4 ng/
ml, p<0.0015). NscLc patients with no disease recurrence during 3-6 
month follow-up showed significant reduction in plasma DNA levels (2.8 
ng/ml), whereas in relapsed subjects plasma DNA levels were significantly 
higher than baseline values. 
Conclusions: the diagnostic power of our quantitative plasma DNA 
test, though quite satisfactory, needs further improvement to meet early-
diagnosis requirements in NscLc. Drastic increase of plasma DNA 
concentration following resection surgery in NscLc did not result from 
malignancy, but the surgical trauma. In the post-operative long-term 
follow up quantitative analysis of plasma DNA seemed to discriminate 
relapse-free patients from recurrent ones proving its potential usefulness 
for radical NscLc therapy effectiveness monitoring.
Disclosure: All authors have declared no conflicts of interest.
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Background: several biological markers have shown their usefulness in 
patients with lung cancer. Urokinase-type plasminogen activator (u-PA) is a 
member of the serine protease, an extracellular matrix protease strictly related 
to tumor aggression. It is localized on the tumor cells surface by binding to a 
specific receptor (u-PAr), which regulates the proteolytic activity around the 
cells. Plasminogen activator inhibitor 2 (PAI-2) regulates the u-PA activity. the 
expression of u-PA and PAr is elevated in malignant tumors, while low levels of 
PAI-2 expression correlates with the presence of metastases. We retrospectively 
assayed the expression of u-PA, u-PAr, and PAI-2 in specimens from non-small 
cell lung carcinoma (NscLc), with the aim of evaluating possible relationship 
between these prognostic markers and the presence of lymph node metastasis.
Materials and methods: Paraffin-embedded archival tumor tissues from 59 
patients with NscLc were used to assess by immunohistochemical staining 
expressions of u-PA and u-PAr, and to measure by enzyme-linked immuno-
sorbent assay levels of PAI-2 antigen. the analysis was performed by reverse 
transcriptase polymerase chain reaction (rt-Pcr). Patients were 42 (71.2%) 
males and 17 (28.8%) females, with a median age of 62 years (range 54-68). 
LN metastases were found in 25 (42.3%, Group A) patients, while 34 (57.7%, 
Group b) were node-negative (pN0). A positive-staining area of more than 
10% was considered as a positive result. the Pearson chi-square (2) test was 
used to compare data.
Results: Positive markers (A vs. b) were found in 15 of 25 vs. 24 of 34 
(u-PA), 13 of 25 vs. 23 of 34 (u-PAr), and 10 of 25 vs. 24/34 (PAI-2) 
specimens, respectively. A significant relationship between u-PAr posi-
tivity and LN metastasis (2=0.019, p=0.018) was found, while both u-PA 
(2=0.396, p=0.283) and u-PAr (2=0.223, p=0.171) were not related to 
LN status.
Conclusions: In patients with NscLc, u-PAr seems to be the key molecule 
for extracellular matrix degradation enzyme and the target molecule of cancer 
metastasis prevention, representing a sensitive marker of prognosis.
Disclosure: All authors have declared no conflicts of interest.
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HELPS RECOGNIZE PULMONARY SARCOMATOID 
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Introduction: Little is known on the use of a modified vimentin histologic 
score (M-VHs) for confirming stable epithelial-mesenchymal transition 
(EMt) and hence the final diagnosis of pulmonary sarcomatoid carcinoma 
(Psc) in small biopsy samples. As Psc are life-threatening tumors, an 
improvement in their diagnostic recognition in small-sized tumor samples 
is clinically warranted.
Methods: Vimentin expression was assessed by immunohistochemistry in 
both preoperative biopsy samples and paired surgical specimens from 20 
pleomorphic carcinomas, two pulmonary blastomas and one carcinosarcoma. 
A M-VHs was devised multiplying three independently assessed parameters, 
i.e. the percentage of positive cells (as assessed semiquantitatively by quin-
tiles, from 0 to 5) by the intensity (as compared to internal positive controls: 
low [1] vs. strong [2]) and the distribution pattern within the cytoplasm (par-
tial [1] vs. diffuse [2]). so settled, the V-MHs ranged from 0 to 20 (maximum 
value resulting from 5x2x2). Forty-six consecutive cases of non-small cell 
lung carcinomas (NscLc) were used as cancer control group for validating 
M-VHs.
Results: No differences in M-VHs were found between biopsies and surgical 
specimens of Psc, so confirming the occurrence of stable EMt and hence 
the specific diagnosis of Psc, whereas the M-VHs in the 46 NscLc was by 
far significantly lower (p<0.0001). All types of Psc shared the same M-VHs. 
Poorly differentiated NscLc showing marked pleomorphism with spindling 
and giant cell changes but not stable EMt did exhibit a significantly increased 
V-MHs.
Conclusions: M-VHs helped morphology to render more definite diagnoses 
on small biopsies of Psc, thus permitting a more planned approach to the 
recognition and the treatment of this life-threatening tumor subset.
Disclosure: All authors have declared no conflicts of interest.
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Purpose: thymidylate synthase (ts) is necessary for DNA synthesis through 
catalyzing the conversion of dUMP to dtMP using folate as a methyl donor. 
the ts promoter has a 28bp double or triple tandem repeat polymorphism 
(2r, 3r) related to ts protein expression. 2r/2r homozygotes, as well as 
guanine to cytosine transition in the second repeat of the 3r allele, are associ-
ated with lower ts expression. Previous studies have suggested that ts activ-
ity is a prognostic factor in non-small cell lung cancer. the aim of the study 
was to analyze the association of ts gene polymorphisms with lung adeno-
carcinoma in serbian patients. 
Methods: A case-control study including 56 late-stage lung adenocarcinoma 
patients and 53 healthy subjects was performed. standard Pcr and restric-
tion fragment length polymorphism analysis were used for ts genotyping. 
Depending on the presence of high (3rG) or low (2r, 3rc) expression alleles, 
ts functional groups were subclassified into HH (3rG/3rG), HL (2r/3rG, 
3rG/3rc) and LL (2r/2r, 2r/3rc, 3rc/3rc) groups. Descriptive analyses 
included genotype and allelic frequencies; the odds ratio (Or) and the 95% 
confidence interval (cI) were calculated as an estimate of relative risk. 
Results: the distribution of the polymorphic variants in patients vs. controls 
was 12.5% vs. 9.4% for HH, 12.5% vs. 16.9% for HL and 75% vs. 73.6% for 
LL. the frequencies of alleles in patients vs. controls were 0.18 vs. 0.17 for H, 
and 0.81 vs. 0.82 for L. there was no significant difference in LL+HL vs. HH 
(2 = 0.042; Or = 0.73; 95% cI, 0.22 – 2.46). A non-significant difference 
in LL vs. HL+LL genotype distribution was observed between patients and 
controls (2 = 0.0025; Or = 1.08; 95% cI, 0.46 – 2.54). 
Conclusions: We found no significant association between the ts polymor-
phisms and the risk of lung adenocarcinoma occurrence in serbia. As this 
study is limited by a relatively small sample size, a further large case-control 
study including analysis of gene-gene interactions with genes coding for other 
folate metabolism enzymes is needed. Finding a potential correlation between 
these polymorphisms and lung adenocarcinoma occurrence could contribute 
to the earlier detection of this disease.
Disclosure: All authors have declared no conflicts of interest.
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Background: Ataxia telangiectasia mutated (AtM) is a multifunctional DNA 
damage signaling protein. Loss of AtM function, as seen in patients with 
ataxia telangiectasia, causes a cancer predisposition and radiation sensitiv-
ity. We have previously reported that PArP inhibition is a useful therapeutic 
approach in mantle lymphoma cells deficient in AtM. recent reports suggest 
that AtM is commonly mutated in non-small cell lung cancers (NscLc). We 
have also shown that loss of AtM expression in early resected NscLc con-
fers a poor prognosis. We hypothesize that AtM-deficient NscLc cells will 
be sensitive to irradiation, and will not be able to activate DNA repair mecha-
nisms. AtM expression and activity is likely to have therapeutic implications 
in NscLc, as it may serve as a potential guide for successfully selecting 
patients for radiotherapy as well as for PArP inhibition.
Methods: the NscLc cell lines NcI-H23, NcI-H226, NcI-H460, and 
A549 were used in this study. AtM expression was assessed in each cell 
line by western blot. AtM functionality was determined by examining active 
phosphorylated AtM following irradiation of the cells and by interrogating 
downstream targets of AtM including p53, checkpoint kinase 2 (chK2), and 
KrAb-associated protein 1 (KAP1). After characterizing each NscLc cell 
line, the biological effects of PArP-1 inhibition and gamma-irradiation on 
viability these cells was examined using the clonogenic survival assay.
Results: Expression level of AtM varies significantly between NscLc cell lines 
with H23 being the most AtM deficient. this AtM deficiency correlated with 
increased sensitivity to radiation and an altered sensitivity to PArP inhibition.
Conclusion: Our preliminary results indicate differences in AtM functional-
ity between different NscLc cell lines following irradiation and that target-
ing AtM deficient NscLc tumour is a rational therapeutic strategy. results 
of the downstream activity of AtM in these cells, and the biological conse-
quences of AtM deficiency will be presented and discussed.
Disclosure: All authors have declared no conflicts of interest.
115P
AN INDUCIBLE SYSTEM TO STUDY CHEMOTHERAPY 
RESISTANCE IN NON-SMALL CELL LUNG CANCER
t.M. Marti, M.L. Albisser, I.N. Kotov, Y. shi, E. Felley-bosco, r.A. stahel 
Clinic and Policlinic of Oncology, University Hospital Zürich, Zürich, 
SWITZERLAND
Introduction: Occurrence of chemotherapy resistance is a major obstacle in 
the treatment of non-small cell lung cancer (NscLc). Inhibition of transle-
sion synthesis DNA polymerase κ sensitizes NscLc tumors to cisplatin and 
reduces the formation of chemotherapy resistance. DNA polymerase κ consists 
of the catalytic subunit rEV3 and the structural subunit rEV7. surprisingly, 
we found that lentiviral-based short hairpin rNA–mediated depletion of rEV3 
per se suppresses colony formation of lung, breast, mesothelioma, and colon 
tumor cell lines, whereas control cell lines and a normal mesothelial primary 
culture are less affected. We showed that inhibition of rEV3 expression per se 
in cancer cells leads to an accumulation of persistent DNA damage.
Aim: the aim of this project is to develop a system, which allows us to study 
how rEV3 depletion per se and in combination with chemotherapy affects 
human NscLc tumor growth in a mouse xenograft model.
Results: A549 NscLc cells were transfected with two plasmids, one encod-
ing a tetracycline repressor and the other plasmid encoding a short hairpin 
rNA targeting rEV3 under the control of a promoter containing a tetracycline 
repressor binding site. After initial analysis of rEV3 mrNA expression by 
real-time Pcr, we selected 2 clones with inducible inhibition of rEV3 expres-
sion and 2 clones containing the corresponding scrambled construct. Detailed 
analysis revealed that the inducible inhibition of rEV3 expression was highest 
72 hours after doxycycline addition. At this time point, levels of histone H2AX 
phosphorylation, a marker for DNA damage, were increased by rEV3 deple-
tion whereas scrambled control clones were not affected. Additionally, induc-
ible inhibition of rEV3 expression significantly reduced colony formation.
Significance: translesion synthesis DNA polymerase κ is the main extender 
from mismatches formed after treatment with DNA-damaging agents and is 
thereby a major contributor to the occurrence of chemotherapy resistance. 
Additionally, our previous findings indicate that depletion of rEV3 can be 
applied for susceptible cancers as a potential monotherapy. the inducible sys-
tem will allow us to study the effect of rEV3 depletion per se and in combina-
tion with chemotherapy in the in vivo setting.
Disclosure: All authors have declared no conflicts of interest.
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Background: calcium signaling is known to regulate cell proliferation via 
numerous channels and pathways. A newly emerging therapeutic target in 
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cancer research is the t-type calcium channel. these channels exist in three 
isoforms, ca(v)3.1, 3.2, and 3.3, and are typically expressed in epithelia only 
during development. t-type channels have been implicated in esophageal, 
breast and ovarian cancers but their role in lung cancer has not been thor-
oughly investigated. We set out to assess the expression, function and effect 
of these channels in NscLc cell lines.
Methods: In vitro studies were conducted using A549, H23, H226, H460, 
H522, and H1299 NscLc cell lines. Expression of ca(v)3.1 and 3.2 was 
assessed by Western blot analysis and location by microscopy imaging. 
Functional analyses were conducted using patch clamp studies, which can 
detect the unique t-current generated by the channels. the effects of two 
known channel inhibitors, Mibefradil and NNc-55-0396 on proliferation 
were examined using the Xtt assay.
Results: All NscLc lines tested expressed one or both of the t-type calcium 
channel isoforms, with H226 having the greatest ca(v)3.1 expression and 
H460 having the most 3.2. However, not all lines had functional channels, 
which was partly explained by the location within the cell. Preliminary Xtt 
results suggest the inhibitors can influence the proliferation of these cell lines 
in vitro, but their effect is dependent upon function.
Conclusion: t-type calcium channels may influence proliferation of NscLc 
cell lines. Further inquiry into the clinical significance of t-type channel 
expression in NscLc patients is currently underway using the Glans-Look 
Lung cancer Database, in which expression in resected tumors is correlated 
with patient outcome.
Disclosure: All authors have declared no conflicts of interest.
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Background: cXcr4 is a chemokine receptor that is commonly misex-
pressed in various cancer types, and has been shown to have a direct role 
in the migratory and invasive abilities of metastatic cancer cells when acti-
vated by its ligand, sDF-1 (cXcL12). clinical outcome data from our lab 
has shown that cXcr4 is overexpressed in some lung adenocarcinomas 
and has an adverse effect on overall patient survival, but this effect is only 
observed in female patients. some evidence has suggested that sDF-1 and 
estrogen receptor activity cooperate to regulate each other in a feedback 
loop, however it is unclear what the effect of this is on cXcr4 activity in 
lung cancer cells.
Objectives and methods: to address the mechanism behind these apparent 
sex differences, we selected several non-small cell lung cancer (NscLc) cell 
lines, derived from both male and female sources, and interrogated them for 
cXcr4 expression and activity. Expression of cXcr4 in the cell lines was 
assessed by western blot and quantitative rt-Pcr, and subcellular local-
ization was determined by fluorescence immunohistochemistry. We further 
assayed cXcr4 functionality by looking at downstream activation of the 
MAPK and AKt pathways, as well as performing migration and invasion 
assays in the presence of sDF-1.
Results and conclusions: Our preliminary data shows that cXcr4 is 
expressed in all cell lines tested, and inhibition of either cXcr4 or sDF-1 
with small inhibitors or with blocking antibodies revealed that cXcr4 activ-
ity increases migration of the NscLc cell lines tested. results from these 
experiments and others to illustrate the sex differences in cXcr4 activity will 
be presented and discussed, along with evidence potentially linking estrogen 
receptor expression and activity to cXcr4 function.
Disclosure: All authors have declared no conflicts of interest.
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Purpose: Methylenetetrahydrofolate reductase (MtHFr) is an impor-
tant enzyme of the folate metabolism and is involved in the process of 
carcinogenesis. cytosine to thymine transition at nucleotide 677 (c677t) 
yields a thermolabile variant of this enzyme with reduced activity. 
Previous studies have suggested that MtHFr activity is a prognostic fac-
tor in non-small cell lung cancer. the aim of this study was to analyze 
the association of MtHFr polymorphism with lung adenocarcinoma in 
serbia. 
Methods: A case-control study including 55 late-stage lung adenocarci-
noma patients and 53 healthy subjects was performed. restriction frag-
ment length polymorphism analysis was used for MtHFr genotyping. 
Descriptive analyses included genotype and allelic frequencies; the odds 
ratio (Or) and 95% confidence interval (cI) were calculated as an estimate 
of relative risk. the Hardy-Weinberg equilibrium was tested using the 2 
test. significance was considered for p < 0.05. 
Results: the distribution of c677t genotypes in patients and controls did 
not deviate from the Hardy-Weinberg equilibrium. the distribution of the 
polymorphic variants in patients vs. controls was 61.8% vs. 24.5% for cc, 
32.7% vs. 62.3% for ct and 5.5% vs. 13.2% for tt. the frequencies of 
alleles in patients vs. controls were 0.78 vs. 0.56 for c, and 0.22 vs. 0.44 
for t. A nonsignificant difference in ct+cc vs. tt genotype distribution 
was observed between patients and controls (2 = 1.12; Or = 2.64; 95% cI, 
0.63 – 11.08). For cc vs. tt+ct genotype distribution a significant differ-
ence was observed between patients and controls (2 = 13.79; Or = 4.98; 
95% cI, 2.14 – 11.61). 
Conclusions: An increased frequency of the c allele in serbian lung 
adenocarcinoma patients compared to healthy controls was detected. 
Moreover, a significant corelation between the homozygous cc genotype 
and lung adenocarcinoma occurence was found. As this study was per-
formed on a relatively small sample size further validation is necessary. 
Finding a potential correlation between MtHFr gene polymorphisms 
and lung adenocarcinoma could contribute to earlier detection of this 
disease.
Disclosure: All authors have declared no conflicts of interest.
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LUNG CANCER BY IMAGING MASS SPECTROMETRY
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Purpose: Lipidomics may provide a new direction to study cancer by 
identifying some tumor-specific markers, leading to elucidation of the 
mechanism of tumorigenesis and identification of therapeutic targets. We 
identified novel differentially-expressed lipids between the normal and 
tumor tissues from the same patients that may provide insights into diag-
nosis, prognosis, and therapeutic targets for patients with non-small cell 
lung cancer.
Methods: We performed an imaging MALDI lipidomic study to gain the 
unique lipid alterations that are characteristic of non-small cell lung can-
cer. Imaging MALDI mass spectrometry integrated histopathology and 
lipid expression. Frozen cancer tissues and matched normal lung tissues 
were sliced to a thickness of 10μm and transferred onto a conductive glass 
slide. the matrix for lipid imaging was binary matrix. After laser scan-
ning by MALDI-tOF equipped with a smart beam laser, the images were 
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created for single masses and classified members of lipids at 200μm spa-
tial resolution. based on the spatial distribution, region specific lipids on 
a tissue can be identified by either MALDI-tOF/tOF or Liquid chroma-
tography (Lc)-Ms/Ms. classified mass markers selectively labeled tumor 
and normal regions of non-small cell lung cancer. Unsupervised and 
supervised analysis of image data correlated with histologically stained 
image.
Results: We identified 17 phopholipid species, differentially expressed in 
normal and cancer area from the same patients with non-small cell lung can-
cer. We found 12 phopholipids showing upregulated expression and 5 phop-
holipids showing significant down-regulated expression in the tumor tissues 
from the patient with non-small cell lung cancer.
Conclusions: We successfully showed the feasibility of MALDI imaging 
as a useful tool for the analysis of lipid profiles using lung tissue sections. 
Disclosure: All authors have declared no conflicts of interest.
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Objectives: the human epididymis 4 (HE4) gene product, also known as 
Whey-Acidic-Protein (WAP) four-disulfide core domain protein 2 (WFDc2), 
was identified as the transcript expressed in the epididymis and respiratory 
tract. We previously reported that HE4 is also expressed in pulmonary adeno-
carcinoma. the purpose of this study was to investigate serum levels of HE4 
as biological marker in pulmonary adenocarcinoma. 
Materials and methods: In trained set, 102 patients with pulmonary 
adenocarcinoma underwent surgery in our institute from 2008 to 2011 
were evaluated. 58 healthy controls and 16 benign lung disease were 
compared. In the validation set, we used 105 patients with pulmonary 
adenocarcinoma operated between 2000 and 2007. Postoperative change 
of serum HE4 levels were investigated in 35 patients. the level of HE4 
was determined with ELIsA and compared with clinicopathological 
factors. 
Results: In the trained set, sera in lung adenocarcinoma were signifi-
cantly higher than in healthy controls. receiver operating curve (rOc) 
showed that HE4 was a good discriminator of lung adenocarcinoma 
(cutoff point, 50.3pM, Area under curve (AUc), 0.825; 95% confident 
interval (cI) 0.76-0.89, p<0.001). In the validation set, no significant 
correlation was found between serum HE4 levels and clinicopathologi-
cal factors including age, gender, tumor size, and nodal status. However, 
positive rate of HE4 showed the tendency to correlate to the stag-
ing (36.5% in stage I, 57.1% in stage II, 50% in stage III and 100% in 
stage IV, p=0.057). Furthermore, postoperative change of HE4 serum 
levels showed significant correlation between increase and recurrence. 
Although 6 of 16 patients with postoperative increase recurred, only one 
of 19 patients with decrease or no change HE4 serum levels recurred after 
operation (p=0.032). the five-year overall survival rate was 60.4% in the 
HE4-positive group, compared with 91.9 % in the HE4-negative group 
(p=0.008). 
Conclusions: these data showed that HE4 expression in sera is asso-
ciated with progression of pulmonary adenocarcinoma and a possible 
biomarker.
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RELATIVE INTENSITY OF TP53 MUTATION IS 
ASSOCIATED WITH INTRATUMOR GENETIC 
HETEROGENEITY AND THE PROGNOSIS OF PATIENTS 
WITH EARLY STAGE NON-SMALL CELL LUNG 
CANCERS
s.Y. Lee1, c.Y. Jung2, H. Jeon3, J.Y. Park4, E.J. Lee3, K.M. shin5, J. Lee6, 
s.s. Yoo1, E.b. Lee1, J.Y. Park1 1Lung Cancer Center, Kyungpook National 
University Medical Center, Daegu, KOREA, 2Internal Medicine, Dongsan 
Medical Center, Daegu, KOREA, 3Department of Biochemistry and Cell 
Biology, Kyungpook National University, School of Medicine, Daegu, KOREA, 
4Department of Pathology, Kyungpook National University Medical Center, 
Daegu, KOREA, 5Department of Radiology, Kyungpook National University 
Medical Center, Daegu, KOREA, 6Department of Internal Medicine, 
Kyungpook National University Hospital, Daegum, KOREA
A large number of studies have evaluated the impact of tP53 mutations on 
the prognosis of patients with non-small cell lung cancer (NscLc); however, 
the results of these studies are still controversial. recently, considerable intra-
tumor heterogeneity for genetic alterations has been demonstrated in vari-
ous human cancers, including lung cancer. In the present study, we evaluated 
tP53 mutations in NscLcs and observed remarkable variations in the val-
ues of the relative intensity (rI, intensity of the peak of the mutated allele/
intensity of the peak of the non-mutated allele) of tP53 mutations. We also 
examined whether the rI values were associated with the intratumor hetero-
geneity of tP53 mutations. In addition, we evaluated the relationship between 
the presence of tP53 mutation and survival outcome. tP53 mutation was not 
significantly associated with survival of the patients. However, when tumors 
with tP53 mutation were categorized into two groups, those with a low- and 
high-intensity of the mutation, the latter group had significantly worse sur-
vival compared to those with wild-type tP53 (adjusted hazard ratio = 2.58, 
95% confidence interval = 1.21–5.48, P = 0.01), whereas the former group 
did not. these results suggest that intratumor genetic heterogeneity may be an 
important factor in determining the role of tP53 mutation on the prognosis 
of NscLc patients.
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LUNG CANCER INCIDENCE, EXPRESSION OF TUMOUR 
SUPPRESSOR PROTEIN P53 AND ANTI-APOPTOTIC 
SURVIVING AND SURVIVAL IN CHROMIUM EXPOSED 
INDIVIDUALS
E. Halasova1, t. Matakova2, D. Dobrota2, E. Kavcova3, D. Mistuna4 
1Department of Medical Biology, Jessenius Faculty of Medicine, Martin, 
SLOVAK REPUBLIC, 2Department of Medical Chemistry, Jesseniu Faculty 
of Medicine, Martin, SLOVAK REPUBLIC, 3Clinic of Pulmonary Disorders, 
Jesseniu Faculty of Medicine, Martin, SLOVAK REPUBLIC, 4Clinic of 
Surgery, Jesseniu Faculty of Medicine, Martin, SLOVAK REPUBLIC
Workers chronically exposed to hexavalent chromium have higher inci-
dence of lung cancer. Our study investigates incidence of lung cancer 
types, age of onset of the disease and surviving time among chromium 
exposed workers (smelters, tapers, crane operators) in comparison to non-
exposed persons. We analysed 77 chromium exposed workers and 104 
male controls with diagnosed lung cancer. the average exposure time 
among workers was 18.38 years (range 1–41 years). For investigation of 
possible role of surviving and p53 protein we used immohistochemical 
visualisation. It was found out that chromium exposure decreases the age 
at the onset of the disease of 4.18 years. significant difference between 
the age at the onset of the disease was found between smokers and non-
smokers (P=0.008) in the control group. Non-exposed non-smokers had 
explicitly higher age at the onset of the illness in relation to other groups. 
In exposed group the significant effect of smoking on the age at the dis-
ease onset was not found (P=0.775). small cell lung carcinoma (scLc) 
forms 25.71% of all cases in chromium exposed workers and 16.34% 
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in non exposed individuals. the survival time of patients with NscLc 
and scLc within non-exposed were 12.33 and 17.75 month respectively 
and in exposed group 14.8 and 4.44 month respectively. No correlation 
was found between the age at the diseases onset and time of exposure. 
there was negative correlation between surviving and p53 expression. 
We did not find any correlation between expression of analysed proteins 
and survival time. Occupational exposure to chromium was identified as 
an important risk factor of lung cancer even overlaying effect of smok-
ing. both chromium exposure and smoking decrease the age at the dis-
eases onset. Higher percentage of scLc was found in chromium exposed 
individuals. 
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CC-CHEMOKINE LIGAND 18 INDUCES EPITHELIAL TO 
MESENCHYMAL TRANSITION IN LUNG CANCER A549 
CELLS AND ENHANCES THE METASTATIC POTENTIAL
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Quernheim4, G. Zissel4 1Dep. of Thoracic Surgery, University Medical 
Center Freiburg, Freiburg, GERMANY, 2Thoracic Surgery, University 
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Haematology, University Medical Center Freiburg, Freiburg, GERMANY, 
4Dep.of Pneumology, University Medical Center Freiburg, Freiburg, 
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Lung cancer is one of the leading causes of cancer-related death worldwide 
with more than a million deaths per year. the poor prognosis is mainly 
based on the highly aggressive behavior of this entity, associated with an 
early metastasis. Although the exact mechanisms are still unknown, the 
process of epithelial to mesenchymal transition (EMt) seems to play an 
important role. We already demonstrated that ccL18, a primate specific 
chemokine, is highly elevated in patients with lung cancer and corre-
lates with the survival time of patients with adenocarcinoma of the lung. 
therefore we hypothesized that ccL18 induces EMt in this histological 
subtype. We investigated the effect of ccL18 on A549, an adenocarcinoma 
cell line of the lung, on EMt maker and studied also the effects of ccL18 
on cell functions such as migration, invasion, chemotaxis, chemoresistance 
and proliferation.
Exposure of A549 lung cancer cells to ccL18 in various concentrations 
decreases the epithelial marker E-cadherin, whereas s100A4, a marker 
of the mesenchymal phenotype increases. According to these changes 
sNAIL1, one of the most important transcriptional regulators of EMt, 
was also induced and increases depending on the given ccL18 dose. the 
proliferation rate declines after exposure to ccL18 dose dependently to 
a maximum of 40%. the chemotactic capability after ccL18 exposure 
increased about 50%. therefore ccL18 may be an interesting target in 
therapy of NscLc.
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THE ROLE OF MELATONIN ON THE EXPRESSION OF 
NITRIC OXIDE SYNTHASE IN NSCLC CELL CULTURE IN 
VITRO
A. tavartkiladze Oncology, Grigol Robakidze University, Tbilisi, GEORGIA
Experimental research has confirmed that melatonin plays an important 
role both as an oncopreventive agent and an oncotherapeutic medication. 
It is confirmed that during an oncological disease the quantity of melatonin 
in blood plasma compared with its normal level decreases, and the more 
anaplastic a malignant cell is, the less melatonin it contains. the same par-
allel can be traced in malignant cells regarding expression of the enzyme 
participating in the nitric (II) oxide synthesis (uNOs). Namely, the more 
anaplastic the malignant tumor cell is, the lower the expression of uNOs 
it manifests. Moreover, it was confirmed that the less uNOs the cell con-
tains, the more aggressively the cancer develops and the less sensitive it is 
towards pharmacological therapy. We studied the quality of expression of 
uNOs in cell cultures derived from the biopsy material of lung squamous 
cell cancer - scLc (G3 and G4) (17 cases) by the western blotting method; 
reagent u-NOs antibody catalog Number GtX73127 (Genetex). results 
were compared with the expression of uNOs in the pavement epithelium 
culture of the healthy human bronchi. the changes in uNOs expression after 
administering melatonin (after 10-day incubation in 5% cO
2
 incubator) were 
studied. results were compared with the quality of expression of uNOs in 
initial samples.
results were the following: 1. uNOs expression in scLc cell cultures 
(mostly, in G4 cases) is decreased dramatically - by 53% compared with con-
trol samples. 2. Upon melatonin administration, uNOs expression is moder-
ately increased in G4 malignant cells (by 31% compared with initial samples) 
and sharply increased in G3 malignant cells (by 62% compared with initial 
samples). We may conclude that melatonin is involved in the complex pro-
cesses of the body’s anti-cancer fight and this issue requires a more thorough 
research.
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THE EFFICACY OF PEMETREXED-BASED TREATMENT 
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(NSCLC), AS CORRELATED WITH THE PATHOLOGIC 
FEATURES OF TUMORS
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Sheba Medical Center, Ramat Gan, ISRAEL
Introduction: Non-squamous lung carcinoma has been reported to benefit 
from cisplatin-pemetrexed compared to cisplatin-gemcitabine treatment. this 
finding enhanced efforts to sub-classify NscLc histologically. We were inter-
ested to examine the efficacy of pemetrexed-based systemic treatment as cor-
related with the pathologic features of tumors.
Methods: NscLc patients that were treated with pemetrexed-based chemo-
therapy in a single center during 2007-2011 were identified by a database 
search. Pathology records were reviewed and tumor morphology, immuno-
histochemistry (IHc) results for ttF1, cK7, p63, cK5/6 and level of differ-
entiation were recorded. Progression free survival (PFs) and overall survival 
(Os) were recorded from the medical charts. Outcome was correlated with 
pathologic features by logrank test.
Results: A total of 98 patients treated by a pemetrexed-based regimen were 
identified. 17 patients with incomplete follow up data were excluded, as well 
as 18 patients with incomplete pathology data, leaving 63 patients for our 
analysis. IHc and level of differentiation was available for part of the patients 
(see table), non allowing prognostic evaluation. comparing the patients with 
a diagnosis of adenocarcinoma based on microscopic description to those 
with a diagnosis of non-squamous cell carcinoma based on IHc, PFs was 
similar (6.7 vs 4.4 months, p=0.4, Hr=0.75). Os was significantly better for 
adencocarcinoma bearing patients (non-reached vs 10.2 months, p=0.0006, 
Hr=0.18, 0.006-0.25).
Conclusions: A pathologic diagnosis of adenocarcinoma implies better sur-
vival compared to a diagnosis of non-squamous cell carcrinoma based on 
IHc, among advanced NscLc treated with a pemetrexed-based chemother-
apy regimen. Larger patient cohorts, as well as cohorts not treated with pem-
etrexed, need to be examined to elucidate prognostic vs predictive implication 
of the pathologic method of diagnosis.
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IHC/
differentiation 
Patients with data 
available (%)* Positive (%) Negative (%) 
ttF1 47 (75) 42 (89) 5 (11) 
cK7 33 (52) 31 (94) 2 (6) 
P63 15 (24) 4 (27) 11 (73) 
cK5/6 21 (33) 3 (14) 18 (86) 
Level of 
differentiation 
20 (32) Well to moderate; 
7 (35) 
Poor to 
undifferentiated; 
13 (65) 
*Percent of the patients with clinical and pathological data (N=63).
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SEQUENTIAL USE OF VINORELBINE (V) FOLLOWED 
BY GEFITINIB (G) INDUCES A SYNERGISTIC EFFECT IN 
NON-SMALL CELL LUNG CANCER (NSCLC) CELL LINES
G. barletta, M.G. Dal bello, A. Alama, c. sini, E. rijavec, c. Genova, c. 
bruzzo, Z. cavalieri, F. Grossi Lung Cancer Unit, National Institute for 
Cancer Research, Genova, ITALY
Background: Preclinical studies with tyrosine kinase inhibitors (tKI) 
demonstrate that these agents enhance the antitumor activity of cytotoxic 
chemotherapy although several clinical studies in NscLc patients have 
failed to achieve survival improvement in an unselected population. Aim 
of this study is to identify potential addictive, synergistic or antagonist 
effects between V and G in vitro as a rationale for further investigation in 
the clinical setting.
Methods: Human lung cancer cell lines with wild-type (A-549) and mutant-
type EGFr genes (NcI-H1975) were used as in vitro models to evaluate the 
antitumor activity of G and V using three different schedules: G followed by 
V, V followed by G and the two drugs concomitantly. We also evaluated the 
antiproliferative efficacy of repeated weekly V doses along with sequential 
or continuous G. 
Results: In our evaluation of the growth inhibition effect on A-549 and 
NcI-H1975 of three different schedules, we observed that the V-G sequence 
was more potent than either the G-V sequence or the concomitant admin-
istration of the two drugs. On NcI-H1975 a clear synergistic effect was 
found at highest concentration of V with every concentration of G tested 
only in the sequence of V followed by G. this result was confirmed when 
we evaluated the optimal combination of V and G. the most effective anti-
proliferative result was found when V was given with the sequential admin-
istration of G. A frankly synergistic growth inhibitory effect was observed 
only when A-549 and NcI- H1975 were first exposed to V (day 1 and day 
8) and then treated with G (from day 9 to day 21) compared with V alone 
or G in continuous. 
Conclusion: this study suggests that the schedule of V followed by G is supe-
rior to other sequences with V and G in treating NscLc cell line. this find-
ing is encouraging as a proof of the possible benefit of combining an EGFr 
targeting compound with a cell cycle specific drug and could be a rationale for 
a new treatment strategy in patients with advanced EGFr mutated NscLc. 
the molecular mechanisms involved in the synergistic effect between V and 
G against NscLc cells will be the object of study in the near future. 
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GANETESPIB: AN EFFECTIVE STRATEGY TO 
OVERCOME CRIZOTINIB RESISTANCE IN ALK-DRIVEN 
CANCERS
I. El-Hariry1, J. Acquaviva1, Q. Jiang2, L. Xue2, D. smith1, J.c. Friedland1, 
s. He1, J. sang1, s.W. Morris2, D.A. Proia1 1Synta Pharmaceuticals Corp., 
Lexington, MA, UNITED STATES OF AMERICA, 2Departments of Pathology 
and Oncology, St. Jude Children’s Research Hospital, Memphis, TN, UNITED 
STATES OF AMERICA
Background: the EML4-ALK rearrangement represents nearly 40,000 non-
small cell lung carcinoma (NscLc) patients worldwide each year. While tar-
geted ALK inhibitors such as crizotinib have shown clinical efficacy the vast 
majority of patients will develop resistance, reinforcing the need for new ther-
apies. One such strategy is to target the molecular chaperone ALK depends 
on for protein stabilization.  Indeed, inhibition of Hsp90 by ganetespib has 
shown an encouraging 50% objective response rate in patients with advanced 
ALK+ NscLc. to determine if ganetespib can be an effective strategy for 
ALK inhibitor resistance, we evaluated its activity alone or in combination 
with crizotinib in crizotinib-sensitive and -resistant cancer cells harboring 
ALK fusions.
Methods: H2228 and H3122 NscLc cells, which express EML4-ALK, 
were treated with ganetespib, crizotinib or the combination, and cell viability 
and signaling cascades were assessed both in vitro and in vivo. to generate 
models of crizotinib resistance, H2228 NscLc, H3122 NscLc and NPM-
ALK-expressing baF3 cells were exposed to various crizotinib concentra-
tions. Fifteen different ALK kinase domain substitutions were identified in 
the baF3 cells; clonal NPM-ALK/baF3 cells were made for each resistance 
mutation and assayed for sensitivity to ganetespib. 
Results: Ganetespib was significantly more potent than crizotinib in both 
H2228 and H3122 NscLc cells. the combination of ganetespib with cri-
zotinib resulted in complimentary inhibition of MAPK signaling and strong 
synergistic anticancer activity in vitro and in vivo.  In crizotinib resistant 
H2228 and H3122 cells, ganetespib displayed low nanomolar activity equiva-
lent to that observed in the parental population. Ganetespib treatment induced 
the degradation of wild type and all 15 mutant forms of ALK, resulting in 
potent cell death.
Conclusions: Ganetespib effectively destabilizes EML4-ALK in crizotinib 
sensitive cells and multiple clinically validated ALK mutants in crizotinib 
resistant cells. the complementary actions of directed ALK inhibition with 
crizotinib and indirect ALK inhibition with ganetespib result in synergistic 
anticancer activity and warrants further study.  
Disclosure: All synta employees disclose that they have financial interest in 
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THE DIAGNOSTIC ROLE OF ENDOBRONCHIAL 
ULTRASOUND IN PERIPHERAL LUNG CANCER LESIONS
N. Lalic, b. Perin, b. Zaric, E. budisin, G. stojanovic, s. Jovanovic, M. 
Antonic, N. secen, J. stanic Clinic for Pulmonary Oncology, Institute for 
Pulmonary Diseasaes of Vojvodina, Faculty of Medicine, University of Novi 
Sad, Sremska Kamenica, SERBIA
Background: Endoscopic diagnosis and pathological findings remain the 
benchmark for diagnosis of lung cancer. Endobronchial ultrasound (EbUs) is 
a minimally invasive technique that expands the view of the bronchoscopist 
beyond the lumen of the airway. the sensitivity of transbronchial diagnosis of 
lung cancer showed superiority of EbUs guided bronchoscopy through suc-
cessful placement of probes compared to fluoroscopic guidance only.
Objective: Introducing EbUs guided bronchoscopy to localize the peripheral 
pulmonary lesions (PPL), we attempted to evaluate the feasibility, efficacy 
and safety of its application in the diagnosis of peripheral lung cancer lesions. 
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We compared diagnostic yields of EbUs guided bronchoscopy according to 
diameter, location of lesions and different type of sampling procedures.
Patients and methods: At the Institute for Pulmonary Diseases of Vojvodina, 
serbia 120 patients with PPL underwent EbUs between April 2010 and 
November 2011. A radial ultrasound probe (20MHz Km-bs20-26r) was 
used. the probe was connected to an endoscopic ultrasound system (EU-ME-
1, Olympus, Japan). Our sampling procedures were transbronchial biopsy 
(tbb), catheter biopsy and brush biopsy.
Results: the lesions (14–59mm measured on ct) were visualized by EbUs 
in 99 patients (82%). the overall sensitivity in the diagnosis of PPL was 0.73. 
Overall diagnostic yield for lesions <30 mm was 0.34 and for lesions > 30 
mm was 0.66. Prevalence of malignancy was 68%. sensitivity of tbb (0.86), 
exceeds the other two sampling procedures-catheter biopsy 0.37 and brush 
biopsy 0.33. Multivariate analysis revealed that the diameter and the location 
of the peripheral lung cancer lesions were independent predictors of diagnos-
tic sensitivity of EbUs guided bronchoscopy.
Conclusions: EbUs guided bronchoscopy is effective for diagnosing periph-
eral lung cancer lesions. the diameter, type of sampling procedures and the 
identification of the bronchus leading to the lesions were valuable as factors 
related to a higher diagnostic sensitivity with this procedure.
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THE ROLE OF BLIND PLEURAL BIOPSY IN DIAGNOSIS 
OF PLEURA
V. radosavljevic, M. Obradovic, V. Gardijan Pulmology, KBC Bezanijska 
Kosa, Belgrade, SERBIA
Introduction: blind percutaneous pleural biopsy has traditionally been per-
formed to investigate the etiology of exudative pleural effusion. the aim of 
study was to prove the importance of blind pleural biopsy in diagnosis of 
possible lung cancer.
Material and methods: the study included 100 patients (63 male, 37 female; 
median age: 67) with pleural effusion of unknown etiology which was located 
in the right side in 60 patients, and in the left side in 40 patients. A blind pleu-
ral biopsy was performed on every patient with three as the least number of 
samples of tissue, which were sent for PH verification.
Results: In seven patients (7%) we proved pleuritis specifica (tbc). In 23 
patients (23%) a malign PH finding was found. there were 11 patients (47%) 
with adenocarcinoma, 6 patients (26%) with clearly non-defined carcinosis 
of pleure, 2 patients (8,7%) with mesothelioma pleure, 1 patient (4,3%) with 
metastasis of ductal invasive breast carcinoma, 1 patient (4,3%) with metas-
tasis of non-hodgkin lymphoma, 1 patient (4,3%) with metastasis of medullar 
carcinoma of the thyroid and 1 patient (4,3%) with NscLc.
Conclusion: closed pleural biopsy using a tru-cut needle is effective for the 
specific diagnosis of exudative pleural effusion. In our study needle biopsy 
obtaining pleural tissue was diagnostic in approximately 23% of patients pre-
senting with malignant effusion in the sample. blind pleural biopsy is a rela-
tively safe procedure with several limitations (painful, unpleasant) and a low 
percentage of positive result. but it is still a very acceptable, possible and safe 
method for the diagnosis of uncommon pleural effusion.
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IDENTIFICATION AND CHARACTERIZATION OF 
PROTEINS ISOLATED FROM MICROVESICLES IN 
MALIGNANT PLEURAL EFFUSIONS
K.Y. Lee1, H.J. Kim1, K.P. Kim2 1Internal Medicine, Konkuk University 
Hospital, Seoul, KOREA, 2Molecular Biotechnology, Konkuk University, 
Seoul, KOREA
Microvesicles (MVs, also known as exosomes, ectosomes, microparticles) 
are released by various cancer cells, including lung, colorectal and pros-
tate carcinoma cells. MVs released from tumor cells and other sources 
accumulate in the circulation and in pleural effusion (PE). Although 
recent studies have shown that MVs play multiple roles in tumor progres-
sion, the potential pathological roles of MV in pleural effusion, and their 
protein composition, are still unknown. In this study we report the first 
global proteomic analysis of highly purified MVs derived from pleural 
effusion in the patient with non-small-cell-lung-cancer (NscLc). Using 
nano-Lc–Ms/Ms following 1-D sDs-PAGE separation, we identified a 
total of 912 MV proteins with high confidence. three independent experi-
ments on three patients showed that MV proteins from PE were distinct 
from MV obtained from other malignancies. bioinformatics analyses of 
the Ms data identified pathologically relevant proteins and potential diag-
nostic makers for NscLc, including lung-enriched surface antigens and 
proteins related to EGFr signaling. these findings provide new insight 
into the diverse functions of MVs in cancer progression and will aid in the 
development of novel diagnostic tools for NscLc. Abbreviations: MV, 
microvesicle; NscLc, non small cell lung cancer; PE, pleural effusion; 
Lc, liquid chromatography; Ms/Ms, tandem mass spectrometry
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THE RADIOLOGICAL INCIDENCE OF RILI (RADIATION-
INDUCED LUNG INJURY) AND ITS CORRELATION WITH 
DOSIMETRIC AND CLINIC PARAMETERS
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ciurlia1, s.I. santoro2, V. Valentini1 1Radiotherapy, Policlinico Universitario 
A. Gemelli, Roma, ITALY, 2Radiology, Policlinico Universitario A. Gemelli, 
Roma, ITALY, 3Pneumology, Policlinico Universitario A. Gemelli, Roma, 
ITALY
radiation-induced lung injury (rILI) is the most common side effect 
after radiation therapy for lung cancer. It is known that the radiological 
finding of rILI is not always associated with the clinical manifestation 
of pneumonitis, and it is also not clear if it correlates with a decrease 
of patient’s pulmonary function. In this study, we analyzed the predic-
tive value of dosimetric parameters and Pulmonary Function tests (PFts) 
and their correlation with the radiological incidence of radiation-induced 
lung injury (rILI). Data from 64 patients with non-small cell lung cancer 
(NscLc), stage I-IIIb, treated with (chemo)-radiation in our Institution 
from 2005 to 2010 were analysed. Eligibility criteria were: presence of 
visible tumor on a diagnostic chest ct scan, availability of ct scans 
before irradiation and at 3–6 months follow-up, baseline PFts, with 
at least forced expiratory volume in 1 s (FEV1), forced vital capacity 
(FVc), total lung capacity (tLc), functional residual capacity (Frc) and 
vital capacity (Vc) at 2–4 months follow-up. Data from patients were 
analysed. the worsening of pulmonary function was evaluated comparing 
PFts performed before and after radiotherapy. thirty-two patients (50%) 
developed radiation-induced changes in lung tissue. Logistic regression 
was performed to verify whether the commonly used lung dosimetric con-
straints could be predictive of rILI. MLD was found to be the strongest 
predictor of rILI (Odds ratio: 1.20; 95% cI: 1.04 – 1.39; p: 0.012), but 
even V20, V30, V5, omolateral V20 proved to be significantly related to 
the onset of rILI. Moreover, the prescribed total dose was significantly 
associated with rILI. No patient showed clinical signs or symptoms of 
pneumonitis nor any worsening of PFts resulted in clinically significant 
decrease of patient’s respiratory performance. Our study confirmed the 
important role of dosimetric parameters for the prediction of lung toxicity. 
It also proved that the radiological finding of rILI does not necessarily 
correlate with a worsening of the patient’s respiratory performance, or 
other respiratory symptoms, especially when treatment planning has been 
performed complying with the lung dosimetric constraints.
Disclosure: All authors have declared no conflicts of interest.
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THE MULTI-DISCIPLINARY APPROACH TO NEW LUNG 
CANCER CASES
L.c. connell1, Y. Gahan2, D. tuohy1, c. Kelly1, D.N. carney1 1Medical 
Oncology Department, Mater Misericordiae University Hospital, Dublin, 
IRELAND, 2Respiratory Department, Mater Misericordiae University 
Hospital, Dublin, IRELAND
Introduction: cancer care is increasingly delivered by multidisciplinary 
teams. As more and more treatment options emerge, the complexity of man-
aging a lung cancer patient (pt) has evolved. the multi-disciplinary team 
meeting (MDM) is, for the majority of incident lung cancer cases, the plat-
form from which treatment decisions are determined. We reviewed all new 
lung cancer cases where a multidisciplinary discussion was performed at our 
institution. 
Methods: A prospectively maintained database was retrospectively 
reviewed for all new lung cancer cases discussed at the chest MDM 
from July 1st 2011 to December 31st 2011. clinicopathological variables, 
e.g. histological subtype, tumour stage, smoking status and EcOG per-
formance status were recorded. treatments offered, and key performance 
indicators such as time to review from multi-disciplinary referral as well 
as time to treatment from established diagnosis and discussion were 
documented. 
Results: A total of 61 new lung cancer cases were recorded, including 
20 female and 41 male patients (pts). thirteen (21%) pts were treated 
with surgical resection, and did not necessitate further therapy. thirty 
eight percent had stage IV disease at diagnosis. seven pts were referred 
directly to palliative care only from the meeting. Of the 29 pts referred 
to Medical Oncology for consideration of systemic therapy, 2 declined 
treatment themselves while 9 pts (31%) were deemed unfit by the assess-
ing physician on the basis of worsening performance status and co-mor-
bidities. Of those who proceeded to systemic chemotherapy, time from 
referral to review averaged at 7 days, & time from referral to treatment 
was 14–17 days. 
Conclusion: While the rationale behind the MDM is the involvement of all 
key specialities in making clinical decisions on individual pts, the consensus 
reached at such a meeting is not always in reality the best option for a particu-
lar pt. Multidisciplinary discussions promote more evidence-based recom-
mendations and improved treatment timing, as proven by our single institution 
experience. However, one size does not fit all. treatment recommendations at 
such meetings fail to address pt preference as well as co-morbidities, and 
wider social and psychological issues.
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SHOULD RADIOLOGICALLY “SOLID” TUMOR BE VALID 
FOR LIMITED RESECTION IN SMALL-SIZED LUNG 
CANCER?
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Oh1 1Division of General Thoracic Surgery, Juntendo University School of 
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Background: small-sized lung cancers showing a wide area of ground-grass 
opacity (GGO) on thin-section computed tomography (ct) are considered to 
be a good candidate for limited surgical resection, because of its minimally 
invasive nature. On the other hand, the validity for limited resection of radio-
logically “solid” tumors is still controversial in small-sized non-small cell 
lung carcinoma.
Methods: between 2008 and 2010, 680 consecutive patients underwent 
pulmonary resection for lung cancer. Findings of preoperative computed 
tomography were reviewed for all 680 patients and categorized into three 
parts: pure GGO, mixed GGO, and pure solid. All patients were evalu-
ated with positron emission tomography (PEt) and maximum standard-
ized uptake value (sUVmax) was recorded. several clinicopathological 
features were investigated for detecting predictors for hilar or medi-
astinal lymph node metastasis. Uni- or multivariate analyses were used 
for evaluating the relationship between those factors and lymph node 
metastasis.
Results: there were 227 patients with lung cancer showing solid or mixed 
GGO appearance on thin-section ct scan. Among them, nodal involve-
ment was found pathologically in 42 (26%) patients with pure solid tumors 
in contrast to 4 (6%) patients with mixed GGO tumors (p=0.0002). Among 
131 patients with clinical t1a tumors, there were 94 (71.8%) patients with 
solid tumor, and nodal involvement was observed in 15 (16.0%) in this 
group. Multivariate analysis elucidated the following predictors for no 
lymph node metastasis: mixed GGO tumor, presence of air bronchogram, 
low cEA level and low sUVmax. Among 94 t1a tumor showing pure solid, 
cEA level and sUVmax were the significant predictors for lymph node 
involvement by tumor based on multivariate analysis (p=0.0148, 0.0177). 
the frequency for lymph node metastasis was approximately 27% for 
patients having lung cancer with pure “solid” and high sUVmax even for 
t1a tumor.
Conclusions: Lymph node metastasis is frequently observed for pure 
“solid” lung cancer, especially when tumor shows high sUVmax. If 
limited surgery is indicated for solid lung cancer, the thorough intraop-
erative evaluation of lymph nodes is inevitable for preventing locore-
gional failure. 
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Background: the extent of ground glass opacity (GGO) on thin-section com-
puted tomography (ct) has been reported to be a good prognostic marker for 
lung cancer. However it is not rare to experience difficulty in measuring the 
size of GGO. thus we investigated clinicopathological features in lung cancer 
of which GGO is difficult to measure. 
Materials and methods: A retrospective study was conducted on consec-
utive 572 patients with resected lung cancer of clinical stage IA between 
2004 and 2011. All patients underwent preoperative ct and authors 
reviewed radiological findings for all cohorts. Lung cancers having dif-
ficult GGO to measure are selected and their clinicopathological features 
are investigated. to elucidate characteristic findings, clinicopathological 
features on other lung cancers were also investigated and compared with 
each other. 
Results: there were 71 (12.4%) patients with lung cancer of which 
GGO is difficult to measure. All of these lung cancers showed GGO 
and consolidation on thin-section ct. the consolidation was not eas-
ily measurable because of its scattered distribution, so we defined it as 
lung cancer with scatterd consolidation (Lcsc). Of those, there were no 
nodal metastases at all. the frequency of pathological lymphatic and/or 
vascular invasion were significantly less observed (p<0.0001). In mul-
tivariate analysis for predictors of lymphatic and vascular invasion, new 
category “Lcsc”, cEA (≥5ng/ml), tumor size (>20mm) and c/t ratio 
(>0.5) were independent predictors significantly. And four categories 
(GGO group, Lcsc, Part solid group and Pure solid group) are more 
graduated, more invasive and these distributions were significantly dif-
ferent (p<0.0001)(table 1). Conclusions: New category “Lcsc” has 
been proposed and this resolved the problem that we can’t measure the 
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c/t ratio because of scattered consolidation. Lcsc was independent 
category and minimally invasive lung cancer. We could decide each 
strategy for c-stage IA non-small cell lung cancer, classifying these four 
categories. table 1:
GGO group 
0<C/T 
ratio≤0.5 LCSC
Part Solid 
group 0.5<C/T 
ratio<1
Pure Solid 
group C/T 
ratio=1
P-N1 or 2 0% 0% 8.5% 25% 
Lymphatic 
invasion (+) 
5.5% 16.9% 38.7% 69.5% 
Vascular 
invasion (+) 
3.2% 7.0% 30.2% 65.8% 
Disclosure: All authors have declared no conflicts of interest.
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THE SIZE OF CONSOLIDATION ON THIN-SECTION 
COMPUTED TOMOGRAPHY IS A BETTER PREDICTOR 
OF SURVIVAL THAN THE MAXIMUM TUMOR 
DIMENSION IN RESECTABLE LUNG CANCER
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Surgery, Juntendo University School of Medicine, Tokyo, JAPAN
Background: Ground glass opacity (GGO) is a preoperative prognostic fac-
tor in resectable lung cancer. However, the impact of GGO on the t factor in 
the tNM staging system remains unclear and the maximum tumor dimen-
sion is also an uncertain measurement for assessing the prognosis of early 
lung cancer with a mixture of consolidation and GGO. thus, we sought to 
determine which is a better prognostic factor in clinical stage IA lung cancer 
patients, the size of the solid component on thin-section ct scan or the con-
ventional maximum tumor dimension.
Patients and methods: between January 2004 and January 2011, 398 
consecutive patients with lung cancer that measured less than 30 mm in 
diameter underwent surgical resection at our hospital. Univariate and 
multivariate analyses were performed by the logistic regression procedure 
to determine the relationship between pathologic lymph node metastasis-
positive status and clinical or radiological findings such as the maximum 
dimensions of consolidation and the tumor, the presence of air broncho-
gram, pleural indentation and the preoperative serum carcinoembryonic 
antigen (cEA) level.
Results: Of the 398 patients, 59 (14.8%) had pathologic lymph node metas-
tasis. Univariate analysis revealed four significant predictors of pathological 
nodal involvement: the presence of air bronchogram, the size of consolida-
tion, the maximum tumor dimension and the preoperative cEA level (p<0.01, 
respectively). In a multivariate analysis, the size of consolidation and the 
presence of air bronchogram were significant predictors of nodal metastasis 
(P<0.01, respectively). Among 56 patients with lung cancers that showed con-
solidation larger than 20mm and no air bronchogram, 26 (46.4%) had nodal 
metastasis.
Conclusion: the maximum dimension of consolidation was an independent 
unfavorable prognostic factor, regardless of the maximum tumor dimension. 
this could lead to the more accurate prediction of pathological lymph node 
metastasis with both GGO and a solid component. It may also be useful for 
identifying candidates for limited surgical resection such as segmentectomy 
with nodal dissection in early lung cancers.
Disclosure: All authors have declared no conflicts of interest.
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STEREOTACTIC BODY RADIOTHERAPY (SBRT) USING 
VOLUMETRIC MODULATED ARC THERAPY (VMAT) 
WITH FLATTENING FILTER FREE (FFF) MODALITY FOR 
MEDICALLY INOPERABLE EARLY STAGE NON SMALL-
CELL LUNG CANCER (NSCLC): A PROSPECTIVE SINGLE 
INSTITUTIONAL EXPERIENCE
P. Navarria1, A.M. Ascolese1, E. clerici2, G. reggiori1, M. catalano1, 
s. Pentimalli1, s. castiglioni1, F. Alongi1, P. Mancosu1, M. scorsetti1 
1Radiotherapy and Radiosurgery, Istituto Clinico Humanitas Cancer Center, 
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Purpose: to evaluate preliminary results and toxicity of sbrt using 
Volumetric Modulated Arc therapy (VMAt) with Flattening Filter Free 
(FFF) beams modality for stage I NscLc patients.
Methods and materials: Of the one hundred twenty-two consecutive patients 
with inoperable early-stage NscLc that underwent sbrt at our Institution, 
in the last year 36 were treated with VMAt-FFF beams. For all patients a 
pretreatment ct scan and a whole-body [18F]-fluorodeoxyglucose positron 
emission tomography/ computed tomography (ct-PEt) were acquired to rule 
out any other sites of disease. A pathologic diagnosis was available for 18/36 
(50%). Prescription dose was 48 Gy in 4 consecutive fractions for all patients. 
clinical outcome was evaluated by ct scan and ct-PEt. the incidence of 
pneumonitis was graded according to the NcI ctcAE v3.0 scale.
Results: Median follow up was 9 months (range 3-14 months). response 
was recorded in 35/36 patients (97.2%). Particularly, at the first follow up 
(3 months) 18/36 (50%) had complete remission and 13/36 (36%) partial 
remission major than 50%. No local recurrence occurred. At the last follow 
up all patients were alive. No pulmonary toxicity of grade 2 or greater was 
recorded. No chest pain toxicity occurred. removal of the flattening filter 
(FF) increased the dose rate. the median beam-on time (bOt) was reduced 
by 75% passing from about 8 minutes (with FF modality) to 2 minutes (with 
FFF modality).
Conclusions: sbrt for early-stage NscLc resulted in excellent local control 
with minimal toxicity. VMAt technique improved target coverage while mini-
mizing higher dose to normal tissue with respect to coplanar beam arrange-
ments. Furthermore, the bOt was significantly reduced in FFF modality 
with a subsequent increase of patient comfort and reduction of intra-frac-
tion motion. In our experience sbrt with VMAt-FFF resulted in an earlier 
radiological response compared to FF modality though a longer follow-up is 
needed to assess the effective outcome incidence.
Disclosure: All authors have declared no conflicts of interest.
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EARLY RESPONSE AFTER 40 GY TO CONCURRENT 
RADIOCHEMOTHERAPY (RTCT) AFTER INDUCTION 
CHEMOTHERAPY STRONGLY PREDICTS COMPLETE 
RESPONSE, TIME TO PROGRESSION AND OVERALL 
SURVIVAL IN LOCALLY ADVANCED NON-SMALL CELL 
LUNG CANCER (NSCLC)
Y. Vano1, c. Ortholan2, J. Otto1, P. bondiau3, J. Mouroux4, c. Hébert1, P. 
Hofman5, b. Padovani6, N. Venissac4, M. Poudenx1 1Oncology Department, 
Antoine Lacassagne Cancer Center, Nice, FRANCE, 2Radiation Oncology 
Department, Princess Grace Hospital, Monaco, MONACO, 3Radiation 
Oncology Department, Antoine Lacassagne Cancer Center, Nice, FRANCE, 
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Background: to evaluate the impact of early response after 40 Gy of rtct 
on unresectable stage III NscLc outcome. 
Methods: 85 patients (pts), treated from 2004 to 2011 were included in this 
study. Pts received 2 cycles of induction chemotherapy (ct): cisplatin (c) and 
docetaxel (D) followed by concurrent rtct: 66–70 Gy, 6 weekly cycles of cD. 
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An early assessment by ct-scan was planned at 40–46 Gy. Pts with complete 
and partial response (rEcIst criteria) were considered as early responders 
(Er) while pts with stable or progressive disease were considered as non-
responders (Nr). Median follow-up was 29.5 months [range: 3.9–84.1]. 
Results: Median age was 64 [range: 41–83], 52/85 of pts (61%) were male, 
44/85 (52%), 33/85 (39%) had adenocarcinoma or squamous cell carcinoma 
respectively, 82/85 (96%) had performans status 0 or 1, 51/85 (60%) and 34/85 
(40%) were stage IIIb or IIIA respectively. 82/85 (96%) received the planned 2 
induction cycles, 80/85 (80%) completed > 4 concurrent cycles and mean radi-
ation dose received was 58 Gy [range: 36–70]. 64% of pts were Er (54/85), all 
with partial response. t status at baseline was the only factor associated with 
Er: 77% (33/43) of pts staged t1-t3 were Er vs. 50% (21/42) of pts staged 
t4 (p=0.014). Among the 30 pts who achieved cr, 26 were Er (48%) and 4 
were Nr (14%) (p=0.02). Median time to progression (ttP) was 18 months 
in the Er group vs. 7 months in the Nr group (p<0.001). Median overall 
survival (Os) was 24.5 months [%95cI: 12–36], with 36 and 14 months for 
Er and Nr respectively (p<0.0001). Independent variable for better Os in 
multivariate analysis was only Er (Hr=0.34 [%95cI: 0.18–0.64], p=0.001). 
Independent variables for better ttP in multivariate analysis were stage IIIA 
(Hr=0.32 [%95cI: 0.16-0.62], p<0.0001), surgery (Hr=0.29 [%95cI: 0.10–
0.85], p=0.025) and Er (Hr=0.42 [%95cI: 0.23–0.75], p=0.004). 
Conclusion: Er had a significant better ttP and Os than Nr. since the likeli-
hood of complete response in Nr is low and toxicity is significant, the benefit of 
the rtct completion in these pts is questionable. those results incite to com-
pare in Nr the completion of rtct vs. second-line ct in a prospective trial.
Disclosure: All authors have declared no conflicts of interest.
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IMAGING EARLY RADIOTHERAPY (RT)-INDUCED 
CHANGES OF PROLIFERATION IN PATIENTS WITH NON-
SMALL CELL LUNG CANCER (NSCLC) USING FLT-PET
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Background: [F-18]Fluorothymidine (FLt) is a promising biomarker of 
response to rt. 2 pilot studies in NscLc have reported FLt PEt uptake 
changes at variable time points during concurrent chemo-rt (Everitt 2009, 
Vera 2011). It is unknown, whether FLt uptake decreases early during rt 
alone and whether such changes exceed test-retest variability.
Methods: FLt-PEt imaging is performed in NscLc patients (pts) scheduled 
for radical rt twice at baseline (scans 1, 2) to assess reproducibility and 
after 3–10 rt fractions (scan 3), to assess response. serial blood samples for 
analysis of circulating cell death biomarkers are also taken (M30/65). Data 
are dynamically acquired for 60min on the trueV PEt/ct scanner. 45–60 
minute images are reconstructed using 3D-OsEM, smoothed with a 4mm 
Gaussian filter. tumours are manually delineated on PEt-ct images by a 
specialist thoracic radiologist. sUV reproducibility is measured as (sUV2-
sUV1)/(sUV1+sUV2)*200. rt response is calculated as % change relative 
to single/average baseline value.
Results: 14 evaluable pts had a total of 31 scans: 10 male, 4 female, age 
47-83, stage II(1), III (10), III/IV(3) NscLc treated with radical rt (12 
pts: 55Gy in 20 fractions (#), 1pt: 66Gy in 33#, 1pt: 50Gy in 20#). 5 pts 
are evaluable for reproducibility and 12 for response. Pre-treatment scans 
were done within 2-6 days and on-treatment scans 6-15 calendar days after 
day1 rt (4-11 fractions, 11-30Gy). 38 lesions were delineated: 14 primary 
tumours (6-214cm3, median 70cm3) and 24 nodes (2-22cm3, median 7cm3) 
Mean absolute sUVmean reproducibility was 8.1% (primaries 7.6%, nodes 
8.3%). Following rt malignant lesion sUVmean change ranged from +3.1 to 
-53.6% (average -33.6%, primaries -24.9%, nodes -39.4%). sUVmax average 
reproducibility was 12.2% and response -36.5%. 
Conclusions: rt induces early decreases in tumour FLt uptake which 
exceed baseline reproducibility. We observed less average decrease in pri-
mary tumour uptake compared to previous report using comparable rt dose 
but with concomitant chemotherapy (sUVmax decrease >40%) (Everitt, 
2009). recruitment is ongoing and blood biomarker and updated imaging, 
including kinetic, results will be reported.
Disclosure: P. Koh: PK Koh is supported by a cancer research UK and 
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A CASE-REFERENT STUDY FOR EVALUATING THE 
EFFECTIVENESS OF LUNG CANCER SCREENING IN 
VARESE, ITALY
W. Mantovani1, A. Poli1, L. Dominioni2, s. Pisani3, N. rotolo2, V. conti2, 
M. bocchi1, s. Vittorii1, D. Di Natale2, A. Imperatori2 1Public Health and 
Community Medicine, University of Verona, Verona, ITALY, 2Surgical Sciences 
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Observatory, ASL Varese, Varese, ITALY
Background: the effect of chest x-ray (cXr) screening at population level 
on mortality from lung cancer (Lc) has not been studied adequately and is 
an unresolved issue.
Aim: We applied a case-referent design to evaluate the effect of a five annual 
cXr screening programme on Lc mortality, in a clearly defined population-
based cohort of smokers.
Methods: In July 1997 we invited all smokers of >10 pack-years eligible 
for Lc screening who lived in 50 communities of the Varese Province, to 
participate in a nonrandomized screening by annual cXr exam for five years. 
5,815 smokers (the cohort) were invited. 21% of the cohort (1,244 subjects) 
self-select to participate in screening; 79% did not participate. the cohort was 
followed-up through December 2006, all Lc deaths being recorded. For each 
case, one referent was sampled from the cohort. the referent, alive at the time 
of case death, was matched to case for birth year and gender. the screening 
history of cases and referents was evaluated. the crude Lc risk of death in the 
screened relative to the unscreened subjects was estimated as odds ratio (Or), 
as follows: crude Or = (n. sets of case screened, referent not screened)/(n. 
sets of case not screened, referent screened). to adjust for self-selection bias, 
we applied Duffy’s formula (Appl stat 2002; 51:235–43), using Lc incidence 
as adjusting factor.
Results: crude Or was 0.79 (95%cI, 0.47-1.32), suggesting a Lc mortality 
reduction of 21% in screened versus unscreened subjects. After adjustment 
for self-selection, the effect increased to 41% (Or = 0.59; 95%cI, 0.35-0.99) 
(table).
Conclusion: cXr screening reduced Lc risk of death in a population-based 
cohort of ever smokers. Adjustment for screenee’s self-selection enhanced the 
Lc mortality reduction.
Table. Case-referent sets and CXR screening history
Set n. % 
case and referent both screened 12 7.0 
case screened, referent not screened 26 15.1 
case not screened, referent screened 33 19.2 
case and referent both not screened 101 58.7 
total 172 100 
crude Or of Lc death 0.79 (95%cI, 0.47-1.32) 
Adjusted Or of Lc death 0.59 (95%cI, 0.35-0.99) 
Disclosure: All authors have declared no conflicts of interest.
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DETECTION OF PREMALIGNANT BRONCHIAL 
LESIONS CAN BE IMPROVED BY COMBINATION OF 
AUTOFLUORESCENCE IMAGING (AFI) AND NARROW 
BAND IMAGING (NBI) VIDEOBRONCHOSCOPY
b. Zaric, b. Perin, s. Jovanovic, N. Lalic, G. stojanovic, M. Antonic Clinic 
for Pulmonary Oncology, Institute for Pulmonary Diseases of Vojvodina, 
Faculty of Medicine, University of Novi Sad, Sremska Kamenica, SERBIA
Background: the search for most efficient bronchoscopic imaging tool in 
detection of early lung cancer is still active. the major aim of this study was to 
determine sensitivity, specificity, positive (PPV) and negative predictive value 
(NPV) of each technique and their combination in detection of premalignant 
bronchial lesions.
Patients and methods: this was a prospective trial that enrolled 96 patients 
with indication for bronchoscopy. Major indications were: radiological sus-
picion for lung cancer, surveillance of patients after surgery, evaluation of 
known malignancy, positive sputum cytology and prolonged cough. In each 
patient at least one but no more than 3 biopsies were taken from places iden-
tified as pathological under white light videobronchoscopy (WLb), AFI, 
NbI or their combination. At least one, but no more than 3 biopsies were 
taken randomly from places that appeared normal under each technique. 
Lesions were classified as visually positive if pathological fluorescence was 
observed under AFI or, dotted, tortuous and abrupt ending blood vessels 
were identified under NbI. squamous metaplasia, mild, moderate or severe 
dysplasia and cIs were regarded as histologically positive lesion were. 
Results: sensitivity, specificity, PPV and NPV of WLb in detection of prema-
lignant lesions were 26.5%, 63.9%, 34.4% and 54.9% respectively, correspond-
ing values for AFI were 52%, 79.6%, 64.6% and 69.9% respectively, for NbI 
were 66%, 84.6%, 75.4%, 77.7%, respectively, while corresponding values for 
combination of NbI and AFI were 86.1%, 86.6%, 84.6%, and 88% respectively. 
combination of NbI and AFI significantly improves sensitivity when compared 
to each individual technique (p<0.001). When specificity is of concern combi-
nation of techniques improves specificity of WLb (p<0.001), specificity of AFI 
(p=0.03) but it has no significant influence on specificity of NbI (p=0.53).
Conclusion: combination of NbI and AFI in detection of premalignant bron-
chial lesions increases both sensitivity and specificity of each technique. 
However more prospective, randomized data are needed to validate and con-
firm these findings.
Disclosure: All authors have declared no conflicts of interest.
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BREATH ANALYSIS FOR DISTINGUISHING MALIGNANT 
FROM BENIGN PULMONARY NODULES USING NANO 
ARTIFICIAL OLFACTORY SYSTEM
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Center, Sheba Medical Center, Tel Hashomer, Tel Aviv, ISRAEL, 3Divisions 
of Pulmonary Sciences and Critical Care and Medical Oncology, University 
of Colorado Cancer Center, Aurora, CO, UNITED STATES OF AMERICA, 
4Cancer Center, University of Colorado Cancer Center, Aurora, CO, 
UNITED STATES OF AMERICA, 5Chemical Engineering and Russell Berrie 
Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, 
ISRAEL
the overreaching goal of this study is to tailor a novel Nano Artificial 
Olfactory system (NaNose®) in order to compare the signatures and composi-
tions of exhaled VOcs in people with solitary pulmonary nodules (sPNs) as a 
part of a fast, non-invasive diagnostic method. breath samples were collected 
from 74 volunteers with sPNs in a cross-sectional comparative survey con-
ducted in University of colorado cancer center and Denver Veterans Affairs 
Medical center (Denver, cO, UsA). the exhaled breath was analyzed by 
the NaNose® and, for comparsion, by Gc-Ms for determining the chemical 
nature of the VOcs. Pattern recognition methods were used then to analyze 
the results obtained from Gc-Ms and NaNose® and to correlate the results 
with the clincal data. Discriminant function analysis of the signals of the sen-
sor array containing 5-nm gold nanoparticle sensors and Hbc-functionalized 
random network carbon nanotube sensors discriminated benign from malig-
nant single pulmonary nodules (sPNs) in a high-risk cohort based on lung 
cancer related VOcs profiles (p<0.0001; accuracy 88±2%). Further, it dis-
criminated NscLc from scLc (p=0.0015; accuracy 94±1%) and between 
early vs. advanced disease (p<0.0001; accuracy 88±2%). Further studies are 
required as to evaluate such non-invasive approach in sPNs positive patients 
in the post NLst-era. the results provide a launching pad towards obtaining 
an inexpensive, compact tool that is amenable to widespread screening and 
that has a potential for direct and real-time.
Disclosure: All authors have declared no conflicts of interest.
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DISCRIMINATION OF CLINICAL STAGES IN NON-SMALL 
CELL LUNG CANCER PATIENTS BY SERUM HSP27 AND 
HSP70: A MULTI-INSTITUTIONAL CASE-CONTROL 
STUDY
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Introduction: Lung cancer represents a major healthcare problem and 
biomarkers for detection are not available. We have recently described that 
patients with manifest cOPD evidence elevated levels of serum heat shock 
proteins (HsPs). based on these data, we speculated whether HsPs are also 
increased in lung cancer patients.
Methods: serum levels of HsP27, pHsP27 and HsP70 in patients with early 
(n=34) and advanced (n=72) NscLc were determined by ELIsA. Healthy 
smokers (n=24), healthy never-smoker volunteers (n=33) served as control 
population.
Results: serum levels of HsP27 were elevated in NscLc patients diagnosed 
at an early or advanced stage when compared with both healthy control groups 
(P<0.005 and P<0.0001 respectively). Moreover, HsP27 levels could differ-
entiate between early vs. advanced stage NscLc (P=0.0021). serum levels 
of HsP70 were also significantly elevated in patients with NscLc diagnosed 
at an early or at an advanced stage when compared with either healthy control 
groups (P=0.0028 and P<0.0001 respectively). In univariate logistic regres-
sion models including healthy subjects and patients with NscLc, HsP70 had 
an area under the curve (AUc) of 0.779 (P<0.0001) and HsP27 showed an 
AUc of 0.870 (P<0.0001).
Conclusion: Our data suggest that serum HsP27 levels might serve as a pos-
sible tool to discriminate between early and advanced stage NscLc.
Disclosure: All authors have declared no conflicts of interest.
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FDG-PET/CT FOR RESPONSE EVALUATION IN LOCALLY 
ADVANCED NSCLC PATIENTS – A PILOT STUDY
J. Fledelius1, A. Khalil2, J. Frøkiær3 1Nuclear Medicine, Herning Hospital, 
Herning, DENMARK, 2Oncological Department D, Aarhus University 
Hospital, Aarhus, DENMARK, 3Nuclear Medicine and Pet Centre, Aarhus 
University Hospital, Aarhus, DENMARK
Introduction: About 25% of non small cell lung cancer (NscLc) patients 
have locally advanced disease and can potentially be cured with chemo-radio-
therapy. this treatment is usually accompanied by high complication rates and 
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some patients die shortly after the end of intensive treatment course. being 
able to predict who could benefit from this intensive treatment strategy can 
help us improve the outcome and avoid highly toxic, unbeneficial treatments. 
recently, PErcIst 1.0 was proposed as criteria for standardization of evalu-
ating response by FDG-PEt/ct. the purpose of this study was to investigate 
the usefulness of PErcIst 1.0 in NscLc patients in the daily routine by 
evaluating whether PEt/ct will add more valuable prognostic information 
that could help tailor patient treatment accordingly.
Methods: 21 consecutive patients diagnosed with locally advanced NscLc, 
who had both a baseline PEt/ct scan and an evaluation PEt/ct scan per-
formed after 1–4 cycles of chemotherapy (carboplatine / vinorelbine), prior 
to curative intended radiation therapy, at our institution from september 2009 
until march 2011. the PEt/ct scans were analyzed by one experienced eval-
uator semi-quantitatively according to the recently proposed PErcIst 1.0 
criteria for evaluation of response to treatment, by Wahl et al. (Patient out-
come was not known to the evaluator, at the time of evaluation.) the change in 
sUL peak at the evaluation scan was calculated as according to the PErcIst 
1.0, and compared to progression free survival (PFs).
Results: the percentage change in sUL peak and the resulting response cat-
egories progressive metabolic disease (PD), stable metabolic disease (sMD) 
and partial metabolic disease (PMr) correlate well with time to progression. 
Patients with PMr and sMD had statistically significant longer time to pro-
gression (11 months sE 1.8) as compared to (4 months sE 1.5) in patients 
who had PD.
Conclusion: response by PErcIst 1.0 evaluated early in the course of cura-
tively intended chemo-radiotherapy can be used to predict PFs, and progres-
sion at the early evaluation prior to radiotherapy predicts a poor outcome and 
may in the future be considered a valid indicator for change of therapeutic 
strategy.
Disclosure: All authors have declared no conflicts of interest.
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NSCLC: RADIATION DOSE - TUMOR SIZE RELATED, 
ACCELERATED (1,8 GY BID) RADIOTHERAPY – FINAL 
RESULTS OF A PROSPECTIVE STUDY
K. Dagn1, K. Wurstbauer1, H. Deutschmann1, P. Kopp1, b. Lamprecht2, 
P. Porsch2, b. Wegleitner2, M. studnicka2, F. sedlmayer1 1Department of 
Radiation Oncology, Paracelsus Medical University, Salzburg, AUSTRIA, 
2Department of Pneumology, Paracelsus Medical University, Salzburg, 
AUSTRIA
Purpose: Final results of a prospective study, correlating radiation dose to 
tumor size.
Methods: Doses to primary tumors were adjusted along increasing tumor 
size in 4 groups (<2.5 cm / 2.5-4.5 cm / 4.5-6.0 cm / >6.0 cm). IcrU-doses 
of 73.8 Gy/ 79.2 Gy/ 84.6 Gy/ 90.0 Gy, respectively, were applied. Involved 
nodes received a median dose of 59.4 Gy (54,0-75,6 Gy). Fractional doses 
1,8 Gy bid. conformal target splitting technique was used mostly. 2 cycles 
platin-containing chemotherapy were given before radiotherapy (preferential 
interval to rt <10 days). Primary end points are local and regional tumor 
control, secondary endpoints are survival and tolerability. 2004 – 2009: 160 
consecutively referred, unselected patients with 164 histologically/ cytologi-
cally proven NscLc were enrolled; stage I: 38 patients; II: 6 pts.; IIIA: 69 
pts.; IIIb: 47 pts. Weight loss >5%/3 months: 38 pts. (24%). Patients were 
rigorously followed for locoregional tumor control (by periodic ct and/or 
PEt scan) and toxicity.
Results: Minimum follow-up time is 24,8 months, median follow-up time 38 
months for patients alive (range 24,8–96). We observed 32 local recurrences, 
distributed in the described tumor size groups as follows: 2/27, 20/ 94, 7/30 
and 3/13. ten patients failed regionally only. the local / regional tumor con-
trol rates at 2 years are 77% / 93%, respectively. Median overall survival (Os) 
time is 28,0 months, 2- and 5-year overall survival rates for all patients are 
57% and 19%, respectively. For stage III patients, median Os is 24,3 months, 
2-/ 5-year Os rates 51% / 18%, respectively. 2 treatment-related deaths (pro-
gressive pulmonary fibrosis) occurred in patients with pre-existing pulmo-
nary fibrosis. Further acute toxicity was mild: pneumonitis grade 3 (n=6); 
esophagitis grade 2/ 3 (n=16/ 8). Late esophageal toxicity grade 3 (n=1). No 
further late toxicity scored >grade 1. As in 94% locoregional recurrences 
occured within 2 years, these figures can be regarded as final results.
Conclusions: Dose-escalated accelerated radiotherapy following induction 
chemotherapy is well tolerated. Locoregional tumor control and survival 
compare favourably with the results of simultaneous chemo-radiotherapy, 
which is considered ‘state of the art’ for non-resected NscLc.
Disclosure: All authors have declared no conflicts of interest.
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TRIMODALITY TREATMENT INCLUDING RADICAL 
SURGERY IN ADVANCED STAGE NON-SMALL CELL 
LUNG CANCER – A RETROSPECTIVE, EXPLORATIVE 
STUDY
t. Klikovits, M.A. Hoda, b. Ghanim, c. Aigner, s. taghavi, G. Lang, J. 
Matilla, W. Klepetko Division of Thoracic Surgery, Medical University of 
Vienna, Vienna, AUSTRIA
Background: Advanced stage non-small cell lung cancer (NscLc) is a 
fatal disease, characterized by N2/N3 lymph nodes and/or locally advanced 
tumor. In clinical stage III NscLc the role of surgical resection – combined 
with induction treatment – remains controversial. We aimed to assess the 
clinical outcome of patients undergoing a trimodality therapy regime (induc-
tion chemoradiotherapy and radical resection) for advanced stage NscLc. 
Methods: We retrospectively reviewed the medical files of all consecutive 
patients undergoing induction chemoradiotherapy followed by curative resec-
tion between 1998 and 2010 at our institution. 
Results: A total of 49 patients received induction chemo- and radiotherapy 
followed by radical surgery, including 11 patients (22.4%) with pancoast 
tumors. the patients comprised 34 (69.4%) men and 15 (30.6%) women with 
a mean age of 54.5 years at the time of resection. three segmental resections, 
24 lobectomies, 3 bilobectomies, and 20 pneumonectomies (11 extra- and 9 
intrapericardial) were performed. In 48 patients a complete resection (r0) was 
achieved. 21 (42.9%) patients had a postoperative complication, ranging from 
29.2% after lobectomy to 63% after pneumonectomy (p=0.23). No deaths 
occurred within 30 days. Overall 3-year survival rate was 45%. Overall dis-
ease free survival (DFs) was 10.14 months (95%cI 4.76 – 15.51). In patients 
with pneumonectomy 3-year survival was significantly better than in patients 
with lobectomy (55% vs. 32%, p=0.039; Hr 0,386; 95% cI 0,153 – 0,976). 
Conclusion: Within a trimodality therapy including radical surgery favor-
able results for patients in advanced stage non-small cell lung cancer can 
be achieved. In this series survival in patients undergoing pneumonectomy 
tended to be superior to patients with lobectomy.
Disclosure: All authors have declared no conflicts of interest.
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ADJUVANT CISPLATINUM-DOCETAXEL 
CHEMOTHERAPY IN STAGE IB-II RESECTED NSCLC 
PATIENTS: THE TOLEDO TRIAL
L. bosquee1, P. Germonprez2, J. Aerts3, F. Peters4 1Pulmonology, CHU Sart 
Tilman, Liege, BELGIUM, 2Pulmonology, UZA, Antwerpen, BELGIUM, 
3Pulmonology, Amphia Ziekenhuis, Breda, NETHERLANDS, 4Pulmonology, 
Orbis Medisch Centrum Geleen, Geelen, NETHERLANDS
to evaluate the tolerability of four cycles of adjuvant docetaxel plus cisplatin 
in patients with completely resected stage Ib-II NscLc. this multicenter, 
open, parallel-group study was conducted in 15 hospitals in belgium and 3 
hospitals in the Netherlands between Dec 2005 and sept 2010. the trial was 
designed as a randomized phase II trial with stratification according to stage 
Ib versus II and 2:1 randomization between cisplatin + docetaxel arm (cis 
and Doc both 75 mg/m2 on day 1) (“experimental arm”) versus a 3 w sched-
ule cisplatin + vinorelbine arm (cis 80 mg/m2 on day 1; Vrb 25 mg/m2 on 
days 1 and 8) (“reference arm”). the primary endpoints were success of treat-
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ment delivery (defined as at least 3 cycles of ct with a relative dose intensity 
of 80 % or above) and toxicity (any non-hematological grade 4 toxicity).
Results: 101 of 104 randomized patients (69 cis-Doc, 35 cis-Vrb) started 
the allocated treatment and were included in the intent-to-treat analysis (68 
cis-Doc, 33 cis-Vrb). In arm cis-Doc 52 patients (76%) achieved 3 cycles 
with relative dose intensity of both cisplatin and docetaxel ≥ 80%. In arm 
cis-Vrb 23 patients (70%) completed 3 cycles with relative dose intensity of 
both cisplatin and vinorelbine ≥ 80% In arm cis-Doc 46 patients (68%) expe-
rienced grade 3-4 hematological toxicity (neutropenia and febrile neutrope-
nia) whereas 36 patients (53%) reported non-hematological grade 3 adverse 
events (mainly gastro-intestinal events and fatigue). 1 patient (1%) had grade 
4 cNs cerebrovascular ischemia (unlikely related to study treatment). In 
arm cis-Vrb 26 patients (79%) had grade 3–4 hematological toxicity and 
14 patients (42%) non-hematological grade 3 toxicity. No treatment-related 
deaths were observed.
Conclusions: this randomized Ph II study shows:
a: A larger than expected proportion of patients receiving the reference arm 
(cis-Vrb) , possibly due to the 3 weeks schedule
b: the high percentage (80%) of successful administration of the experimen-
tal arm (cis-Doc) in adjuvant approach, and manageable toxicities .
Follow-up for progression free and overall survival is currently ongoing. 
these results should be confirmed in larger randomized trials focused on sur-
vival analysis.
Disclosure: All authors have declared no conflicts of interest.
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MID-VENTILATION BASED PTV MARGINS IN 
STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR): A 
CLINICAL EVALUATION
H. Peulen, J. belderbos, M. rossi, J. sonke Radiotherapy, NKI-AVL, 
Amsterdam, NETHERLANDS
Introduction: state of the art in sAbr includes the acquisition of a four 
dimensional (4D) planning ct scan. conventionally, an Internal target Volume 
(ItV) is generated from this 4D ct to account for respiratory motion during 
treatment delivery. An alternative approach is to plan on the mid-ventilation 
(midV) ct (frame of the 4D ct with the tumor closest to its time average 
mean position) and use a clincal target Volume to Planning target Volume 
(PtV) expansion based on a margin recipe, to simultaneously account for 
respiratory motion and other geometrical uncertainties¹. this approach leads to 
considerably smaller margins especially for patients with larger tumor motion. 
the purpose of this study was to evaluate the validity of this approach.
Materials and methods: two hundred patients (107 males, 93 females) 
treated between June 2006 and March 2010 were analyzed. Mean age was 73 
years; tumor stage was t1 in 167 patients, t2 in 30 patients and lung metasta-
ses in 3 patients. tumors were located in the right and left upper lobe in 73 and 
70 patients, right middle lobe in 4 patients, right and left lower lobe in 30 and 
23 patients. In all patients a 4D ct was acquired and subsequently the midV 
ct scan was selected. tumor amplitudes were determined in left-right (Lr), 
cranio-caudal (cc) and anterior-posterior (AP) direction, and used to calcu-
late patient specific PtV margins². Patients were generally treated with 3x18 
Gy using static Intensity Modulated radiotherapy or Volumetric Modulated 
Arc therapy using online 3D/4D cone beam ct guidance.
Results: After a median follow up of 17.8 months, local recurrence (within 
the PtV) occurred in 4 patients. In this patient cohort the median Lr, cc and 
AP peak-to-peak amplitude were 2 mm (range 0-9), 4 mm (0-39) and 3 mm 
(0-14), respectively. the median 3D vector length was 6.9 mm (0-39). In case 
of local recurrence the median 3D vector length was 7.4 mm (3-13.9), with in 
every quartile one event.
Conclusion: An excellent local control of 98% was established using the 
MidV approach combined with online image guidance using sAbr in early 
stage lung cancer. this provides strong support to incorporate respiratory 
motion directly into the PtV instead of using an ItV.
¹Wolthaus et al. IJrObP, 2008 
²sonke et al. IJrOPb, 2009
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RADIOFREQUENCY (RF) ABLATION AS ALTERNATIVE 
THERAPY FOR EARLY STAGE LUNG CANCER AND 
SINGLE METASTASIS: OUR EXPERIENCE IN 26 
PATIENTS NOT ELIGIBLE FOR SURGERY
F. raveglia1, A. sacrini2, A. Luciani3, A. Leporati4, A. rizzi1, A. baisi1 
1Thoracic Surgery, A. O. San Paolo, Università degli Studi di Milano, Milano, 
ITALY, 2Radiology, A.O. San Paolo, Milano, ITALY, 3Oncology, A.O. San Paolo, 
Milano, ITALY, 4Thoracic Surgery, A.O. San Paolo, Milano, ITALY
Objectives: surgery is the treatment of choice for localized primary lung 
cancer and single metastasis. Unfortunately many patients are excluded from 
surgery because of risks related to age and comorbidities. We retrospectively 
analyzed our experience to evaluate rF ablation as an alternative procedure 
in these selected cases. 
Methods: From 2008 to 2011, 26 patients aged between 63 and 88 under-
went ct-guided rF ablation for single pulmonary lesion. 13 patients were 
affected by primary cancer stage I-II (N0), 10 by single metastasis arising 
from tumor already resected and 3 by advanced stage (IIIb-IV) lung can-
cer. these 3 cases underwent rF ablation for hemoptysis or pain palliation. 
Patients were excluded from surgery due to comorbidities (21), advanced 
stage (3) or refusal (2). 22 patients presented a smaller than 3 cm lesion. they 
required a single needle passage; the others required 2-3 passages. Patients 
were followed-up with ct in the first 6 months and subsequently with PEt/
ct. Data were analyzed by the Kaplan-Meier method. 
Results: complete necrosis was always obtained in smaller than 3 cm lesions. 
In 15 cases we registered a post-procedure pneumothorax; 11 required a 
drainage. the medium hospital stay was 3 days. At follow-up 10 deaths were 
recorded (9 for recurrence). the median survival was 30 months. survival 
was 100% at 6 months, 95.2% at 12 months, 71.9% at 24 months and 21.6% 
at 32 months. there were relapses in all patients with lesions bigger than 3 
cm, in 4 with primary cancer smaller than 3 cm, and in 3 with metastasis. 
Disease-free survival was 25 months divided as follows: 100% at 6, 86.3% at 
12, 47.4% at 24 and 17.8% at 32 months. Palliation cases obtained symptom 
remission for 6 months. 
Conclusions: Our data suggest rF ablation as a successful alternative in 
selected patients with high surgical risks. Its therapeutic efficacy appears to 
be limited to single lesions smaller than 3 cm. 
Disclosure: All authors have declared no conflicts of interest.
148P
DIFFERENTIAL CLINICAL CHARACTERISTICS OF 
OPERATED PATIENTS WITH LUNG SQUAMOUS CELL 
CARCINOMA AND ADENOCARCINOMA
s. Johnson1, K. Laitakari1, J.M. Mäkinen2, r. Mäkitaro1, r. bloigu3, 
E. Lappi-blanco4, E. rauvala5, A. Jartti5, r. Kaarteenaho1 1Respiratory 
Research Unit and Clinical Research Center, Oulu University Hospital, 
OYS, Oulu, FINLAND, 2Institute of Diagnostics, Department of Pathology, 
University of Oulu, Oulu, FINLAND, 3University of Oulu, Medical Informatics 
Group, Oulu University, Oulu, FINLAND, 4Institute of Diagnostics, 
Departments of Pathology, University of Oulu and Oulu University Hospital, 
Oulu, FINLAND, 5Department of Radiology, Oulu University Hospital, OYS, 
Oulu, FINLAND
Background: squamous cell carcinoma (scc) and adenocarcinoma (ADc) 
comprise 50-80 % of non-small cell carcinomas of lung. recent studies have 
shown differences in molecular networks between scc and ADc subtypes. 
Moreover, chemotherapeutic treatment of scc and ADc is nowadays differ-
ent, which emphasizes need of accurate diagnostics.
Hypothesis and aims: We hypothesized that lung scc and ADc may have 
various clinical characteristics. Our aim was to compare the clinical features 
of the patients with scc and ADc, who had been operated and diagnosed 
by histology.
Material and method: A retrospective study material consisted of 232 
patients who were treated by surgical lung operation in Oulu University 
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Hospital, Oulu, Finland, between the years of 1998 and 2007. Diagnoses were 
confirmed by histological evaluation of lung resection material. the clinical 
data was gathered systematically by using a specific form that was planned 
for the study. clinical, histological and radiological data was re-evaluated by 
pulmonologists as well as pulmonary radiologists and pathologists.
Results: Of the 130 patients with scc and 102 patients with ADc, 59 were 
women and 173 men. Proportion of women was 14.6% in scc and 39.0% in 
ADc. 96.9% of scc patients were ex- or current smokers while 75.5% of 
ADc patients were smokers and 15.7% non-smokers. survival of the patients 
with scc was 50.9 months when that of the ADc patients was 43.2 months. 
6.2% of scc and 7.8% of ADc patients had a family history of cancer. 79.2% 
of scc patients and 45.0% of ADc patients got sole surgical treatment. 6.2% 
of surgically treated scc patients and 25.5% of ADc patients were given 
adjuvant chemotherapy. common symptoms at the time of diagnosis in 
patients with scc and ADc were cough (39.2% versus 18.6%), hemoptysis 
(23.0% versus 9.8%) and dyspnoea (23.1% versus 16.7%).
Conclusion: clinical characteristics of the patients with scc and ADc 
showed variable features with differential sex, survival, smoking habits and 
symptoms. We concluded that scc and ADc are clinically, and not only by 
molecular biology and histology, differently behaving lung diseases.
Disclosure: All authors have declared no conflicts of interest.
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CLINICAL, MOLECULAR FEATURES AND PROGNOSIS 
IN A SERIES OF PATIENTS (PTS) NEVER-SMOKERS WITH 
RESECTED NON-SMALL CELL LUNG CANCER (NSCLC)
A. Martinez-Martí1, P. Martinez rodriguez2, s. cedres Perez2, I. sullivan2, 
N. Murtra2, J. Jimenez2, c. Aura2, J. Hernandez3, M. canela4, E. Felip2 
1Oncology, Vall d’Hebron University Hospital, Barcelona, SPAIN, 2Medical 
Oncology, Vall d´Hebron University Hospital, Barcelona, SPAIN, 3Pathology 
Department, Vall d´Hebron University Hospital, Barcelona, SPAIN, 4Thoracic 
Surgery Department, Vall d’Hebron University Hospital, Barcelona, SPAIN
Purpose: Describe the clinical and pathological features of NscLc from nev-
er-smokers and correlate the clinical and molecular findings with prognosis.
Methods: From March 1996 to september 2011, 26 never-smoker patients 
with NscLc were treated at our institution with radical surgery. We analized 
the tumor samples from these patients who underwent complete resection. 
Molecular data available for EGFr (real-time Pcr) and ALK (FIsH) were 
collected retrospectively from medical records.
Results: twenty-six pts were identified: 22 pts (85%) were female. All were 
caucasian and never-smokers. Median age was 69 years (range 33-82) and 
100% were adenocarcinoma (ADc). According to the tNM 7tH edition the 
p-stage was: IA, 7.6% (2 pts); Ib, 38.4% (10 pts); IIA, 7.6% (2 pts); IIb, 
11.5% (3 pts); IIIA, 26.9% (7 pts); IIIb, 7.6% (2 pts). Neoadjuvant chemo-
therapy (ct) was administered in 4 pts, adjuvant ct in 7 pts and adjuvant 
radiotherapy (rt) in 2 pts. Median overall survival (Os) was 32.79 months 
(m) (range 2.96–189.01) and median disease free survival (DFs) was 16.63 
m (range 2.96–115.46). Fifteen pts had recurrence disease (57.7%), with 
a relapse-free interval of 14.1 m (range 6.25–78.94): local disease in 7 pts 
(47%) and distant disease in 8 pts (53%). Median overall survival among 
patients who relapsed was 35.76 m (range 4.80-189.01). Molecular analysis 
was performed in 13 pts (EGFr-mutation status was determined in 12 pts and 
ALK in 7 pts). We found EGFr-mut in 9/12 pts (3 pts with exon 19 delec-
tion, 6 pts with mut exon 21 L858r) and ALK positive in 1/7 pts. First-line 
treatment used in 11 pts: 4 pts (36%) received platin-based ct with partial 
response (Pr) in 3 pts. 7 pts (64%) received target therapy achieving Pr in 2 
pts and complete response (cr) in 2 pts.
Conclusion: Absence of smoking history defined a subset of NscLc popula-
tion characterized by female gender, adenocarcinoma histology and a great 
portion of molecular alterations. Most of these patients present an oncogene 
alteration with available target therapies.
Disclosure: All authors have declared no conflicts of interest.
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EFFECT OF RADICAL TREATMENT ON EXERCISE 
CAPACITY AND MUSCLE FORCE IN PATIENTS WITH 
INTRATHORACIC CANCER
b. salhi1, c. Haenebalcke2, s. Perez-bogerd3, M. Nguyen4, K. Vermaelen1, 
V. surmont1, J.P. van Meerbeeck1, E. Derom1 1Respiratory Medicine, 
University Hospital Ghent, Ghent, BELGIUM, 2Respiratory Medicine, AZ 
Sint Jan, Bruges, Bruges, BELGIUM, 3Respiratory Medicine, CHU St Pierre 
Brussels, Brussels, BELGIUM, 4Respiratory Medicine, CHU Sart Tilman, 
Liege, BELGIUM
Introduction: radical treatment in patients (pts) with intrathoracic cancer 
aims to prolong life and restore quality of life. Data on its effect on exercise 
capacity and muscle force after radical treatment are scarce.
Aim: to investigate the effect of radical treatment on exercise capacity, mus-
cle force and quality of life in a cohort of consecutive pts with newly diag-
nosed lung cancer or pleural mesothelioma.
Methods: In pts with c-stages I-IIIb lung cancer or c-stage I-II mesothelioma 
pulmonary function, exercise capacity, peripheral muscle force and quality of 
life were assessed before and either 6 weeks (w) after surgery when applied 
as sole therapy, or 2 w after combined modality therapy (any combination of 
chemotherapy with radical radiotherapy and/or surgery). Data are presented 
as median with 95% cI and compared with Wilcoxon’s test.
Results: 117 pts (86 male, age: 64 years (47 – 77), bMI: 25 kg/m2 (18 – 34), 
40% cOPD; 35 pack years (0 - 70)), 105 NscLc, 6 scLc and 6 mesothe-
lioma were enrolled in the study: 50% underwent surgery as sole therapy, 12% 
surgery + chemotherapy, 24% chemotherapy + radiotherapy, 10% surgery + 
chemotherapy + radiotherapy and 4% radiotherapy only. 24 pts dropped out 
and 18 are still under treatment. the maximal exercise capacity and 6MWD 
decreased significantly after treatment (from 100 Watt (48 – 184) to 82 Watt 
(38 – 147) and the 6MWD from 515 m (388 – 632) to 482 m (328 – 617)). 
Fatigue and pain increased significantly after treatment (VAs pain from 1 
points (0 – 9) to 2 points (0 – 8) and FAct-F from 9 points (3 – 30) to 13 
points (3 – 33)).
Conclusion: radical therapy for intrathoracic cancer significantly affects 
exercise capacity, muscle force, pain and fatigue. Mature data on all patients 
will be available at the meeting.
Before treatment After treatment 
FEV
1
 (%pred.) 88 (54 – 116) 72(48 – 106)* 
Vc (%pred.) 101 (92 – 111) 87 (72 – 104)* 
DL,
cO
 (%pred.) 73 (43 – 125) 55 (30 – 106)* 
VO
2
max (%pred.) 69 (39 – 109) 58 (33 – 83)* 
VO
2
max/kg (ml/min/kg) 20 (12 – 30) 16 (10 – 26)* 
6MWD (%pred.) 77 (59 – 95) 63 (51 – 95)* 
QF (%pred.) 67 (33 – 107) 61 (28 – 96)* 
Max.Load (%pred.) 79 (43 – 137) 64 (30 – 115)* 
*P<0.05
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EARLY CEREBRAL RELAPSE IN PATIENTS 
UNDERGOING RADICAL TREATMENT FOR NON-SMALL 
CELL LUNG CANCER
E. Mitkina tabaksblat, M.M. Knap, P. Meldgaard, A. Khalil Oncological 
Department D, Aarhus University Hospital, Aarhus, DENMARK
Background: Despite complete surgical resection of primary non-small cell 
lung cancer (NscLc), brain metastases are frequent causes of initial recur-
rence. We evaluated the incidence of brain metastases in patients who under-
went complete resection for NscLc followed by adjuvant chemotherapy 
(Act) and factors associated with risk of brain relapse.
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Methods: the records of 180 patients who underwent curative-intent sur-
gery and Act for NscLc from 2005 to 2009 and enrolled in the follow-up 
program were reviewed. All of patients were neurologically intact at the ini-
tial staging. Patients who had brain metastases at the time of diagnosis were 
excluded from analysis. the incidence of brain metastases was estimated 
using the Kaplan-Meier method. A univariate analysis assessed factors asso-
ciated with the development of brain metastases.
Results: 178 patients were evaluable. Median age 64±7,7 years, 96(53,3%) 
were male and 84(46,7%) female. Median follow-up of all patients was 41 
months. brain metastases as the sole site of first relapse was observed in 17 
(9,6%) patients. Act was given to 94,1% of them. Postoperative pathologi-
cal stage distribution was: stage Ib, 2 patients (11,8%), stage IIa, 3 patients 
(17,6%); stage IIIa, 11 patients (64,7%); stage IV (t2bN0M1a), 1 patient 
(5,9%). Adenocarcinomas, squamous cell carcinomas and large cell carcino-
mas were found in 10(58,8%), 4(23,5%), 3(17,6%) of patients, respectively. 
the 2 years actuarial rate of brain metastases was 11,7%. All of the patients 
developed brain metastases within 18 months after complete resection of pri-
mary lung tumor. On univariate analysis, postoperative higher stages (≥IIIa) 
of NscLc (relative risk [rr]=3,3; 95% confidence interval (cI) 1.2–9.1; 
logrank p=0,0001), larger (>3cm) tumor size (rr=1,9; 95% cI, logrank 
p=0,006) were associated with significant increased risk of brain metastases.
Conclusion: the patients with operable NscLc without neurological symp-
toms at the time of diagnosis have a high incidence of early intracranial recur-
rence. We consider that brain imaging should be included as essential part of 
preoperative evaluation in patients with large tumor size (>3cm).
Disclosure: All authors have declared no conflicts of interest.
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ACCELERATED HYPOFRACTIONATED RADIOTHERAPY 
IN INOPERABLE LUNG CANCER USINGTOMOTHERAPY: 
THE LAUSANNE EXPERIENCE
H. bouchaab1, s. Peters2, H.b. ris3, P. tsoutsou1, r.O. Mirimanoff1, M. 
Ozsahin1, O. Matzinger1 1Radio Oncology, CHUV, Lausanne, SWITZERLAND, 
2Oncology, Multidisciplinary Oncology Center, Lausanne, SWITZERLAND, 
3Thoracic Surgery, CHUV, Lausanne, SWITZERLAND
Purpose/objective: to asses the feasibility and the acute toxicity of acceler-
ated radiotherapy in medically inoperable, non-small-cell lung cancer patients 
using an hypofractionated rt schema by helical tomotherapy, maintaining 
the dose at the organs at risk (bED2GY) below the values of conventional 
radiotherapy.
Material/methods: between March 2011 and December 2011, 13 patients 
were enrolled to receive accelerated hypofractionated radiotherapy. Patients 
had documented I or IIA stage non-small-cell lung cancer. Multiphase chest 
computed tomography simulation scan was performed in all cases. the dose 
prescription for the ItV was 60Gyin 5 bi-weekly fractions. Dose to the organs 
at risk did not exceed normal tissue tolerance limits. Acute toxicity was regis-
tered using the ctcAE,v 3.0.
Results: Median follow up was 6 months. No acute grade 3 toxicity was 
observed. All patients were alive at their last follow up with no evidence of 
disease-progression.
Conclusions: Preliminary data demonstrate the feasibility of bi weekly treat-
ment of the tumor by accelerated hypofractionated intensity-moudulated 
radiotherapy, without major toxicity. Further long follow up is needed.
Disclosure: All authors have declared no conflicts of interest.
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PATTERNS OF RECURRENCE AFTER TREATMENT WITH 
CONTINUOUS HYPERFRACTIONATED ACCELERATED 
RADIATION THERAPY IN NON-SMALL CELL LUNG 
CANCER
G. Walker, D. Muthukumar, r. Vijayan Oncology, Royal Derby Hospitals, 
Derby, UNITED KINGDOM
Introduction: cHArt is a novel method of radiotherapy delivery, which 
would combat the accelerated repopulation of tumour cells during radiother-
apy. continuous Hyperfractionated Accelerated radiation therapy (cHArt) 
using 54 Gy given in 1.5 Gy fractions, 3 times daily for 12 consecutive days 
has been compared with conventional radiotherapy (60 Gy in 6 weeks). this 
resulted in a 9% absolute improvement in 2 year survival. (29% v 20%, 
p=0.004, hazard ratio=0.77) for cHArt. However, 61% of the patients treated 
with cHArt died with disease in the chest and 50% had distant metastatic 
disease. We retrospectively studied the patients treated by cHArt in our cen-
tre, to evaluate the outcome and observe patterns of recurrence.
Methods: the medical records of patients treated with cHArt for stage 
I-III-b between 2004–2009 were reviewed. Disease recurrence in tumour bed, 
ipsilateral hilum, and/or mediastinum was considered a local/regional recur-
rence (Lrr). Nodal failures were defined as a new or enlarging LN>1 cm 
on short axis on ct. the actuarial rates of Lrr and distant recurrence were 
estimated using the Kaplan-Meier method. time to disease recurrence and 
overall survival were evaluated.
Results: 37 patients were treated with cHArt between January 2004 and 
January 2009. Most patients treated were stage 1A or stage 1b suggesting 
increased use of concurrent chemoradiotherapy for bulky tumours and locally 
advanced stage disease. 43% of patients recurred during the study period. 
66% of the recurrences were locoregional. brain and pleura were the other 
sites of recurrence. Median time to recurrence was 35 months. (cI: 17 – 53.) 
Median survival for patients was 21 months, which meets the standard of 16.5 
months set by the pivotal cHArt trial. Estimated 2-year survival is 46.5%, 
within this cohort, compared with 29% in the 1997 trial. there was also a 
trend for poorer short-term survival, if over the age of 70, although this was 
not statistically significant (p=0.7)
Conclusion: In spite of the relative early stage disease of the patient cohort, 
a significant proportion had local recurrence. this might suggest the need 
for further dose escalation or the need for combination with radiosensitising 
agents.
Reference: saunders et al. cHArt versus conventional radiotherapy in non-
small-cell lung cancer: a randomised multicentre trial. Lancet 1997; 350: 
161-165.
Disclosure: All authors have declared no conflicts of interest.
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LONG-TERM RESULTS OF COMBINED TREATMENT 
WITH POSTOPERATIVE ACCELERATED 
HYPERFRACTIONATED RADIOTHERAPY IN OPERABLE 
LUNG CANCER
Y.A. ragulin1, Y.s. Mardynsky2, V.N. Medvedev1, D.V. Kudryavtsev2, 
L.V. Kursova2 1Thoracic, Medical Radiological Research Center, Obninsk, 
RUSSIAN FEDERATION, 2Radiology, Medical Radiological Research Center, 
Obninsk, RUSSIAN FEDERATION
the role of post-operative radiotherapy (POrt) in radically resected non-
small cell lung cancer treatment is still under discussion. New methods of 
radiotherapy are necessary for increase of results of the combined treat-
ment. the study included 40 patients (pts) with NscLc stage II-III and 
intrathoracic lymph nodes metastases (N1-2), which in the period from 
1998 to 2004 completed a combined treatment with POrt in the acceler-
ated hyperfractionated regimens. From subsequent analysis excluded two 
patients who died of postoperative complications within 4 months after the 
operation. All the pts were performed radical surgery an adequate level (20 
lobectomy, 16 pneumonectomy, 2 bilobectomy), 13 pts received accelerated 
hyperfractionated radiotherapy: 1.25 Gy, 2 fractions a day, other 25 patients: 
accelerated hyperfractionated radiotherapy on the uneven pattern of crush-
ing daily dose 2 fractions 1 and 1.5 Gy to a total dose 45–50 Gy (86,6-94 
units tDF) in all patients, which is equivalent to a dose of 52–56 Gy with 
conventional fractionation. the median age was 55 years (39–69 years). 
stage II disease was diagnosed in 16 pts, III in - 22. radiation therapy 
began 3-5 weeks after surgery. radiation esophagitis occurred in 58% pts 
(Grade 1 - in 14 pts, grade 2 - in 6, grade 3 - y 2), one pt had an unplanned 
S56 Copyright © 2012 by the European Lung Cancer Conference and the International Association for the Study of Lung Cancer
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interruption for 14 days due to esophagitis. the clinical signs of radiation 
pneumonitis in the final stages of treatment were observed in 7 (18.4%) 
pts. the overall 3-year and 5-year survival was 42% and 29%, respectively. 
characteristically, 50% of pts died from progression of underlying disease 
in the first 1.5 years after surgery, and distant metastases were detected in 
14 of them, which corresponds to 37% of all enrolled in the study. this may 
indicate a high risk of subclinical distant metastases in N1-2 stages. Local 
recurrences were observed in 13% of pts. It is known for the death of 6 
(15.8%) patients with concomitant diseases of the heart, blood vessels and 
lungs. combined treatment with postoperative accelerated hyperfraction-
ated radiotherapy can achieve relatively satisfactory survival rates against a 
background of moderate radiation reactions.
Disclosure: All authors have declared no conflicts of interest.
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EXTENSIVE VS LIMITED SURGERY IN SENIOR LUNG 
CANCER PATIENTS
N. Lukavetskyy, t. Fetsych Oncology Department, Lviv Medical University, 
Lviv, UKRAINE
surgery remains the only potentially curative options for treatment of NscLc. 
the number of elderly patients with lung cancer at a curative stage is growing. 
there is a need for additional refinement in the selection process and postop-
erative care in this growing subgroup. the aim of our study was to determine 
the influence of type of surgical resection on postoperative outcome in elderly 
patients.
Patients and methods: We performed retrospective review of the clinical 
records of all senior patients (>70years) with lung tumors operated on tho-
racic department in 2000–2005. Patient with lung metastases and benign 
lesions, received perioperative chemo and/or-radiotherapy were excluded. All 
cases were re-staged according to the 7th edition of the tNM classification. 
Ppo-FEV1 was estimated according Ers/Ests clinical guidelines on fitness 
for radical therapy in lung cancer patients (2009). the patients were divided in 
2 groups - those who underwent pneumonectomy (group-1; 26 patients) and 
after lung resection (group-2; 13 patients after lobectomy and 1 patient after 
wedge resection). survival rates were calculated according to the Kaplan-
Meier method.
Results: Histology type of tumors, pathological classification and preopera-
tive comorbidities status was compared in both groups. One patient in group-1 
died from perioperative complication and no one in group-2. One or more 
minor complications occurred in 7 patients of group-1 and two patients of 
group-2. Pulmonary ventilation time during pneumonectomy - 178±5.6 min. 
(ppo-FEV1 from 28% till 56.37%), pulmonary ventilation time during lobec-
tomy was 156±7.2 min. (ppo-FEV1 from 50% till 88%). However group-2 
patients have statistically significant better survival (median 26,33 month) 
compared with group-1 patients (median 17,83 month) (p=0.045).
Conclusions: Older age should not be considered contraindication for lung 
resection and surgery can be performed at acceptable risk in elderly patients. 
Additional functional evaluation is indicated in specific subgroup of elderly 
lung cancer patients.
Disclosure: All authors have declared no conflicts of interest.
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EFFICACY AND SAFETY OF MULTIMODALITY 
THERAPY OF LOCALLY ADVANCED NON-SMALL CELL 
LUNG CANCER AT THE BRITISH COLUMBIA CANCER 
AGENCY
W.W. shan1, s. sun1, c. Ho1, J. Laskin1, b. Melosky1, H. carolan2, M. Liu2, 
K. Evans3, r. Finley3, N. Murray1 1Medical Oncology, British Columbia 
Cancer Agency, Vancouver, BC, CANADA, 2Radiation Oncology, British 
Columbia Cancer Agency, Vancouver, BC, CANADA, 3Surgical Oncology, 
British Columbia Cancer Agency, Vancouver, BC, CANADA
Background: surgery following concurrent cisplatin-based chemotherapy 
and radiation (trimodality therapy) for locally advanced non-small cell lung 
cancer (NscLc) remains controversial, with high mortality associated with 
trimodality therapy in some landmark trials. In this retrospective study, we 
evaluated the feasibility, safety, and efficacy of trimodality and bimodality 
therapy over an 11 year period at an academic center where the treatment plan 
was reached by multi-disciplinary conference consensus.
Methods: between January 1999-2010 at the Vancouver cancer centre, 177 
patients were identified with locally advanced NscLc treated with platinum and 
etoposide chemotherapy and ≥40Gy radiation therapy, with or without surgical 
resection. Patient characteristics extracted included sex, age, weight loss, perfor-
mance status, race, smoking history, tumor stage, histology and location, method 
of mediastinal staging, chemoradiation treatment details, hemoglobin, albumin, 
and LDH. Outcome measures included overall survival, disease relapse, patho-
logical response rate and treatment associated morbidity and mortality.
Results: see table below.
Conclusions: Locally advanced NscLc patients treated with concurrent bimo-
dality chemoradiation in this series achieved survival outcomes similar to those 
reported in the literature. Multi-disciplinary selection for trimodality therapy was 
associated with better survival and low treatment related mortality. the selection 
process does not allow assessment of the contribution of surgery to efficacy. 
However, the safety and favourable survival of trimodality therapy for patients so 
selected is sufficient for this model of care to continue as a standard at bccA.
Bimodality 
(N=131) 
Trimodality 
(N =46) 
sex Female 45% 63% 
Male 55% 37% 
Age Median (years) 60 61 
range 32–82 40–73 
Weight loss <5% 73% 89% 
5–10% 18% 9% 
>10% 9% 2% 
Ps 0 26% 43% 
1 63% 52% 
2 8% 4% 
3 3% 0% 
race Asian 23% 11% 
caucasian 71% 89% 
smoking 
history 
current 52% 50% 
Former 30% 39% 
Non-smoker 18% 11% 
stage IIb 4% 11% 
IIIA 56% 63% 
IIIb 40% 24% 
Histology scc 34% 33% 
Adeno 33% 50% 
Other 33% 17% 
surgical 
details 
Pneumonectomy – 35% (20%  
L & 15% r) 
Lobectomy – 65% 
complications Hospitalization 24% 11% 
Death on treatment 5% 2% 
survival Median Os 19.6 
months 
68 months 
5-year Os 17.5% 53.2% 
Disclosure: All authors have declared no conflicts of interest.
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COMPARATIVE EVALUATION OF GEMCITABINE/
CARBOPLATIN AND CISPLATIN/ETOPOSIDE WITH 
CONCURRENT CHEMORADIATION IN LOCALLY 
ADVANCED NON SMALL CELL CARCINOMA LUNG IN 
TERMS OF RESPONSE AND TOXICITIES
V. roshan1, N.A. Khan2, M.A. teli2, M.M. Lone2 1Dept of Radiation 
Oncology, All India Institute of Medical Sciences, New Delhi, INDIA, 
2Radiation Oncology, SKIMS, Srinagar, INDIA
Objectives: to assess the impact of these protocols on 1) Locoregional con-
trol of disease. 2) overall survival of the patients 3) time to disease progres-
sion 4) toxicity associated with these two regimens.
Study Design: Hospital based, prospective case controlled simple ran-
domised study.
Material and methods: A total of 60 histopathologically proven patients 
were taken, randomised into two arms with 30 patients in each arm, the 
baseline parameters of patients in each arm were well balanced with 
regard to various clinical and demographic parameters. In arm 1 patient 
received three cycles gemcitabine and carboplatin followed by concur-
rent chemo radiation with cisplatin (as radiosensitizer) followed by three 
more cycles of the same drugs. similarly Arm 2 received three cycles of 
cisplatin and etoposide followed by concurrent chemo radiation with cis-
platin followed by three more cycles of same drugs. After completion of 
treatment patients were followed three monthly and evaluated for response 
and toxicities. student t test and Kaplan Meier methods were used for 
survival analysis.
Results: Out of 60 patients, forty six patients were male and 4 patients were 
female, more than 85% patients were smokers. the common presenting symp-
toms were cough (77%) and hemoptysis (37%). Most common histology in 
both arms was squamous cell carcinoma (90%).On completion of treatment, 
there was (33.3%) complete response and (56.7%) partial response in study 
group and 30.0% complete response and 53% partial response in control 
group. toxicities noted in study arm are neutropenia (57%) anaemia (20%) 
and thrombocytopenia (30%) as compared to control group in which neutro-
penia (23%) anaemia (26%) and thrombocytopenia (3.3%).In control group 
renal toxicity and oesophagitis was (13.3%) and (23%) and in study group( 
3.3%) and (16.7 %) respectively. DFs was (33.3%) in study and (26.7% ) in 
control.
Conclusions: Gemcitabine and carboplatin provides marginal survival bene-
fits with acceptable and manageable toxicity profiles as compared to cisplatin 
and etoposide in locally advanced Non small cell ca lung.
Disclosure: All authors have declared no conflicts of interest.
158P
OUR FIRST EXPERIENCE WITH THE INTEGRATION OF 
POSITRON EMISSION TOMOGRAPHY IN RADIATION 
THERAPY PLANNING OF NON SMALL CELL LUNG 
CANCER
A. Masarykova1, D. scepanovic1, M. Pobijakova1, D. Lederleitner1, P. Povinec2 
1Radiation Oncology, National Oncology Institute of Slovakia, Bratislava, 
SLOVAK REPUBLIC, 2Nuclear Medicine, PET Centrum BIONT, Bratislava, 
SLOVAK REPUBLIC
Background: Positron emission tomography (PEt) with [18F] fluoro-2-de-
oxy-d-glucose (FDG) has proven to be a valuable diagnostic and staging tool 
for non small cell lung cancer (NscLc).
Purpose: to prospectively study the integration of 18FDG-PEt in radiation 
therapy planning and its impact on the planning target volume (PtV), target 
coverage, and lung toxicity in patients with NscLc.
Methods: twenty three patients presenting with stages I-III NscLc on 
ct, referred for radical radiation therapy, underwent both 18FDG-PEt and 
ct simulation procedures on the same day. ct and a 18FDG-PEt were 
obtained in treatment position in an integrated PEt/ct scanner, and coreg-
istered images were used for three-dimensional conformal radiation therapy 
planning (3Dcrt). First, volume delineation was performed on the ct data. 
In a second step, the corresponding PEt data were used as an overlay to 
the ct data to define the gross tumor volumes (GtV) and planning target 
volumes (PtV). Delineation was done independently by radiation oncologist 
and nuclear radiologist. standard margins were applied to each GtV to gen-
erate a PtV, and standardized treatment plans were designed and calculated 
for each PtV. the two 3Dcrt plans for each patient were compared with 
respect to the GtV, PtV, mean lung dose (MLD) and volume of normal lung 
receiving ≥20 Gy (V20).
Results: Of the 23 patients who were planned with 3Dcrt, PEt increased 
the radiation therapy volume in 14 patients (61%). PEt helped to dis-
tinguish tumor from atelectasis in 5 patients with atelectasis. In 4 of 23 
(17%) patients, 18FDG-PEt information changed management strategy. 
these patients were diagnosed with metastatic disease based on 18 FDG-
PEt and received palliative radiation therapy. Increases in the target 
volumes led to increases in the MLD and V20. Decreases in the target 
volumes in the patients with atelectasis led to decreases in these lung tox-
icity parameters.
Conclusions: the information provided by 18FDG-PEt would have contrib-
uted to a substantial reduction of the GtV. this applies particuarly for patients 
with tumor-associated atelectasis. radiation targeting with fused 18 FDG-PEt 
and ct images resulted in alterations in radiation therapy planning in over 
70% of patients by comparison with ct targeting.
Disclosure: All authors have declared no conflicts of interest.
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RADIATION-INDUCED LUNG INJURIES COMPLICATED 
BY ABSCESS FORMATION
Y.A. ragulin1, L.V. Kursova2 1Thoracic, Medical Radiological Research 
Center, Obninsk, RUSSIAN FEDERATION, 2Radiology, Medical Radiological 
Research Center, Obninsk, RUSSIAN FEDERATION
In some cases radiation therapy given to patients with locally advanced lung 
cancer is complicated by destructive processes with cavitations in the lung. 
between 2006 and 2011 12 patients (pts) with radiation pneumonitis and 
pneumofibrosis grade 4 complicated by abscess formation were treated. All 
pts had previously received chemoradiotherapy for lung cancer to a total dose 
50-70 Gy. After anticancer treatment it took from 6 months to 4 years for a 
cavity to form. Destructive cavities sized maximally 9-16 cm had commu-
nications with bronchi of various caliber. the Karnofsky index (Ps) was at 
first visit from 30% to 60% (on the average 40%). Pts with chronic destruc-
tive processes treated in an inpatient setting, where anti-inflammatory ste-
roid and nonsteroid, broncholitic, mucolytic and antiaggregant agents were 
administered along with disintoxication, anesthetic, haemostatic, antitussive 
drugs, artificial hypotension and cavity sanation. the mentioned agents were 
administered until the pain relief, normalization of the body temperature, 
stabilization of the general condition, alleviation of cough and dyspnea were 
achieved. then, substitutive, metabolic, reparative and immune agents were 
added and treatment was performed until the Ps reached a stable value of 
60-80%. this approach improved the clinical and radiological symptomatol-
ogy, reduced the number of complications, exacerbations and hospitaliza-
tions associated with them, improved the exercise tolerance and quality of 
life. After treatment Ps increased to 60-80% in all the pts. 9 pts are alive 
at the present time (5 pts have lived 5 years, 4 pts have lived 2 years since 
the beginning of follow-up). After cavity formation 3 pts lived 2, 2.5 and 3 
years, respectively. their deaths resulted from pulmonary hemorrhage. Work 
experience with radiation pneumonitis and pneumofibrosis complicated by 
pulmonary suppuration suggests that it is necessary to use all the available 
methods of delivering drugs to the lung cavity on the background of com-
plex step-by-step systemic therapy. such therapeutic methods do not remove 
the empyema or abscess cavities. However, they improve quality of life and 
extend life expectancy for pts.
Disclosure: All authors have declared no conflicts of interest.
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LARGE CELL NEUROENDOCRINE CARCINOMA: 
RETROSPECTIVE ANALYSIS OF 24 CASES FROM 4 
ONCOLOGY CENTERS IN TURKEY
b.b. Oven Ustaalioglu1, A. Ulas2, G. Ozturk2, N. turan3, A. bilici1, U. Demirci3, 
N. Alkıs2, M. seker1, O.b. Oksuzoglu4, M. Gumus5 1Medical Oncology, Kartal 
Education and Research Hospital, Istanbul, TURKEY, 2Medical Oncology, 
Dr. Abdurrahman Yurtarslan Ankara Oncology Education and Research 
Hospital, Ankara, TURKEY, 3Medical Oncology, Gazi University Medical 
Faculty, Ankara, TURKEY, 4Medical Oncology, Ankara Numune Education 
and Research Hospital, Ankara, TURKEY, 5Division of Medical Oncology, 
Kartal Research and Training Hospital, Istanbul, TURKEY
Background: Large cell neuroendocrine carcinoma (LcNEc) of the lung 
is classified as variant of large cell lung carcinoma by the World Health 
Organization. However the clinical and biological behaviours of LcNEc 
resemble small cell lung carcinoma (scLc) with high mitotic index and posi-
tivity of tumor cells with neuroendocrine markers. because small series were 
reported in the literature, there is no consensus about management of this sub-
set. In the present study we evaluated the incidence and prognosis of LcNEc 
in four oncology centers in turkey.
Materials and methods: We analyzed 24 patients with diagnosis of LcNEc 
from the medical data of 3138 non-small cell lung cancer patients who were 
diagnosed and treated between 2008-2010 in 4 different medical oncology 
centers in turkey.
Results: Median age was 56 (range; 36-64), most of the patients were male 
and three of them were women. ten out of 24 patients (41.6%) had locally 
advanced or metastatic disease so operation could not be performed. Five 
patients (20.8%) were staged as stage I, 6 (25%) with stage II, 5 (20.8%) 
with stage III and 8 (33.3%) with stage IV. All patients had a history of 
smoking. twelve patients (50%) received chemotherapy post-operatively. 
At a median of 14.4 months of follow-up (range; 3-59) median Os and 
PFs times were 32.7 and 9.5 months, respectively. tNM stage and the 
performance of surgery were significantly related with both Os and PFs 
(p<0.05).
Conclusion: LcNEc was diagnosed generally post-operatively. Prognosis of 
LcNEc is poor so surgery alone is not sufficient for long survival, and adju-
vant chemotherapy has been suggested.
Disclosure: All authors have declared no conflicts of interest.
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CASE STUDIES OF PULMONARY RESECTION FOR 
LARGE-CELL NEUROENDOCRINE CARCINOMA
M. Naruke General Thoracic Surgery, Eiju General Hospital, Tokyo, JAPAN
Aims: the World Health Organization (WHO) currently classifies large-
cell neuroendocrine lung carcinoma (LcNEc) as a distinct subtype of pul-
monary large-cell carcinoma. However, the survival after surgical-resection 
of LcNEc appears to be substantially worse than for other non-small-cell 
carcinoma (NscLc), resembling more the survival of small-cell carcinoma. 
the question remains whether LcNEc is best treated the same as other 
NscLc. LcNEc is rare and every case that is treated should be analyzed 
carefully. 
Methods: the records of 5 LcNEc (2.6%) out of 195 patients, who under-
went an intended curative resection for lung cancer in our institute during 
a 10-year period beginning in December 2002, were reviewed. the patients 
consisted of 5 male current smokers, with a median age of 70 years (64-82). 
the clinical stages were 2 in stage Ib, 2 in stage IIA, and 1 stage IIIA. 
All patients underwent an anatomical resection with systematic lymph node 
dissection or lymph node sampling. One patient with positive mediastinal 
lymph node had neoadjuvant chemotherapy and received postoperative 
radiation to the mediastinal area. Median follow-up time was 31 months 
(15-68). 
Results: the two patients with clinical stage IIA were upgraded to patho-
logical stage IIIA after operation. One of them who was pathological 
stage IIIA died of cerebral infarction without cancer recurrence 2 years 
after the operation. the neoadjuvant chemotherapy of 3 courses (cispla-
tin + gemcitabine) for a patient with positive mediastinal lymph node 
reduced node size. recurrence of disease was observed in two patients 
with pathological stages Ib and IIIA. they died at 55 and 15 postop-
erative months, respectively. they received systemic chemotherapy for 
recurrent diseases and one of them received adrenalectomy for adrenal 
metastases. 
Conclusion: Neoadjuvant chemotherapy should be considered only as com-
plementary technique to surgery for LcNEc. the role of adjuvant therapy 
for LcNEc should be examined in a larger trial.
Disclosure: All authors have declared no conflicts of interest.
162P
CLINICOPATHOLOGICAL FEATURES, TREATMENT 
MODALITIES AND SURVIVAL ANALYSES OF PATIENTS 
WITH NON SMALL CELL LUNG CANCER: A SINGLE 
CENTER EXPERIENCE IN TURKEY
A. Ulas1, A.G. Durnalı2, A. bilici3, E. Arpacı1, s. tokluoglu1, F.P. turkoz1, t. 
Yetısyıgıt1, G. celenkoglu2, N. Alkıs1 1Medical Oncology, Dr. Abdurrahman 
Yurtarslan Ankara Oncology Education and Research Hospital, Ankara, 
TURKEY, 2Medical Oncology, Ankara Oncology Education and Trial Hospital, 
Ankara, TURKEY, 3Medical Oncology, Dr. Lutfi Kirdar Kartal Education and 
Research Hospital, Istanbul, TURKEY
Aim: We aimed to analyse the clinicopathological features, treatment modali-
ties and also survival of cases with NscLc.
Methods: seven hundred and thirty-eight patients followed in a period of 10 
years with a diagnosis of NscLc at the Department of Medical Oncology, 
Ankara Oncology Education and research Hospital were included. Overall 
survival (Os) was calculated with Kaplan Meier survival analyses by using 
log-rank test.
Results: the majority of patients (87.3%) were male and 12.7% of them were 
female. the rate of smoking was 84.6%. the most frequent initial symptoms 
were dyspnea (76%), cough (70%), asthenia (53%) and weight loss (49%). 
EcOG performance status (Ps) of patients were Ps 0, 2.2%, Ps 1, 44.6%, 
Ps 2, 39.3% and Ps 3, 13.9% respectively. the most common histological 
types were squamous cell carcinoma (39.8%) and adenocarcinoma (34.4%). 
the majority of patients (89.9%) were diagnosed in locally advanced and 
metastatic stages. the most common sites of metastasis were bone and brain. 
Five-year Os rate was 10.5% for the entire cohort. In 11.9% of patients sur-
gery could be performed with pneumenectomy in 16, lobectomy in 61 and 
segmentectomy in 3 patients. radiotherapy (rt) was administered to 73.8% 
of patients and 35 of them had adjuvant rt, 190 had primary rt, 351 had 
paliative rt. seventy-three of patients treated with rt received chemother-
apy (ct). twenty-eight of them were treated with ct as adjuvant setting 
and 3 of them received neoadjuvant ct. A total of 489 patients were treated 
with first line palliative ct, 159 second line palliative and 35 third line pal-
liative ct. In 17.2% of the patients only supportive treatment was carried 
out. Univariate analysis indicated that the presence of metastasis, EcOG Ps, 
primary rt, primary ct and palliative ct were important prognostic factors 
for Os. In the multivariate analysis, EcOG Ps (Hr; 1.42, p<0.001), primary 
rt (Hr; 1.97, p<0.001), palliative ct (Hr; 1.70, p<0,001) and the presence 
of metastasis (Hr; 1.42, p=0,005) were found to be important prognostic 
indicators for Os. 
Conclusions: Our results showed that the majority of our patients were male, 
most of them were younger than 65 years and the most common histopatho-
logical subtype was squamous cell carcinoma. It was found that surgery 
in early stage, systemic ct and rt in advanced stage prolonged Os and 
improved the symptoms.
Disclosure: All authors have declared no conflicts of interest.
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A NEW GENETIC SIGNATURE DEFINING TWO 
PROGNOSTIC GROUPS AMONG PATIENTS WITH 
COMPLETELY RESECTED EARLY NON-SMALL CELL 
LUNG CANCER
F. Hernando1, J. sanz2, J.r. Jarabo1, s. Hernandez2, J.A. López García 
Asenjo3, A.M. Gómez1, b. Pérez Villamil4, E. Fernández1, J. calatayud1, E. 
Díaz-rubio4 1Department of Thoracic Surgery, Hospital Clínico Universitario 
San Carlos, Madrid, SPAIN, 2Department of Pathology, Hospital Clínico 
Universitario San Carlos, Madrid, SPAIN, 3Department of Pathology, 
Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, 
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Objectives: Among patients with completely resected early (I and II) non 
small cell lung cancer (NscLc), 25-30% develops recurrence within 5 years. 
biology behaviour of tumours seems to define different prognosis even among 
these early patients. the aim of this study was to look for a group of genes 
defining subgroups of patients with different prognosis.
Methods: Patients with completely resected early NscLc were eligible for 
the study.
those cases receiving adjuvance were excluded. Patients with previous onco-
logical history were not considered for the study either. rNA was extracted 
from frozen samples with more than 70% tumor cells. tumors were analyzed 
using microarray expression 4x44 K (Agilent). the data were normalized and 
subjected to unsupervised analysis (clustering and k-means) to classify sam-
ples based on expression profiles. Association of identified molecular sub-
groups with clinical, pathological and molecular variables and disease free 
survival (DFs) was analyzed.
Results: Eighty-four patients were selected (60 stage I and 24 stage II). 
All of them were homogeneously operated on in the same institution by 
the same surgical team. systematic lymph node dissection was performed 
in all cases. Neither histological subtype nor tumor stage was associated 
with DFs. We identified two molecular subgroups of NscLc based on 
50 genes. Most of them encode proteins directly or indirectly related to b 
lymphocytes (as immunoglobulin molecules, cD79a, cD19, POU2AF1 or 
pErp1). Other proteins as tNFrsF17, sLAM7F, cD139; cXcL13, IrF4, 
cD27, Pim-2 or cD38, although nonrestricted to b cells, are strongly asso-
ciated with b cell homeostasis, proliferation and survival. Disease free 
survival was significantly better for the group of good prognosis [Hazard 
ratio 3.4 (cI 95%: 1.6 – 7.3; p= 0.001)]. An external dataset (n=162) was 
used to validate our molecular classification based on these 50 genes.
Conclusions: Expression of these 50 genes could make up a new genetic 
signature for NscLc. It could define subgroups of patients with differ-
ent prognosis among those with completely resected early-staged NscLc. 
Immunosurveillance seems to be important in tumoral behaviour among ana-
lyzed patients.
Disclosure: All authors have declared no conflicts of interest.
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BIOMARKERS OF TORCH TRIAL ON FIRST-
LINE ERLOTINIB FOLLOWED BY SECOND-LINE 
CHEMOTHERAPY IN ADVANCED NON-SMALL CELL 
LUNG CANCER PATIENTS
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Background: tOrcH was a randomized phase 3 trial, conducted in Italy 
and canada, comparing 1st-line erlotinib followed at progression by cispla-
tin/gemcitabine vs. the standard reverse sequence in unselected patients (pts) 
with advanced NscLc. Primary endpoint was overall survival (Os); 900 
pts were planned. the study was stopped after 760 pts, as the first interim 
analysis showed inferiority of the experimental arm. Exploratory analyses 
for EGFr activating mutations (mut), KrAs mut and EGFr gene copy num-
ber (GcN) were conducted after study closure, on 319 (42%) tumor samples 
available.
Methods: EGFr exon19 deletions were identified using Pcr fragment anal-
ysis on macro-dissection enriched tumor DNA, with positive cases confirmed 
by sequencing. EGFr exon 21 and KrAs codons 12/13 were analysed by 
sequencing. Mutations were confirmed in independent Pcr products and 
EGFrL858r negative cases were confirmed by MassArrAY (sequenom). 
EGFr GcN was evaluated by FIsH, classified by colorado system.
Results: Pts with known marker status were distributed similarly between 
arms. EGFr and KrAs mut and EGFr GcN status were known in 275 
(36%), 276 (36%) and 196 (26%) pts respectively. Mutations were found in 
39/275 (14%) for EGFr and 73/276 (26%) for KrAs; 102/196 (52%) pts 
had high EGFr GcN tumors. No significant imbalances between arms were 
noted. EGFr mut was significantly more common in females, East Asians 
and never smokers; KrAs mut was less common in never smokers. there was 
no interaction between any biomarker and treatment efficacy for Os and total 
PFs (progression-free survival after both lines). For first PFs, only EGFr mut 
but neither KrAs mut nor EGFr GcN showed significant interaction with 
treatment. Pts with EGFr mut had improved first PFs with erlotinib (Hr 
0.60, 95%cI 0.30-1.20) compared to EGFr wild type (Wt) pts (Hr 2.07, 
95%cI 1.58-2.71; interaction p=0.006). Among EGFr Wt pts, there was no 
interaction between EGFr GcN and treatment efficacy.
Conclusion: Pts with EGFr mut experienced greater benefit from erlotinib 
followed by 2nd-line chemotherapy, while EGFr Wt pts derived greater ben-
efit from standard sequence of 1st-line chemotherapy prior to erlotinib.
Disclosure: M.s. tsao: Honorarium from roche, OsI, AstraZeneca canada; 
received research grant from roche. G.D.c. santos: Honorarium from 
boehringer-Ingelheim canada. F. Perrone: Dr. Perrone received payment for 
lectures from roche. c. Gridelli: Dr. Gridelli acted as a consultant for roche 
and Eli Lilly, and received honoraria from roche and Eli Lilly. All other 
authors have declared no conflicts of interest.
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KRAS MUTATIONAL STATUS IMPACT PROGRESSION 
FREE SURVIVAL OF PATIENTS TREATED WITH 
PLATINUM BASED CHEMOTHERAPY IN NSCLC
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San Giovanni Hospital, Rome, ITALY
Background: KrAs mutations in NscLc are supposed to indicate a poor 
prognosis and poor response to anticancer treatment. However, such evidence 
is only drawn from retrospective series giving controversial results. Moreover, 
it is possible that the various KrAs mutations differently affects prognosis, 
carcinogenesis and drug response as demonstrated in preclinical setting. 
Aim of this study is to prospectively assess the prognostic value of KrAs 
mutations in NscLc patients treated with a first line platinum containing 
regimen. this is a properly planned ancillary study within the tAILOr trial 
(Nct00637910) which is mainly focused on the second line.
S60 Copyright © 2012 by the European Lung Cancer Conference and the International Association for the Study of Lung Cancer
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Methods: tissue and blood samples were collected at diagnosis in the whole 
cohort of registered patients. KrAs status was centrally determined with 
standard direct sequencing and KrAs genotype was assessed by real time 
Pcr. the primary hypothesis is a difference in PFs according to KrAs 
mutational status; the impact of the three more frequent KrAs substitutions 
(G12c, G12V, and G12D) was also explored. the analysis was planned at 
occurrence of 200 events (Hr≥1.49, power 80%, 2-tailed alpha 10%), in a 
cox model adjusting for Performance status and radical surgery.
Results: Out of 565 patients registered, 341 (60.5%) were evaluable for 
KrAs and 85(25%) were mutated. At a median follow-up of 17 months 
KrAs mutated patients showed a statistically significant worse PFs (Hr 1.42 
95%cI 1.06-1.94; p=0.02). No differences among doublets were observed 
in KrAs mutated patients. the most frequent KrAs mutations were: G12c 
(36.4%), G12V (21.1%), G12D (16.4%), others (25.9%). Prognostic differ-
ences among variants are observed. Final genotype analyses are ongoing.
Conclusions: this is the first prospective, pre-planned and adequately sized 
evaluation of KrAs in NscLc. Patients mutated for KrAs seem to have a 
higher risk of progressing. these results suggest that KrAs mutation epi-
demiology in this setting highly differs from that of colon cancer. clinical 
data suggest that tailored strategies for these patients are warranted and our 
preclinical studies will help in clarifying the molecular mechanisms.
Disclosure: All authors have declared no conflicts of interest.
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ACTIVITY OF THE PAN-HER TYROSINE KINASE 
(TK) INHIBITOR DACOMITINIB (PF-00299804) IN 
REFRACTORY NONADENOCARCINOMA (NON-A) NON-
SMALL CELL LUNG CANCER (NSCLC) AND COMPARED 
WITH ERLOTINIBIN THE 2ND-/3RD-LINE SETTING
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Introduction: In the br21 study of erlotinib (E) in 2/3rd line NscLc,1 
median overall survival (Os) was 6.7 months and median progression-free 
survival (PFs) 2.2 months. Inferior outcome was demonstrated for patients 
(pts) with non-A versus adenocarcinoma. Dacomitinib, an irreversible inhibi-
tor of human epidermal growth factor receptors (HEr)-1/EGFr, -2, and -4 
tKs, was evaluated in phase (P) II trials in i) chemotherapy (ct) and EGFr 
tKI-refractory KrAs wild-type NscLc2 as a single agent and ii) versus E in 
2nd-/3rd-line NscLc.3 Here results for non-A pts are reported.
Methods: 16 pts in the Us PII ct and EGFr-tKI refractory study and 65 pts 
(dacomitinib = 32; E = 33) in the global randomized PII 2nd-/3rd- line study 
had non-A histology. Pts were EcOG Ps = 0–2; the dacomitinib starting dose 
was 45 mg QD. the primary endpoint was objective response rate (Orr; 
rEcIst) for the refractory study and PFs for 2nd-/3rd- line. Other endpoints 
were Orr, PFs, Os, patient-reported outcomes, safety, pharmacokinetics, 
and exploratory biomarkers.
Results: Of the 16 refractory non-A pts (12 squamous), 1 had a Pr. clinical 
benefit rate (cbr) (cr, Pr or sD ≥24 weeks) was 18.8% (95% cI: 4.0, 45.6), 
median PFs was 11.1 weeks (95% cI: 5.6, 17.9), median Os was 26.6 weeks 
(95% cI: 9.9, 35.9); survival at 6 months and at 1 year was 50.0% (95% 
cI: 24.5, 71.0) and 21.9% (95% cI: 5.6, 44.9), respectively. For 2nd-/3rd- line 
non-A pts, there was a non-significant trend in favor of dacomitinib [Hr 0.65, 
i.e. 54% improvement (95% cI: 0.36, 1.18), 2-sided P=0.152; with a median 
PFs of 8.7 weeks for dacomitinib compared with 8.0 weeks for E]. For Os, 
the Hr was 0.74 (95% cI: 0.41, 1.34), 2-sided P=0.323; cbr was 21.9% 
(7/32; 1 Pr, 1 cr) for dacomitinib and 9.1% (3/33) for E.
Conclusions: Dacomitinib demonstrated activity in non-A pts after progres-
sion on E and 1–2 prior cts, and comparable activity to E in the 2nd-/3rd- line 
setting. these findings support a potential role for a pan-HEr tKI in non-A 
NscLc and ongoing PIII studies in this population.
1. shepherd et al NEJM 2005;353:123
2. campbell et al AscO 2010 abstr 7596
3. ramalingam et al EsMO 2010 abstr 365 PD
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EVALUATION OF SYMPTOM IMPACT OF DACOMITINIB 
(PF-00299804) VS ERLOTINIB IN PATIENTS WITH 
ADVANCED NSCLC AFTER CHEMOTHERAPY FAILURE: 
RESULTS FROM A PHASE 2 RANDOMIZED CLINICAL 
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Introduction: NscLc patients (pts) experience many cancer-related symp-
toms (sx; eg, cough, dyspnea, pain, hemoptysis, fatigue). Decreasing tumor 
burden may reduce/delay these sx and favorably impact global Health related 
Quality of Life (HrQOL). Dacomitinib is an irreversible, small molecule 
inhibitor of EGFr/HEr-1, HEr-2, and HEr-4 tyrosine kinases. In a global 
multicenter, open-label randomized phase 2 study (Nct00769067) of 2nd/3rd-
line NscLc, dacomitinib showed improved progression-free survival (PFs; 
primary objective), hazard ratio 0.66 (95% cI, 0.47, 0.91), 2-sided P=0.012, 
and manageable toxicity vs erlotinib.1 Here we report impact on core lung 
cancer sx.
Methods: Pts progressing after 1–2 prior chemotherapies were randomized 
1:1 to dacomitinib (45 mg) vs erlotinib (150 mg) orally QD. A secondary 
objective was to explore HrQOL. Disease/treatment-related sx were recorded 
using the EOrtc QLQ-c30 and QLQ-Lc13 and scored using the scoring 
manual.2 scores were summarized by the mean (and 95% cI) for each group 
and plotted over time. Mean changes from baseline (cycle 1, Day 1) were also 
reported for each group.
Results: between Nov 2008 and Oct 2009, 188 pts were randomized. baseline 
scores were similar between the 2 treatments and on-study completion rates 
were high (above 84%). Key NscLc sx were improved in pts receiving 
dacomitinib vs erlotinib with clinically meaningful improvements (>10 points 
on 100 point scale). the difference in mean change from baseline favored 
dacomitinib at most time points (table).
Conclusions: Dacomitinib demonstrated favorable clinical benefit vs 
erlotinib and improvements in common NscLc sx. such findings are 
important when considering the totality of benefit of a potential new 
therapy.
1. ramalingam et al EsMO 2010 365PD
2. Fayers et al EOrtc QLQ-c30 scoring manual. EOrtc publications 2001
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Mean change from baseline within treatment arms for dacomitinib/erlotinib:
higher positive scores = worsened symptom* 
Symptom (n) 
Baseline (dacomitinib/
erlotinib) D10–14 Week 4 Week 8 Week 12 Week 16 
Fatigue (88/89) 39/38 0/3 (79/70) 1/7 (79/78) 1/12 (61/61) 5/8 (44/37) 2/6 (37/24) 
Pain (90/88) 28/33 1/2 (79/70) 0/4 (80/78) 3/2 (62/61) 2/3 (43/37) 4/3 (37/24) 
Dyspnea single item (90/88) 33/35 4/4 (79/70) 5/3 (80/78) 4/6 (61/61) 8/3 (44/37) 5/1 (37/24) 
Dyspnea 3-item (89/88) 34/33 6/0 (78/67) 2/1 (79/77) 1/1 (61/61) 6/1 (43/37) 8/1 (36/21) 
coughing (89/88) 43/41 7/0 (78/70) 13/3 (79/77) 13/0 (61/61) 16/5 (43/37) 19/0 (36/22) 
Pain in chest (89/88) 23/27 -5/5 (78/69) 9/6 (79/77) 8/1 (61/61) 8/2 (43/37) 5/5 (36/21) 
Pain in arm or shoulder (89/88) 25/23 1/2 (78/69) 2/3 (79/77) 5/7 (61/61) 2/4 (43/37) 6/3 (36/22) 
*Data are rounded to nearest whole number 
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Background: Patients (p) with advanced NscLc have few treatment options 
after progressing to 1st-line platinum doublet chemotherapy (PDc). several 
preclinical and phase I studies have suggested that sequential administration 
of erlotinib (E) and docetaxel could avoid possible negative interactions and 
optimize the benefit obtained against NscLc. this randomized phase II was 
designed to address the clinical benefit obtained with the use of sequential 
administration of docetaxel and intermittent E.
Methods: 70 p with advanced NscLc progressing to previous PDc for 
advanced disease were randomized (1:1):
Group A (n = 34): Docetaxel 75 mg/m•	 2 day 1 and intermittent E (day 2-16), 
up to 4 cycles, followed by E in monotherapy
Group b (n = 36): E in monotherapy.•	
treatment was administered until unacceptable toxicity or disease progres-
sion. Primary endpoint: rate of p free of progression at 6 months; second-
ary endpoints: progression-free survival (PFs), overall survival (Os), disease 
control rate (Dcr) and safety. the study has completed enrolment. At the 
date of cut-off for this communication, data of 60 patients were available: 30 
in Group A/30 in Group b.
Results: baseline characteristics: non-adenocarcinoma (60.3%), current/for-
mer smokers (95%), male (90%) and stage IV (87.9%). 6 months PFs: 13.5% 
in the sequential arm. PFs: 2.7 months (m) in Group A (95% cI 2.1 – 3.8) 
and 2 m in Group b (95% cI 1.7 – 2.4) p value 0.08. Median Os: 11.0 m 
(95% cI 4.5 – 13.4) in group A and 4.7m (95% cI 2.5 – 6.6) in Group b with 
a p value 0.02. Dcr: 44.4% in the experimental group whereas in the E one 
was 30.8%. Adverse events (AEs), including skin rash and diarrhea, were all 
generally tolerable. Of interest, the low number of p developing neutropenia 
in the D + E arm.
Conclusions: Although the primary objective has not been met, an encour-
aging benefit on survival has been shown in the exploratory analysis, with a 
median overall survival of 11 months for patients treated with the sequential 
regimen. Final data will be presented during the meeting.
Disclosure: All authors have declared no conflicts of interest.
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EFFECT OF DENOSUMAB VERSUS ZOLEDRONIC ACID 
ON OVERALL SURVIVAL IN PATIENTS WITH LUNG 
CANCER AND BONE METASTASES: RESULTS FROM A 
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Background: Denosumab (XGEVA®) is a fully human rANKL antibody 
approved to prevent skeletal-related events in patients with solid tumors and bone 
metastasis. We now present overall survival (Os) data for patients with lung can-
cer and bone metastases who participated in a phase 3 trial of denosumab versus 
zoledronic acid (ZA) for preventing srEs in patients with bone metastasis from 
solid tumors (except breast and prostate) or with multiple myeloma.
Methods: Patients were equally randomized to receive either a monthly 
subcutaneous denosumab injection (120 mg) or intravenous ZA (4 mg; dose 
adjusted for renal function). Daily calcium and vitamin D supplements were 
recommended. An exploratory analysis was conducted to assess Os among 
patients with lung cancer, including both non-small cell lung cancer (NscLc) 
and small cell lung cancer (scLc), who received either denosumab or ZA.
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Results: A total of 811 patients with lung cancer (702 NscLc; 109 scLc) 
enrolled. the mean age of patients was 61 years; most were male (71%) 
and caucasian (88%). 89% of patients in both treatment groups received 
prior chemotherapy. 85% of denosumab and 80% of ZA patients had an 
Eastern cooperative Oncology Group (EcOG) status of 0 or 1. Os was 
prolonged with denosumab over ZA for all patients with lung cancer as 
well as the subgroups with NscLc and scLc (table). the difference in 
Os observed between treatment groups was not affected by prior chemo-
therapy or difference in EcOG status between the groups. Adverse event 
(AEs) rates among these patients were similar between groups (96.8% 
denosumab, 95.4% ZA). serious AEs occurred less frequently with deno-
sumab (66.0%) than ZA (72.9%). Osteonecrosis of jaw was balanced 
(0.7% denosumab, 0.8% ZA; P=1.0). Hypocalcemia AE rates were 8.6% 
denosumab and 3.8% ZA.
Conclusion: Denosumab treatment is associated with significantly 
improved overall survival versus zoledronic acid in patients with lung 
cancer.
Table. Median Months of Overall Survival in Lung Cancer 
Patients Treated With Denosumab or ZA
Subgroup Denosumab ZA 
Hazard Ratio 
(95% CI) P-value 
All lung cancer 
patients (n = 811) 
8.9 months 7.7 months 0.80 (0.67–0.95) 0.01 
NscLc (n = 702) 9.5 months 8.1 months 0.78 (0.65–0.94) 0.01 
squamous cell 
carcinoma (n = 163) 
8.6 months 6.4 months 0.68 (0.47–0.97) 0.035 
Adenocarcinoma  
(n = 400) 
9.6 months 8.2 months 0.80 (0.62–1.02) 0.075 
scLc (n = 109) 7.6 months 5.1 months 0.81 (0.52–1.26) 0.36 
Funding: Amgen. A. Foreman (Amgen) provided writing support.
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LONG-TERM SURVIVORS WITH ADVANCED NON-
SQUAMOUS NON-SMALL CELL LUNG CANCER 
(NSNSCLC) TREATED WITH FIRST-LINE (1L) 
CHEMOTHERAPY (CT) PLUS BEVACIZUMAB (B) AND 
MAINTENANCE (MTC) B
J. de castro1, D. Isla2, J.L. González-Larriba3, s. Vázquez4, b. Massuti sureda5, 
J.M. sánchez-torres6, M. Dómine7, A. calles8, J.V. cardona9, P. Garrido Lopez10 
1Medical Oncology, Hospital Universitario La Paz, Madrid, SPAIN, 2Medical 
Oncology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, SPAIN, 
3Medical Oncology, Hospital Clínico San Carlos, Madrid, SPAIN, 4Medical 
Oncology, Hospital Lucus Augusti, Lugo, SPAIN, 5Medical Oncology, Hospital 
General Universitario de Alicante, Alicante, SPAIN, 6Medical Oncology, MD 
Anderson Cancer Center, Madrid, SPAIN, 7Medical Oncology, Fundación 
Jiménez Díaz, Madrid, SPAIN, 8Medical Oncology, Hospital Universitario 
Madrid Sanchinarro - Centro Integral Oncológico Clara Campal, Madrid, 
SPAIN, 9Medical Department, Roche Farma, S.A., Madrid, SPAIN, 10Medical 
Oncology, Hospital Ramon y Cajal, Madrid, SPAIN
Background: b plus ct followed by mtc b has been shown to improve out-
comes in patients (pts) with nsNscLc. In the clinical setting, some pts are 
able to receive prolonged mtc treatment (tx) with b. the aim of our research 
was to explore their clinical characteristics, in order to assess the behavior of 
these pts who benefit most from b.
Methods: In 30 spanish institutions we studied retrospectively data from 
104 pts with advanced nsNscLc receiving long-time mtc b defined by a 
median PFs ≥ 9 months (m), which represents an increase in PFs of approx-
imately 50%, as compared with historical data. clinical and histological 
characteristics, tx received, Orr, median PFs and Os, and safety data 
were recorded.
Results: Pts characteristics: median age 57 years (yr); caucasian: 98%; 
EcOG Ps 0/1/2 (%): 61/38/2; male: 61%; current/former/never smok-
ers (%): 36/45/19; baseline hypertension (HtN)/cardiovascular disease 
(%): 24/9; adenocarcinoma: 82%; stage IV: 84%; 84% of pts presented 
≤2 metastatic sites; central tumor location: 30%; tumor cavitation: 4%; 
among 40 pts tested, 8% presented activating EGFr mutations. 1L ct 
was: carboplatin/cisplatin doublets (%): 57/43; median no. of cycles for 
ct/b and mtc b was 6 and 18, respectively. Median b dose was 7.5 
mg/kg. Orr: 83%. Of 71% of pts who had evidence of PD to 1L, 90% 
received second-line (2L) tx. 77% of pts who progressed to 2L, received 
a third-line (3L). b was maintained in 26% and 24% of pts receiving 
2L and 3L. Median PFs: 15 m (cI 95%:14-16); median Os: 31 m (95% 
cI: 22-39). 1 and 2 yrs survival rates (%): 97 (95% cI: 93 - 100) and 62 
(95% cI: 51 - 73). Most frequent b related toxicities (%): gr 1/2 epistaxis 
(22/0), gr 1/2 HtN (12/6), grade 1/2/3 asthenia (2/6/4) and gr 1/2/3 pro-
teinuria (3/3/1).
Conclusions: to our knowledge, these are the first data reported of long-
term survivors with advanced nsNscLc treated with 1L ct/b plus long-
time mtc b. Although prospective evaluation is required, the outstanding 
median Os (31 m) and 2-yr survival (62%) point out the importance of 
selecting tx and the role of mtc b after 1Lb. b was very well tolerated, 
without significant life-threatening toxicities. subgroup analyses will be 
presented.
Disclosure: J.V. cardona: J.V. cardona works for roche Farma, s.A. 
as Medical Manager. All other authors have declared no conflicts of 
interest.
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RESULTS OF THE FIRST ITALIAN EXTERNAL QUALITY 
ASSURANCE SCHEME FOR SOMATIC EGFR MUTATION 
TESTING IN NON-SMALL-CELL LUNG CANCER
N. Normanno1, c. Pinto2, G. taddei3, M. Gambacorta4, F. castiglione3, 
c. clemente5, A. Marchetti6 1Department of Research, Cell Biology and 
Biotherapy Unit, Naples, ITALY, 2Medical Oncology, S. Orsola-Malpighi 
Hospital, Bologna, ITALY, 3Department of Human Pathology and Oncology, 
University of Florence, Firenze, ITALY, 4Division of Pathology, Ospedale 
Niguarda Ca’ Granda, Milano, ITALY, 5Pathology and Cytopathology Unit, 
Casa di Cura San Pio X, Milano, ITALY, 6Center of Predictive Molecular 
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Background: Assessment of the mutational status of the epidermal growth 
factor receptor (EGFr) is mandatory in order to choose the most appropri-
ate first-line treatment for non-small-cell lung cancer (NscLc) patients. the 
Italian Association of Medical Oncology (AIOM) and the Italian society of 
Pathology and cytology (sIAPEc) started an external quality assessment 
(EQA) scheme for EGFr testing in 2011.
Methods: ten specimens (3 biopsies and 7 surgical specimens) with known 
EGFr mutation status were validated in 3 referral laboratories and then pro-
vided to 47 laboratories participating in the EQA. Participating laboratories 
registered at the website, and were requested to perform DNA extraction and 
analysis using their usual method and to submit their results within a 4 week 
timeframe. A board of experts from AIOM and sIAPEc evaluated the results 
according to a pre-defined scoring system that assigned 2 points to the correct 
genotype and 0 points to false-negative or false-positive results. the threshold 
to pass the EQA was set at >18/20 points. centers failing to pass the I round 
were offered to participate to a II round that was organized with the same 
rules of the I round.
Results: All the centers participating to the EQA submitted the results 
within the timeframe. DNA sequencing (79%) was the main methodologies 
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used by the participants, while few centers used Pyrosequencing (17%) 
or the real time Pcr (4%). A significant number of analytical errors 
was observed, including both false-negative and false-positive results. 
Fourteen out of 47 centers (30%) did not pass the I round having reached 
a score ≤18 points. A difference was observed between the testing meth-
ods: 0/10 laboratories that used Pyrosequencing or real time Pcr failed, 
whereas 14/37 (38%) laboratories that employed Pcr/sequencing made 
analytical errors. Eight of the 14 centers that failed in the I round passed 
the II round. Overall, 41/47 (87%) of the Italian centers passed the EGFr 
EQA.
Conclusions: the results of this first Italian quality assessment for EGFr 
testing in NscLc suggest that EGFr mutational analysis is performed with 
good quality in the majority of Italian centers.
Disclosure: All authors have declared no conflicts of interest.
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THE RELEVANCE OF DISEASE STABILIZATION (SD) AS 
A SURROGATE END-POINT IN ADVANCED NON-SMALL-
CELL LUNG CANCER (NSCLC) PATIENTS TREATED 
WITH ERLOTINIB (E) IN SECOND/THIRD LINE
F. Grossi1, c. Genova1, G. barletta1, E. rijavec1, c. sini1, M.G. Dal bello1, 
P. Pronzato2, P. Venturino3, G. Pappagallo4 1Lung Cancer Unit, National 
Institute for Cancer Research, Genova, ITALY, 2Medical Oncology A, 
National Institute for Cancer Research, Genova, ITALY, 3Medical Affairs, 
Roche, Monza, ITALY, 4Clinical Epidemiology Office, Azienda ULSS 13, 
Mirano, ITALY
Background: sD has often been viewed as a result of uncertain clinical value. 
With the advent of E in advanced NscLc, increasing numbers of patients 
(pts) achieve sD as a best response. In clinical practice is a common observa-
tion an high proportion of sD pts receiving E with durable sD. the aim of this 
analysis was to compare the PFs and Os in pts with advanced NscLc who 
achieved confirmed sD or complete/partial response (cr+Pr) after second/
third line treatment with E. 
Methods: Data from 684 italian pts, entered into the trUst trial (tiseo 
M et al. Lung cancer 2008), were analyzed. E was given orally at 150 mg 
per day and was continued until disease progression, development of unac-
ceptable toxicity or patient’s refusal. We define confirmed sD (csD) if the 
patients’ PFs was ≥5 months (response to E were per-protocol evaluated 
every two months) and reconfirmed sD (rsD) if the patients’ PFs was ≥8 
months. 
Results: Pts characteristics: median age 67 years (31-89); females/
males = 219/465 pts (32%/68%); never/former smokers = 191/493 pts 
(28%/72%); squamous/adeno/bAc/large cell/NOs = 163/361/26/21/113 
pts (24%/53%/4%/3%/16%); Ps 0-1/2-3 = 557/127 pts (81%/19%). In 83 
pts (12%) E was given as first-line therapy in pts unable to receive che-
motherapy; 305 pts (45%) had received 1 prior line and 296 (43%) 2 prior 
lines of chemotherapy. Four hundred and twenty-eight pts were evaluable 
for response in second/third line: cr+Pr were 44 (10%) and 226 pts (53%) 
obtained a sD with 139 pts (32%) with csD and 83 pts (19%) with rsD. 
the median PFs estimates (with 95% cI) were 13.1 months (9.8-16.4) for 
cr+Pr pts, 9.9 months (8.2-11.4) for csD pts and 14 months (12-16) for 
rsD. the median Os estimates (with 95% cI) were 24.0 months (17-31) for 
cr+Pr pts, 17.9 months (14.4-21.5) for csD pts and 24.9 months (18.1-
31.7) for rsD. 
Conclusions: Our findings demonstrate for the first time the relevance of 
achieving disease stabilization with E treatment. Pts obtaining csD or rsD 
had durable PFs and Os comparable, particularly for rsD, with PFs and Os 
of those having cr+Pr.
Disclosure: P. Venturino: roche employee. All other authors have declared 
no conflicts of interest.
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CO-DEVELOPMENT OF A FOLATE RECEPTOR 
TARGETED DRUG CONJUGATE (EC145) AND A FOLATE 
RECEPTOR TARGETED IMAGING AGENT (EC20) IN 
THE TREATMENT OF ADVANCED ADENOCARCINOMA 
NSCLC
M.J. Edelman1, P. bonomi2, W. Harb3, s. Pal4, r. boccia5, M. Kraut6, J. 
rogers7, D. Morgenstern8, b. conley9, E. Garon10 1Division of Hematology/
oncology, University of Maryland Greenebaum Cancer Center, Baltimore, 
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Institute, Southfield, MI, UNITED STATES OF AMERICA, 7Hematology/
oncology, Health Science Center of West Virginia University, Mogantown, 
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Inc., West Lafayette, IN, UNITED STATES OF AMERICA, 9Hematology/
oncology, Michigan State University, East Lansing, MI, UNITED STATES 
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STATES OF AMERICA
Background: the folate receptor (Fr) is overexpressed on many epithelial 
cancers, including adenocarcinoma of the lung. Ec145 is a conjugate of folate 
that is coupled chemically to desacetylvinblastine hydrazide (DAVLbH), spe-
cifically targets the Fr. Ec20 uses the identical folate-targeting moiety but 
is conjugated to a technetium-chelating agent to allow for in vivo imaging 
and identification of tumor Fr status. this phase 2 study evaluates the poten-
tial use of the 99mtc-Ec20 agent to select advanced Fr-positive lung cancer 
patients to be treated with Ec145.
Methods: Patients with adenocarcinoma of the lung, EcOG Ps 0-2 progres-
sive after ≥ 2 prior therapies, and had ≥ 1target lesion expressing Fr on the 
Ec20 scan, were eligible. Ec145 was administered at 1 mg IV daily x 5 for 
3/4 weeks for 2 cycles, and then at 2.5 mg IV tIW on weeks 1 and 3 every 
4 weeks for 6 cycles. the primary endpoint of the study was clinical ben-
efit response (cbr) defined as the ability to receive ≥ 4 courses of therapy. 
secondary endpoints included response rate (rr), progression-free survival 
(PFs), and overall survival (Os).
Results: 43 patients were enrolled and received ≥ 1 dose of Ec145; 70% had 
≥ 3 prior therapies. cbr was observed in 26% of patients, and one (2.3%) had 
a Pr. superior clinical benefit response and survival was observed in patients 
in which all target lesions expressed Fr (Fr++)compared to those who had 
at least one but not all target lesions positive for Fr (Fr+), 50% vs. 14% and 
10.8 vs. 3.4 months, respectively. the most common drug-related AEs were 
fatigue (37%) and constipation (33%), with no grade 4 toxicity. the majority 
of patients discontinued therapy due to progressive disease, and none due to 
toxicity.
Conclusions: Intriguing efficacy results were seen in heavily pre-treated 
patients who had all target tumor lesions expressed Fr by Ec20 scan (Fr++). 
99mtc-Ec20 scan offers a non-invasive way to select patients that are most 
likely going to benefit from treatment with Ec145. A randomized phase 2 
study of Ec145 and Ec145 plus docetaxel vs. docetaxel in Fr++ 2nd line 
adenocarcinoma lung cancer will start shortly.
Disclosure: M.J. Edelman: I have received research funding and consul-
tant honoraria from Endocyte. P. bonomi, W. Harb, s. Pal, r. boccia, M. 
Kraut, J. rogers, b. conley, E. Garon: research funding from Endocyte. D. 
Morgenstern: Employee of Endocyte.
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EGFR EXON 20 INSERTION MUTATIONS IN NSCLC: 
FREQUENCY AND TREATMENT OUTCOMES WITH EGFR 
DIRECTED TKIS
t. Ovcaricek1, M. Unk2, I. Kern3, t. cufer2 1Oncology, University Clinical 
Center Maribor, Maribor, SLOVENIA, 2Oncology, University Clinic 
Golnik, Golnik, SLOVENIA, 3Pathology, University Clinic Golnik, Golnik, 
SLOVENIA
Introduction: Among EGFr gene mutations, exon 19 deletions and exon 21 
point mutations are the most common. these are often termed classic activat-
ing mutations due to their enhanced sensitivity to EGFr tKI. However, not 
all mutations have the same effect. there is growing evidence that exon 20 
insertions are a unique type of EGFr mutations. Its true frequency within the 
larger EGFr mutated NscLc pool is unknown, with reports describing fre-
quency from 1 to 10%. Although limited, most reports indicate that patients 
(pts) with exon 20 insertions are not as responsive to tKI as pts with classical 
activating mutations. the aim of our study was to evaluate frequency of exon 
20 insertions and treatment outcomes in pts harbouring these types of muta-
tions treated with EGFr directed tKIs.
Patients and metods: 803 pts with pathologically confirmed adenocarci-
noma or NscLc not other specified were routinely screened for EGFr muta-
tions between years 2009-2011 in slovenia. A commercially available kit 
(therascreenKit ®) was used for mutation analysis. 150 out of 803 pts (18.6 %) 
were positive for EGFr mutations and 21 (14%) had exon 20 insertions. 
Among them 11 pts (52%) were treated with tKIs (erlotinib or gefitinib) for 
advanced disease, 9 pts received tKIs as 1st line therapy and 2 as 2nd line 
therapy. clinicopathological and follow-up data were retrospectively col-
lected from medical charts.
Results: the frequency of exon 20 insertions within EGFr mutated pts pool 
was 14 %. Most of the pts harbouring these mutations were females 12 (57%), 
never smokers (44%) and 91.0% had adenocarcinoma. According to the 
rEcIst criteria, none of 11 pts responded to tKI therapy; in 7 pts (63.6%) 
stagnation was achieved and 4 pts (36.4%) had disease progression. Median 
PFs from tKI treatment initiation was only 2.5 months.
Conclusion: the frequency of exon 20 insertions in routinely screened col-
lective of NscLc pts is low. the low radiographic response and short PFs 
indicate lower sensitivity of these type of EGFr mutations to the treatment 
with tKI, especially compared to high response rates of around 70% and long 
PFs rates of 9-13 months reported in pts harbouring classic activating EGFr 
mutations.
Disclosure: All authors have declared no conflicts of interest.
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PROGNOSTIC EFFECT OF EXCISION REPAIR CROSS-
COMPLEMENTATION GROUP 1 (ERCC1) IN PLATINUM 
TREATED ADVANCED NON-SMALL CELL LUNG 
CANCER
r.M. Gaafar1, M.A. Hussein2, A.A. bahnassy1, s.s.A. shamaa2 1Medical 
Oncology, National Cancer Institute, Cairo, EGYPT, 2School of Medicine, 
Mansoura University Hospital, Mansoura, EGYPT
Purpose: Although current treatment option for advanced non–small-cell 
lung cancer (NscLc) relies on cisplatin-based chemotherapy, individualized 
approaches to therapy may improve response or reduce unnecessary toxic-
ity. Excision repair cross-complementing 1 (Ercc1) has been associated 
with cisplatin resistance. We hypothesized that assigning cisplatin based on 
pretreatment Ercc1 expression (both protein and mrNA) would improve 
response and survival. 
Patients and methods: From March 2009 to April 2010, 61 chemother-
apy naïve stages IIIb and IV NscLc patients were enrolled. Ercc1 pro-
tein and mrNA expression was detected from pretreatment biopsies by 
Immunohistochemistry and real-time quantitative Pcr assays, respectively. 
Patients received cisplatin based regimen in the form of cisplatin plus (etopo-
side or gemcitabine or docetaxel or vinorelbine).the primary end point was 
the impact of Ercc1 expression on PFs and Os. 
Results: All biopsy specimens (61) were candidate for mrNA detection; 31 
patients (50.8%) showed positive Ercc1 expression while only 52 biopsy 
specimens were candidate for protein detection; 34 patients (65.4%) showed 
positive Ercc1 expression. complete concordance among the rt-QPcr and 
IHc for detection of Ercc1 expression was detected in 38 out of the 52 cases 
(73%). Positive Ercc1 expression was associated with short PFs (P < 0.001 
for mrNA and P = 0.001 for protein). Positive Ercc1 expression was asso-
ciated with short Os (P = 0.001 for mrNA and P = 0.003 for protein). Also, 
positive Ercc1 expression was associated with poor response to cisplatin 
based chemotherapy (P < 0.001 for mrNA and P = 0.027 for protein). 
Conclusions: this prospective study further validates Ercc1 as a reliable 
biomarker for customized chemotherapy in advanced NscLc patients and 
shows that high expression of Ercc1 by IHc or rt-Pcr was significantly 
associated with poor outcome in advanced NscLc patients treated with plati-
num based chemotherapy. 
Disclosure: All authors have declared no conflicts of interest.
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INCORPORATING CRIZOTINIB INTO CLINICAL 
PRACTICE AS A NEW STANDARD OF CARE (SOC) IN 
ALK-POSITIVE NON-SMALL CELL LUNG CANCER 
(NSCLC)
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the EML4 –ALK gene fusion was identified in NscLc in 2007 and has 
a prevalence of 3–5% in NscLc of largely adenocarcinoma histology. 
crizotinib (Xalkori®) is an oral, AtP-competitive, small molecule ALK and 
MEt receptor tyrosine kinase inhibitor, which has developed as a poten-
tial new sOc for ALK-positive NscLc. Following promising early activ-
ity, in 2008 a Phase 1 protocol (PrOFILE 1001; Nct00585195, Pfizer), 
was expanded via an ALK-positive NscLc cohort (confirmed by break-
apart FIsH assay). An open-label, multicenter, phase II study of crizotinib 
in advanced ALK-positive NscLc (PrOFILE 1005; Nct00932451, Pfizer) 
was initiated in 2010. A total of 119 (PrOFILE 1001) and 136 (PrOFILE 
1005) patients with ALK-positive NscLc were evaluable for safety and effi-
cacy. Median age was 51 and 52 years, respectively, and most patients were 
pretreated. clinical antitumor activity was dramatic, with rapid and durable 
responses (table). Orrs were independent of age, gender, number of prior 
regimens and EcOG performance status, and far exceeded the Orrs of 
16.3% and 9.7% in patients who received 1st- and 2nd-line chemotherapy, 
respectively, prior to crizotinib. Updated median PFs for PrOFILE 1001 
(excluding 1st-line patients) will be presented. the most common treatment-
related AEs were Grade 1 vision disorder (62%), nausea (53%), diarrhea 
(43%), and vomiting (40%). Visual effects were transient with no effect 
on activities of daily living. Grade 3 or 4 treatment-related AEs included 
increased ALt/Ast, pneumonitis, neutropenia and lymphopenia. based on 
these data, crizotinib and the break-apart ALK FIsH assay were simulta-
neously approved by the FDA for the treatment of advanced ALK-positive 
NscLc in 2011. Us NccN, cAP-IAsLc-AMP, and Japanese lung cancer 
biomarker guidelines have since recommended routine screening of patients 
with NscLc for ALK-positivity. crizotinib could therefore now be consid-
ered sOc in these patients.
Table:
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PROFILE 1001 PROFILE 1005 
Evaluable patients n=116 n=133 
Objective response rate 
(Orr; Pr+cr) 
61% (95% cI: 
52%, 70%) 
51% (95% cI: 
42%, 60%) 
Median Duration of response 42 weeks 48 weeks 
Median Duration of treatment 32 weeks 22 weeks 
Median Progression-free 
survival (PFs) 
10 months (95% 
cI: 8.2, 14.7) 
Not yet available 
Disclosure: J. soria: I have served Pfizer Oncology in an advisory role and 
have also received honoraria from Pfizer Oncology. F. blackhall: I have served 
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received honoraria and research funding from Pfizer Oncology.
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PRELIMINARY EXPOSURE RESPONSE (ER) ANALYSIS 
OF CRIZOTINIB IN PATIENTS WITH ALK-POSITIVE 
ADVANCED NON-SMALL CELL LUNG CANCER
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Background: crizotinib (Xalkori®) is a first-in-class oral ALK inhibitor, 
which was approved by the Food and Drug Administration for the treatment 
of advanced ALK-positive non-small cell lung cancer (NscLc). Er analy-
ses were conducted for efficacy and safety endpoints from two crizotinib 
trials.
Methods: Data from 255 patients receiving crizotinib 250 mg bID in two 
clinical studies (A8081001: n=119; A8081005: n=136) were analyzed. 
Logistic regression was used for safety endpoints (ALt elevation, neutro-
penia, fatigue) and objective response rate (Orr); cox regression was used 
for progression-free survival (PFs; study 1001 only). Exposure was mea-
sured by model-predicted average steady state concentration and observed 
geometric mean trough concentration. the models included potential con-
founders and effect modifiers. to identify factors to predict low exposure, a 
model-building approach was used and models were fit separately for each 
study.
Results: In both studies, a positive Er relationship was observed for Orr. 
the odds ratios comparing lowest sextile exposure group to the median expo-
sure were 2.15 (95% cI: 1.19–3.86) and 1.69 (95% cI: 1.01–2.81) for studies 
1001 and 1005, respectively. In addition, PFs showed a positive Er rela-
tionship, though it was not statistically significant. No clinically meaningful 
Er relationships were found for safety endpoints. there were trends toward 
higher risk of neutropenia with higher exposure (p>0.05 in both studies). 
there were trends toward less risk of fatigue (p<0.05, study 1005 only) and 
less risk of ALt elevations (p<0.05, study 1001 only) with higher exposure. 
Low average daily dose (ADD) was the primary driver of low exposure. In 
both studies, the lowest Orr was observed in the lowest sextile exposure 
group, which included most subjects with ADD less than 450 mg (90% of the 
nominal 500 mg). In study 1001, there was a trend of correlation with use of 
cYP3 inducers and low exposure.
Conclusions: this preliminary Er analysis of crizotinib showed favorable 
benefit-risk assessment at the recommended 250 mg bID dose regimen.
Disclosure: J. French: I have served Pfizer Oncology in an advisory role 
and also hold stock in Pfizer Oncology as a consequence of being a former 
employee of Pfizer Oncology. W.W. tan, D. Kang, A. bello and P. selaru: I am 
an employee of Pfizer Oncology and hold stock in Pfizer Oncology. All other 
authors have declared no conflicts of interest.
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IN SEARCH OF A BETTER THERAPEUTIC APPROACH TO 
NSCLC: THE ROLE OF EML4-ALK TRANSLOCATION
A. Antunes, A. barroso, s. conde, s. Neves, b. Parente Pulmonology, 
Centro Hospitalar Vila Nova de Gaia/Espinho, EPE, Vila Nova de Gaia, 
PORTUGAL
the study of molecular characteristics of NscLc plays an increasing role 
in choosing the best therapy. In addition to the use of tKIs in the first –line 
treatment of EGFr mutated NscLc advanced disease, now arises the use of 
crizotinib in tumors with EML4-ALK translocation. the EGFr mutation and 
EML4-ALK are mutually exclusive, the latter being more frequent in non-
smokers with non-squamous histology. the study of these characteristics with 
the best benefit to the patient is only possible with a structured methodology 
that enables its systematic and timely execution. 
Aim: to present the methodology used during 2011 in our service to carry out 
cytogenetic and molecular study of NscLc. Demographics, clinical, cytoge-
netic and molecular characterization of the study population. 
Methodology: In all new cases of NscLc, the EGFr exons 18-21 were 
sequenced. After sequencing, the non-smokers or former smoker patients 
with wild-type EGFr and non-squamous histology were subjected to FIsH 
analysis to investigate the EML4-ALK rearrangement. It was made a descrip-
tive statistical analysis of demographics, clinical, cytogenetic and molecular 
features of the study population.
Results: EGFr was sequenced in 138 cases of NscLc, 98 (71%) were male. 
the most common histology was adenocarcinoma - 92 cases (67%), followed 
by squamous cell carcinoma - 29 patients (21%) and poorly differentiated 
NscLc - 17 (12%). regarding smoking, 52 patients were active smokers and 
40 non-smokers and 46 former smokers. At diagnosis, stage IV - 79 patients 
(57%) was the most frequent. the EGFr was mutated in 16 patients - muta-
tion rate of 11.5%. 57 patients were eligible for the study EML4-ALK. In five 
of these, the material available was insufficient for diagnosis. We found two 
positive cases (3.8% rate of translocation), both adenocarcinomas – one male 
former smoker patient and one non-smoker female patient. 
Discussion: With these results it appears that one of the problems in the search 
of EML4-ALK is the suitability of the samples, as in 8.8% of cases, the study 
was not possible. the rate of translocation found is consistent with the litera-
ture. the use of a systematic strategy allows the molecular characterization of 
tumors in order to a correct and timely therapeutic management.
Disclosure: All authors have declared no conflicts of interest.
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THE MANCHESTER LUNG CANCER GROUP 
EXPERIENCE OF EGFR MUTATION ANALYSIS AND 
TREATMENT OUTCOMES
r. Peck1, E. connolly2, P. taylor1, F. blackhall3, c. Faivre-Finn4, A. Wallace5, 
Y. summers1 1Pulmonary Oncology Unit, University Hospital of South 
Manchester, Manchester, UNITED KINGDOM, 2Undergraduate Medicine, 
University of Manchester, Manchester, UNITED KINGDOM, 3Medical 
Oncology, Christie Hospital NHS Trust, Manchester, UNITED KINGDOM, 
4Department of Clinical Oncology, The Christie NHS Foundation Trust, 
Manchester, UNITED KINGDOM, 5Genetic Medicine, Central Manchester 
University Hospitals NHS Foundation Trust, Manchester, UNITED 
KINGDOM
the presence of Epidermal Growth Factor receptor (EGFr) activating muta-
tions in patients with NscLc was first described in 2005. tumours exhibiting 
these mutations show sensitivity to treatment with an oral tyrosine Kinase 
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Inhibitor. testing for EGFr mutations in patients with non-squamous NscLc 
began in the Greater Manchester and cheshire network in the last quarter of 
2009. We audited the notes of consecutive patients who were identified with 
an activating EGFr mutation by the central Manchester Genetics Laboratory 
between November 2009 and October 2011. A total of 110 mutations were 
identified in tumour tissue from 98 patients. 13.6% were in exon 18, 38.2% 
in exon 19, 15.4% in exon 20 and 32.8% in exon 21. 65% of patients were 
female. the median age was 69 years (36-89). Notes were available for 78 
patients, 56 of whom received treatment with an EGFr tKi. 5 had previously 
received radical treatment and 17 never received treatment. 6.4% were cur-
rent smokers, 41% were ex-smokers, 29.6% had never smoked and smoking 
history was not documented in 23%. An initial response to treatment was seen 
in 75%, with stable disease in 15%.the mean duration of treatment was 7.5 
months (2 weeks – 18 months), with 23 patients still receiving a tKi at the 
time of data analysis. the most commonly seen toxicities were diarrhoea and 
rash. Only 1 patient had no documented toxicity from their tKi. 16 patients 
(28%) had treatment discontinued or interrupted because of toxicity. In 8 of 
these, treatment was re-introduced at a reduced dose, and 3 patients went 
back to full dose. Our results confirm that treatment with a tKi is effective 
for patients with EGFr mutations, with a side effect profile consistent with 
published data.
Disclosure: All authors have declared no conflicts of interest.
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CAN MUTATIONS OF EGFR AND KRAS OF SERUM BE 
PREDICTIVE AND PROGNOSTIC MARKERS IN PATIENTS 
WITH ADVANCED NON-SMALL CELL LUNG CANCER 
(NSCLC)?
s.t. Kim, Y.H. Kim Division of Hematology-oncology, Department of 
Medicine, Korea University Anam Hospital, Seoul, KOREA
Background: the status of Epidermal growth factor receptor (EGFr) and 
Kirsten ras (KrAs) mutations have been used widely in management of 
patients with non-small cell lung cancer (NscLc). However, it may be diffi-
cult to get tumor tissue for analyzing the status of EGFr and KrAs mutation 
in large proportion of patients with advanced disease
Patients and methods: We obtained pairs of tumor and serum samples 
from 57 patients with advanced NscLc, between March 2006 and January 
2009. EGFr mutation status from tumor samples and KrAs mutation sta-
tus from serum samples was analyzed by genomic polymerase chain reac-
tion and direct sequence and EGFr mutation status from serum samples 
was determined by the peptide nucleic acid locked nucleic acid (PNA-LNA) 
Pcr clamp.
Results: EGFr mutations were detected in the serum samples of 11 patients 
and in the tumor samples of 12 patients. Fourteen patients revealed KrAs 
mutation in the serum sample. EGFr mutation status in the serum and 
tumor samples was consistent in 50 (87.7%) of the 57 pairs (correlation 
index; 0.62 P<0.001). Only 5 of 57 (8.7%) patients showed mutation of 
both EGFr and KrAs in serum sample. twenty-two of 57 patients (38.5%) 
received EGFr-tKIs as any line therapy. the response for EGFr-tKIs was 
significantly associated with EGFr mutations in both tumor samples and 
serum samples (p<0.05). the status of KrAs mutation in serum was not 
predictive for the response of EGFr-tKI (p>0.05). there was no signifi-
cant differences in Os according to the status of EGFr mutations in both 
serum and tumor samples (p>0.05) and KrAs mutations in serum samples 
(p>0.05).
Conclusion: the status of EGFr and KrAs mutation in serum was not prog-
nostic in patients with advanced NscLc. However, the clinical usefulness of 
EGFr mutation of serum as a selection marker for EGFr-tKIs sensitivity in 
NscLc might be allowed, not KrAs mutation.
Disclosure: All authors have declared no conflicts of interest.
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EGFR MUTATION IN AUSTRIAN PATIENTS WITH NSCLC: 
A RETROSPECTIVE STUDY
M.J. Hochmair1, M. Miler1, U. setinek1, K. Kirchbacher2, A. Mohn-staudner1, 
M. Kaufmann1, I. Kapfhammer1, M.b. Arns3, K. Patocka4, O.c. burghuber1 
1Department of Respiratory and Critical Care Medicine, Otto Wagner 
Hospital, Vienna, AUSTRIA, 2Medizinische Abteilung – Lungenabteilung, 
Wilhelminenspital, Lehrkrankenhaus der medizinischen Universität, Vienna, 
AUSTRIA, 3Pulmologische Abteilung, LKH Hochegg, Grimmenstein, 
AUSTRIA, 4Abteilung für Atmungs- und Lungenerkrankungen, KH Hietzing, 
Vienna, AUSTRIA
Introduction: Point mutations of the Epidermal growth factor receptor 
(EGFr) in non-small cell lung cancer (NscLc) predicts the response 
to tyrosine kinase inhibitors. commonly mutations occur more in never 
smokers, adenocarcinomas, women and East Asians. In the largest 
European screening trial the frequency of caucasian spanish patients was 
16.6% (1). However, the frequency of EGFr mutations in NscLc from 
Austrian patients is unknown. 
Aim: to evaluate the prevalence of EGFr mutation in Austrian patients 
with NscLc. 
Methods: From January 2010 to October 2011 tumor tissue from 
bronchoscopy, ct-guided and ultrasound guided biopsies and surgi-
cal specimen with histological type of Adenocarcinomas (Ac) and 
NscLc NOs (Not Otherwise specif ied) excluding squamous cell car-
cinomas and large cell carcinomas were tested for EGFr mutations 
from 4 hospitals in Austria with high expertise in the management of 
lung cancer. the mutation detection was performed in one specialisted 
laboratory with the therascreen EGFr29MutationKit from Dxs on a 
Light cycler 480. 
Results: 581 patients (550 Ac, 31 NOs) were tested. EGFr mutations 
were found in 87 patients (14.97 %). 71 patients (12.22 %) carried an 
activated Mutation (Exon 19 Deletion and Exon 21 L858r). 
Conclusion: these results indicate that Austrian patients with NscLc 
harbor somatic EGFr mutations at a frequency similar to other European 
caucasian patients with NscLc. Reference: [1] screening for epidermal 
growth factor receptor muations in lung cancer. rosell et al. NEJM 361 
(10) 2009 Disclosure: All authors have declared no conflicts of interest.
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EGFR MUTATION AND TYROSINE KINASE INHIBITOR 
(TKI) TREATMENT IN A DANISH (CAUCASIAN) 
POPULATION OF ADVANCED NSCLC PATIENTS AT 
ODENSE UNIVERSITY HOSPITAL 2010-11
r. Kjeldsen1, K.H. Hansen1, K.E. Olsen2, N.G. Hansen3, O. Hansen1 
1Oncology, Odense University Hospital, Odense, DENMARK, 2Pathology, 
Odense University Hospital, Odense, DENMARK, 3Respiratory Medicine, 
Odense University Hospital, Odense, DENMARK
Background and method: the multi disciplinary lung cancer team at Odense 
University Hospital has since July 2010 recommended a test for EGFr muta-
tion in patients with advanced adenocarcinoma prior to possible chemo-
therapy. Out of 348 new cases with lung cancer from our primary uptake 
area, 98 consecutive patients have been tested until November 2011. Nine 
patients (9.2%) had the mutation. In female never-smokers and ex-smokers 
the mutation rate was 26.9%. In the same period the test (therascreen Dxs, 
Qiagen) has also been applied in patients with relapse and in patients referred 
from other hospitals. Out of a total number of 199 tested, 21 subjects with 
EGFr-mutation have been found. We here report the treatment and outcome 
for these patients.
Material: Among the 21 patients 19 were females and 2 males. One patient 
was a current smoker, the remaining pts. were either never-smokers (7 pts.) 
or ex-smokers (13 pts.). sixteen pts. were treated with a tKI, 12 of them 
as first line treatment. Five pts. with mutation did not receive tKI: two 
died before treatment could start and two were assessed would not benefit 
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from the treatment. One underwent curative intended chemo-radiotherapy. 
Performance status of the 16 treated pts were Ps 0: 2 pts., Ps 1: 9 pts. and 
Ps 2: 5 pts.
Results: As of January 2012, 7 pts were still treated with tKI. sixteen 
months being the longest follow up time. Mean follow up time was 7 
months. seven pts had progression after 2, 5, 6, 7, 8, 8 and 11½ months of 
treatment. two pts died without known progression within 1 and 2 months 
respectively. the mean progression free survival was 8.2 months and the 
mean overall survival Os 15.4 months. 
Discussion: We found a mutation rate of 10.5 % among the tested pts. the 
mutation positive subgroup is typically non-smoking females. the patients 
treated had 8 months of PFs though many patients were still being suc-
cessfully treated at end of inquiry. Further follow-up must show the long 
term effect of tKI on EGFr mutated tumors but the results so far are 
encouraging. 
Disclosure: All authors have declared no conflicts of interest.
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ARCHER: A RANDOMIZED DOUBLE-BLINDED PHASE 
III STUDY OF DACOMITINIB (PF-00299804) VERSUS 
ERLOTINIB FOR ADVANCED (ADV) NON-SMALL CELL 
LUNG CANCER (NSCLC)
V. Antic1, M. boyer2, P. Janne3, t. Mok4, K. O’byrne5, L. Paz-Ares6, s.s. 
ramalingam7, J. Liang8, I. taylor8, s. Letrent9 1Medical Oncology, Pfizer 
AG, Zürich, SWITZERLAND; 2Medical Oncology, Sydney Cancer Centre, 
Camperdown, AUSTRALIA; 3Medical Oncology, Dana-Farber Cancer 
Institute, Boston, MA, UNITED STATES OF AMERICA; 4Department of 
Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, 
CHINA; 5Medical Oncology, St James Hospital, Dublin, IRELAND; 6Medical 
Oncology, Hospital Universitario, Virgen del Rocío, Seville, SPAIN; 7Winship 
Cancer Institute, Emory University, Atlanta, GA, UNITED STATES OF 
AMERICA; 8Medical Oncology, Pfizer Oncology, New London, CT, UNITED 
STATES OF AMERICA; 9Medical Oncology, Pfizer Oncology, La Jolla, CA 
UNITED STATES OF AMERICA
Introduction: Human epidermal growth factor (HEr/EGFr) family 
receptor signalling regulates tumor cell proliferation, invasion, angiogen-
esis, metastasis, and apoptosis. selective, reversible EGFr/HEr1 tyrosine 
kinase inhibitors (tKI) are used for the treatment of unselected patients 
(pts) with adv NscLc after failure of 1st-line chemotherapy (ct) and in 
pts with EGFr-mutated NscLc. A randomized phase II trial compared 
dacomitinib, an orally available irreversible pan-HEr tKI, with erlo-
tinib, in pts who had received 1–2 prior systemic therapy regimens for 
adv NscLc. Dacomitinib demonstrated significantly longer progression-
free survival (PFs) vs erlotinib in the overall population (12.4 vs 8.3 
weeks; Hr=0.66, p=0.012), with benefit consistent across several clinical 
and molecular subgroups. Median PFs in the KrAs wild-type (wt) sub-
group was 16.1 vs 8.3 weeks for dacomitinib and erlotinib, respectively 
(Hr=0.55, p=0.006).
Methods: ArcHEr is a randomized, double-blinded, phase III clinical 
trial comparing the efficacy and safety of dacomitinib with erlotinib in pts 
with locally adv or metastatic NscLc (pathologically confirmed radio-
logically measurable disease), 1–2 prior ct regimens, EcOG Ps 0–2, 
and tissue available for molecular analysis. Approximately 800 pts will 
be randomized to receive dacomitinib 45 mg or erlotinib 150 mg orally 
once daily. the primary endpoint is PFs with overall survival, objective 
response rate, duration of response, safety and tolerability, and pt reported 
outcomes of health-related quality of life and disease-/treatment-related 
symptoms as secondary endpoints. Efficacy will be analyzed in two co-
primary populations: (1) all enrolled pts with adv NscLc, and (2) pts with 
KrAs wt NscLc. study design provides 90% and 80% power to detect 
≥33% and ≥45% improvement in PFs in all pts receiving dacomitinib vs 
erlotinib, and in pts with KrAs wt NscLc, Hr ≤0.75 and 0.69 using a 
1-sided stratified log-rank test at a significance level of 0.015 and 0.01, 
respectively. the final primary analysis stratified log-rank test will include 
baseline EcOG Ps, KrAs mutation status and EGFr mutation status as 
stratification factors.
Disclosure: V. Antic: I am an employee of Pfizer AG and have stock owner-
ship in Pfizer AG. M. boyer: Advisory role - Pfizer Oncology, boehringer 
Ingelheim Honoraria - Pfizer Oncology, boehringer Ingelheim, Eli Lilly, 
Amgen research funding - Pfizer Oncology. t. Mok: Advisory role - 
AstraZeneca, roche, Eli Lilly, Merck serono, Eisai, bMs, AVEO, Pfizer 
Oncology, beiGene Honoraria - AstraZeneca, roche, Eli Lilly, Merck 
serono, Eisai, bMs, AVEO, Pfizer Oncology, beiGene research funding – 
AstraZeneca. K. O’byrne: Advisory role and honoraria - Pfizer Oncology. 
L. Paz-Ares: I have served Pfizer Oncology in an advisory role and have 
received honoraria from Pfizer Oncology. s.s. ramalingam: Advisory role 
- AVEO, Abbott, Astellas, Lilly, Genentech, boehringer Ingelheim, Pfizer 
Oncology. J. Liang and I. taylor: I am an employee of Pfizer Oncology and 
hold stock in Pfizer Oncology. s. Letrent: both myself and an immediate 
family member are employees of Pfizer Oncology and hold stock in Pfizer 
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GGCP041/09: A GALICIAN STUDY OF SECOND-LINE 
ERLOTINIB IN PATIENTS WITH ADVANCED NON-
SQUAMOUS NON-SMALL CELL LUNG CANCER 
(NSNSCLC)
s. Vázquez Estévez1, M.J. Villanueva silva2, J.L. Fírvida Pérez3, M. Lázaro 
Quintela2, s. Varela Ferreiro1, G. Huidobro Vence1, O. Fernández calvo3, 
b. campos balea4, c. Grande Ventura2, K. Areses3 1Medical Oncology, 
Hospital Universitario Lucus Augusti , Lugo, SPAIN, 2Complexo Hospitalario 
Universitario de Vigo, Vigo, SPAIN, 3Complexo Hospitalario de Ourense, 
Ourense, SPAIN, 4Complejo Hospitalario de Pontevedra, Pontevedra, SPAIN
Background: Efficacy of oral erlotinib has been conclusively established in 
2nd line setting (br.21 and trUst studies) and the outcomes are similar to 
those provided by other approved chemotherapeutical agents (tItAN study). 
Higher responses rates have been found in p with Asian ethnicity, adenocar-
cinoma, women and never smokers, where predictive EGFr mutations occur 
more frequently; even though erlotinib has a significant effect on survival in 
all subgroups of patients. this observational study evaluates the efficacy of 
2nd line erlotinib in unselected p with nsNscLc in 4 Galician institutions.
Methods: Unselected p with advanced nsNscLc were treated with 150 mg/
day of erlotinib as 2nd line therapy until unacceptable toxicity or progressive 
disease. EGFr mutational status was retrospectively tested when feasible, 
and serum carcinoembryonic antigen (cEA) monitored during the treatment 
period.
Results: baseline characteristics of 45 p included at the time of this analysis: 
mean age of 61.7 yrs. (range: 38-83); 80% male; 73.3% adenocarcinoma; 
71.1% stage IV; 7/69/24% Ps EcOG 0/1/2; 29/33/38 % never/current/for-
mer smokers. EGFr activating mutation testing was performed in 24 p (53%) 
and 2 positive cases were found (8%), both with metastatic adenocarcinoma 
(stage IV). the median PFs was 3.3 (95% cI: 1.6-5.1) and the median Os 
10 months (95% cI: 7.5-12.5). Among p without EGFr mutations, erlotinib 
conferred a median Os of 8.1 months (95% cI: 1.4-14.9). Out of 31 p evalu-
able, radiologic response was achieved in 7 p (22.6%), for an overall disease 
control rate of 45.2%. No unexpected toxicities were reported: 60 % of p 
experienced cutaneous toxicity (6.6% grade ¾), 22.2% asthenia (4.4% grade 
¾) and 17.8% diarrhea (2.2% grade ¾). Only 3 p discontinued due to adverse 
events.
Conclusions: this study confirms the efficacy and safety of 2nd line erlo-
tinib in a clinical practice scenario and the outcomes in p with non-squamous 
NscLc are equivalent to those reported with the chemotherapy for salvage 
therapy. Moreover, the absence of mutations does not preclude the benefit 
from the drug. Updated data of the study will be presented.
Disclosure: All authors have declared no conflicts of interest.
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TREATMENT WITH EGFR TYROSINE KINASE 
INHIBITORS BEYOND PROGRESSION IN LONG-TERM 
RESPONDERS TO ERLOTINIB IN ADVANCED NON-
SMALL CELL LUNG CANCER: A CASE-CONTROL STUDY 
OF OVERALL SURVIVAL
M. Faehling1, r. Eckert2, s. Kuom1, W. spengler3 1Klinik für Kardiologie 
und Pneumologie, Klinikum Esslingen, Esslingen, GERMANY, 2Oncology, 
Oncology Group Practice, Wendlingen, GERMANY, 3Medizinische Klinik 
Abteilung Ii, Uniklinik Tübingen, Tübingen, GERMANY
Introduction: some patients with advanced NscLc show prolonged disease 
stabilization on treatment with an EGFr-tyrosine kinase inhibitor (tKI) such 
as erlotinib. It is so far not clear how to treat patients who progress after pro-
longed response to erlotinib. We hypothesized that tKI therapy beyond pro-
gression with added chemotherapy, radiotherapy or best supportive care (bsc) 
may improve survival compared to chemotherapy, radiotherapy or bsc alone.
Patients and methods: We retrospectively analyzed all NscLc patients treated 
with erlotinib at our institutions since 2004 who progressed after at least stable dis-
ease on erlotinib for at least six months (n=41). twenty-seven patients were treated 
with tKI beyond progression (tKI patients), of whom 24 received erlotinib and 3 
afatinib. Fourteen patients did not receive further tKI treatment after progression 
(controls). Overall survival (Os) from progression on tKI and Os from diagnosis 
of lung cancer was analyzed for the whole population and case-control subpopu-
lations of pairs matched for gender, smoking status, and histology.
Results: treatment with tKI and chemotherapy was well tolerated with no 
increase in grade 3 and 4 toxicities. tKI-patients had a significantly longer 
Os from progression on tKI (case control: median 21.0 vs. 3.0 months, Hr 
0.175) and longer Os from diagnosis of lung cancer (case control: median 
28.5 vs. 15.3 months, Hr 0.335).
Conclusions: In long-term erlotinib responders, treatment with tKI beyond pro-
gression in addition to chemotherapy or radiotherapy is feasible and well toler-
ated with limited toxicity. tKI-treatment beyond progression leads to prolonged 
Os compared to treatment with tKI-free chemotherapy or radiotherapy.
Disclosure: All authors have declared no conflicts of interest.
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GEFITINIB AND ERLOTINIB IN ADVANCED NON-
SMALL –CELL LUNG CANCER (NSCLC) PATIENTS: 
A RETROSPECTIVE REVIEW FROM THE HOSPITAL 
UNIVERSITARIO CENTRAL DE ASTURIAS
J.P. berros, E. Esteban, N. Villanueva, P. Jimenez, J.M. Vieitez, E. Gutierrez, 
c. Alvarez, Q. Perez, A.L. ruiz, D. rubi Medical Oncology, Hospital 
Universitario Central De Asturias, Oviedo, SPAIN
Background: Gefitinib (G) and erlotinib (E), both specific tyrosin kinase 
Inhibitors (tKIs) have demonstrated efficacy in second and third line treatment 
of patients with NscLc. the aim of this study has been to report the experience 
of a single centre with the utilization of these agents in an unselected population.
Methods: A retrospective analysis was carried out from August 2002 to March 
2008 of patients with advanced NscLc treated with G or E. criteria of response 
and toxicity were those recommended by OMs and Kaplan and Meier method 
for determination of median progression free (PFs) and overall survival (Os).
Results: 131 patients were treated with tKI (17 with Gefinitib and 114 with 
Erlotinib). Patients treated with Gefitinib (G) received all 250 mg/day and 150 
mgs of median with Erlotinib (E) (50-150). Epidemiological characteristics 
were as follow (G/E); median of age (55(38-74)/60(37-80)), Karnosfky (70(50-
100)/70(50-100)), lines of previous chemotherapy (2(1-6)/2(1-5)). Percentage 
of males (76/68), stage IV (88/89), never smokers (29/29) and non-squamous 
histology (88/80). Among 131 patients considered evaluable for activity, there 
were 6% objective responses rate (Orr) in the G and 17% in E group with 
an additional 47% of disease stabilization with G and 36% with E group. the 
median PFs and overall survival with G were 73 and 282 days, with E 90 
and 210, respectively.Never smokers,development of rash, diarrhoea, EGFr 
mutation and prior chemotherapy response or stabilization were independent 
variables related longer Orr, PFs and Os. the most important toxicities 
grade 1-2 were (G/E; %): rash (59/63), diarrhoea (18/21), pneumonitis (0/1), 
pancreatitis (0/1) and grade 3-4 toxicities (0/20).Dose reduction and/or delay 
of treatment were required in any patients with G and 18% with E.
Conclusion: In this retrospective analysis the efficacy of G and E in terms 
of Orr and survival have been confirmed in an unselected group of patients 
with advanced NscLc. the tKI gefitinib seems to have similar efficacy but 
with a better profile of toxicity than erlotinib.
Disclosure: All authors have declared no conflicts of interest.
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DRUGS FREE OF CHARGE IN LUNG CANCER TRIALS: 
AN ANALYSIS OF PHARMACEUTICAL COST SAVINGS
c. Genova1, N. Diaz Gaitan1, E. rijavec1, G. barletta1, c. sini1, M.G. Dal 
bello1, c. Donato1, P. Pronzato2, F. Grossi1 1Lung Cancer Unit, National 
Institute for Cancer Research, Genova, ITALY, 2Medical Oncology A, National 
Institute for Cancer Research, Genova, ITALY
Background: the cost of new anticancer drugs has dramatically increased in 
recent years. the global financial crisis forces to implement countermeasures 
in order to limit pharmaceutical expenses. sponsored clinical trials that pro-
vide drugs free of charge may be a useful tool in order to reduce drug costs. 
the aim of this analysis is to evaluate the effect of clinical trials on pharma-
ceutical expenditure savings. 
Methods: We evaluated the cost of drugs administered in clinical practice and 
in clinical trials (considering only the standard regimens that were adminis-
tered also in clinical practice) in 2010 at the Lung cancer Unit of the National 
Institute for cancer research in Genova, Italy. the cost of drugs was cal-
culated on the price charged at our Institute in 2010. the supposed cost of 
experimental treatments replacing standard therapy was converted in the cost 
of the treatments that would have been chosen in clinical practice, considering 
histology, line of treatment and number of administered cycles. 
Results: From 1/1/10 to 12/31/10, 197 patients affected by lung cancer or 
pleural mesothelioma were treated. 152 patients (77.6%) received treatment 
in clinical practice or in non-sponsored trials (18 patients in 4 trials), while 44 
(22.4%) received a standard treatment in one of the 12 sponsored clinical trials 
recruiting in 2010. the total number of administered cycles was 579, of which 
436 (75.3%) in clinical practice or non-sponsored trials and 143 (24.7%) in 
sponsored clinical trials. the overall cost of care (excluding supportive care 
and hospitalization) was 990.688,69 Euro. the cost of drugs administered in 
clinical practice or in non-sponsored trials was 725.665 Euro (73,2%), while 
the cost of drugs administered in clinical trials was 265.023,69 Euro (26,8%). 
Conclusions: Participation in sponsored clinical trials in which drugs are pro-
vided free of charge offers substantial savings on drug expenditure; further-
more, this analysis does not take into account the grant which covers the cost 
per patient of radiological and laboratory exams, as well as operating costs of 
the study (study coordinators, research nurses, sub-investigators).
Disclosure: All authors have declared no conflicts of interest.
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EFFECT OF ENOBOSARM ON OVERALL SURVIVAL IN 
A PHASE IIB STUDY IN NSCLC PATIENTS WITH >8% 
WEIGHT LOSS
s. Dodson, M. Hancock, M.A. Johnston, M. steiner Medical Affairs, GTx, 
Inc., Memphis, TN, UNITED STATES OF AMERICA
Background: At diagnosis, up to 50% of lung cancer patients have substan-
tial weight loss, increasing to >80% prior to death. Much of this weight loss 
is attributed to muscle wasting-leading to a decline in physical function and 
other detrimental effects. studies show that NscLc patients with wasting at 
diagnosis are less able to tolerate chemotherapy, have worse outcomes and 
shorter survival. the negative impact of wasting underscores the importance 
of preventing and treating this condition early. We conducted a Phase IIb, 
randomized, double-blind, placebo-controlled, study to evaluate the effect of 
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enobosarm, a selective androgen receptor modulator, on muscle wasting and 
physical function in patients with cancer.
Methods: subjects (n=159) were randomized to oral enobosarm or placebo for 
16 weeks. subjects were males >45y and postmenopausal females, had experi-
enced ≥2% weight loss in the 6 months prior to randomization, and had NscLc, 
colorectal cancer, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia or 
breast cancer. the primary endpoint was change in total lean body mass. We 
report on overall survival in the entire study population and NscLc cohort 
based on weight loss of > or ≤8% in the 6 months prior to randomization. 
Results: In placebo subjects (Itt), overall survival was significantly (P=0.003, log 
rank) reduced in subjects with >8% weight loss compared to subjects with ≤8% 
weight loss. Among NscLc subjects (n=61) placebo subjects with >8% weight 
loss demonstrated a similar survival disadvantage (P=0.04); 4 month Kaplan-
Meier estimates 100% vs 49% ±14.8%. In enobosarm treated subjects in the Itt 
and NscLc groups, baseline weight loss did not negatively affect survival.
Conclusions: Preceding weight loss among NscLc patients not treated with 
enobosarm is predictive of decreased survival. NscLc subjects randomized 
to placebo with >8% weight loss at baseline were 2x more likely to die than 
subjects with ≤8% weight loss. In the enobosarm group baseline weight loss 
was not predictive of survival. these data suggest that enobosarm may over-
come the negative prognostic effect of >8% weight loss. Further research is 
needed to assess the effect of enobosarm on overall survival.
Disclosure: s. Dodson: I am member of senior leadership and own stock in 
the Gtx. M. Hancock and M.A. Johnston: I am an employee and own stock in 
Gtx, Inc. M. steiner: I am cEO, on the board and own stock in Gtx, Inc.
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EFFECT OF ENOBOSARM, A SELECTIVE ANDROGEN 
RECEPTOR MODULATOR, ON PHYSICAL FUNCTION IN 
NSCLC PATIENTS WITH MUSCLE WASTING
s. Dodson, M. Hancock, M.A. Johnston, M. steiner Medical Affairs, GTx, 
Inc., Memphis, TN, UNITED STATES OF AMERICA
Background: Muscle wasting in cancer patients leads to decline in physical 
function. At diagnosis, >50% of lung cancer patients have substantial wast-
ing, increasing to >80% prior to death. Data shows that NscLc patients with 
muscle wasting are less likely to tolerate chemotherapy, have worse outcomes 
and shorter survival. this has detrimental consequences early in a patient’s 
malignancy, underscoring the importance of diagnosing and treating this con-
dition at an early stage. Literature shows that a 10% improvement in physi-
cal function is a substantial clinically meaningful benefit. We conducted a 
randomized, double-blind, placebo-controlled study to evaluate the effect of 
enobosarm on muscle wasting in physical function in patients with cancer. 
Methods: subjects (n=159) were randomized to oral enobosarm or placebo 
for 16 weeks. subjects were males >45y and postmenopausal females, with 
≥2% weight loss in 6 months prior to randomization and had NscLc, col-
orectal cancer, non-Hodgkins lymphoma, chronic lymphocytic leukemia, or 
breast cancer. the primary endpoint was change in lean body mass and QOL 
and physical function as secondary endpoints. For this analysis, clinical ben-
efit is defined as 10% improvement in physical function. 
Results: 103 subjects (MItt) had stair climb assessed at baseline and week 
16. Enobosarm subjects demonstrated clinical benefit compared to placebo 
(P=0.03). Among NscLc subjects, 28 were included in the physical function 
analysis. 78% treated with enobosarm responded compared to 30% treated 
with placebo (P=0.02). Physical function was postitivley correlated with QOL 
as assessed by the FAAct questionnaire further substantiating clinical benefit 
(spearman correlation coefficient = 0.60, P=0.001). 
Conclusions: Enobosarm was well tolerated ad showed statistically significant & 
clinically relevant improvement in physical function and NscLc subjects. clinical 
benefit in stair climb power correlated with a clinically relevant improvement in 
quality of life. these data provide evidence that enobosarm may play an important 
role in management NscLc by improving physical function & quality of life.
Disclosure: s. Dodson: I am a member of senior leadership and own stock in 
Gtx, Inc. M. Hancock and M.A. Johnston: I am an employee and own stock in 
Gtx, Inc. M. steiner: I am the cEO, on the board and own stock in Gtx, Inc.
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PLEURO-PULMONARY TUBERCULOSIS FOLLOWING 
CHEMOTHERAPY FOR LUNG CANCER IN A HIGH 
TUBERCULOSIS PREVALENCE COUNTRY
N. singh, K. Madan, A.N. Aggarwal, D. behera Pulmonary Medicine, 
PGIMER, Chandigarh, INDIA
Background: chemotherapy (ctx) is a risk factor for occurrence of infections. 
tuberculosis (tb) is a common infection in high prevalence countries. Data on 
tb incidence following ctx for lung cancer (Lc) is limited. the current study 
was conducted to assess the incidence of pleuro-pulmonary tb following ctx 
for Lc at a tertiary care institute in North India. 
Methods: retrospective data analysis of newly diagnosed Lc patients receiving 
ctx over a three-and-half year period. Diagnosis of tb was made by presence 
of suggestive clinico-radiological features (fever, cough, pleuritic chest pain, new 
parenchymal infiltrates or new onset pleural effusion on chest imaging) along with 
demonstration of acid fast bacilli (AFb) in sputum/pleural fluid/bronchoalveolar 
lavage (bAL) fluid and/or growth of Mycobacterium tuberculosis on culture. For 
biopsy/cytology specimens, diagnosis of tb was established by demonstration of 
granulomatous inflammation with AFb. Descriptive statistics are used. 
Results: Of 763 patients diagnosed during the study period, those excluded from 
analysis were 14 who did not receive any form of definitive treatment, 23 with 
non-bronchogenic histologies and 64 who received oral EGFr-tKIs as first line 
(sole) treatment for non-small cell Lc. Among the remaining 662 Lc patients 
who received ctx and comprised the study population, six (0.9%) patients devel-
oped tb (four pulmonary and two pleural). Diagnosis was by sputum micros-
copy, bAL fluid microscopy and pleural biopsy in two patients each. tb involved 
right lung/pleura in five patients and all patients developed tb on same side as 
primary tumor. All patients were treated with standard four drug anti-tubercular 
therapy. Demographic, treatment and survival profile is presented in table. 
Conclusions: Incidence of pleuro-pulmonary tb following ctx for Lc is 
low even in a high prevalence country like India. Occurrence of tb on same 
side as primary tumor in all patients warrants further studies for causality and 
mechanism determination.
Patient Characteristics:
Age^ 47.3 (15.6) years 
Males 5 (83.3%) 
current/ex-smokers 3 (50.0%) 
Histology 
squamous 2 (33.3%) 
small cell 2 (33.3%) 
Non-squamous NscLc 2 (33.3%) 
stage IIIb-IV at Lc Dx 4 (66.7%) 
Extra-thoracic metastasis at Lc Dx 3 (50.0%) 
baseline performance status of EcOG 0-1 5 (83.3%) 
cycles of chemotherapy* 4.5 (2-6) 
Objective response to chemotherapy 
Partial response 4 (66.7%) 
stable disease 2 (33.3%) 
time interval between Lc Dx and tb Dx* 144 (56-317) days 
time interval between last chemotherapy  
cycle and tb Dx* 
55 (36-182) days 
Overall survival* 312 (200-504) days 
survival after tb Dx* 174 (100-199) days 
^Mean (standard deviation); *Median (inter-quartile range); Lc = lung cancer; tb 
= tuberculosis; Dx = diagnosis
Disclosure: All authors have declared no conflicts of interest.
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EFFICACY AND FEASIBILITY OF GEMCITABINE AND 
CARBOPLATIN AS FIRST-LINE CHEMOTHERAPY IN 
ELDERLY PATIENTS WITH ADVANCED NON-SMALL 
CELL LUNG CANCER
K. Lim, W. Lee, K. Kim, H. Lee, s. Han, s. song, W.J. Kim, s. Lee Internal 
Medicine, Kangwon National University School of Medicine, Chuncheon-si, 
KOREA
Background: Although platinum-based chemotherapy is a standard first-line 
treatment in advanced non-small cell lung cancer (NscLc), further research 
for the safety and efficacy of combination chemotherapy in elderly patients 
has been required. the purpose of this study was to evaluate the efficacy and 
safety of gemcitabine and carboplatin as first-line treatment in elderly patients 
with advanced NscLc and to evaluate the prognostic factors.
Methods: Eligibility included: 1) age 70-89, 2) histologically confirmed 
NscLc, 3) chemotherapy-naive, 4) advanced disease with stage IIIb or IV, 
5) EcOG Ps 0-2, 6) adequate organ function. Patients received intravenous 
carboplatin (AUc=5) on day 1 and gemcitabine (1000 mg/m2) on days 1 and 
8, every 3 weeks. response evaluation was done every 6 weeks with rEcIst 
criteria and toxicity was evaluated with NcI-ctcAE.
Results: between May 2007 and Oct 2011, 40 patients were enrolled. Median age 
was 73.9 years (range: 70.0–84.6), and there were 27 men (67.5%). 37 patients 
(92.5%) had EcOG Ps 0-1 and 3 patients (7.5%) had Ps 2. Histology was 
squamous cell carcinoma (42.5%) and adenocarcinoma (57.5%). the median 
number of cycles was 4 (range: 1-6). best responses were partial response in 
22 (55.0%) patients and stable disease in 13 (32.5%). Overall response rate was 
55.0% (95% cI: 39.8–69.3). the median progression-free survival (PFs) and 
overall survival (Os) were 5.9 months (95% cI: 4.5-7.3) and 9.6 months (95% 
cI: 8.2–11.0), respectively. 6-month PFs rate and 1-year survival rate were 
49.0% (95% cI 32.9–62.5) and 34% (95% cI: 22.1-50.5), respectively. Grade 4 
hematologic toxicities were neutropenia (7.5%), thrombocytopenia (7.5%) and 
anemia (5.0%). Frequent non-hematological toxicities were fatigue (40.0%), 
stomatitis (15.0%), and nausea/vomiting (10.0%), which were predominantly 
Gr 1/2. Histologic subtype of adenocarcinoma was a significant prognostic fac-
tor for PFs (p=0.024) and also had favorable tendency to Os.
Conclusions: Gemcitabine and carboplatin combination chemotherapy can 
be considered as an effective and manageable treatment option in elderly 
advanced NscLc patients with good performance status.
Disclosure: All authors have declared no conflicts of interest.
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MANAGEMENT OF ELDERLY ADVANCED NON-SMALL 
CELL LUNG CANCER (NSCLC) PATIENTS: ANALYZING 
“REAL-LIFE” PRACTICE PATTERNS
F. El-Gehani, Z. breckenridge, A. Dechaphunkul, s. Ghosh, r. sangha Dept. 
of Medical Oncology, University of Alberta, Edmonton, AB, CANADA
Background: In advanced EGFr wild-type NscLc, platinum-doublet che-
motherapy (ct) combinations are commonly accepted as the reference regi-
mens for fit patients (pts), with demonstrated improvement in overall survival, 
quality of life and symptom control. Greater than 40% of advanced NscLc 
pts are aged ≥ 70 yrs and evidence supports benefit of the elderly population 
with combination ct in those with a good performance status (Ps) and lim-
ited comorbidities. Given the paucity of data in the non-clinical trial setting, 
we explored the practice patterns in managing this subpopulation in a large 
North American cancer centre.
Methods: A population-based, retrospective, chart review was conducted in 
elderly (≥ 70 yrs) advanced EGFr wild-type or unknown NscLc pts who were 
diagnosed in Northern Alberta, canada from 2007 to 2009. baseline clinical 
characteristics, treatments, toxicity data, and patient outcomes were collected.
Results: From 2007 to 2009, 349 elderly pts with stage IV NscLc were diag-
nosed. Age range was 70 to 93 yrs with a median of 76 yrs. two-hundred ninety 
pts (83%) received best supportive care (bsc) alone; key factors influencing 
this decision were poor Ps (EcOG Ps ≥ 2; 75%), patient choice (14%), and 
significant comorbidities (8%). Of 59 elderly pts (17%) who received ct, 51 
(86%) received platinum-doublet ct with a median of 4 cycles per patient. A 
significant proportion (44%) had delays in administration of ct due to hemato-
logic and non-hematologic toxicities. this resulted in dose reductions for 14% 
of elderly pts. Although there was not a cr, 7 pts (12%) had a Pr, and 26 pts 
(27%) had sD for a disease-control rate of 38%. Median overall survival (Os) 
was 11.6 months for those receiving ct and 2.3 months for bsc alone (1-yr Os 
of 49% and 12%, respectively). 
Conclusions: this study demonstrates that in the elderly Albertan population, 
a significant majority of pts do not receive ct, primarily due to poor Ps. this 
possibly explains the underrepresentation of these pts in lung cancer clinical 
trials. For those elderly pts who are fit to receive ct, survival is comparable to 
the broader population of advanced NscLc but is hindered by toxicities and 
subsequent delays in ct administration. Further interrogation into the risk to 
benefit ratio determinants are needed.
Disclosure: All authors have declared no conflicts of interest.
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EFFICACY AND SAFETY OF PEMETREXED AS SECOND-
LINE TREATMENT IN ELDERLY PATIENTS (PTS) WITH 
ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG 
CANCER (NSCLC): A RETROSPECTIVE ANALYSIS
A. Passaro1, A. Pochesci1, M. Palleschi1, A. Pellegrino2, M.A. Fabbri3, 
F. Urbano1, V. Gentile1, c. Manai1, I. Pavese2, E. cortesi1 1Medical Oncology 
Division, Sapienza - University of Rome, Rome, ITALY, 2Department of 
Oncology, San Pietro Fatebenefratelli Hospital, Rome, ITALY, 3Department 
of Medical Oncology, Ospedale Belcolle, Viterbo, ITALY
Background: In elderly pts with advanced NscLc, and no major co-morbid-
ities, chemotherapy or target agents, are the standard of care in second-line 
treatment, after a first platinum-based regimens. No randomized clinical trial 
evaluating age related efficacy and safety of pemetrexed.
Patients and methods: We retrospectively analysed elderly pts (≥65), with no 
major co-morbidities, with diagnosis of non-squamous advanced/metastatic 
NscLc, treated with pemetrexed (500 mg/m2, d 1, every 3 wks), after first-line 
platinum-based chemotherapy. In an exploratory analysis, we considered the fol-
lowing factors in order to evaluate a potential influence on response and safety: 
age (<75 vs ≥75), adenocarcinoma (adk) histology vs other non-squamous carci-
noma (non-scc), performance status (0 vs 1/2), presence of brain metastases.
Results: 65 elderly pts (median age 71, range 60 to 85) were evaluated. Pts 
were (%): male 72; stage IV 77; EcOG Ps 0/1-2 58/42; adk/large cell/other 
non-scc 77/8/15; previous cisplatin/carboplatin 56/44; brain metastases 26. 
Median cycles of pemetrexed were 5.8. Orr was 43.1%. cr was reached 
in 2 pts (3.1%); Pr in 26 pts (40%), sD in 27 pts (41.6%) and PD in 10 pts 
(15.3%). the overall population median PFs was 4.1 months (95% cI: 2.9 - 
5.4). Median PFs (months) according to different factors resulted: 2.9 vs 4.2 
(p=0.18) in pts with brain metastases vs no; 4.4 vs 1.4 (p<0.0001) for adk vs 
other non-scc and in pts with EcOG Ps 0 vs 1/2 was 4.6 vs 2.5 (p=0.009). 
No significant PFs differences between the age groups (<75 vs ≥75) were 
observed (4.4 vs. 3.5; p = 0.7). Low incidence of clinically significant grade 
(G) 1/2 adverse events (AEs) occurred. G3 hematologic AEs were (%): ane-
mia 4.6; neutropenia 9.2; piastrinopenia 6.2. G3 non-hematologic AEs were 
(%): fatigue 9.2, nausea 4.6; vomiting, diarrhea, rash, mucositis and > ALt 
were under 2%. No pts developed neurosensory toxicities.
Conclusion: Long-term survival and good tolerability resulted in our elderly 
pts treated with pemetrexed in second-line; in this setting, single agent may be 
recommended too, in pts with a good EcOG Ps, independently from age.
Disclosure: All authors have declared no conflicts of interest.
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ROLE OF COMBINED ERLOTINIB AND TEMOZOLAMIDE 
IN ADENOCARCINOMA LUNG WITH BRAIN 
METASTASES IN ELDERLY PATIENTS
M.K. behera1, A. sharma2, P.K. Julka1, G.K. rath2 1Radiation Oncology, Dr. 
Bra Irch, All India Institute of Medical Sciences (AIIMS), New Delhi, INDIA, 
2Dept of Radiation Oncology, All India Institute of Medical Sciences, New 
Dehli, INDIA
Aims: to evaluate the feasibility and tolerance of Erlotinib and temozolamide 
in elderly patients of adenocarcinoma lung with brain metastases.
Background: brain metastases are found in ~10-25% at the time of diagnosis, 
and ~40-50% of all patients with lung cancer develop brain metastases during 
the course. Most patients present with multiple lesions. brain metastases are 
usually associated with poor outcomes and shortened survival of 6 months or 
less. standard treatment options include symptomatic therapy with steroids 
and whole-brain radiotherapy (Wbrt). the poor outcomes and relapses fol-
lowing Wbrt alone indicate a need for new therapeutic options.
Material amd methods: A total of 9 elderly patients of biopsy proven 
adenocarcinoma lung with brain metastases (on MrI) were analyzed from 
July 2010 to December 2011 with respect to patient’s characteristics, che-
motherapy, radiotherapy and treatment outcomes. the patients’ age ranged 
from 58 to 75 years. All the patients were planned for palliative radiation of 
30 Gy/10#/2 weeks to local disease with Wbrt of 20 Gy/5#/1 week with 
concurrent temozolamide@ 75mg/m2 followed by assessment for further 
therapy after 3 weeks of radiation. All the patients were evaluated 3 weekly 
for assessment of symptom relief and improvement or progression.
Results: All the patients completed the scheduled radiation with oral ste-
roids. After 3 weeks all the patients were started on Erlotinib@ 150 mg, 
daily and temozolamide@ 150-200 mg/m2, D1-5, 4 weekly. 3 of the patients 
progressed and died between 3 and 6 months. 1 patient defaulted during the 
radiation therapy and another after completion of 6 cycles of oral chemother-
apy. Only 4 patients could complete the 12 cycles of oral chemotherapy with 
temozolamide and Erlotinib, 4 weekly. Only 1 patient needed dose reduction 
of Erlotinib to 100 mg due to grade III rashes in 3rd cycle. side effects were 
managed conservatively in rest. the patients who improved after local and 
brain rt have shown to tolerate the further oral chemotherapy. these patients 
are still alive with the metastatic disease.
Conclusion: the combination of Erlotinib with temozolomide represents a 
promising strategy for treating brain metastases in adenocarcinoma lung and 
appears to be safe and tolerable.
Disclosure: All authors have declared no conflicts of interest.
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ERLOTINIB AS FRONTLINE TREATMENT FOR ELDERLY 
PATIENTS (P) WITH ADVANCED NON-SQUAMOUS NON-
SMALL CELL LUNG CANCER (NSNSCLC): GGCP044/09 
STUDY
J.L. Fírvida Pérez1, s. Vázquez Estévez2, J. casal rubio3, M. Alonso bermejo4, 
s. Varela Ferreiro5, M.J. Villanueva silva3, J. Afonso Afonso6, O. Fernández 
calvo4, K. Areses4, b. campos balea5 1Department of Medical Oncology, 
Complexo Hospitalario de Ourense, Ourense, SPAIN, 2Medical Oncology, 
Complexo Hospitalario Universitario de Vigo, Lugo, SPAIN, 3Complexo 
Hospitalario Universitario de Vigo, Vigo, SPAIN, 4Complexo Hospitalario 
de Ourense, Ourense, SPAIN, 5Hospital Universitario Lucus Augusti, Lugo, 
SPAIN, 6Complejo Hospitalario Arquitecto Marcide, Ferrol, SPAIN
Background: NscLc is primarily a disease of older people with a median 
age of approximately 70 years (y) at diagnosis. Platinum combination chemo-
therapy (ct) has shown to be more effective than single agents but it is asso-
ciated with more toxicity. Erlotinib is an EGFr tK inhibitor with a favourable 
toxicity profile and its oral administration makes it suitable to treat elderly 
p. No much is known about its efficacy and toxicities in this subpopulation, 
often under-represented in clinical trials. this Galician study aims to evaluate 
the efficacy and safety of erlotinib as 1st-line treatment (tx) for elderly p with 
advanced nsNscLc. 
Material and methods: Elderly p (≥70 years old) with stage IIIb/IV nsN-
scLc were included in this prospective observational study. Erlotinib was 
orally administered at a dose of 150 mg daily until disease progression or 
intolerable toxicity. PFs (primary objective) and Os were measured from 
time of diagnosis. 
Results: A total of 31 p were enrolled. baseline characteristics: Mean age 
78 y (range 70-85); female 67.7%; adenocarcinoma (including bAc) 90.3%; 
never/current/former smokers (%): 54.8/16.1/22.6 (6.5% unknown), stage IV 
84%; EcOG Ps 0/1/2 (%): 6.4/45.2/48.4. the median PFs was 6.4 and the 
median Os was 9.9 months. Out of 26 evaluable p, 8 had Pr and 8 sD, for 
an Orr of 30.8% and a Dcr of 61.6%. the most common adverse event 
was skin rash, 38.7% (9.6% grade 3-4), diarrhoea, 25.8% (3.2% gr. 3-4) and 
asthenia, 19.3% (no gr 3-4 were reported). 5 p (16.1%) needed dose reduc-
tion and 3 p withdrew the tx due to grade 3 diarrhoea, eye perforation and 
esofaghitis, respectively. 
Conclusions: these results in real-life settings confirm that erlotinib is an active 
and well tolerated agent as frontline tx in elderly p (≥70) in nsNscLc. response 
rate is similar to that achieved with ct in younger people; benefit in PFs is mod-
est, but median Os is acceptable, taking into account that half of the p had a Ps 
of 2. EGFr mutation testing should be strongly encouraged among elderly p.
Disclosure: All authors have declared no conflicts of interest.
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A PHASE II STUDY OF WEEKLY PACLITAXEL 
COMBINED WITH CARBOPLATIN VERSUS THE 
STANDARD EVERY 3-WEEKS PACLITAXEL AND 
CARBOPLATIN FOR ELDERLY PATIENTS WITH 
PREVIOUSLY UNTREATED ADVANCED NON-SMALL 
CELL LUNG CANCER
H.M. El shenshawy1, s. taema1, E. ElZahaaf1, D. sharaf Eldeen1, W. 
Elbeshbeshi1, A. Fathy2 1Clinical Oncology and Nuclear Medicine, Mansoura 
University Hospital, Mansoura Faculty of Medicine, Mansoura, EGYPT, 
2Thoracic Medicine, Mansoura University Hospital, Mansoura Faculty of 
Medicine, Mansoura, EGYPT
Background: Paclitaxel and platinum-based chemotherapy is considered to 
be a standard approach for locally advanced and metastatic non-small cell 
lung cancer (NscLc). In recent years, paclitaxel on a weekly schedule in 
combination with carboplatin has been widely used because it is associated 
with a lower incidence of neuropathy and myelosuppression. Otherwise, only 
a few studies are available in elderly patients with NscLc.
Purpose: the aim of our study was to evaluate the efficacy and safety of weekly 
paclitaxel combined with carboplatin compared with the classic 3-weekly 
schedule of paclitaxel and carboplatin as initial therapy and the feasibility of 
subsequent maintenance therapy versus observation in elderly patients with 
locally advanced ( stage IIIb) and metastatic (stage IV) NscLc.
Methods: Eighty-six patients ≥ 65 years with stage IIIb-IV NscLc were 
randomly assigned to one of the following arms: arm1, paclitaxel 90 mg/m2 
weekly for 3 of 4 weeks with carboplatin (area under the curve {AUc} =6) 
on day 1 of each 4 week cycle; and arm 2, paclitaxel 200 mg/m2 with carbo-
platin (AUc=6) on day 1 of each 3-week. After four cycles of chemotherapy, 
those with objective response or stable disease were randomized to weekly 
paclitaxel (70mg/m2, 3 of 4 weeks) or observation as maintenance therapy. 
Primary end point was response while second end points included survival 
and toxicity.
Results: All patients were evaluable for response, overall responses were 
recorded in 42.9% in arm 1 versus 31.8% in arm 2; stable disease was 38.1% 
in arm 1 versus 27.3% in arm 2 and progressive disease was 19% in arm 1 
versus 40.9% in arm 2. the median time to progression and median survival 
times were 7 months and 10.8 months in arm 1 versus 5.6 months and 9 
months in arm 2, respectively. the 1-year survival rates were 47.6% in arm 
1 versus 36.4% in arm 2. Grade 3/4 anemia was more common in arm 1 
(23.8%) than arm 2 (9.1%). Grade 3/4 neutropenia and febrile neutropenia 
S72 Copyright © 2012 by the European Lung Cancer Conference and the International Association for the Study of Lung Cancer
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occurred in 14.3% and 4.7% in arm 1 versus 22.7% and 9.1% in arm 2. Grade 
2/3 neuropathy occurred in 4.7% in arm 1 versus 13.6% in arm 2.
Conclusions: Efficacy was similar between the weekly regimen and the stan-
dard regimen of carboplatin and paclitaxel for elderly patients with advanced 
NscLc and may be advantageous based on its favorable tolerability profile.
Disclosure: All authors have declared no conflicts of interest.
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A PHASE I-II EVALUATION OF THE SAFETY AND 
EFFICACY OF THE ORAL HSP90 INHIBITOR DEBIO 0932 
IN COMBINATION WITH SOC IN FIRST- AND SECOND-
LINE THERAPY OF STAGE IIIB OR IV NSCLC - THE 
HALO STUDY (HSP90 INHIBITION AND LUNG CANCER 
OUTCOMES)
H. van Ingen1, D. Purcea2, s. brienza1, L. Paz-Ares3 1Medical Affairs, 
Debiopharm SA, Lausanne, SWITZERLAND, 2Biostatistics, Debiopharm SA, 
Lausanne, SWITZERLAND, 3Oncology Service, Hospital Virgen del Rocío, 
Sevilla, SPAIN
Background: Debio 0932 is an oral second-generation Heat shock protein 
90 (HsP90) inhibitor, structurally unrelated to geldanamycin. In pre-clinical 
models and in the recently completed dose-escalation part of a Phase I study 
(Nct01168752), Debio 0932 has shown promising signs of efficacy in Non 
small-cell Lung cancer (NscLc). Further investigations into the potential 
role of Debio 0932 in NscLc are warranted.
Study design: this study will include patients with advanced NscLc (stage IIIb 
or IV) without known EGFr mutation, and will consist of three parts. Part A is an 
open-label dose escalation study of Debio 0932 in combination with standard of 
care (sOc) in patients who are candidates for first-line- or second-line treatment. 
First-line sOc consists of cisplatin + gemcitabine in case of squamous histology, 
and cisplatin + pemetrexed in case of non-squamous histology. second-line sOc 
consists of docetaxel. Part b is a randomized, double-blind, placebo-controlled 
study of Debio 0932 in combination with first-line sOc in 138 patients who did 
not receive previous systemic treatment for advanced NscLc. Patients who sub-
sequently develop progressive disease in Part b will enter into Part c, in which 
a second randomization will assign patients to double-blind treatment with doc-
etaxel + placebo or docetaxel + Debio 0932. Approximately 100 patients are 
expected to enter Part c. Part b has a primary endpoint of PFs at 6 months; 
key secondary endpoints include best overall response rate, duration of objective 
response, change in tumour size from baseline until 6 months, and Os. Part c 
has a primary endpoint of change in tumour size from baseline until 6 months; 
key secondary endpoints include best overall response rate, duration of objective 
response, PFs at 6 months, and Os. Potential pharmacogenomic, tumour phar-
macogenetic, proteomic, and pharmacogenetic factors predictive of response to 
Debio 0932 will be assessed.
Conclusion: this international multi-center study will investigate the role of 
Debio 0932 in the first- and second line treatment of advanced NscLc. study 
results are expected in 2014.
Disclosure: H. van Ingen and D. Purcea: I am an employee of Debiopharm. s. 
brienza and L. Paz-Ares: I am a consultant to Debiopharm.
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BEVACIZUMAB (B), CISPLATIN (C) AND PEMETREXED 
(P) PLUS MAINTENANCE B IN CHEMO-NAïVE PATIENTS 
(PTS) WITH ADVANCED NON-SQUAMOUS NON-SMALL 
CELL LUNG CANCER (NSNSCLC): A PHASE II STUDY
G. Lopez Vivanco1, s. carrera revilla1, A. sancho Gutierrez1, I. Marrodan 
ciordia1, E. Azkona Uribelarrea1, E. Iruarrizaga Ovejas1, I. rubio Etxebarria1, 
J.V. cardona2, A. Muñoz Llerena1 1Oncology, Hospital de Cruces, Bilbao, 
SPAIN, 2Medical Department, Roche Farma, S.A., Madrid, SPAIN
Background: b in combination with platinum doublets followed by continu-
ation maintenance with b prolongs survival and delays progression in chemo-
naïve pts with advanced (nsNscLc). P in combination with c is efficacious 
in advanced nsNscLc as frontline treatment. this phase II study aims to 
evaluate the efficacy and safety of b, c and P plus maintenance b in chemo-
naïve pts with advanced nsNscLc.
Methods: chemo-naïve pts with unresectable stage IIIb or IV nsNscLc 
were treated of c (75 mg/m2), P (500 mg/m2), and b (7.5 mg/kg) on day 
1 every 21 days up to 6 cycles. Pts with response or stable disease (sD) 
received maintenance b (7.5 mg/kg) every 21 days until disease progres-
sion or unacceptable toxicity. the primary endpoint was median progression 
free survival (PFs). secondary endpoints included objective response rate 
(Orr), overall survival (Os), safety and analysis of K-ras mutations and 
plasma VEGF levels.
Results: From 4/09 to 12/11, 27 pts were enrolled in the study. Data of 21 
pts are presented. Median age was 58 years (range 42-74); male/female (%): 
81/19; EcOG 0/1 (%): 5/95; adenocarcinoma/large cell carcinoma (%): 95/5. 
Median follow-up is 4.7 months. 53% of pts received at least 6 cycles of 
treatment and 20% received up to 12 cycles. Among the 15 pts assessable for 
response, the Orr was 47% (95% cI, 21-73) and disease control rate was 
87%. Median PFs was 6.0 months (95% cI, 1.9-7.5). Grade 3/4 hematologic 
toxicity was neutropenia (9%/0). Most frequent grade 3/4 non-hematologic 
toxicities were fatigue (29%/0), venous thrombosis (14%/0), pulmonary 
embolism (9%/0) and dyspnea (5%/5%). there were no grade 3/4 hemor-
rhagic events. Data on survival and the analysis of K-ras mutations and VEGF 
levels will be presented.
Conclusions: treatment with b, c and P plus maintenance b is feasible and 
effective as front-line treatment of pts with advanced nsNscLc. these data 
provide further evidence that b may be used in combination with multiple 
standard, platinum-based doublets in this setting.
Disclosure: All authors have declared no conflicts of interest.
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MAINTENANCE THERAPY FOR ADVANCED NON-SMALL 
CELL LUNG CANCER: HOW DOES MY PATIENT FEEL 
ABOUT IT?
A. sibille, L. Peeters, b. Anrys, O. christel, c. Dooms, K. Nackaerts, I. 
Wauters, J. Vansteenkiste Leuven Lung Cancer Group, Respiratory Oncology 
Unit (Pulmonology), Leuven, BELGIUM
Introduction: several randomized trials on maintenance therapy (Mt) for 
metastatic non-small cell lung cancer (NscLc) have demonstrated benefit in 
progression-free survival. recent data also showed a significant overall sur-
vival (Os) gain for Mt with pemetrexed or erlotinib. Yet, in this non-curative 
treatment setting, the benefit has to be weighed against the potential burden of 
treatment. In the absence of data regarding patients’ preferences towards Mt, 
we undertook a patient survey.
Methods: this pilot study surveyed patients with stage IV NscLc sched-
uled for standard first-line platinum-based doublet chemotherapy out-
side of a therapeutic clinical trial. the survey could be carried out in a 
a ‘neutral’ hypothetical context, i.e. without consequences for Mt, as it 
was performed in the (short) timeframe where Mt was not reimbursed 
in belgium, and as this was made clear when the patients agreed to par-
ticipate. the patients had a questionnaire at baseline, after two, and after 
four cycles of chemotherapy, always before the result of tumour response 
assessment was known. ten questions covering the overall attitude towards 
Mt, the clinical benefit expected by patients, the acceptance of side-ef-
fects, and the modes of administration were autonomously completed by 
the patients.
Results: thirty patients were included. Overall, patients had a positive 
attitude towards Mt. At baseline, 60% were in favour, 40% were unsure, 
and no single patient was opposed. Mt resulting in an Os benefit of six, 
three or one month, respectively, was considered worthwhile by 83%, 
67%, and 43% of patients, respectively. With some decrease of these per-
centages over time, especially for the Os benefit of one month. Effects 
on symptom control were crucial for about 90% of the patients at any 
timepoint. there was a slight preference for oral versus i.v. administra-
tion. side effects were accepted by the majority as long as they were mild 
to moderate.
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Conclusion: Our survey showed that metastatic NscLc patients are in gen-
eral in favour of Mt. they expect either an Os benefit of at least several 
months, or better symptom control, in balance with mild to moderate side 
effects.
Disclosure: J. Vansteenkiste: Holder of Eli-Lilly chair in respiratory 
Oncology at Leuven University (research funding). All other authors have 
declared no conflicts of interest.
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A PHASE II STUDY OF PEMETREXED IN HEAVILY 
PRETREATED NON-SQUAMOUS NON-SMALL-CELL 
LUNG CANCER: HANSHIN ONCOLOGY  
GROUP 001
N. Katakami1, M. satouchi2, F. Imamura3, Y. Kotani4, s. Yokota5, t. 
Nishimura6, r. Kaji1, Y. Hattori7, s. Negoro8 1Division of Integrated Oncology, 
Institute of Biomedical Research & Innovation, Kobe, JAPAN, 2Department 
of Pulmonary Medicine, Hyogo Prefectual Cancer Center, Akashi, JAPAN, 
3Department of Pulmonary Oncology, Osaka Medical Center for Cancer and 
Cardiovascular Diseases, Osaka, JAPAN, 4Division of Pulmonary Medicine, 
Kobe University Graduate School of Medicine, Kobe, JAPAN, 5Department of 
Internal Medicine, Toneyama National Hospital, Toyonaka, JAPAN, 6Division 
of Respiratory Medicine, Kyoto-Katsura Hospital, Kyoto, JAPAN, 7Division of 
Respiratory Medicine, Hyogo Cancer Center, Akashi, JAPAN, 8Department of 
Medical Oncology, Hyogo Cancer Center, Akashi, JAPAN
Background: Pemetrexed has shown substantial activity in non-squamous 
non-small-cell lung cancer (NsqNscLc) and is one of the current standard 
agents in second-line settings due to its efficacy and favorable tolerabil-
ity profile. We conducted phase II study to evaluate the safety and effi-
cacy of pemetrexed in Japanese patients with previously treated, advanced 
NsqNscLc.
Patients and methods: Patients with stage IIIb (wet) or IV NsqNscLc, 
performance status (Ps) 0/1/2, previous two to five regimens of chemotherapy 
were enrolled and received pemetrexed (500 mg/m2 Day 1, every 21 days) 
until disease progression. the primary endpoint was progression-free sur-
vival (PFs). the secondary endpoints included overall survival (Os), objec-
tive response rate (Orr), disease control rate (Dcr), and safety. the trial has 
been registered at UMIN-ctr (www.umin.ac.jp/ctr/index/htm), registration 
identification number UMIN000002467.
Results: From August 2009 to May 2010, 46 patients were enrolled: 
median age 65 yrs; 52% women; Ps 0/1/2 26%/67%/7%, respectively; 
no. of previous treatment regimens were 2/3/4/5 in 48%/26%/24%/2%, 
respectively; EGFr activating mutation status was positive/wild/unknown 
for 30%/48%/22%, respectively. Median duration of follow-up was 13.5 
months, with 80% patients progressed and 50% deceased. Median of 7 
cycles of pemetrexed was administered. Median PFs was 4.2 months 
(95%cI: 3.3, 6.4). Median Os was 15.8 months (95%cI: 10.7, NA). Orr 
was 8.7% (95%cI: 2.4, 20.8) and Dcr was 63.0% (95%cI: 47.5, 76.8) 
(cr 0%, Pr 8.7%, sD 54.3% and PD 28.3%, by monitoring commit-
tee). In a total of 261 cycles of therapy, G3/4 neutropenia was observed in 
7%/3% cycles, G3/4 anemia in 1%/0% cycles, and G3/4 thrombocytopenia 
in 1%/0% cycles, respectively. the most common G3/4 non-hematologic 
adverse events were hyperkalemia (2%) and elevation of aminotransferase 
(2%).
Conclusions: treatment with pemetrexed in previously treated Japanese 
NsqNscLc patients is feasible and shows encouraging activity.
Disclosure: All authors have declared no conflicts of interest.
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CARBOPLATIN AND PEMETREXED FOR NON-
SQUAMOUS NON-SMALL CELL LUNG CANCER – 
OVERALL SURVIVAL AND TOXICITY
r. Andersen, A. Mellemgaard Oncology, Herlev University Hospital, Herlev, 
DENMARK
cisplatin/pemetrexed has been shown to be superior to cisplatin/gemcit-
abine in terms of overall survival for NscLc with non-squamous cell 
histology. Although cisplatin is advantageous when compared to carbo-
platin from a survival point of view, the toxicity is also more pronounced, 
and carboplatin is often preferred in palliative treatment. In clinical tri-
als, patients are highly selected, and results from randomised trials does 
not always transform to clinical practice. In this retrospective study we 
examine how patients with advanced, non-squamous NscLc respond to 
treatment with carboplatin plus pemetrexed (c/P). the study included all 
patients diagnosed with advanced or metastatic NscLc (not eligible for 
concomitant chemo-radiation) treated with c/P in the first-line setting. 
chemotherapy cycles were repeated every 3 weeks for up to 4 cycles. 
Patients were ct-scanned at baseline, after 3 cycles of chemotherapy and 
approximately every third month hereafter. Assessments of toxicity were 
made according to the common toxicity criteria (ctc, version 3.0). From 
November 2009 to December 2010, a total of 83 patients received first-
line treatment with c/P. Following first line therapy, 17 patients went on 
to receive curative intended radiation, survival data is only shown for the 
remaining 66 patients.
Performance status N Median overall survival, mths 
0 28 13.6 
1 29 8.0 
2 8 10.8 
3 1 3.0 
Adverse event N % 
Neutropenic fever, grade3+ 3 4 
Nausea, grade 3+ 2 2 
transfusion of rbc’s 17 20 
trombocytopenia, grade 4 3 4 
In our study an Os of 10.0 months was observed for patients in EcOG Ps of 
0 or 1. the corresponding Os in a Norwegian study of c/P was 8,7 months 
(EcOG Ps=0-1). A recent study which compared c/P with c/docetaxel 
showed an Os in the c/P arm of 14.9 months (EcOG Ps=0-2). toxicity rates 
were similar to those observed in clinical trials.
Disclosure: All authors have declared no conflicts of interest.
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PREDICTIVE FACTORS FOR LONG-TERM RESPONSE 
TO PEMETREXED TREATMENT IN ADVANCED NON-
SQUAMOUS, NON-SMALL-CELL LUNG CANCER 
PATIENTS
J. Kwon1, Y.J. Kim2, K. Lee2, H.I. Yoon2, J.H. Kim2, J. Lee2, c. Lee2, J.s. 
Lee2 1Department of Internal Medicine, Seoul National University Hospital, 
Seoul, KOREA, 2Department of Internal Medicine, Seoul National University 
Bundang Hospital, Seongnam, KOREA
Introduction: this study intended to identify the novel predictive factors 
affecting the duration of the response and survival rates in pemetrexed treat-
ment in advanced non-squamous, non-small cell lung cancer.
Method: We performed a retrospective analysis of the clinical 
and pathology data of all consecutive patients with advanced non-
squamous, non-small-cell lung cancer treated with pemetrexed as a 
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second or further line of treatment between June of 2003 and June of 
2010. the primary objective was progression-free survival, and sec-
ondary objectives were response rate, disease control rate, and overall 
survival.
Results: two hundreds and seventeen patients were enrolled. Median age 
at diagnosis was 63.2. Male patients represented 51.6% and patients in the 
never-smoker category accounted for 53.9% of all patients. In 176 patients 
(81.1%), adenocarcinoma was confirmed histologically. Pemetrexed was 
used as a second-line therapy in half of all patients (108 patients, 49.8%). 
the overall response rate was 15.6% and the disease control rate was 
59.4%. Median progression-free survival was 3.0 months and median over-
all survival was 10.3 months. In a multivariate analysis, good performance 
status and non-exposure to gemcitabine were independent predictive fac-
tors of progression-free survival. Pemetrexed was well tolerated in most 
patients, except for one patient who showed grade 3 hematologic toxic-
ity. treatment-related discontinuation due to pemetrexed-related adverse 
events was rare (3.7%).
Conclusion: the performance status and whether a patient had been exposed 
to gemcitabine were significant predictive factors of progression-free 
survival.
Disclosure: All authors have declared no conflicts of interest.
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THE EFFECT OF PEMETREXED CONTAINING  
REGIMES ON OVERALL SURVIVAL IN NON-SQUAMOUS 
NSCLC
r. stevens1, H. booth2, M. button1 1Oncology, Velindre NHS Trust, Cardiff, 
UNITED KINGDOM, 2School of Medicine, University of Leeds, Leeds, 
UNITED KINGDOM
Background: scagliotti’s paper in 2008 suggested that pemetrexed and cispl-
atin (pem-cis) produces longer overall survival (Os) compared to gemcitabine 
and cisplatin (gem-cis) in non-squamous NscLc. (12.6 vs 10.9 months). 
However, Gronberg’s paper in 2009 comparing pemetrexed and carboplatin 
(pem-carbo) and gemcitabine and carboplatin (gem-carbo) showed no differ-
ence in Os (7.8 vs 7.5 months). NIcE guidance in sep 2009 permits the use 
of pem-cis in 1st line locally advanced or metastatic non-squamous NscLc. 
this retrospective study examines the effect of the NIcE guidance on overall 
survival in non-squamous NscLc.
Methods: We included all non-squamous NscLc patients registered in our 
centre between 1st sep 2008 and 1st April 2011. those treated with palliative 
chemotherapy were identified and their clinical records examined. Overall 
survival (Os), progression free survival (PFs) and chemotherapy toxicities 
were recorded. Data was analysed using sPss.
Results: 111 patients were included in the study. 26 patients received 
pemetrexed containing regimes. 20 of these patients received pem-carbo 
due to a number of factors including patient co-morbidities and infu-
sion time. PFs in those receiving pemetrexed regimes was 3.8 months 
(cI 2.6 – 5.1) and 5.8 months for other platinum doublets (cI 4.5 – 7.2). 
Median Os was 13.7 months for those receiving pemetrexed regimes 
(cI 9.1 – 18.3) and 10.5 months for those receiving platinum doublets 
(cI 8.4 – 12.7). Pem-carbo did not appear inferior to pem-cis in PFs 
or Os. Overall, grade 3 or 4 toxicities were lower than reported in the 
clinical trials but haematological toxicities were high in the pem-cis 
patients.
Conclusions: Overall survival in this study matches those reported in the 
scagliotti paper and is better than those reported in the Gronberg paper 
despite the high frequency of carboplatin containing regimes. small numbers 
mean that no significant differences were found but the data supports the use 
of pemetrexed regimes in non-squamous NscLc. 
Disclosure: All authors have declared no conflicts of interest.
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CLINICAL PROFILE AND PATTERNS OF PROGRESSION 
(PD) OF PATIENTS (PTS) WITH ADVANCED NON-
SQUAMOUS NON-SMALL CELL LUNG CANCER 
(NSNSCLC) TREATED WITH FIRST LINE BEVACIZUMAB 
(B): AVVA STUDY
J. de castro1, M. Domine2, J.M. Garcia-bueno3, s. saura4, r. Garcia5, M. 
sereno6, O. Juan7, E. Pujol8, b. rubio9, M. cobo10 1Medical Oncology, 
Hospital Universitario La Paz, Madrid, SPAIN, 2Medical Oncology, Clin Nstra 
Senora de la Concepcion, Fundacion Jimenez Diaz, Madrid, SPAIN, 3Medical 
Oncology, Complejo Hospitalario Universitario de Albacete, Albacete, SPAIN, 
4Medical Oncology, Hospital Universitario de Gran Canaria Dr. Negrín, 
Las Palmas de Gran Canaria, SPAIN, 5Medical Oncology, Hospital General 
Universitario Gregorio Marañon, Madrid, SPAIN, 6Medical Oncology, 
Hospital Infanta Sofia, Madrid, SPAIN, 7Medical Oncology, Hospital Arnau 
de Vilanova, Valencia, SPAIN, 8Medical Oncology, Hospital Santa Bárbara, 
Soria, SPAIN, 9Medical Oncology, Centro Integral Oncologico Clara Campal, 
Madrid, SPAIN, 10Medical Oncology, Hospital Regional Universitario Carlos 
Haya, Malaga, SPAIN
Background: b in combination with platinum doublets prolongs survival and 
delays PD in chemo-naïve pts with advanced nsNscLc and its safety profile 
has been widely described in clinical trials. In this study we aim to evaluate 
the behavior, clinical profile and patterns of PD of real-life nsNscLc pts 
treated with b in 44 spanish institutions.
Methods: AVVA is a multicenter, epidemiological study to define the clini-
cal profile (gender, age, Ps, histology, stage, comorbidities, tumor load, tx, 
response and tolerability) and describe the patterns of PD. Pts diagnosed with 
advanced nsNscLc and evidence of PD after treatment (tx) with standard 
chemotherapy (ct) plus b up to 6 cycles followed by maintenance b were 
included.
Results: Data of 158 pts are presented. clinical profile was: median age 58 
years (range 34-79); male 65%; stage IV 91%; adenocarcinoma 77%; EcOG 
Ps 0/1/≥2 (%): 35/56/9; never/current/former smokers (%): 23/40/37. 64% of 
pts presented relevant concomitant disease at baseline (27% cardiovascular 
disease, 24% pulmonary disease). tx received: b plus carboplatin-doublet/
cisplatin-doublet/other (%) 70/25/5. Median no. of cycles for ct/b: 6/9. 
Patterns of PD: 44% presented high tumor load (tumor diameter ≥55mm and 
≥5 lesions); 97% of pts presented intra-thoracic disease, 53% presented extra-
thoracic disease and 13% only pulmonary disease. High tumor load was asso-
ciated with extra-thoracic disease (p<0.05). Orr was 53% (95% cI: 45-61) 
and disease control rate was 85%. best response was achieved after a median 
of 4 cycles (range 1-16). EcOG 0/1 at PD (%): 15/50. Median PFs was 7.7 
months (95% cI: 7.3-8.1). No differences were found in Orr or PFs accord-
ing to tumor load and intra/extra-thoracic disease. Grade 3/4 toxicities were: 
venous thrombosis (3.2%/0), proteinuria (0.6%/0), hemoptysis (0.6%/0), pul-
monary embolism (0/0.6%) and mucositis (0.6%/0).
Conclusions: b was effective in this real-life patients’ population, irrespec-
tive of tumor load and location of the disease. these results confirm the well-
established safety profile and the efficacy of b as frontline tx in nsNscLc.
Disclosure: All authors have declared no conflicts of interest.
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INCREASE IN THE ERYTHROCYTE MEAN 
CORPUSCULAR VOLUME (MCV) IN NON-SMALL CELL 
LUNG CANCER (NSCLC) PATIENTS TREATED WITH 
PEMETREXED-BASED CHEMOTHERAPY
E.s. santos1, c.A. Perez1, J.E. Gomez1, L. raez2 1Hematology/oncology, 
University of Miami/Leonard M. Miller School of Medicine, Miami, FL, 
UNITED STATES OF AMERICA, 2Thoracic Oncology Program, Memorial 
Cancer Institute, Pembroke Pines, FL, UNITED STATES OF AMERICA
Introduction: Pemetrexed (Pem) is approved for maintenance chemotherapy 
(MtX) in patients (pts) with advanced NscLc. Pem MtX has become a 
common practice either alone or in combination with bevacizumab (bev). 
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because Pem is well tolerated, pts can remain on therapy for a prolonged 
period. We report an increase in the erythrocyte McV without megaloblastic 
anemia and without apparent clinical significance.
Method: 45 non-squamous NscLc pts previously treated with Pem-based 
therapy either as initial treatment followed by MtX Pem or Pem/bev or sec-
ond line (2nd) therapy were studied. McV values were collected and those pts 
whose McV were above normal range (80-98 fl) at one point during therapy 
are reported. All patients received daily folic acid (FA) and vitamin b12 
(Vitb12) at least every 3 cycles of Pem. FA, Vitb12, homocysteine (Hom), 
and methylmalonic acid (MMA) levels were measured on those pts still on 
active MtX who also had high McV.
Results: 41 pts received platinum/Pem/bev triplet as initial therapy followed 
by Pem/bev or Pem MtX, 2 pts with Pem/bev as 2nd line, and 2 pts with Pem 
alone as 2nd. Median age: 64 years old (34-84); 27 pts males; 29 pts (64%) 
Hispanic. 27 pts (60%) developed an elevated McV (range: 98.1-114). For 
the entire cohort, median # cycles of Pem given 12 (range: 2-38). In those pts 
who had high McV, the median # of Pem cycles given was 12 (range: 5-38). 
All pts had normal or low McV prior to therapy. 32 pts had progressed and 
are not longer on MtX. 8/13 pts on active MtX had high McV; 5 of these 8 
pts were available for FA, Vitb12, MMA, and Hom measurement. All values 
were within normal limits. the McVs of these 5pts were: 101.6, 100, 102.1, 
102.2, and 104.8 from baseline values of: 74.4, 89.3, 92.8, 89.7, and 89.6, 
respectively. the hemoglobin levels of these pts were 12.2, 13.2, 15.4, 11.4, 
and 11 g/dL, respectively with normal Wbc and platelets.
Discussion: Pem is a structural analogue of FA and uses the same biochemi-
cal machinery as natural folates for membrane transport and intracellular 
polyglutamation. We report here patients treated with Pem for a prolonged 
periodwith proper FA and Vitb12 supplementation that have an increased 
McV with no abnormal levels of co-factors. Pem induces macrocytosis by 
a thymidylate-independent mechanism. this observation will be further vali-
dated in the other pts still on Pem-based MtX.
Disclosure:
E.s. santos and L. raez: Eli Lilly speaker bureau; no other conflict of inter-
est to declare. J.E. Gomez: Eli Lilly speaker bureau. No other relationship to 
disclose. All other authors have declared no conflicts of interest.
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CLINICAL USEFULNESS OF PULMONARY FUNCTION 
TEST IN PATIENTS WITH ADVANCED NON-SMALL CELL 
LUNG CANCER RECEIVING CHEMOTHERAPY
s.H. Lee1, J.H. Ha2, c.D. Yeo2, K.H. Park2, c.K. Park2, J.s. Kim2, M.s. 
Kim2, s.s. Kim2, s.J. Kim2 1Internal Medicine, St. Paul’s Hospital Catholic 
University of Korea, Seoul, KOREA, 2Internal Medicine, Catholic University 
of Korea, Seoul, KOREA
Background: chemotherapy for non-small ling cancer (NscLc) induces 
some change in pulmonary function. baseline and changes in specific pul-
monary function tests may be useful for prediction in survival.
Methods: A retrospective review of a prospective database of patients with 
NscLc who underwent platinum-based first-line chemotherapy, had pulmo-
nary function tests performed both before and after therapy was performed. In 
this study, patients who were treated with radiotherapy or lung resection were 
omitted. baseline values and change in the pulmonary function test (PFt) 
before and after treatment were entered into a multivariate model in which the 
dependent variable was survival.
Results: there were 53 patients. significant improvements (p < 0.05) were 
recorded after chemotherapy in forced expiratory volume in 1 second %pred. 
(FEV1, 8.04%pred.), FEV1/ forced vital capacity (FEV1/FVc, 4.09%pred.) 
and forced expiratory flow 25–75%pred. (FEF25-75%, 14.69%pred.). Lung 
diffusion for carbon monoxide adjusted with hemoglobin (DLcO adjusted) 
was significantly impaired after chemotherapy (10.02%; p=0.002). there 
was no significant difference in change of PFt according to tumor response 
and regimen. Univariate analysis of the factors affecting survival revealed 
that response to chemotherapy, baseline FVc %pred., FEV1 %pred., FEV1/
FVc and FEF25-75% in liter, changes after chemotherapy in residual volume 
(rV) in liter and DLcO adjusted were significant for survival. On multivariate 
analysis, progressive disease after chemotherapy (Hr 15.323; 95% cI 3.846-
61.042; p<0.001) and decrease is 8% or less in DLcO adjusted (Hr 3.082; 
95% cI 1.302-7.298; p=0.010) were factors for reduced survival.
Conclusions: A decrease in DLcO adjusted after chemotherapy may predict 
survival, especially if the decrease is 8% or less. these results should be con-
sidered in the patients with advanced NscLc who underwent chemotherapy.
Disclosure: All authors have declared no conflicts of interest.
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SPIROMETRY IN PATIENTS WITH STAGE IV NON-SMALL 
CELL LUNG CANCER (NSCLC)
r. Mendis1, c.F. McDonald2, t. John1, F.J. O’Donoghue2, s.c. White1 
1Department of Medical Oncology, Austin Hospital, Heidelberg, VIC, 
AUSTRALIA, 2Department of Respiratory and Sleep Medicine, The Austin 
Hospital, Heidelberg, VIC, AUSTRALIA
Background: symptom control is paramount in the palliative management 
of stage IV NscLc. Given the common risk factor of smoking, patients with 
NscLc are likely to have concurrent chronic obstructive pulmonary disease 
(cOPD). Once stage IV NscLc is diagnosed, the familiar focus tends to be 
palliation using chemoradiotherapy. the investigation and treatment of co-
existing cOPD may be neglected resulting in incomplete management of dys-
pnoea. We sought to determine the frequency of spirometry in patients being 
worked up for stage IV NscLc in a tertiary oncology unit.
Method: records of 130 current/ ex-smokers with stage IV NscLc were 
reviewed. symptoms at first consultation, co-morbidities, possible contrib-
uting factors to dyspnoea, use of bronchodilators as well as the results of 
any spirometry performed within six months prior or post first review were 
recorded. Global initiative for chronic obstructive lung disease (GOLD) stag-
ing system was used to document cOPD severity [stage I Forced Expiratory 
Volume (FEV) I ≥ 80%, stage II 50-80%, stage III 30-50%, stage IV <30%].
Results: Median age was 66.5 years (37-87) and 69% were male. At first 
consultation, 61/130 (46%) patients complained of dyspnoea. Of these, 75% 
(46/61) were not known to have prior cOPD. Only 14/46 (30%) were referred 
for spirometry, resulting in 10/14 (71%) being diagnosed with cOPD (40% 
GOLD stage I, 20% stage II, 20% stage III, 10% stage IV). twenty eight 
of the 46 patients had at least one other known factor potentially contribut-
ing to dyspnoea. Eighteen patients were breathless without a clear cause. 
However, only 6/18 (33%) were referred for spirometry and 4/6 patients 
(66%) had cOPD. the median pack years smoked was 37. Only 3/46 (6.5%) 
breathless patients were on bronchodilators at the time of first consultation 
as a result of spirometry in the context of their cancer diagnosis.
Conclusion: A minority of patients (30%) with stage IV NscLc and dys-
pnoea without known cOPD underwent spirometry; 71% had cOPD when 
tested. cOPD is a clear contributor to dyspnoea in this group of patients and 
warrants timely investigation and intervention. Any patient with a smoking 
history should have spirometry during work up for stage IV NscLc, regard-
less of other contributors to dyspnoea.
Disclosure: All authors have declared no conflicts of interest.
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SIMPLE MULTIPLES OF MEDIAN OVERALL SURVIVAL 
(OS) MAY NOT ESTIMATE SURVIVAL IN PATIENTS WITH 
NON-SMALL CELL LUNG CANCER (NSCLC) TREATED 
WITH FIRST-LINE EGFR-TARGETED AGENTS
A. Lerner, M. Williams Oncology, UCLH, London, UNITED KINGDOM
Introduction: For patients with incurable cancer, being able to estimate prog-
nosis remains important. Previous work has shown that simple multiples of 
the median Os can estimate survival in patients with lung and breast cancer 
receiving palliative chemotherapy1,2. We investigated whether this is true for 
NscLc patients treated with first-line EGFr-targeted agents.
Methods: We used similar methods to previous authors1. We initially con-
firmed our methodology in an analysis of 11 first-line chemotherapy trials for 
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NscLc. We then analysed all trials where at least 50 patients received first 
line therapy with only EGFr-targeted agents. We extracted data on a range of 
survival points (90%, 75%, 50%, 25% & 10%) from survival curves. We com-
pared these with calculated multiples (0.25, 0.5, 2 and 3) of the median Os.
Results: We identified 10 trials utilising EGFr targeted agents which met our 
criteria and included an Os curve. 5 trials used gefitinib, 5 used efitinib. table 
1 summarises the results. Only 48% of estimates of survival were within 0.75-
1.33 times the actual value. this is significantly worse than the agreement 
seen with conventional cytotoxic agents. In particular, 82% of the estimated 
values were incorrect for the worst case scenario (90% percentile), largely as 
a result of over-estimation.
Conclusions: this work shows that the relationship between median Os and 
other survival points, which holds for patients treated with chemotherapy, 
may not hold for those treated with first-line EGFr-targeted agents. Kiely et 
al1 observed that in patients treated with chemotherapy, the survival distribu-
tion was closely approximated by an exponential distribution. the incongru-
ence of our results with this relationship suggests that EGFr-targeted agents 
may impact differently on Os.
References: 1. Kiely et al. JcO February 1, 2011 29.4 456-463 2. Alam et al. 
13th World conference on Lung cancer, 2009
Table 1: Median OS & proportion of actual survival to estimated 
survival at different survival points.
Median 
OS Weeks 90% 75% 25% 10% 
chen 2012 51 2.6 1.3 0.8 NA 
Ebi 2008 51 2.1 1.5 1.0 NA 
Hesketh 2008 22 1.4 1.2 0.9 0.5
Jackman 2007 48 1.5 1.3 1.2 NA 
Maemondo 2010 134 0.7 0.8 NA NA 
Mitsudomi 2010 134 0.7 0.8 NA NA 
Mok 2008 80 1.5 0.9 NA NA 
rossel 2009 122 1.3 1.1 1.8 NA 
satoh 2011 standard dose 110 0.9 0.9 1.4 NA 
satoh 2011 Low dose 141 0.5 0.7 1.0 NA 
stinchcombe 2011 26 1.6 1.9 1.0 1.0 
Values in bold lie outside 0.75 – 1.33 range. NA: Missing Data
Disclosure: All authors have declared no conflicts of interest.
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FOLATE-CONJUGATED MESOPOROUS SILICA 
NANOPARTICLES FOR CYTOSOLIC PHOSPHOLIPASE A2α 
TARGETED NONSMALL LUNG CANCER THERAPY
s. sundarraj, s. Kannan Zoology, Bharathiar University, Coimbatore, 
INDIA
We developed a targeted anticancer drug delivery system based on folate-
conjugated rattle-type siO
2
 hollow mesoporous spheres combining receptor-
mediated targeting moieties. Mesoporous silica nanoparticles functionalized 
by surface hyper branching polymerization of poly (ethylene imine), PEI, 
were further modified by introducing both fluorescent and Folic acid (FA) 
ligands, with the aim of specifically targeting cancer cells. the internaliza-
tion of the particles in cell lines expressing different levels of folate recep-
tors was studied. Flow cytometry was used to quantify the mean number of 
nanoparticles internalized per cell. Four times more particles were internal-
ized by cancer cells expressing folate receptors as compared to the normal 
cells expressing low levels of the receptor. Pyrrolidine-2, an anticancer drug, 
was introduced into MsNs. the release of Pyrrolidine-2 from MsN-FA had 
a sustained release pattern, and the Pyrrolidine-2 loaded MsN-FA exhibited 
greater cytotoxicity, apoptosis and cPLA
2
 activity than free Pyrrolidine-2 
and Pyrrolidine-2 loaded MsNs due to the increase of cell uptake of anti-
cancer drug delivery vehicles mediated by the FA receptor. therefore, we 
conclude that folate-conjugated mesoporous spheres have potential for tar-
geted anticancer drug delivery for cancer therapy.
Disclosure: All authors have declared no conflicts of interest.
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WHY IS CHEMOTHERAPEUTIC INTERVENTION SUCH A 
RELATIVELY RARE OCCURRENCE IN STAGE IV NSCLC?
W. boland, K. skolnik, s. Otsuka, J. Macklow, D. Morris, D.G. bebb 
Oncology, Translational Laboratories, University of Calgary, Tom Baker 
Cancer Centre, Calgary, AB, CANADA
Introduction: Nearly 40% of NscLc patients present at diagnosis with stage 
IV disease. because they represent a significant percentage of lung cancer 
cases and have the most guarded prognoses, improving patient care in this 
group would have a meaningful clinical impact. standard 1st line treatment 
with a platin-based doublet has been shown to significantly extend survival, 
but experience at our institution suggests that many stage IV NscLc patients 
do not receive any systemic treatment at all. Potential reasons for not receiv-
ing cytotoxic treatment are poor performance status, advanced age, and trav-
elling distance. the goal of this study was to ascertain why stage IV NscLc 
patients do or do not receive chemotherapy.
Methodology: All patients diagnosed with stage IV NscLc at the tom baker 
cancer centre in 2003-2006 were included (n=832). Demographic infor-
mation was extracted from the Glans-Look Database and clinical data was 
retrieved from medical charts. Patient history was reviewed for referral pat-
terns, oncology consultations, if chemotherapy was offered, and, if not, why 
it was declined. We calculated travel distance of each subject to the medical 
centre using patient’s postal codes and Google™ software.
Results: Of the 832 patient cohort, only 193 patients (23.2%) received sys-
temic treatment (21.0% no treatment, 55.8% rt only, 16.2% chemo and rt, 
and 7.0% chemo only). Patients who received systemic treatment had a MOs 
of 11 months while those who did not had an MOs of 2.3 months. Preliminary 
results show that EcOG status was the primary stated reason for not receiv-
ing chemotherapy followed by rapid progression, death before first medical 
oncologist appointment, and concerns regarding age and comorbidities. rural 
location was not indicated as a factor. However, within the full cohort we 
found an inverse correlation between driving distance to the cancer centre 
and use of systemic therapy.
Conclusion: A range of factors influence the administration of chemotherapy 
in stage IV NscLc. some, such as rapid disease progression, are less sus-
ceptible to modification. However, the importance of EcOG status and travel 
distance suggests that the development of less toxic therapies and the creation 
of rural treatment centres may encourage greater uptake of systemic treatment 
in this patient group. Full results will be presented.
Disclosure: All authors have declared no conflicts of interest.
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THE RELATION BETWEEN LEUCOCYTOSIS AND 
OVERALL SURVIVAL IN ADVANCED STAGE NON SMALL 
CELL LUNG CANCER
D. colak1, A. Aksahin2, U. Ersoy1, M. Altinbas1, b. sonmez1, s. Urvay1 
1Medical Oncology Clinic, Ankara Yildirim Beyazit Education and Research 
Hospital, Ankara, TURKEY, 2Medical Oncology Clinic, Kayseri Education 
and Research Hospital, Kayseri, TURKEY
Introduction: Non small cell lung cancer (NscLc) is a heterogeneous clini-
cal entity that can have different clinical behaviours even within the same 
stage of disease. since prognosis is quite dismal especially in advanced stages 
of diseases, more attention has been focused on the identification of prog-
nostic factors. Performance status of the patient, stage of disease and weight 
loss are classical prognostic factors for advanced stage NscLc, but still new 
factors are needed. In some recent studies tumor related leucocytosis has been 
found to be a negative prognostic factor for overall survival in advanced stage 
NscLc patients. In this study, we aimed to evaluate the relation between 
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pretreatment leucocyte levels and overall survival in advanced stage NscLc 
patients.
Material-method: the files of advanced stage and histologically proven 
NscLc patients, who had admitted to and been treated in our clinic between 
March 2008 and March 2011, were evaluated retrospectively. Demographical 
datas, diagnosis date, performance status at diagnosis, stage, pretreatment 
leucocyte levels, date of last visit or death of all patients were noted. the 
exclusion criteria were concomitant infections, bone marrow metastasis at 
diagnosis or administration of steroids.
Results: the files of 95 advanced stage NscLc patients were evaluated. 14 
were female (%14,7) and 81 were male (%85,3). Median age was 63 (37-88) 
in the whole group, 70 (42-78) in females and 63 (37-88) in males. According 
to pretreatment leucocyte values, the patients were divided into 4 subgroups. 
the values were ≤10000/mm3 in Group 1, >10000- ≤15000/mm3 in Group 
2, >15000-≤20000/mm3 in Group 3 and >20000/mm3 in Group 4. the sub-
groups were similar with respect to age, sex and performance status of the 
patients (p levels were 0,295; 0,753 and 0,362 respectively). Median survival 
was 13,3 months in Group 1, 8,6 months in Group 2, 5,7 months in Group 
3 and 0,9 months in Group 4. there was a significant difference for overall 
survival between the groups (p:0,000).
Conclusion: In this study pretreatment leucocytosis is shown to be a nega-
tive prognostic factor for overall survival stage in advanced stage NscLc 
patients. this relation is more pronounced as the pretreatment leucocyte lev-
els increase.
Disclosure: All authors have declared no conflicts of interest.
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NEUROENDOCRINE TUMORS OF THE LUNG: 
RETROSPECTIVE CLINICAL DATA AND CURRENT 
TRIALS
W. Engel-riedel1, J. Zimmermann1, c. Ludwig1, E. stoelben1, M. serke2, M. 
thomas3, r. castellana4, c. May5, I. Nimmrich5, M. Potzner5 1Lungenklinik 
Merheim, Kliniken der Stadt Köln gGmbH, Köln, GERMANY, 2Des Deutschen 
Gemeinschafts-diakonieverbandes Gmbh, Lungenklinik Hemer, Hemer, 
GERMANY, 3Department of Internal Medicine - Thoracic Oncology, Clinic 
for Thoracic Diseases/University of Heidelberg, Heidelberg, GERMANY, 
4Oncology, Novartis Farmaceutica S.A., Barcelona, SPAIN, 5Bu Oncology, 
Novartis Pharma, Nürnberg, GERMANY
Objective: Neuroendocrine tumors (NEt) of the lung can be divided in typi-
cal carcinoid (tc), atypical carcinoid (Ac), large cell neuroendocrine carci-
noma (LcNEc) and small cell lung carcinoma (scLc). tc, Ac, and LcNEc 
are rare tumors with a reported prevalence of approximately 3% among sur-
gically resected lung cancers. However, there is only little information on 
the exact prevalence of lung NEt and no treatment standards exist. targeted 
therapies such as mtOr inhibitors and somatostatin analogs are discussed as 
promising approach. Here we present retrospective clinical data on lung NEt 
from one institution and current clinical trials as new treatment options.
Patients and methods: retrospective analysis of 1690 surgically resected 
lung cancer patients was performed in Lungenklinik Merheim (January 2007– 
December 2010). For patients with a diagnosis of tc, Ac, LcNEc, and 
LcNEc with scLc we compared the data in terms of age, sex, smoking 
habits, tumor stage, and survival.
Results: Among the resected patients, 35 (2,1%) were diagnosed with tc, 8 
with At (0,5%), 32 with LcNEc (1,9%) and 8 with LcNEc/scLc (0,5%). 
LcNEc highly correlated with smoking and patients were diagnosed at 
a later stage compared to those with carcinoids. Patients with tc and Ac 
happened more likely to be women, never-smokers and were mainly diag-
nosed in stage I. there was no significant difference in age between these 
groups. the mtOr inhibitor rAD001 and the somatostatin analog sOM230 
have proven efficacy for treatment of NEts. based on the need for treatment 
options of patients with advanced lung NEt, the following trials have been 
set up: A combination trial of rAD001 and carboplatin/paclitaxel for patients 
with advanced LcNEc is actively recruiting patients in 10 German study 
sites. In addition, a 3-arm phase II study to evaluate the efficacy and safety of 
sOM230 and rAD001 alone or in combination in the treatment of patients 
with advanced (unresectable or metastatic) tc and Ac of the lung and thymus 
will start shortly.
Conclusions: Lung NEt is rather rare. retrospective analysis of the pre-
sented data allows us to differentiate between these patients in terms of prog-
nosis. the importance of clinical trials is recognized and will be addressed in 
two clinical trials.
Disclosure: W. Engel-riedel, M. serke, M. thomas and I. Nimmrich: 
Honoraria of Novartis Pharma GmbH. r. castellana: the author is employee 
of Novartis Farmaceutica s.A. c. May and M. Potzner: the author is employee 
of Novartis Pharma GmbH. All other authors have declared no conflicts of 
interest.
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HYPERBARIC OXYGENATION WITH CHEMOTHERAPY 
IN TREATMENT OF PATIENTS WITH NSCLC
M. Kopp1, I. Koroleva1, s. Kozlov2, M. Popova1, J. Kutyreva1 1Chemotherapy 
Department, Samara Regional Clinical Oncology Dispensary, Samara, 
RUSSIAN FEDERATION, 2Oncology, Samara State Medical University, 
Samara, RUSSIAN FEDERATION
Background: by the time of diagnosis more than 75% of all lung cancer 
patients have locally advanced or metastatic process. According to WHO, at 
different stages of treatment to 80% of lung cancer patients need chemother-
apy. Malignant neoplasm lead to the development of tissue oxygen deficiency 
or directly related to acute or chronic hypoxia. Hypoxia of normal tissues is 
a one of the reasons of chronic anemia in patent with advanced NscLc. We 
conducted an analysis of toxicity of chemotherapy in patients with NscLc by 
means of chemotherapy concurrently with hyperbaric oxygenation.
Materials and methods: between October 2010 and November 2011 42 
patients with advanced NscLc were treated with chemotherapy regimen 
(cisplatin 75mg/m2 on day 1 + Etoposide 120mg/m2 in 1, 3, 5 days). cycles 
repeated every 21 days. We used two hyperbaric pressure chambers: bLKs 
303MK and bLKs-307 Khrunichev. Hyperbaric oxygenation procedures are 
held under pressure 1.3 atm for 40 minutes, 1 time a day every day for 5 con-
secutive days. All the patients were divided into 2 groups. 15 patients received 
chemotherapy only. 27 patients received chemotherapy simultaneously with 
hyperbaric oxygen therapy. 15 patients received chemotherapy only. Patients 
were not given any prophylaxis of neutropenia. toxicity was evaluated with 
common toxicity criteria, Version 3.0.
Results: Grade 2 anemia was reported in 28% patients treated with chemo-
therapy and hyperbaric oxygenation and in 40% patients treated with che-
motherapy only. the beneficial effect of hyperbaric oxygenation was also 
demonstrated by a quick recovery of hemoglobin levels than in controls. We 
evaluated the dose intensity of chemotherapy. Dose reductions and increased 
periods between cycles of chemotherapy are associated with poor outcomes 
of chemotherapy. Dose intensity in patients received chemotherapy with 
hyperbaric oxygenation was 92%, but in group of chemotherapy only dose 
intensity was 81%.
Conclusions: this results show that hyperbaric oxygenation procedures 
with the chemotherapy reduced grade of anemia in patients with advanced 
NscLc.
Disclosure: All authors have declared no conflicts of interest.
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BODY MASS INDEX (BMI), IS IT A PROGNOSTIC FACTOR 
IN METASTATIC NON SMALL LUNG CANCER?
s. Arifi, Z. benbrahim, H. benhammane, L. Ammadour, N. Mellas, O. 
Elmesbahi Medical Oncology, University Hospital of Hassan II, Fez, 
MOROCCO
Background: cancer cachexia adversely affects survival and quality of life. 
the aim of our study was to establish the correlation between low bMI and 
survival in Moroccan patients with metastatic non small cell lung cancer 
(NscLc).
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Methods: We reviewed 115 cases of metastatic NscLc diagnosed between 
January 2007 to June 2011 at the Medical Oncology Department at Hassan II 
University Hospital. Low bMI was defined as < 18.5 kg/m2.
Results: Median age was 57 ± 10 years. 83, 5% of patients were men. 81% of 
patients were treated with platinum based chemotherapy. 36% had a low bMI 
at diagnosis. the mean bMI among patients with low bMI was 17 Kg/m². 
Low bMI was more frequently associated with hypoalbuminemia (p=0,008). 
However, it was not correlated to age, sexe, performance status, number of 
metastatic sites involved. the median duration of follow-up was 7.4 months 
(1-99 months). Low bMI was significantly correlated to Os in patients with 
metastatic NscLc (median of 5 versus 8 months, p =0, 01). the median of 
DFs was shorter (4 versus 6 months), but not significantly different (p=0, 15). 
No significantly increased toxic death rates were observed among patients 
with low bMI (p=0.27).
Conclusion: Low bMI could be a prognostic marker to predict unfavorable 
Os in patients with metastatic NscLc.
Disclosure: All authors have declared no conflicts of interest.
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PROGNOSTIC FACTORS FOR SURVIVAL OF 
SYMPTOMATIC PATIENTS WITH MALIGNANT PLEURAL 
EFFUSION WHO UNDERWENT PALLIATIVE TALC 
PLEURODESIS
F. Lumachi1, F. Mazza2, D.A. santeufemia3, s. tumolo3, A. Del conte3, 
M. Ermani4, G.b. chiara5, s.M. basso5 1Department of Surgical & 
Gastroenterological Sciences, University of Padua, School of Medicine, Padova, 
ITALY, 2Pneumology, S. Maria degli Angeli Hospital, Pordenone, ITALY, 3Clinical 
Oncology, S. Maria degli Angeli Hospital, Pordenone, ITALY, 4Department 
of Neurosciences, University of Padua, School of Medicine, Padova, ITALY, 
5Chirurgia 1, S. Maria degli Angeli Hospital, Pordenone, ITALY
Background: Pleural carcinomatosis usually represents the final common 
pathway in several metastatic diseases, especially breast, ovarian, and colonic 
cancer, leading to malignant pleural effusion (MPE). this complication is 
common in several patients with advanced malignancy, and usually leads 
patients to suffer from significant dyspnea, which may reduce their quality 
of life. several interventions have shown to be useful to palliate the symp-
toms, including video-assisted thoracoscopic (VAts) pleural drainage, and 
talc or chemical pleurodesis. In patients with MPE, pleurodesis prevents re-
accumulation of the effusion and thereby of symptoms. there is no evidence 
for an increase in mortality following talc pleurodesis, but factors affecting 
survival of treated patients are unclear. the aim of this study was to evaluate 
prognostic factors for survival of symptomatic patients with MPE.
Patients and methods: thirty-five patients (median age 70 years, range 
42-83) with MPE underwent VAts, evacuation of the pleural fluid, and talc 
pleurodesis. there were 25 (71.4%) males and 10 (28.6%) females, and the 
causes of MPE were breast or ovarian cancer, non-small cell lung carcinoma, 
and malignant pleural mesothelioma in 14, 12, and 9 cases, respectively. the 
relationship of factors to survival was analyzed calculating the log-rank test 
using Kaplan-Meyer method. the cox’s regression model was also used.
Results: Overall, the mean follow-up was 9.8±8.7 months, while the median 
postoperative survival for the entire group was 15.5 months (95% cI 2-29). 
We did not find (log-rank test) any relationship between both gender (p=0.53) 
and underlying malignancy associated with MPE (p=0.89, 0.48, and 0.36 for 
secondary cancer, lung cancer, and mesothelioma, respectively) and survival. 
similarly, no correlation was found (cox’s regression) between both age of 
the patients (p=0.44) and quantity of pleural fluid (p=0.88) and survival.
Conclusions: Our results show that the prognosis of patients with MPE who 
underwent palliative talc pleurodesis is independent of age, gender, type of 
malignancy, and amount of pleural effusion, suggesting the usefulness to treat 
all patients with symptomatic MPE.
References
 1. Pilling JE, et al. J torac Oncol 5: 1544, 2010
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ZOLEDRONIC ACID ROLE IN SRES PREVENTION: AN 
ADVANTAGE FOR ALL PATIENTS WITH ADVANCED 
NSCLC AND BONE METASTASES?
E. Del signore1, F. De Marinis2 1Pneumo-oncology, San Camillo-Forlanini 
High Specialization Hospital, Rome, ITALY, 2Department of Lung Disease, 
AO San Camillo-Forlanini, Rome, ITALY
Introduction: the purpose of this study is to investigate the impact of 
Zoledronic Acid (ZA) administration in prevent srEs in pts with advanced 
non-small cell lung cancer (A-NscLc). 
Methods: We observed retrospectively 148 pts, whose 135 valued, with 
NscLc and bM diagnosed (2007-2010) at the same time of the primary 
tumor or later during the treatment. the effectiveness of treatment with ZA 
was valued in terms of time at the diagnosis of bone metastasis and time at 
first or second srEs during the treatment. Furthermore we valued the effec-
tiveness of treatment to relieve pain (Visual Analogic scale) and improve 
Quality of Life (EOrtc-QoL scale).
Results: We analyzed 135/148 pts. Median age was 61 years. After diagnosis of 
bM, pts was treated with ZA at the standard dose of 4 mg every 28 days. In 53% 
bM was observed at the time of diagnosis of primary disease, in 47% during the 
chemotherapy. srEs never occurred in 31 pts (44%) with stadium IV for bone 
metastasis; 14 pts (47%) with stadium IV for metastasis in other sites and then 
on bone; 8 pts (23,5%) with early stage in progression on bone.the first srE 
occurred at the time of the diagnosis in 29 pts (41%) with stadium IV for bone 
metastasis; in 12 pts (40%) with stadium IV for metastasis in other sites and 
subsequent bone progression; in 18 pts (53%) with early stage in which bone 
progression occurred during chemotherapy or follow-up. During the treatment 
with ZA experienced the first srE: 11 pts (15%) with stadium IV for bone 
metastasis, after 2 months; 4 pts (13%) with stadium IV for metastasis in other 
sites, after 4,5 months; 8 pts (23,5%) with early stage and subsequent bone pro-
gression, after 5 months. bone pain was observed in 80% of pts and in 60% it 
decreased during the treatment with ZA associated with improved QoL. 
Conclusions: this retrospective analysis about role of Zoledronic Acid to 
prevent srEs in NscLc pts with bM shows that pts in stadium IV for bone 
metastasis at the time of diagnosis or occurred during treatment have major 
probability to never experienced srE rather than at the time of bone diagnosis 
or during treatment. In these pts the treatment with ZA could soothe bone pain 
and improve Quality of Life.
Disclosure: All authors have declared no conflicts of interest.
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SURGICAL OUTCOMES OF ADVANCED NSCLC (STAGE 
IIIB & IV)
J.H. Kim1, J. Hwang1, J.H. Park2, H.W. Lee2, H.J. baek2 1Thoracic Surgery, 
Dongnam Institute of Radiological and Medical Sciences, Busan, KOREA, 
2Thoracic Surgery, Korea Institite of Radiological and Medical Sciences, 
Seoul, KOREA
Background: the role of surgery in stage IIIb or IV NscLc (AJcc 6th 
edition) patients is very limited. but stage shifting to operable patients with 
stage IIIA or IV NscLc to IIIA in the AJcc 7th edition has been made. so 
we analyzed the long term results of the surgical resection for the operable 
patients with stage IIIb or IV NscLc in a single institute.
Methods: From January 1990 to December 2009, 102 patients with stage 
IIIb (t4) NscLc and the 36 patients with stage IV (separate tumor in ipsi-
lateral different lobe) NscLc were operated on in a Korean cancer center. 
We retrospectively analyzed the long-term survival and the risk factors for 
long-term survival of the 138 patients.
Results: some 59 (42.7%) patients had major organ invasion in the medi-
astinum; separate tumor in ipsilateral different lobes were seen in 43 (31.1%) 
patients and satellite nodule in the same lobe were seen in 36 (26%) patients 
among the 138 stage IIIb or IV NscLc patients with surgery. N0 stage was 42 
(30.4%) patients, N1 stage was 29 (21%) patients and N2 stage was 67 (48.6%) 
patients. Lobectomy was performed in 56 (40.5%) patients, bilobctomy was 
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performed in 14 (10.1%) and pneumonectomy was performed in 68 (49.2%). 
complete resection was achieved in 123 (89.1%) and operation mortality rate 
was 6.5% (9/138 patients). Median survival was 34 months and 5-year and 
10-year survival rates were 34.6% and 21.9%, respectively. recurrence, sur-
gery alone, N2 stage, and incomplete resection were risk factors of long-term 
survival in multivariate analysis.
Conclusion: Although the role of surgery in stage IIIb, IV NscLc patients 
is very limited, the long-term outcomes of surgical resection of these patients 
are tolerable in our Korean cancer center. so we thought the shifting of stage 
of the group with operable stage IIIb or IV NscLc to IIIA is appropriate.
Disclosure: All authors have declared no conflicts of interest.
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PRIMARY LOCATION OF SMALL CELL LUNG CANCER 
(SCLC) AND TTF-1 EXPRESSION: ARE MOST SCLCS 
REALLY OF HILAR ORIGIN?
E. Miyauchi1, H. Ono1, H. Ninomiya1, K. Inamura1, N. Motoi1, M. Nishio2, 
s. Okumura3, Y. Ishikawa1 1Division of Pathology, The Cancer Institute, 
Japanese Foundation for Cancer Reserch, Tokyo, JAPAN, 2Thoracic Medical 
Oncology, Cancer Institute Hospital of JFCR, Tokyo, JAPAN, 3Thoracic 
Surgical Oncology, Cancer Institute Hospital of JFCR, Tokyo, JAPAN
Backgroud: small cell lung cancer (scLc) has been believed to occur at the 
hilar part of lung. thyroid transcription factor-1 (ttF-1), a transcription fac-
tor for alveolar cell differentiation, is expressed in terminal bronchiolar cells 
and alveolar type II cells, and is therefore a marker of peripheral lung cells. 
ttF-1 is expressed in 80-97% in scLc as well as in 63%-84% of adenocar-
cinoma, suggesting scLc is of the origin of peripheral lung cells. However, 
the fact of frequent ttF-1 expression in scLc is not consistent with the long-
standing notion that scLc is derived from hilar neuroendocrine cells such as 
Kultschitzky cells. In this study, we examined whether or not scLc is really a 
hilar type tumor and ttF-1 would have prognostic relevance.
Methods: 96 consecutive patients with scLc, of which detailed ct pictures 
were available and were diagnosed with biopsies and/or surgical materials 
during 2004-2011, were enrolled. scLcs diagnosed only by cytology were 
excluded. We evaluated the location of primary tumor (central or peripheral) 
by ct at diagnosis. tumors originating at a segmental or more proximal bron-
chus were classified to be of hilar type, whereas lesions arising at distal to 
segmental bronchi were of peripheral type. Expression of ttF-1 was detected 
immunohistochemically using formalin-fixed paraffin-embedded specimens. 
Disease-specific survival was obtained for all the cases.
Results: 72 of 96 scLcs (75%) proved to be of peripheral type. the nuclear 
immunoreactivity of ttF-1 was identified in 79 tumors (82%). Among these, 
69 (87.3%) were peripheral type. ttF-1 expression was significantly cor-
related with the peripheral location of primary tumor (P<0.001). the hilar 
type tumors without ttF-1 expression (n=14) had significantly better median 
survival time than those with ttF-1 expression or of peripheral type (n=82) 
(21.0 vs 50.3 months respectively; P=0.032).
Conclusions: ttF-1 expression was strongly associated with peripheral loca-
tion. scLc of hilar type and without ttF-1 expression showed significantly 
better prognosis. scLc may be classified into two subtypes: hilar and periph-
eral types with different prognosis.
Disclosure: All authors have declared no conflicts of interest.
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TIME TO TREATMENT FAILURE IN LIMITED DISEASE 
SMALL-CELL LUNG CANCER PATIENTS WITH POOR 
INITIAL PERFORMANCE STATUS WHO RESPONDED TO 
CHEMORADIOTHERAPY
F. Manapov1, s. Kloecking2, M. Niyazi1, c. belka1, G. Hildebrandt3, r. Fietkau4, 
G. Klautke4 1Radiation Oncology, Ludwig-Maximilian University Munich, 
Munich, GERMANY, 2Tumorregister, University of Rostock, Rostock, GERMANY, 
3Radiation Oncology, University of Rostock, Rostock, GERMANY, 4Radiation 
Oncology, Friedrich-Alexander University Erlangen, Erlangen, GERMANY
Background: Limited disease (LD) small cell lung cancer (scLc) can only 
rarely be cured by chemoradiotherapy (crt). Dose- and time density is a cru-
cial aspect for efficient treatment of scLc. Optimal local control is important 
due to the low sensitivity of recurrent disease to any treatment. In these condi-
tions knowledge about timing of recurrence can help optimize follow up and 
enhance effectiveness of the second-line therapy.
Patients and methods: 125 LD scLc patients with initial performance 
status (Ps) WHO 2-3 who responded to crt were retrospectively reviewed. 
conventionally fractionated thoracic irradiation (trt) was applied in the 
concurrent (group 1) or sequential (group 2) mode. time from initial diagno-
sis and treatment close to the local relapse, any distant and brain recurrence 
was recorded and analysed.
Results: Median time from initial diagnosis to local relapse was 376 (95% cI: 
260 – 492) and 401 (95% cI: 241 – 560) days (p = 0.8); to any distant recur-
rence 275 (95% cI: 178 – 372) and 298 (95% cI: 241 – 355) days (p = 0.7) 
and to brain recurrence 330 (95% cI: 216 – 444) and 273 (95% cI: 221 – 325) 
days (p = 0.7) in the concurrent and sequential group respectively. Median time 
from end of chemotherapy to local relapse was 200 (95% cI: 132 – 268) and 
309 (95% cI: 174 – 444) days (p = 0.5); to any distant recurrence 151 (95% cI: 
71 – 231) and 157 (95% cI: 105 – 209) days (p = 0.7) and to brain recurrence 
123 (95% cI: 15 – 231) and 151 (95% cI: 101 – 201) days (p = 0.7) in group 
1 and 2 respectively. Median time from end of trt to local relapse was 316 
(95% cI: 231 – 401) and 196 (95% cI: 127 – 265) days (p = 0.3); to any distant 
recurrence 180 (95% cI: 74 – 286) and 84 (95% cI: 31 – 137) days (p = 0.2) 
and to brain recurrence 213 (95% cI: 104 – 322) and 73 (95% cI: 17 – 129) 
days (p = 0.2) in the group 1 and 2 respectively. Patients treated with concur-
rent crt developed brain metastases more often (19/51, 37% versus 15/74, 
20%, p < 0.049), however there was a clear trend to different temporal distribu-
tion of brain recurrence in the concurrent and sequential group (p = 0.084).
Conclusion: Using a time analysis we defined relevant intervals from initial 
diagnosis and treatment end to onset of recurrence disease to further optimize 
a follow-up protocol in LD scLc patients responded to crt.
Disclosure: All authors have declared no conflicts of interest.
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COMPARATIVE EVALUATION OF CONCURRENT 
VERSUS SEQUENTIAL CHEMORADIATION IN LIMITED 
STAGE SMALL CELL LUNG CANCER -TERTIARY CARE 
CENTRE (AIIMS) EXPERIENCE
V. roshan1, P. shukla1, F.A. Ansari1, N.A. Khan2, A. Malik1, A. sharma1, M. 
behra1, I. Ahmad1, M. bhandari1, G.K. rath1 1Dept. of Radiation Oncology, 
All India Institute of Medical Sciences, New Delhi, INDIA, 2Radiation 
Oncology, SKIMS, Srinagar, INDIA
Objectives: to study overall survival, response and toxicities associated with 
two arms, and to consider timing of thoracic radiotherapy in small cell lung 
cancer. Frequency of metastasis after Prophylactic cranial Irradiation.
Material and methods: 60 patients with small cell lung cancer were studied 
over a period of three years from March 2008 to October 2011. thirty patients 
in each arm, both arms were well balanced in terms of patients characteris-
tics. Arm one received three cycles of chemotherapy (cisplatin and etoposide) 
followed by thoracic radiation of 45Gy by AP/PA portals followed by three 
cycles of chemotherapy. In second arm radiation was started from day 1 of 
chemotherapy (cisplatin and etoposide), both groups completed six cycles 
of chemotherapy. After completion of primary treatment, PcI was done in 
patients with complete response.
Results: the concurrent chemotherapy arm showed better survival than the 
sequential arm (p=0.31).the median survival was 28 months in the concur-
rent arm and 20 months in the sequential arm. two year survival rate was 
56.3% in the concurrent arm versus 32% in the sequential arm. More tox-
icities were seem in the concurrent arm compared with the sequential arm. 
Frequencies of brain metastasis after PcI in sct-rt and cct-rt patients 
were 14.9% and 7.1%, respectively.
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Conclusions: concurrent chemoradiation seems better than sequential 
chemoradiation, however the results are not statistically significant. As com-
pared to sequential chemoradiation, concurrent chemoradiation showed more 
toxicity. Outcomes may improve further by applying PcI at earlier stages.
Disclosure: All authors have declared no conflicts of interest.
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SUBGROUP ANALYSIS OF OVERALL SURVIVAL 
ACCORDING TO THE DURATION OF 
CHEMORADIOTHERAPY IN LIMITED DISEASE SMALL-
CELL LUNG CANCER PATIENTS WHO RESPONDED TO 
MULTIMODALITY TREATMENT
F. Manapov1, s. Kloecking2, M. Niyazi1, G. Hildebrandt3, c. belka1, r. 
Fietkau4, G. Klautke4 1Radiation Oncology, Ludwig-Maximilian University 
Munich, Munich, GERMANY, 2Tumorregister, University of Rostock, Rostock, 
GERMANY, 3Radiation Oncology, University of Rostock, Rostock, GERMANY, 
4Radiation Oncology, Friedrich-Alexander University Erlangen, Erlangen, 
GERMANY
Background: chemoradiotherapy (crt) represents a standard treatment in 
limited disease (LD) small cell lung cancer (scLc). timing of thoracic irra-
diation (trt) as an obligatory part of crt has been the subject of several 
randomised trials. When considereing only trials with concurrent platinum-
based crt, several meta-analyses reported significantly improved overall sur-
vival (Os) when a short interval between the first day of chemotherapy and 
the last day of trt was documented. In our previous study we demonstrated 
that duration of crt correlates with Os in LD scLc patients with poor 
initial performance status. to search for optimal crt duration a subgroup 
analysis of Os in LD scLc patients responded to multimodality treatment 
was performed.
Patients and methods: 147 LD scLc patients with initial Ps WHO 1-3 
who responded to crt were retrospectively reviewed. conventionally frac-
tionated thoracic irradiation (trt) was applied in the concurrent or sequen-
tial mode. Platinum- as well as non platinum-based chemotherapy was used. 
Duration of crt was defined as a time from initial diagnosis to the date 
of last treatment applied for LD scLc without inclusion of PcI. survival 
was analysed according to the Kaplan-Meier method and measured from the 
date of initial diagnosis. surviving patients were censored at the date of last 
follow-up. survival curves for each subgroup were compared using the log-
rank test.
Results: According to the crt duration 147 patients were divided into 
four subgroups: 1 - (up to 100 days) 19 (13%) patients, 2 - (101 – 150 days) 
18 (12%) patients, 3 - (151 – 200 days) 49 (33%) patients and 4 - (201 days 
and more) 61 (42%) patients, respectively. Median survival for the entire 
cohort was 510 (95 cI: 434 – 586) days: 602 (95 cI: 261 – 943) days in 
subgroup 1, 325 (95 cI: 258 – 392) days in subgroup 2, 532 (95 cI: 441 – 
623) days in subgroup 3 and 524 (95 cI: 415 – 633) days in subgroup 
4. However, difference in median survival between the subgroups did not 
reach significance.
Conclusion: Our results show that the subgroup of patients who have com-
pleted crt up to 100 days from initial diagnosis demonstrate a potentially 
better survival compared to the rest of cohort but the difference was not sig-
nificant. Further studies powered to determine the impact of crt duration on 
survival in LD scLc patients are initiated. 
Disclosure: All authors have declared no conflicts of interest.
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WEEKLY DIVIDED CARBOPLATIN COMBINED WITH 
IRINOTECAN IN PATIENTS WITH SMALL-CELL LUNG 
CANCER AS THE FIRST-LINE TREATMENT
c. son1, M.s. roh2, s.J. Um1 1Pulmonology, Dong-A Medical Center, Busan, 
KOREA, 2Pathology, Dong-A Medical Center, Busan, KOREA
Background: systemic chemotherapy is a mainstay of treatment in patients 
with small-cell lung cancer (scLc). However, adverse effects of chemothera-
peutic agents, especially platinum-based, cause neutropenia, infection, sepsis, 
and even death. Weekly divided platinum-based chemotherapy in concurrent 
chemo-radiation of non-small cell lung cancer is an acceptable regimen. We 
tested the feasibility of divided platinum-based chemotherapy in scLc with-
out concurrent radiation.
Materials and methods: Patients with chemotherapy-naive scLc received 
carboplatin 2 AUc combined with irinotecan (60mg/m2) at day 1, 8, and 15 
every 4 weeks for 4 cycles at an out-patient department. the primary end-
point was evaluation of overall response rate, and secondary endpoints were 
treatment-related serious adverse events and discontinuation of chemotherapy 
due to side effects.
Results: thirty (25 extensive stage and 5 limited stage) patients were enrolled. 
complete response, partial response, stable disease, and progressive disease 
were 5 (16.7%), 21 (70.0%), 1 (3.3%), and 3(10.0%), respectively. serious 
adverse events happened 5 times in 2 patients; 1 patient stopped chemother-
apy due to side effects.
Conclusions: Weekly divided carboplatin combined with irinotecan is a fea-
sible regimen in previously untreated scLc patients. 
Disclosure: All authors have declared no conflicts of interest.
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TOPOTECAN AND CAV CHEMOTHERAPY FOR 
RECURRENT SCLC: THE WEST OF SCOTLAND 
EXPERIENCE
s. slater, s. Nowicki, J. Graham, J. Hicks Medical Oncology, Beatson, West 
of Scotland Cancer Centre, Glasgow, UNITED KINGDOM
scLc has a high response rate to first line chemotherapy but response is 
short lived. Oral topotecan is licensed for second line chemotherapy and in 
October 2009 was approved for the West of scotland. clinical trials have 
shown that IV topotecan is comparable to cAV, oral topotecan has a survival 
advantage over best supportive care and oral topotecan and IV topotecan 
have similar efficacy. A retrospective case note review was undertaken of 
63 patients who received oral topotecan or IV cAV second line for recur-
rent scLc during time period October 2009 to April 2011. results were 
analysed using sPss version 19. 39.3% of patients were given oral topotecan 
and 60.3% IV cAV. Overall survival for patients receiving topotecan was 13 
weeks (95% cI, 6.9 – 19.1) versus 24 weeks (95% cI, 18.3 –29.7) (log rank 
p< 0.001). of the 25 patients who received topotecan for cycle 1 only 33.3% 
of patients received full dose, 2.3 g/m2 days 1-5. Furthermore, only 18.5% 
received equivalent of 4 cycles of topotecan, 33.3% 1 cycle, 44.4% 2 cycles 
and 3.7% 3 cycles. In comparison, 92.7% of patients received full dose of 
cAV for cycle 1. 12.2% received 1 cycle of cAV, 31.7% received 2 cycles, 
39% 3 cycles and 2.4% for both 5 and 6 cycles. Myelosuppression was the 
most common dose limiting toxicity with 29% of patients experiencing this 
with topotecan versus 12.2 % with cAV. However, neutropenic sepsis was 
similar in both groups 17% in cAV and 12.9% in topotecan patients. 19.5% 
of cAV patients developed infections requiring dose delays versus 6.5% in 
topotecan group. Grade 3 fatigue was similar in both groups 12.2 % in cAV 
and 16.1% in topotecan group. the patients who received topotecan second 
line had significantly lower survival rates than those receiving cAV. One of 
the reasons for this is concern of haematological toxicity resulting in sub-
optimal dosing of topotecan and thus, oncologists opting to prescribe cAV 
second line rather than topotecan. Most of the patients in this case series 
did not start with full dose topotecan and yet still experienced high rates of 
myelosuppression. the cAV patients tolerated higher equivalent doses than 
the topotecan patients.
Disclosure: All authors have declared no conflicts of interest.
S81Copyright © 2012 by the European Lung Cancer Conference and the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume  7, Number 6, Supplement 1, June 2012 Abstracts
223P
SMALL CELL LUNG CANCER: BETTER THAN ITS 
REPUTATION? A POPULATION BASED STUDY
H. rostad1, E.H. strøm2, H. scott2, M.P. ramnefjell3, t. strand1 1Research 
Dept, Cancer Registry of Norway, Oslo, NORWAY, 2Department of Pathology, 
Oslo University Hospital, Oslo, NORWAY, 3Department of Pathology, 
Haukeland University Hospital, Bergen, NORWAY
Introduction: this study was undertaken to identify patients with small 
cell lung cancer (scLc) who were alive five years or more after the diag-
nosis in a National, unselected population (Norway). 
Methods: During 2000-2005 lung cancer was diagnosed in 8 253 men and 
5 188 women. the proportion of scLc was 1 274 (15.1%) in men and 996 
(19.2%) in women. the completeness of the cancer registry of Norway is 
99%. All reports on patients diagnosed as having limited or disseminated 
scLc and who were alive five years or more were reviewed and eventually 
revised by pathologists at 17 different institutions. 
Results: 94 patients with scLc were alive more than 5 years after diag-
nosis. Of these surgical resection was performed in 12 cases. the distribu-
tion between disseminated and limited was 6% and 94%, respectively. In 
45 cases the diagnosis was based on bronchoscopy and histology. After 
pathology review the initial diagnosis of scLc were sustained in 75 
patients while 15 were revised. 
Conclusion: After revision of specimen 3.2% of patients with scLc were 
alive more than 5-year after diagnosis. this group should be looked closer at 
1) for further confirmation of diagnosis and 2) for prognostic biomarkers.
Disclosure: All authors have declared no conflicts of interest.
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MULTIMODAL APPROACH TO THE MANAGEMENT 
OF THYMOMA AND THYMIC CARCINOMA: MONO-
INSTITUTIONAL EXPERIENCE
A.M. Ascolese1, P. Navarria1, E. clerici2, G. reggiori1, s. Arcangeli1, 
s. Pentimalli1, s. castiglioni1, F. Alongi1, P. Mancosu1, M. scorsetti1 
1Radiotherapy and Radiosurgery, Istituto Clinico Humanitas Cancer Center, 
Rozzano (Milan), ITALY, 2Radiotherapy, University of Milan, Milan, ITALY
Purpose: to evaluate the role of radiation therapy (rt) in patients with thy-
moma and thymic carcinoma in terms of toxicities, loco-regional control and 
survival.
Materials and methods: between December 2003 and March 2011, 44 
consecutive patients were treated with radiotherapy for thymoma or thymic 
carcinoma. Each patient was evaluated, before and after treatment, by a mul-
tidisciplinary team including medical oncologists, radiation oncologists and 
thoracic surgeons. the patient’s general condition, the histologic classifica-
tion (WHO) and stage of disease were considered for the definition of the 
most appropriate treatment. surgery plus chemotherapy (ct) and rt was 
performed in 27/44 (61%) of patients, ct and rt in 8/44 (18%) and surgery 
and adjuvant radiation therapy in 9/44 (21%). the median radiation dose was 
54 Gy (range 44-60 Gy). clinical outcome was evaluated by means of ct 
scan. the incidence of pneumonitis was graded according to the NcI ctcAE 
v3.0 scale.
Results: the median follow up was 48 months (range 14 -94 months). No 
“in field” recurrence occurred. No pulmonary toxicity greater than G2 was 
observed. Minor toxicity occurred: radio-dermatitis G1 in 3 (7%) patients, 
dysphagia G2 in 11/44 (25%), and fatigue in 9/44 (20%). Overall-survival 
at five years was 75%, distant metastases were found in 5/44, all in thymic 
carcinoma cases.
Conclusions: Although the population of the study included patients with 
thymoma and thymic carcinoma with different stages of disease, local con-
trol and survival are satisfactory with minimal toxicities. Due to the high 
sensitivity of thymoma and thymic carcinoma to radiation therapy there 
is much interest in evaluating the role of rt in the treatment of this rare 
tumour.
Disclosure: All authors have declared no conflicts of interest.
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MULTIDISCIPLINARY MANAGEMENT OF THYMOMA:  
A SINGLE INSTITUTIONAL EXPERIENCE-LARGE 
SERIES
s. rathod1, A. Munshi1, s. Paul1, K. Prabhash2, J.P. Agarwal1 1Radiation 
Oncology, Tata Memorial Centre, Mumbai, INDIA, 2Medical Oncology, Tata 
Memorial Hospital, Mumbai, INDIA
Background: thymoma is the most common tumour of the anterior medi-
astinum. surgery is the mainstay of treatment, with adjuvant radiation rec-
ommended for invasive thymomas. because of its indolent natural history 
and rarity, prospective randomized trials may not be feasible hence the best 
possible evidence can be large series. A retrospective analysis of thymoma 
patients managed at our institution is presented.
Methods: All patients presenting to thoracic disease management group 
at tata Memorial centre during 2006-2011 were screened. Amongst 115 
patients with histo-pathological confirmation of thymoma, 62 patients’ medi-
cal records could be retrieved and presented in this study. Masaoka staging 
and WHO classification was used. the clinical and therapeutic factors and 
follow up parameters were recorded and survival was calculated. Effect of 
prognostic factors was compared.
Results: sixty two patients were identified (36M, 26F; age 22-84, median 
51.5 years). Majority (57%) of thymoma were stage I-II and 82% of thymic 
carcinoma were stage III-IV. WHO classification showed 10/23/18/18/13/18% 
were subtypes A/Ab/b1/b2/b3/c respectively. Mean tumour size was 
smaller in patients with myasthenia (5.3cm) than the entire group (7.6cm). 
Neoadjuvant therapy was offered to five unresectable stages III or IVa 
patient’s with 40% resectability rates. Median overall survival was 60 months 
(Inter quartile-range 3-44 months) with overall survival rate (Os) at 3 year 
being 90%. resectable tumours had better outcomes (94%) than nonresect-
able (81%) at 3 years (p=0.1). three year overall survival was 96% for stage 
I-II, 91% for stage III, and 69% for stage IV. stage was the only significant 
(p=0.01) prognostic factor on multivariate analysis. Myasthenia gravis did 
not negatively influence survival (88% Vs 91%; p=0.85) and corroborates 
with literature.
Conclusion: thymoma with associated paraneoplastic syndromes presents 
as early whereas thymic carcinoma as advanced disease. staging is an impor-
tant prognostic factor. treatment of thymoma depends on the resectability of 
the disease and surgery is the mainstay of therapy. Aggressive multimodal-
ity treatment should be offered to advanced stage patients and yields good 
survival rates.
Disclosure: All authors have declared no conflicts of interest.
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THE ESCALATION OF PNEUMOTOXICITY IN 
TREATMENT OF LOCALLY ADVANCED MALIGNANT 
THYMOMA AND THE EFFECT OF PENTOXIFYLLINE
J. stejskal1, M. Kubecova2, D. Dvorakova3, V. Ulrych1, J. Vanasek1 1Department 
of Radiation Oncology, Regional Hospital Pardubice, Pardubice, CZECH 
REPUBLIC, 2Department of Radiation Oncology, Charles University Hospital 
Praha, Praha, CZECH REPUBLIC, 3Department of Medical Oncology, 
Hospital Náchod, Náchod, CZECH REPUBLIC
Purpose: Malignant thymoma belongs among rare neoplasms. the optimal 
therapy for locally advanced malignant thymoma (LA Mt) is controversial. 
Locally advanced stages and postoperative residual disease of tumorous por-
tion are great risks for patients. Adjuvant therapy using chemotherapy (ct) 
and radiotherapy (rt) brings contradictory results. this management can be 
limited by escalation of pneumotoxicity.
Methods: between 1998 - 2008 we assessed and retrospectively analysed 
18 patients who were treated postoperatively by the ct and rt. the treat-
ment took place in the following sequence: surgery (s) + ct ± rt. the ct 
regimens were used: (cDDP+doxorubicin+etoposide or cyclophosphamide) 
and (ADOc: doxorubicin+cDDP+vincristine+cyclophosphamide). Planned 
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radiation doxorubicin+cDDP+vincristine+doses ranged from 50-60 Gy. side 
effects were classified according to ctc v 3.0.
Results: the median age at the time of histopathological verification was 58 
(range 38 to 75). three patients (17%) underwent biopsy only. Fifteen patients 
(83%) in clinical stages III and IVa underwent the resection to various extent. 
the number of applied chemotherapy cycles was 4 - 8. radiation doses were 
applied in the range of 45-68 Gy. radiation pneumonitis (rP) of grade 1/2 
was observed in 13 patients (72%) and grades 3/4 in 6 patients (33%), in 
the group ADOc in 5 patients (83%). the best local control of the disease 
was observed in the group treated with the sequence of s+ct+rt using the 
ADOc chemotherapy regimen. In this group the median time to tumor pro-
gression was 38 vs 17 months against the others, respectively (p=0.0001). 
However, in these patients the escalation of toxicity with severe manifestation 
of rP, that resulted in post-irradiation fibrosis, was observed. the manifesta-
tions of rP were softened by oxygenotherapy, antibiotics, corticoids and pen-
toxifylline (PE). Median time to recover rP grade 3/4 was 4.9 vs 2.8 months 
with the application of pentoxifylline.
Conclusions: Postoperative intensive treatment with chemotherapy and radio-
therapy in patients with LA Mt leads to an improvement of the local control 
of the disease. the escalated toxicity, mainly the radiation pneumonitis, can 
be reduced by the application of pentoxifylline.
Disclosure: All authors have declared no conflicts of interest.
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UPDATED ANALYSIS OF EORTC 08983: A RANDOMISED 
TRIAL OF RALTITREXED AND CISPLATIN VERSUS 
CISPLATIN IN MALIGNANT PLEURAL  
MESOTHELIOMA
J.P. van Meerbeeck1, r. Gaafar2, c. Manegold3, H. Phillips4, s. Margerit5, 
b. Hasan5 1Thoracic Oncology, Ghent University Hospital, Gent, BELGIUM, 
2Medical Oncology, National Cancer Institute, Cairo University, Cairo, 
EGYPT, 3Chirurgische Klinik, Medizinische Fakultät Mannheim der 
Universität Heidelberg, Mannheim, GERMANY, 4EMEA, Hospira UK 
Limited, Royal Leamington Spa, UNITED KINGDOM, 5Data Center, EORTC, 
Brussels, BELGIUM
Background: EOrtc 08983 randomised 250 chemotherapy-naive patients 
with advanced pleural mesothelioma to receive cisplatin 80 mg/m² IV on 
day 1, alone (arm A) or combined with raltitrexed 3 mg/m² IV (arm b) (Van 
Meerbeeck, J clin Oncol 2005; 23:6881-9).
Method: An unplanned updated overall survival (Os) analysis based on the 
data as of May 5, 2011. Os is defined as time from randomisation to death 
from any cause.
Results: After a median follow up of 98 months, 118/124 participants in 
arm A and 115/126 in arm b were deceased. seventeen (6 and 11) patients 
were censored at the last date known to be alive: 12 (4 and 8) had their 
survival status not updated due to sites not responding, 2 in arm b are alive 
and 3 (2 and 1) are lost to follow up. Progressive disease was the cause of 
death in 87% of deaths in both arms. the median survival time in arm b is 
11.4 months (95% cI 9.5 - 13.7) as compared to 8.8 months (7.7- 10.7) on 
arm A.the hazard ratio is 0.77 (95% cI0.6 -1.0) in favour of arm b. the 
p-value for the log-rank test is 0.0491, which is still below the nominal 
cut-off value of 0.049266 alpha level that was used at the time of the final 
analysis.
Conclusions: the results of this updated analysis confirm the superior effi-
cacy of the raltitrexed/cisplatin combination over cisplatin alone in the first 
line palliative treatment of patients with malignant pleural mesothelioma.
Disclosure: H. Phillips: H Phillips is an employee of Hospira UK Ltd, pro-
ducer of raltitrexed. All other authors have declared no conflicts of interest.
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PROLONGED SURVIVAL OF PATIENTS WITH 
LOCALISED MALIGNANT PLEURAL MESOTHELIOMA 
AFTER HIGH DOSE HEMITHORACIC RADIOTHERAPY 
TO AN INTACT LUNG
M. Feigen1, M. Lawlor1, s.t. Lee2, c. Hamilton1 1Radiation Oncology Centre, 
Austin Health, Heidelberg West, VIC, AUSTRALIA, 2Nuclear Medicine and 
Centre for Pet, Austin Health, Heidelberg, VIC, AUSTRALIA
Introduction: Mesothelioma patients will obtain best palliation with treat-
ment that controls their enlarging tumour masses, which originate in the 
pleura of one hemithorax and spread into surrounding organs, producing 
distressing local symptoms of pain and respiratory impairment. As most are 
unsuitable for extrapleural pneumonectomy and chemotherapy provides poor 
local control, we postulated that high doses of radiotherapy to large volumes 
would provide the best and most durable symptom relief.
Methods: In 2003 our institution began a prospective program of high dose 
radiotherapy for mesothelioma patients using new technological advances 
and precision targeting of all viable tumour with 18F-FDG PEt scans. We 
believed that radiation toxicity could be limited by advanced techniques 
with 3-D treatment planning and delivery. All patients had histologically 
confirmed malignant pleural mesothelioma of any subtype, confined to one 
hemithorax with normal lung, liver and renal function. None had undergone 
a pneumonectomy.
Results: From 2003 to 2011, 44 patients aged 37-76 received doses of 45-60 
Gy to part or all of one complete hemithorax over 6 weeks, using 3D-conformal 
or, in 27 cases, intensity-modulated radiotherapy (IMrt). 84% had advanced 
stage III-IV disease on planning PEt scans. 21 had a pleurectomy/decortica-
tion, 16 a pleurodesis and 5 only a biopsy. 19 were chemotherapy-naive and 22 
had progressed after palliative chemotherapy. Median survival of all patients 
was 22 mths from diagnosis (range 7-91). survival is 80%, 39% and 7% at 1, 
2 and 5 years, and 15 are still living. 26 deaths were from progressive disease 
(in 25 outside the irradiated volume), mostly in the contralateral lung or the 
ipsilateral lung that had been excluded from radiotherapy in our early patients 
while we established our normal tissue tolerance constraints. Apart from one 
debatable death from pneumonitis, there were no grade 4 or 5 toxicities.
Conclusions: Many believe mesothelioma to be radioresistant and that toxic-
ity is prohibitive if high doses are given with the affected lung in situ. Our 
experience provides clear evidence that radiation is arguably the most effec-
tive single targeting agent for mesothelioma and new technologies including 
IMrt allow high doses to be delivered safely to large volumes. survival is 
not compromised.
Disclosure: All authors have declared no conflicts of interest.
229O_PR
GLYCOPEPTIDE SERUM MARKERS FOR MALIGNANT 
PLEURAL MESOTHELIOMA DIAGNOSTICS
F. cerciello1, A. Nicastri2, M. choi3, D. bausch-Fluck4, A. Ziegler5, O. Vitek6, 
E. Felley-bosco5, r.A. stahel5, r. Aebersold7, b. Wollscheid4 1Institute 
of Molecular Systems Biology , Department of Biology and Laboratory of 
Molecular Oncology, Clinic of Oncology, ETH Zurich and University Hospital 
Zurich, Zurich, SWITZERLAND, 2Department of Experimental and Clinical 
Medicine, Magna Graecia University, Catanzaro, ITALY, 3Department of 
Statistics, Purdue University, West Lafayette, IN, UNITED STATES OF 
AMERICA, 4Institute of Molecular Systems Biology, Department of Biology, 
ETH Zurich and NCCR Neuro Center for Proteomics, University and ETH 
Zurich, Zurich, SWITZERLAND, 5Laboratory of Molecular Oncology, 
Clinic of Oncology, University Hospital Zurich, Zurich, SWITZERLAND, 
6Department of Statistics and Department of Computer Science, Purdue 
University, West Lafayette, IN, UNITED STATES OF AMERICA, 7Institute of 
Molecular Systems Biology, Department of Biology, ETH Zurich and Faculty 
of Science, University Zurich, Zurich, SWITZERLAND
Background: Malignant pleural mesothelioma (MPM) is an aggressive can-
cer of the pleura caused by asbestos exposure. recent therapeutic advances 
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have raised growing interest in the identification of serum accessible diagnos-
tic markers for MPM. Here, we used mass-spectrometry (Ms) based tech-
nologies for the identification and clinical verification of glycopeptide MPM 
candidate biomarkers in serum. Glycopeptide MPM candidate biomarkers 
were selected from a pool of glycopeptides discovered through comparison of 
the surfaceome of MPM with control cell lines. the clinical significance of the 
selected glycopeptides was verified by using selected reaction Monitoring 
(srM) in serum from cohorts of MPM patients and controls. 
Methods: the surfaceome of four MPM (epithelioid and biphasic) and four 
control (pleura and lung adenocarcinoma) cell lines was investigated by using 
cell surface capturing (csc) technology and label free quantitative mass 
spectrometry. Glycopeptides detected in higher abundance in the MPM sur-
faceome were selected for srM-based quantitative analysis in patient sera 
enriched for N-glycopeptides. 
Results: surfaceome analysis revealed 500 N-glycopeptides, corresponding to 
more than 300 cell surface N-glycoproteins from MPM-derived cell lines. 56 can-
didate biomarker peptides were selected for initial srM quantification and verifi-
cation in serum of patient cohorts. the cohorts consisted of 25 MPM patients (13 
epithelioid and 12 biphasic, stage I-IV), 25 healthy donors and 25 non-small-cell 
lung cancer patients (16 adenocarcinoma and 9 squamous, stage III-IV) matched 
per sex and age. We verified the robustness of our approach based on serum anal-
ysis of the mesothelioma marker soluble mesothelin–related protein (sMrP). 
Conclusion: the relative quantitative investigation of the MPM surfaceome 
revealed serum accessible potential MPM candidate biomarkers. srM technol-
ogy enables now the parallel verification of glycopeptide candidate biomarkers 
in serum samples of selected patient cohorts. A multiplexed 56 peptides srM-
assay for MPM was established and evaluated in 75 serum samples.
Disclosure: All authors have declared no conflicts of interest.
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ASSESSMENT OF CIRCULATING MIRNAS AS 
POTENTIAL BIOMARKERS FOR MALIGNANT PLEURAL 
MESOTHELIOMA (MPM)
M.b. Kirschner1, Y.Y. cheng1, b. badrian2, J. creaney3, J.J. Edelman4, A.W. 
Musk3, b.W. robinson3, s. Klebe5, N. van Zandwijk1, G. reid1 1Asbestos 
Diseases Research Institute, University of Sydney, Concord, NSW, AUSTRALIA, 
2Lung Institute of Western Australia, University of Western Australia, Nedlands, 
WA, AUSTRALIA, 3National Research Centre for Asbestos Related Diseases, 
University of Western Australia, Nedlands, WA, AUSTRALIA, 4Cardiothoracic 
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NSW, AUSTRALIA, 5Department of Anatomical Pathology, Flinders University 
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the definitive diagnosis MPM often depends on the availability of a biopsy of 
sufficient size. the identification of a biomarker that can be easily measured 
in blood with a potential use in the early detection setting would represent an 
important step forward. recently it has been shown that microrNAs (mir-
NAs) detectable in serum or plasma represent a class of potential new biomark-
ers. In this study we investigated the ability of certain mirNAs in plasma and 
serum to serve as a diagnostic marker for MPM. Using Agilent 8x15k mirNA 
microarrays we profiled mirNA expression in plasma samples from healthy 
volunteers and patients with MPM. candidate mirNAs identified in the arrays 
were validated by taqMan assay-based quantitative real-time Pcr or using the 
OpenArray real-time Pcr platform. Microarray-based expression profiling of 
plasma from 5 MPM patients and 3 healthy controls identified 17 mirNAs 
with significantly differential abundance in the two sample groups. Validation 
of these mirNAs in a series of plasma samples from 15 MPM patients and 13 
controls (healthy controls and patients with coronary artery disease) revealed 
that levels of mir-625* are not only significantly elevated in plasma of MPM 
patients (4-fold higher, p=0.004), but are also able to discriminate between 
MPM patients and controls with an accuracy of 82.4 %. Furthermore, levels 
of two mirNAs previously reported to be associated with MPM, mir-29c* 
and mir-92a, were also elevated in our MPM series however without reach-
ing statistical significance. Assessing levels of mir-625* in serum of another 
series of MPM (N= 30) and asbestosis (n=10) confirmed that mir-625* was 
significantly (p=0.023) elevated only in serum of MPM patients and was able 
to discriminate between cases and controls with an accuracy of 79.3 %. Finally, 
mir-625* was also found to be present at significantly higher levels (2-fold 
higher, p= 0.006) in tumour specimen from 18 MPM patients who underwent 
extrapleural pneumonectomy than in normal mesothelium (pericardial tissue). 
taken together these data provide evidence that mir-625* has the potential to 
serve as a novel blood-based biomarker for MPM.
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RATIONAL FOR A PHASE I CLINICAL STUDY USING FAP 
SPECIFIC RE-DIRECTED T CELLS IN MESOTHELIOMA 
PATIENTS
c. Hagedorn1, P. schuberth1, A. soltermann2, G. Jakka1, E. Felley-bosco1, M. 
van den broek1, W. Weder3, r.A. stahel1, c. renner4, U. Petrausch4 1Oncology, 
University Hospital Zurich, Zürich, SWITZERLAND, 2Institute of Surgical 
Pathology, University Hospital Zurich, Zürich, SWITZERLAND, 3Thoracic 
Surgery, University Hospital Zurich, Zürich, SWITZERLAND, 4Immunology, 
University Hospital Zurich, Zürich, SWITZERLAND
Introduction: In re-directed t cells, the antigen-specificity of t cells is engi-
neered through introduction of a chimeric antigen receptor (cAr). cArs 
consist of an antigen-binding molecule, a trans-membrane domain and a sig-
nalling domain. In this project, we generated re-directed t cells that recognise 
Fibroblast Activation Protein (FAP). FAP is expressed in the tumour stroma 
of the majority of carcinomas and is thought to be a key player in promoting 
tumour growth and malignancy. Here, we investigate the therapeutic potential 
of anti-FAP re-directed t cells targeting human malignant pleural mesothe-
lioma (MPM), which usually express FAP on the tumour cells.
Methods: Human peripheral mononuclear cells (PbMcs) were isolated by 
Ficoll gradient centrifugation followed by Magnetic Activated cell sorting 
(MAcs) of cD8+ t cells. Purified t cells were retrovirally transduced to 
express the FAP-specific cAr. the anti-FAP cAr constists of a single-chain 
fragment recognising FAP, a human IgG domain and cD3z and cD28 sig-
nalling domains. to test antigen-specificity and functionality of anti-FAP 
re-directed t cells, their capacity to lyse targets and produce interferon  
(IFN-) in an antigen-specific manner was assessed in vitro. Furthermore, 
FAP as target for re-directed t cells was analyzed in MPM and healthy human 
tissue by immunohisto-chemistry and immune fluorescence microscopy.
Results: FAP expression was detected in all histological subtypes of human 
MPM in the tumour cells and in the tumour stroma. Expression of FAP-specific 
cArs has been confirmed on 293t cells as well as on human cD8+ t cells. In 
vitro characterisation showed specific target cell lysis by anti-FAP re-directed 
t cells Furthermore, re-directed t cells secreted antigen-specifically IFN-.
Conclusion: We generated functional anti-FAP re-directed t cells and inden-
tified FAP as a target molecule in MPM. Experiments are under way to dem-
onstrate antigen-specific functionality in FAP positive tumours in vivo. We 
plan to start a pilot phase I trial in 2012 to investigate the safety of anti-FAP 
re-directed t cells in patients with MPM, who are not eligible for multi-modal 
therapy and not in need for immediate palliative chemotherapy.
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EVALUATION OF DIFFERENT EXTERNAL 
RADIOTHERAPY TECHNIQUES FOR THE TREATMENT 
OF MALIGNANT PLEURAL MESOTHELIOMA AFTER 
EXTRAPLEURAL PLEUROPNEUMONECTOMY
J. Krayenbuehl1, M. Hartmann2, O. riesterer1, t. Lomax2, s. Kloeck1, E. 
Hug2, I. ciernik3 1Radiation and Oncology, University Hospital Zurich, 
Zurich, SWITZERLAND, 2Center for Proton Radiation Therapy, Paul-Scherrer 
Institute, Villigen, SWITZERLAND, 3Department of Radiation Oncology, 
Dessau Medical Center, Dessau, GERMANY
Background and Purpose: Postoperative radiotherapy reduces local relapses 
of malignant pleural mesothelioma after radical surgery. comparative 
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planning for intensity modulated radiotherapy (IMrt) volumetric intensity 
modulated arc therapy (VMAt) and proton therapy (Pt) was performed.
Material and methods: Eight patients treated with IMrt or VMAt after 
extrapleural pleuropneumonectomy (EPP) were replanned with Pt and either 
with VMAt or either with IMrt. A comparison of dose homogeneity (DH), 
target volume (tV) coverage, mean and maximal dose to organs at risk (OAr) 
was performed. robustness of each technique was evaluated in respect to the 
dose distribution variation in respect of air cavity volume decrease.
Results: Dose coverage and DH of the planning target volume (PtV) were 
similar for IMrt, VMAt and Pt for the volume covered by >95% (V95) and 
<5% (V105). the mean dose (md) to the contralateral kidney, contralateral 
lung, liver, heart, and spinal cord was significantly reduced with Pt compared 
to IMrt and VMAt. A decrease of V13 and V20 for the lung was observed 
for VMAt in comparison to IMrt. After EPP, air cavities were common 
(range 0 – 1250 cm3), decreasing up to 20cm3/day. the photons plans were 
more robust than Pt plans, in respect to the PtV coverage (V90, V95), when 
air volume decreased in the resected lung. VMAt plans were less affected 
than IMrt plans, if changes in the air cavity volumes occurred.
Conclusion: both, proton and photon plans achieved good target coverage 
and DH. Pt accomplished additional dose sparing of all OArs compared to 
IMrt or VMAt, and VMAt showed better results than IMrt. Pt dose dis-
tributions were more susceptible to changing air cavities during the treatment 
period emphasizing the need for replanning and adaptive rt for Pt.
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A PHASE 2 STUDY OF SORAFENIB AFTER FIRST 
LINE PLATINUM CONTAINING COMBINATION 
CHEMOTHERAPY IN MALIGNANT MESOTHELIOMA
s. Papa1, s. Popat2, r. shah3, b. McLennan4, r. Lal4, L. Lang-Lazdunski4, P. 
Marsden1, Z. Viney4, D. Landau4, J. spicer1 1Division of Cancer Studies, King’s 
College London, London, UNITED KINGDOM, 2Oncology, Royal Marsden 
Hospital, London, UNITED KINGDOM, 3Maidstone & Tunbridge NHS Trust, 
Maidstone Hospital, Maidstone, UNITED KINGDOM, 4Oncology, Guy’s and 
St Thomas NHS Foundation Trust, London, UNITED KINGDOM
Background: the incidence of mesothelioma is rising, with a predicted peak 
in the UK expected in 2020. cisplatin and pemetrexed first line confers a sur-
vival benefit, but with a median progression-free survival of only 5.7 months. 
sorafenib inhibits the raf/MEK/ErK signalling pathway, as well as tyrosine 
kinases including receptors for VEGF which are present at particularly high 
circulating levels in mesothelioma patients. Antibodies to VEGF, VEGFr1 & 
VEGFr2 inhibit mesothelioma growth.
Methods: sorafenib at 400mg bD was assessed in a single arm multi-centre 
phase 2 study. A simon 2-stage design was used. Eligible patients had received 
prior platinum combination chemotherapy. the primary endpoint was progres-
sion-free survival (PFs) at 6 months assessed by ct using modified rEcIst. 
Published reference values for PFs in mesothelioma (Francart et al. 2006 J 
clin Oncol) provide a benchmark of 28% progression-free at 6 months.
Results: A total of 53 patients have been treated, 41 male and 12 female. 
Primary histology was epithelioid (37), sarcomatoid (2), mixed (7). No his-
tological sub-group was recorded in 7 patients. 96% of patients had a per-
formance status of 0 or 1. the most frequent adverse events were fatigue, 
hand-foot syndrome, diarrhoea and hypertension. Overall treatment was well 
tolerated with few grade 3 and no grade 4 toxicities. At 6 months 34% of 
patients were progression free, despite all patients having already received 
prior chemotherapy. A total of 5 patients remained on study beyond one 
year.
Conclusions: sorafenib is well tolerated in patients with mesothelioma after 
completion of platinum containing chemotherapy. PFs compares favourably 
to that reported for other targeted agents in this disease.
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THIRD, FOURTH AND SUBSEQUENT LINES IN 
MALIGNANT MESOTHELIOMA
s.c. costa1, E. carcereny costa2, L. capdevila riera2, c. bugés sánchez2, 
A. Martinez Marti2 1Medical Oncology, Hospital Gemans Trias i Pujol, 
Badalona, SPAIN, 2Hospital Germans Trias I Pujol, Medical Oncology, 
Catalan Institute of Oncology ICO Badalona, Badalona, SPAIN
Introduction and objectives: Malignant mesothelioma is a low incidence 
neoplasm whose natural history is poorly modified by treatments received. 
the objective is to analyze the potential impact of third-line treatment and 
subsequent survival of patients. 
Material and methods: the study includes cases of malignant mesothelioma 
diagnosed in our hospital during the period between 2003 and 2010 treated 
with palliative chemotherapy. the variables recorded were: age, sex, Ps, 
smoking, asbestos, histological subtype, stage, treatment, progression-free 
survival (PFs) and overall survival (Os). statistical analysis was performed 
using sPss. 
Results: 38 patients were included (73.7% men and 26.3% women) with 
a mean age of 68.7 years; 15.8% smokers and 44.7% former smokers. 
31.6% had contact with asbestos. 52.6% had Ps1 and 7.9% Ps2 at diag-
nosis. Histology: 39.5% epithelial, 26.3% sarcomatous, 5.3% mixed and 
28.9% undifferentiated. 52.6% were stage III and 44.7% stage IV. Os was 
17.5 months with a PFs of 8.57 months. 15 patients received three or more 
lines of treatment. these had an average age of 64.6 years and 66.7% were 
men; 13.3% were smokers and 40% former smokers; 26.7% had contact with 
asbestos, 60% Ps0 and 40% Ps1. Histology: 40% epithelial, 20% sarcoma-
tous, 13.3% mixed and 26.7% undifferentiated. the Os was 28.62 months 
with PFs 9.72 months. the PFs of patients with Ps 0 was 23.16 months ver-
sus 13.89 months for patients with Ps 1-2 (p 0.05). Difference in Os between 
patients treated with 1 or 2 lines versus those treated with 3 or more lines was 
18.28months (28.62m vs 10.34m, p 0.01). 
Conclusions: Patients treated with 3 or more lines of chemotherapy have a 
higher Os. this difference may be due to chemotherapy or patient charac-
teristics. In the subgroup of patients treated with 3 or more lines of chemo-
therapy the percentage of patients with Ps 0 is higher (39.5% versus 60%) 
acting as a prognostic factor. No other prognostic factors have been identified 
by the small sample available. New clinical and molecular analysis attempted 
to be made.
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RETROSPECTIVE ANALYSIS OF CLINICOPATHOLOGIC 
AND SURVIVAL DATA OF MALIGNANT PLEURAL 
MESOTHELIOMA (MPM) PATIENTS IN A SINGLE 
CENTER SERIES
s. cedres Perez1, A. Martinez Marti1, P. Martinez rodriguez1, D. torrejon 
castro2, I. sullivan1, E. Pallisa3, N. Murtra1, M.A. Montero4, J. Hernandez4, 
E. Felip1 1Medical Oncology, Vall d´Hebron University Hospital, Barcelona, 
SPAIN, 2Institut D’oncologia, Vall d´Hebron University Hospital, Barcelona, 
SPAIN, 3Radiology, Vall d´Hebron University Hospital, Barcelona, SPAIN, 
4Pathology Department, Vall d´Hebron University Hospital, Barcelona, 
SPAIN
Background: Malignant pleural mesothelioma (MPM) is an aggressive 
tumor linked to asbestos exposure and a marked increase in the incidence is 
predicted over the next decades in Europe and developing nations. We investi-
gated the overall survival (Os) and variables affecting survival in patients (p) 
diagnosed of MPM in our institution. 
Methods: Forty nine patients diagnosed of MPM in Vall d´Hebron University 
Hospital between November 2002 and september 2011 were retrospectively 
reviewed. baseline factors analyzed were age, performance status (Ps), his-
tology, stage, chemotherapy (ct), neutrophil to lymphocyte ratio (NLr) and 
tumor markers. survival data were calculated by the Kaplan-Meier method.
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Results: Patient’s characteristics: median age 68 years (31-88years), males 
75.5%, Ps 1: 67.3%, asbestos exposure 53.1%, chest pain 77.6%, dyspnea 
75.5%, pleural effusion 91.8%, clinical stage III: 55.1%, epithelial subtype 
71.4% and NLr>5 in 44.9% of all patients. cA125 was elevated in 15/23 p, 
cEA in 2/32 p and ca 15.3 in 10/16 p. All patients were considered initially 
unresectable and 71.4% received ct in 1st line and 34.7% in 2nd. response 
rate in 1st line was 75.3% (Pr:27%, sD 48.3%) and in 2nd line 46.7% 
(Pr:6.7%, sD 40%). After a median follow up of 9.2 months the median 
Os was 15.2 months. We found significant increase in Os in patients with 
epithelial subtype (23.4 vs 5.0 months in no-epithelial, p<0.001), Ps1 (14.7 
vs 2.2 months in Ps 2, p=0.036), NLr ≤5 (26.5 vs 13.4 months, p=0.025) 
and patients who received 2nd line ct (8.9 and 26.4 months p second line, 
p=0.05). Although no significant, age, tumor stage, absent thoracic pain and 
response to ct were associated with better Os. Patients with tumor markers 
elevated at baseline were followed during ct and we only found changes 
in ca15.3≥20% over baseline in concordance with radiological response 
(increase ca15.3 in 6/6 p progression, decrease 1/1 p with response and no 
changes 2/2 p with stable disease). 
Conclusion: In our series of 49 MPM patients, epithelial subtype, Ps, NLr 
and treatment with second line therapy are prognostic factor for survival. 
ca15.3 warrants further study to clarify its potential use as a marker of che-
motherapy efficacy in p with MPM.
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PROGNOSIC FACTORS AFFECTING SURVIVAL IN 
MALIGNANT MESOTHELIOMA (ANALYSIS OF 125 
SUBJECTS)
b. Komurcuoglu Pulmonology, Dr.Suat Seren Education Hospital for Chest 
Disease and Surgery, Izmir, TURKEY
Determining the pre-treatment prognostic factors in malignant pleural mesothe-
lioma (MPM) is of importance in terms of both estimating the course of disease 
and determining the patients who are candidate to multimodal therapy. Aim of 
the current study was to determine the prognostic factors affecting survival in the 
patients with MPM. One hundred and twenty five patients who had been diagnosed 
histologically as having MPM over the past 5 years were evaluated retrospectively. 
relationships of survival of the patients with their age, gender, exposure to asbes-
tos, smoking history, platelet, hemoglobin, leukocyte (Wbc), serum lactate dehy-
drogenase (LDH) values, their histology, performance scores and stage of disease 
were examined. Advanced clinical stage, N2 nodal involvement and presence of 
distant metastasis were found to be related to survival. sarcomatous histology was 
found to be poor prognostic factor independently of other factors. We showed that 
histological subtype and stage of disease were the most important parameters in 
planning the treatment, especially in determining the patients who were candidate 
multimodal treatment and estimating the prognosis.
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CLINICO-PATHOLOGICAL CHARACTERISTICS 
OF IRANIAN PATIENTS WITH MALIGNANT 
MESOTHELIOMA REFERRED TO “NATIONAL 
RESEARCH INSTITUTE OF TUBERCULOSIS AND LUNG 
DISEASE”: A SINGLE INSTITUTE STUDY FROM IRAN
K. Khodadad1, A. Khosravi1, Z. Esfahani-Monfared1, s. Karimi2, s. seifi1, 
s. Pojhan3 1Thoracic Oncology, National Research Institute of TB and Lung 
Disease, Tehran, IRAN, 2Thoracic Pathology, National Research Institute of 
Tuberculosis and Lung Disease, Tehran, IRAN, 3Thoracic Surgery, National 
Research Institute of Tuberculosis and Lung Disease, Tehran, IRAN
Malignant Mesothelioma (MM) is a malignancy of the pleura with a dismal 
prognosis despite multimodality treatments such as extrapleural pneumo-
nectomy (EPP), chemotherapy and radiation therapy. Approximately 70% of 
MM is associated with documented asbestos exposure. this study provides a 
general overview on Iranian patients’ characteristics, referred to our thoracic 
surgery and/or Oncology clinics within past 13 years.
Results: In this retrospective study, clinico-pathological data of 58 patients 
with definite diagnosis of MM was retrieved and analyzed. these patients 
belonged to different geographical regions of Iran. this study showed that 
male to female ratio of patients was 2.22 (40/18) with mean age of 53.13±11.43 
years (range 25-75). Most common presenting symptoms were dyspnea 
(65.5%), cough (20.7%) and chest pain (13.8%). the majority of patients had 
regionally invasive or metastatic disease at the time of diagnosis (stage Ib: 
1.7%, stage II: 32.8%, stage III: 15.5%, stage IV: 50%). the histologic sub-
types were: epithelioid: 51.7% (n=30), biphasic 10.3% (n=6), sarcomatoid 
3.4% (n=2), Lymphohistiocytic 1.7% (n=1) and in 32.8% (n=19) the subtype 
was not determined. EPP, EPP followed by adjuvant chemotherapy (+/- radia-
tion therapy) and chemotherapy alone were performed in 8.6 % (n=5), 8.6% 
(n=5) and 79.4 % (n=46) of patients, respectively. two patients didn’t undergo 
any treatment. smoking history was positive in 41.4% (n=24) of patients and 
only 17.2% (n=34) of them had documented asbestos exposure.
Conclusion: We speculate that the most Iranian patients referred to our insti-
tute were diagnosed in advanced stages. Furthermore, in view of less common 
documented exposure to asbestos in Iranian patient, other environmental, 
genetic factors, along with viral oncogens (e.g. sV-40) presumably contribute 
to development of MM in majority of Iranian patients. More studies in this 
regard are warranted.
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THE BURDEN OF MESOTHELIOMA MORTALITY: 
ESTIMATION AS THE FIRST STEP TO PREVENTION
A. Jamil, b. Prathibha Medicine, East Kent Hospitals NHS Trust, Ashford, 
UNITED KINGDOM
Background: Mesothelioma is a rare cancer that principally affects the pleura 
and is almost always caused by asbestos exposure. the disease is rapidly fatal; 
most of those affected dying within a year of diagnosis. Mesothelioma inci-
dence has increased in south East England of which East Kent is a major part, 
particularly for men aged over 70 years, reflecting areas of asbestos use in 
shipbuilding and industry in the past.
Methods: Work-related cancers are largely preventable. the aim of the study 
is to estimate the current burden of cancer in the area of East Kent in the UK 
attributable to occupational factors, and identify carcinogenic agents, indus-
tries and occupations for targeting risk prevention. Data of all cases diagnosed 
at East Kent Hospitals NHs trust were collected retrospectively from April 
2009 to March 2010.
Results: there were a total of 15 cases in East Kent Hospital NHs trust, 
UK over the period of one year which is a significantly high number as 
compared to previous years, the current population being 614,576. All of 
them were male. Median age was 74 years and median survival from diag-
nosis was 8.9 months. All of them had histological or cytological confirma-
tion and 85% had documented evidence of definite or probable exposure 
to asbestos. there were seven cases that were treated with chemotherapy 
and 6 patients had advanced malignancy and received radiotherapy and 
2 patients with advanced malignancy had palliative treatment only. No 
patient had radical surgery and there was minimal difference in relative 
survival between men with localised and non-localised disease stage. 
Conclusion: In Great britain, where asbestos use continued later than 
many other countries, the peak is anticipated to occur later between 2011 
and 2115. between 1981 and 2000, North East England and south East 
England were the areas with the highest standardised mortality ratios. 
cancer networks, especially those with primary care trusts with high inci-
dence, need to be aware of this disease and ensure that risk reduction 
strategies and services are in place to assist these patients. More research 
is needed to understand the interrelationships of prognostic factors, treat-
ment choices and survival, and to determine the best care and support for 
these patients and their families.
Disclosure: All authors have declared no conflicts of interest.
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STEREOTACTIC BODY RADIOTHERAPY (SBRT) USING 
VOLUMETRIC MODULATED ARC THERAPY (VMAT) 
WITH FLATTENING FILTER FREE (FFF) MODE FOR 
LUNG METASTASES IN OLIGOMETASTATIC PATIENTS: 
A PROSPECTIVE SINGLE INSTITUTIONAL EXPERIENCE
P. Navarria1, s. Pentimalli1, A.M. Ascolese1, E. clerici2, G. reggiori1, A. 
tozzi1, s. castiglioni1, F. Alongi1, P. Mancosu1, M. scorsetti1 1Radiotherapy 
and Radiosurgery, Istituto Clinico Humanitas Cancer Center, Rozzano 
(Milan), ITALY, 2Radiotherapy, University of Milan, Milan, ITALY
Purpose: Data on the use of stereotactic body radiation therapy (sbrt) in 
oligometastatic patients are emerging and the early results on local control 
are promising. Aim of this study was to evaluate results and toxicity of 
sbrt using VMAt-FFF in lung metastatic patients from different primary 
tumors.
Methods and materials: One hundred forty-five consecutive patients treated 
between October 2010 to september 2011 were included. the most common 
primary cancers were lung and colon-rectal. One hundred sixty-seven sbrt 
were performed. All patients had oligometastatic disease. Dose prescription 
was 48 Gy in 4 consecutive fractions for peripheral lesions with maximum 
diameter < 3 cm, 60 Gy in 6 consecutive fractions for central lesions and 32 
Gy in 4 consecutive fractions for lesions with maximum diameter between 3 
and 5 cm or in case of multiple lesions in the same lung. clinical outcome was 
evaluated by ct scan and ct-PEt. the incidence of pneumonitis was graded 
according to the NcI ctcAE v3.0 scale.
Results: Median follow-up was 9 months (range 3-14). response was 
recorded in 134/167 lesions (80%). At the last follow up 132/155 of patients 
(85%) were alive. No pulmonary toxicity of grade 2 or greater was recorded. 
No chest pain toxicity occurred. removal of the flattening filter (FF) increased 
the dose rate. the median beam-on time (bOt) was reduced by 75% passing 
from about 8 minutes (with FF modality) to 2 minutes (with FFF modality).
Conclusion: sbrt is a feasible, safe and effective local treatment option 
for pulmonary metastases in patients with contraindications to surgery or for 
palliation of symptomatic pulmonary metastases. VMAt technique improved 
target coverage while minimizing higher dose to normal tissue with respect 
to coplanar beam arrangements. Furthermore, the bOt was significantly 
reduced in FFF modality with a subsequent increase of patient comfort and 
reduction of intra-fraction motion. In our experience sbrt with VMAt-FFF 
resulted in a good radiological response though a longer follow-up is needed 
to assess the effective outcome incidence and to select patients with better 
prognosis.
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SIGNIFICANCE OF LOW DOSE DISTRIBUTION IN 
DEVELOPING RADIATION PNEUMONITIS AFTER 
HYPOFRACTIONATED RADIOTHERAPY USING 
HELICAL TOMOTHERAPY FOR PULMONARY 
METASTASES
c. Kay1, J.Y. Kim2, J.Y. Jung1, K.J. Kim3 1Radiation Oncology, The Catholic 
University of Korea Incheon St. Mary Hospital, Incheon, KOREA, 2Radiation 
Oncology, The Catholic University of Korea Yeouido St. Mary Hospital, Seoul, 
KOREA, 3Diagnostic Radiology, The Catholic University of Korea Incheon St. 
Mary Hospital, Incheon, KOREA
Hypofractionated radiotherapy (Hrt) has been commonly used for pulmo-
nary metastases since tumorcidal dose can be accurately delivered to the 
target without increasing dose to adjacent normal lung. However, radiation 
pneumonitis (rP) is still a major problem and sometimes a fatal complica-
tion after Hrt. to determine the relationship of normal lung volume and dif-
ferent levels of radiation dose in clinically significant rP, we retrospectively 
investigated the data from patients treated with Hrt using helical tomo-
therapy for lung metastases. total 45 patients were included and median age 
was 53 years old. Average number of pulmonary metastases was 4.7 (range, 
1~10) and median 50 Gy (range, 30~60 Gy) was delivered to PtV (planning 
target volume) in 10 fractions during 2 weeks. rP was diagnosed by chest 
X-ray or computed tomography after Hrt and its severity was determined 
by ctcAE version 4.0. A rOc (receiver Operating characteristic) curve 
of MLD (mean lung dose) and Vn (volume percentage of lung receiving 
more than n Gy; range V5~V50 in 5 Gy interval) was investigated to find the 
cutoff values, the sensitivity and the specificity. And we compared the aver-
age values of Vn and MLD in two groups of the patients who suffered from 
grade II or more rP (Gr.II-rP) and the patients who didn’t experience rP. 
the Gr.II-rP was developed in 12 patients (26.6%). In the patients, MLD, 
V5, V10, V15, V25 and V30 showed significance in developing Gr.II-rP 
(p<0.05). Among these, MLD and V5 were most powerfully significant. 
And their cutoff points, sensitivity and specificity were 13.79 Gy, 75.0% 
and 69.7%, respectively in MLD (p=0.009) and 80.75%, 75% and 63.6%, 
respectively in V5 (p=0.004). the other parameters such as age, sex, perfor-
mance status, number of targets, sum of PtVs’ volumes, previous thoracic 
rt, chemotherapy, total dose, daily dose and even NtcP were not statisti-
cally significant in developing any rP. And the mean values of Vn below 
V30 and average MLD of two groups were statistically different (p<0.05). In 
present study, the Vn less than V30 and the MLD were thought important to 
develop Gr.II-rP. so, we have to try to decrease not only MLD but also the 
lower dose distribution area less than V30 for safe Hrt using helical tomo-
therapy in multiple pulmonary metastases. However, further clinical study 
should be required to confirm this outcome.
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SCREENING FOR BRAIN METASTASIS (BM) IN 
PATIENTS (PTS) WITH STAGE III NON-SMALL CELL 
LUNG CANCER (NSCLC): HAS MAGNETIC RESONANCE 
IMAGING (MRI) AN ADDITIVE VALUE COMPARED TO 
COMPUTED TOMOGRAPHY (CT)?
L. Hendriks1, A. Dingemans2, G. bootsma1, N. scheppers1, P. Hofman3, b. 
brans4, D. De ruysscher5 1Pulmonology, Atrium Medical Centre, Heerlen, 
NETHERLANDS, 2Pulmonary Diseases, Maastricht University Medical 
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Introduction: 30% of pts with NscLc present with stage III disease and 
are candidates for treatment with curative intent. As the brain is a common 
site for dissemination, excluding bM is important before starting aggressive 
treatment. current guidelines advise to perform a post contrast MrI or a con-
trast enhanced ct (cE-ct) of the brain in these pts. MrI is in small studies, 
including not only stage III NscLc, reported to be superior to ct in diagnos-
ing occult bM. However, ct and Mr technology have evolved. If cE-ct 
performed in the same setting as the standard whole body 18F-deoxyglucose-
positron emission tomography (18FDG-PEt-ct) could lead to the same yield 
of bM detection as 18FDG-PEt-ct with low dose ct (LD-ct) and separately 
MrI, a substantial gain in time and resources could be expected. the aim of 
this retrospective study is to investigate the additive value of MrI to ct when 
both are performed in standard work-up.
Methods: All pts who underwent 18FDG-PEt-ct in the diagnostic work-up 
for lung cancer between January 2008 and september 2011 were reviewed. 
Pts with stage III disease without taking into account results of brain MrI or 
ct and who were candidates for curative treatment were selected. Pts with 
neurological symptoms that required brain imaging were excluded. the cE- 
or LD-ct was compared to the MrI to investigate whether additional asymp-
tomatic bM were detected on MrI. Development of bM within a year after 
negative MrI was scored.
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Results: From the 510 18FDG-PEt-ct’s performed, 429 pts were diagnosed 
with NscLc. 3 pts had occult bM on cE-ct but otherwise no metastasis. 
97/429 pts had stage III and were eligible for curative treatment. 77/97 (79%) 
pts underwent a MrI (MrI not made because of for example diagnostic work-
up elsewhere or contra-indication for MrI), 45/77 (58%) cE-ct and 32/77 
(42%) LD-ct. In none of the cE-ct pts bM were detected on MrI. In 5/32 
LD-ct pts (16%) bM were detected on MrI. 9/77 pts (12%) without bM 
on MrI at diagnosis developed bM within a year, 2/9 (22%) were already 
progressive outside the brain.
Conclusion: In this retrospective study it seems that there is no additive value 
of MrI when 18FDG-PEt-ct with cE-ct is performed in the diagnostic 
work-up of neurologically asymptomatic stage III NscLc pts in order to 
exclude bM. A prospective trial is thus warranted.
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resection of lung metastasis is a growing field in thoracic surgery. currently 
no randomized trial exists to guide physicians in this field. Indication and 
technique therefore vary dependent on personal conviction. the aim of 
this analysis was to evaluate the technical and oncological outcome of 
pulmonary metastasectomy. We retrospectively analysed all patients who 
underwent pulmonary metastasectomy in our department between January 
2005 and June 2010. Follow-up was accomplished by maintenance in the 
outpatient clinics of our medical-center or by questionnaire of the after-
caring physicians. We identified 301 patients who underwent curative 
intended pulmonary metastectomy. In 62 patients (20.6%) the Nd-YAG 
laser was used. Despite significantly higher numbers of resected lesions in 
laser-assisted resections compared with wedge and anatomical resections 
(median 7.0 vs. 2.0; p<0.01) there was no significant difference in surgi-
cal and overall morbidity exept for pneumonia (11.3% vs. 2.9%; p<0.01). 
Follow-up was completed for 85.4% of patients. After median follow-up 
of 20.2 months (range 0 to 75.5 months) 42.5% of patients suffered from 
recurrence. Mean disease-free interval was 12.9 months (range 0 to 60.6 
months). there was a significant correlation between tumor-free resection 
margin (p<0.01), number of metastases (p<0.02) and disease-free survival 
in univariate analysis. Although we found a significant difference between 
laser and non-laser resections regarding classification as r0 (p<0.01), 
we did not find a significant correlation between surgical technique and 
disease-free interval (p=0.09). regression analysis confirmed tumor-free 
resection margins to be the only significant independant factor influenc-
ing disease-free survival (p<0.03). the number of metastases no longer 
reached significance (p=0.09).the technique used for resection (p=0.34) 
did not have an influence. Despite the higher number of resectable lesions 
in laser-assisted metastasectomy the complication rate was not increased 
except for the rate of pneumonia. Even though laser-resected lesions were 
more frequently classified as non r0-resections the technique did not have 
an influence on disease-free interval. the number of metastasis seems to be 
of minor importance.
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Background: the consensus remains insufficient about repeated metasta-
sectomy for pulmonary recurrence from colorectal cancer. In this study, we 
evaluated outcomes of repeated metastasectomy in these patients.
Materials and methods: From 1995 to 2009, 99 patients had undergone 
a pulmonary metastasectomy from colorectal cancer at our institute. Over 
a median follow-up of 39.7 months, 31 patients received second metas-
tasectomy (21 wedge resections, 5 segmentectomies, 4 lobectomies, and 
1 chest wall resection). Of these, ten had over 3 nodules, and six had 
bilateral metastases. the median disease-free interval was 16.0 months. 
Among these 31 patients, 21 showed pulmonary recurrence again and of 
those, 11 patients underwent third resection (9 wedge resections, and 2 
lobectomies).
Results: there was no postoperative mortality. Of the 31 patients who 
underwent second metastasectomy, overall and disease-free 3-year survival 
rates were 59.5% and 32.0%, respectively, after second operation. Of the 11 
patients who received third metastasectomy, overall survival rate was 45.0% 
at 3 years after third operation.
Conclusions: repeated pulmonary resection after first metastasectomy can 
be performed without severe complications and provides good prognosis in 
patients with recurrent metastasis from colorectal cancer. Our outcomes sug-
gests that the aggressive but parenchyma-saving metastasectomy can improve 
the results of repeated pulmonary metastasectomy in patients with multiple 
and bilateral pulmonary metastases.
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Purpose: to evaluate clinical efficacy of re-irradiation using Helical 
tomotherapy for locally recurrent non small cell lung cancer or metastatic 
lung cancer.
Methods and materials: between March 2006 and April 2011, 16 cases with 
non-small cell lung cancer or metastatic lung cancer who developed local 
recurrence after stereotactic body radiation therapy (sbrt) using Helical 
tomotherapy. 5 patients had non-small cell lung cancer and 10 patients had 
multiple metastatic lung cancer. All patients received previous sequential 
chemoradiotherapy (median dose; 50 Gy). We defined the gross tumor vol-
ume (GtV) as recurrent tumor mass on ct and planning target volume (PtV) 
as an anatomical extension of GtV was defined 0.5~1 cm margin from GtV. 
Median dose to GtV and PtV was 45 Gy (45~61.2 Gy) and 40 Gy (35~57.5 
Gy). the treatment schedule of helical tomotherapy was from 10 fractions 
to 28 fractions during 2-6 weeks. the response was evaluated at 1 month 
after completion of treatment and then every 2, 3 months thereafter. rEcIst 
(response Evaluation criteria in solid tumors) was used to determine 
response of tumor and ctcAE (common terminology criteria for Adverse 
Events) v3.0. was used to evaluated treatment toxicity .
Results: Median follow-up was 8 months (2–16 months) and median age 
was 49.5 years. Median time from initial treatment to recurrence was 8.5 
months (2-36 months). treatment response rate was 56.3 % (Pr; 9/16 cases). 
Disease control time was median 3.5 months (1-16 months) and median 6 
months (1-16 months) in non-small-cell lung cancer. Median overall survival 
amounted to 9.1 months. All patients showed grade I radiation peumonitis. 
Acute toxicity was grade II esophagitis in 1 patient and grade III esophagitis 
in 1 patient. Late toxicity was grade III radiation peumonitis in 1 patient 7 
months later.
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Conclusion: Palliative and salvage re-irradiation using Helical tomotherapy 
may be suggested as an effective and safe treatment in locally recurrent non-
small-cell lung cancer or metastatic lung cancer with previous radiotherapy. 
More cautious patient selection could increase the benefit of reirradiation 
using Helical tomotherapy.
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surgery in treatment of pulmonary metastases of sarcomas of bones and 
soft tissues has the increasing value. For improvement of results its com-
bination with other antitumor methods are necessary. since 2004 in our 
center after revealing of isolated pulmonary metastases of malignant 
tumors at different steps of combined treatment, as well as in the process of 
follow-up for patients (pts), a multimodality treatment including preopera-
tive distant radiotherapy, induction and/or consolidation chemotherapy and 
open surgical metastasectomies is performed. Preoperative radiotherapy is 
carried out in 3 Gy fractions twice a day with an interval of 4 hours, 3 treat-
ment days per week to a total dose 30 Gy on biggest metastatic lesions. 
Metastasectomies and manipulations in the pulmonary parenchyma are per-
formed with surgical neodymium YAG laser MY 40 (wave length 1318 nm). 
From April 2004 to December 2011, in thoracic and radiology departments 
Mrrc 33 patients (15 women and 18 men) aged from 16 to 70 years, with 
malignant osteosarcomas and soft tissue sarcomas, who had pulmonary 
nodules revealed by x-ray and ct multimodality treatment was carried out. 
9 pts had initially metastatic tumors with lung lesions in other cases metas-
tases were reveled after treatment of primary tumor. the primary malignan-
cies were presented: 1) osteosarcoma - 13 pts; 2) chondrosarcoma - 3 pts; 3) 
soft tissue sarcomas - 17 pts. A total 57 surgeries were performed, 13 pts had 
bilateral surgeries, the maximum number of surgeries in one patient was 6. 
the largest number of metastases in one surgery was 103. time of observa-
tion for patients from the first surgery in the lungs amounted to: In the group 
of pts (n=13) with osteosarcomas - from 10 to 90 months, 6 pts died with 
disease progression; All pts with chondrosarcoma (n=3) died with disease 
progression from 3 up to 22 months; In the group of pts (n=17) with soft 
tissue sarcoma from 1 to 90 months, 4 pts died with disease progression. 
there was no treatment related mortality. thus, precise resection of neo-
dymium YAG laser combining with radio- and chemotherapy is adequate 
and functional sparing treatment method in lung metastases of sarcomas. 
such surgeries do not only increase the survival rate of patients, but also 
maintain their quality of life.
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Background: breast cancer (bc) accounts for about one-third of cases of 
cancer in women. bc occurs predominantly in elderly women, continue to be 
one of the most common causes of cancer death, and mainly metastasizes to 
the skeleton and lung. Although complete excision of primary tumor improves 
survival in patients with advanced metastatic disease, pulmonary metastasec-
tomy plays a role in the management of patients. However, patients with small 
metastasis have a better overall survival, and thus the early detection of lung 
metastases (LM) is crucial. Indeed, in several studies, risk factors (rFs) such 
as age, stage of the disease, serum tumor markers, and other biological param-
eters obtained from pathological specimen, have been evaluated. the aim of 
this study was to analyze their role in differentiating patients at risk of having 
LMs among a cohort of women with bc.
Patients and methods: We retrospectively reviewed data regarding a series 
of 348 women (median age 60 years, range 28-85) who underwent curative 
surgery for pt1-2, N0-1 (stage I and IIA) invasive ductal breast carcinoma. 
During five-year follow-up, 15 (4.3%) patients developed LMs (cases), 
and 39 (11.2%) other type of cancer relapse, while 294 (84.5%) were dis-
ease-free (controls). the followings parameters were considered: age of 
the patients, size of the tumor (t), axillary lymph node (AN) status (N), 
estrogen (Er) and progesterone (Pr) receptor negativity, human epidermal 
growth factor receptor 2 (HEr2) and nuclear antigen Ki67 overexpression, 
adjuvant chemotherapy. Odds ratio (Or) estimates and the associated 95% 
confidence interval (cI) were obtained, and the significance level was set 
at p<0.01.
Results: Age<50 (Or=4.55, 95%cI 1.58-13.05, p=0.005), and N1 status 
(Or=8.03, 95%cI 2.48-25.98, p=0.0002) were statistically significant rFs for 
LM from bc. tumor size>2 cm (t2) (Or=2.90, 95% cI 1.02-8.27, p=0.041), 
and Er negativity (Or=3.51, 95% cI 1.21-10.17, p=0.018) were weak rFs, 
while Pr negativity (Or=2.01, 95% cI 0.70-5.73, p=0.14), HEr2 (Or=1.48, 
95% cI 0.49-4.49, p=0.32) and Ki67 (Or=1.72, 95% cI 0.59-4.99, p=0.23) 
overexpression, and no chemotherapy administration (Or=1.06, 95% cI 
0.35-3.20, p=0.55) were independent of LMs onset.
Conclusions: N1 patients aged <50 have a significantly increased (>8-fold) 
risk of developing LMs.
Disclosure: All authors have declared no conflicts of interest.
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Background: Involvement of consumers and the general public is an impor-
tant means of improving cancer services. How to involve consumers in cancer 
research has not previously been documented. the objective of this study was 
to explore different ways of involving consumers in cancer research in one 
regional network.
Methods: We formed a consumer research Partnership (crP) in 2009 
of around 25 members consisting of consumers and the professionals who 
wish to help in both promoting and participating in consumer involvement in 
cancer research. this study evaluated the activities of the crP from March 
2010 to March 2011. We used the following indices to judge the level of 
consumer involvement: number of projects involving consumers through the 
group, types of projects, level of involvement and the methods of involving 
consumers.
Results: Fifteen projects were submitted to the crP group during the 
12-month period studied. Of these, 8 projects were clinical trials, 3 were 
qualitative research projects, 2 were patients’ surveys and 2 were non-
randomised interventional studies. seven projects requested consumer 
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involvement on patient information sheets for clinical trials. Out of these 7 
applications, 3 also requested consumers’ help in designing research ques-
tionnaires and another 3 requested that consumers should be involved in their 
project management group. In addition, 4 projects involved consumers in the 
proposal development phase and another 4 projects asked for advice on how 
to increase trial recruitment, conduct patient interviews or help with grant 
applications.
Conclusions: the creation of the crP and this audit of its activity has docu-
mented how consumers can be involved in cancer research at all levels. In 
particular, consumers have a role to play in advising on patient information 
sheets and in designing/managing clinical projects.
supported by thames Valley cancer Network, thames Valley cancer research 
Network, Experimental cancer research centre and NIHr biomedical 
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Objectives: Our cancer NGO aims to analyze palliative care issues/needs & 
their status. EsMO/WHO urgently need to focus on the development of pal-
liative care for lung cancer patients. For developing nations this approach will 
certainly have a positive impact on lung cancer management. NGOs working 
in remote areas can develop policy paper for implementation in the rural/
tribal areas.
Method: Our NGO volunteers & nurses conducted this pilot study in six 
rural villages of India. 7 nurses, 2 physicians & 1 counselor participated. 
146 Patients, 34 caregivers, 18 spiritual/community leaders participated. 
relief of distressing symptoms was reported in 80%. responses on pal-
liative care were analyzed using questionnaires, while community/spiritual 
leaders participated through focus group discussions. 90% of participants 
expressed a need for a model that incorporates palliative services into the 
mainstream of medical therapy which should be emphasized as the standard 
care approach.
Results/findings: Poor wellbeing, appetite, pain and fatigue were most 
prevalent symptoms reported by the patients. 50% of the patients reported 
severe pain and 9% reported no pain. spiritual pain control had the high-
est correlation to QOL in comparison to functional, emotional, physical 
and social wellbeing. 90% of patients and caregivers reported free com-
munication about illness. We also need to modify attitudes of caregivers 
towards psychosocial needs of lung cancer patients & their families. Lung 
cancer care hospitals must have separate departments for handling these 
issues.
Conclusions/Recommendation: this study gives a demographic picture 
of terminal cancer patients and family caregivers in the public health-
care system and some aspects of palliative care. resource-poor nations 
need NGOs to develop such programs in the absence of government-run 
healthcare setups. We NGO activists need the ELcc conference to dis-
cuss our project ideas/concerns/difficulties with senior researchers from 
UsA/Europe. EsMO must take the initiative in propagating such efforts 
in developing nations. Development of a comprehensive lung cancer 
service program is a distant dream in resource poor nations. We NGO 
patient advocates need international funding support for palliative care 
programs.
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Objectives: [1] to assess knowledge, perception and attitudes of nurse in 
cancer-NGO. set-up on nursing care of lung-cancer-patients. [2] to improve 
lung-cancer-care which is a prevalent disease in rural/tribal population of 
the developing world among all age groups and sex. Nurses caring for 
individuals with cancer have an important role in assessing patient needs 
and providing necessary care. the cancer nurse is key in promoting both 
patient/family coping and adaptation through interventions of 1) patient 
education, 2) symptom management, and 3) therapeutic support. cancer 
nursing is specialty practice and requires knowledge and skills beyond gen-
eral preparation.
Methods: From October 2010: Questionnaires based study consisted of 
two sections. 1] Information about respondents. 2] Methods to elicit nurse’s 
knowledge perception and attitudes in care of cancer patients. All question-
naires were returned and analyzed using simple statistical method. We also 
designed framework for orientation/cME that would novices to experts in 
providing nursing care for cancer patients. this presentation outlines role of 
cancer nurse, impact on patient outcomes and education required for compe-
tent practice.
Result: N=23 nurses aged between 20-35 years enrolled from district hos-
pital & rural catholic mission in rural/tribal India. 18 females, 5 males. 
knowledge, perception and attitudes of nurses towards cancer care is 
minimal with only 10 showing special skill, perception and good attitudes 
towards caring for cancer patients as opposed to 9 with little knowledge 
and low perception to caring for cancer patients and the remaining 4 with 
no specific knowledge and perception towards nursing care of cancer 
patients.
Conclusion: Oncolo gy nursing is an important specialty but neglected. there 
are limited training centers in India. resources are scarce for such initiatives. 
trained nurses can improve QOL of cancer patients. Oncology training pro-
grams and motivation will improve the knowledge perception and attitudes 
of nurses in the cancer patient’s care. this presentation will describe role of 
cancer-nurses, impact on patient QOL, and education required for competent 
clinical care of cancer patients.
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